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Background: Globally, more than 100,000 people die annually from opioid overdose, and this 
number continues to increase. In the UK, opioid-related deaths are at an all-time high. The 
depressant effects of opioids on breathing centres in the brain cause ‘respiratory depression’ 
with effects on regular breathing rhythm and neural respiratory drive (signals coming from 
brain to breathing muscles), which then impairs the adequately balanced levels of blood 
oxygen and carbon dioxide. Mechanisms of opioid overdose and the degree of opioid-induced 
respiratory depression among long-term users are not well understood.  
Aims: This thesis incorporates retrospective analyses as well as direct clinical investigations 
to examine risk factors for overdose, as captured through clinical samples and in a clinical 
research facility, exploring influence of dose, route of administration and pre-existing disease. 
Methods: Primary and secondary data were collected and analysed. Primary data collection 
involved two clinical studies utilising novel objective markers of respiratory depression. First, 
an observational study investigated the severity of respiratory depression in long-term heroin 
users on an opioid substitution treatment. The second clinical study, in a clinical research 
facility, examined effects of varying doses of pharmaceutical heroin (diamorphine) on 
physiological markers of respiratory depression and observed and subjective ratings of drug 
effect. Secondary data analysis involved physiological data from a previous clinical study, and 
data extraction from historical literature.  
Results: Major impairment of respiratory function was identified across a broad clinical 
sample of dependent opioid users, and particularly following intravenous heroin administration 
(studied in an experimental clinical laboratory context).  
Conclusions: Without a practical, ‘gold standard’ measure of respiratory depression, it is 
crucial that reliable and sensitive techniques are used to elucidate the complex physiological 
responses to opioid use. Important next steps are identified for research to inform better 
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Aims of the Thesis  
The underlying basis of opioid overdose is alterations at the respiratory centres in the brain 
caused by inhibitory effects of opioid agonists, leading to respiratory depression. Immediately 
after injection of heroin, a decrease in respiratory drive can occur, leading to hypoventilation, 
resulting in an increase in carbon dioxide (hypercapnia) and a reduction in blood oxygen levels 
(hypoxaemia). This is presumed to underlie fatal opioid overdose cases. Even whilst patients 
are tolerant, experienced and administer stable doses of pharmaceutical opiates that are 
individually-titrated, overdose can still occur. Inter-subject variability and the factors underlying 
this susceptibility to overdose in certain individuals are poorly understood.  
 
This thesis aims to: 
1. investigate the prevalence and severity of opioid-induced respiratory depression in 
long-term opioid-dependent users; 
2. examine the influence of personal drug use and addiction treatment characteristics 
on the severity of respiratory depression; 
3. investigate the relevance of underlying respiratory disease in opioid-dependent users; 
4. examine the influence of route of heroin administration on respiratory depressant 
responses to a dose of injectable heroin; 
5. investigate physiological responses to varied doses of injectable heroin as a marker 
for overdose; 
6. investigate subjective and observed ratings of drug effect in response to heroin dose 
and variations of heroin dose. 
 
Chapters 1 and 3 are descriptions of literature and provide rationale behind the aims of this 
thesis. Chapter 2 examines historical data on deaths from a particularly distinct time in UK 
heroin addiction treatment. The main results for the thesis begin in chapter 5 which is devoted 
to an observational study of respiratory function and respiratory depression among opioid 
users compared to non-addict controls. It aims to investigate a variety of characteristics and 
factors thought to underlie overdose. Chapter 6 incorporates secondary analysis of a previous 




Chapter 7 discusses the development of the heroin overdose study (AOO). Through service 
user consultations, key aspects of the study design are described. The many obstacles and 
difficulties of conducting experimental clinical trials are also highlighted in this chapter. 
Chapter 8 is the final results chapter of this thesis and details the results of this dose-







1 Overdose, a Global Overview 
1.1 Preface 
Heroin-related mortality has been, and is still, a major public health concern in the UK and 
globally (Office for National Statistics (ONS), 2018; United Nations Office on Drugs and Crime 
(UNODC), 2018; World Health Organisation (WHO), 2017). There have been increases in 
heroin- and opioid-related deaths across the globe. Since 2014, there has been a staggering 
64% increase in opioid-related deaths in England and Wales, and rates are now at the highest 
since records began (ONS, 2018). The latest figures show that the number of deaths is 
relatively similar to the previous two years, indicating that it might have stabilised.  
 
In 2006, half of all reported heroin-related deaths in Europe were from the UK and Germany 
(Frisher et al., 2012), and this still continues to be the case with the UK taking up 31% and 
Germany around 15% (European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
2017). This has attracted surprise as well as concern as the number of injecting drug users 
appeared to be decreasing in the UK, Europe and much of the world (EMCDDA, 2012; Hay  et 
al., 2012; UNODC, 2014). In fact, in the UK, the prevalence of heroin use has consistently 
been the lowest of all commonly used drugs (Home Office, 2012), yet opiates are most 
significantly and disproportionately involved in drug-related deaths (ONS, 2016).  
 
With a large focus on overdose deaths specifically, this opening chapter draws attention to 
the national and global overview of the opioid crisis and concludes on the reason for the crisis 
in the UK over the last five years, with a discussion of the problems faced in analysing drug-
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1.2 Overview of the Prevalence of Drug Use, Morbidity and 
Mortality  
In 2015, 5% of the global adult population used drugs at least once, and of those users, 0.6% 
had a drug use disorder (UNODC, 2018). The burden of disease is usually calculated as 
disability-adjusted life years (DALYs) (UNODC, 2017). In 2015, opioids accounted for the 
largest proportion of burden of disease attributable to drug use disorders with 70%, or almost 
12 million DALYs (UNODC, 2017).  A review of literature found that 3% of patients taking 
opioids for chronic non-cancer pain developed opioid use disorders (Fishbain, Cole, Lewis, 
Rosomoff, & Rosomoff, 2008).  
 
It is thought that around 35 million people worldwide (range 28.3 million to 42.7 million) misuse 
prescription opioids and 17.7 million are estimated to have used the opiates heroin and opium 
(UNODC, 2017). This is a growing concern in the USA where it has been coupled with an 
increase in the use of heroin and fentanyl, which has led to an epidemic and increase in 
morbidity and mortality related to opioids. According to the UNODC world drug report, there 
are also indications that heroin use in Western and Central Europe is increasing, indicating 
that the long-term downward trend of heroin use might be coming to an end (UNODC, 2017).  
 
Additionally, in some countries, such as Estonia and Finland, a combination of a reduction of 
heroin availability and an increase in substitution treatment for heroin use disorders has meant 
that transitions to other opioids such as fentanyl have been observed. The heroin market 
plummeted in 2001 and 2002 and was displaced by fentanyl and buprenorphine. In a study in 
2014, 18 European countries reported that more than 10% of opioid treatment admissions 
were for opioids other than heroin (including diverted methadone, buprenorphine, fentanyl, 
codeine, morphine, tramadol and oxycodone) (EMCDDA, 2016). Acetylfentanyl, an analogue 
of fentanyl, is also a growing concern, with 32 reported deaths in Europe between 2013 and 
2015, two of which were in the UK (UNODC, 2017). 
 
A study into the prevalence of non-medical use of opioids was conducted through parallel 




followed by the UK, reported the highest prevalence of non-medical use of opioids for both 
lifetime and past-year use. Higher levels of prescription opioid misuse were seen in older age 





1.3 Global Drug-Related Deaths  
There are many different definitions of ‘drug-related deaths’, but they include all or some of 
the following: overdoses, deaths from Human Immunodeficiency Virus/Acquired Immune 
Deficiency Syndrome (HIV/AIDS) and Hepatitis C Virus (HCV) through injecting drugs; 
behavioural disorders by use of psychoactive substances; intentional self-harm and self-
poisoning (suicide) by exposure to psychotropic substances; unintentional deaths and trauma 
resulting from drug use (e.g. motor vehicle accidents) (UNODC, 2017).  
 
Globally, it is estimated that there were 450,000 deaths attributable to drug use in 2015 (WHO, 
2017). Of these, just over one-third (167,750 deaths) were the direct result of drug use (76% 
of which were related to opioids), and two-thirds were indirectly attributable to drug use e.g. 
from HIV/AIDS and HCV contracted through unsafe injecting practices (UNODC, 2018). The 
Global Burden of Disease study of 2015 stated that most of the causes of morbidity and 
mortality could be attributed to drug use (Kassebaum et al., 2016). North America sees the 
highest number of drug-related mortality, with one in four deaths occurring here. Australia and 
New Zealand (Oceania) also see a high drug-related mortality rate, at 2.5 times the global 
average (UNODC, 2017).   
 
1.3.1 North America 
Overdose deaths continue to rise, and have tripled between 1999 and 2015 and increased by 
11.4% in the past year alone to the highest level ever recorded in the USA (Rudd, Seth, David, 
& Scholl, 2016). Between 2012 and 2015, the number of overdose deaths from synthetic 
opioids other than methadone increased by 265% (and between 2014 and 2015 by 72%) and 
was thought to be driven by illicit fentanyl use. In 2016, 948,000 people aged 12 and older 
used heroin and 12 million people misused prescription opioids (Substance Abuse and Mental 
Health Services Administration (SAMHSA), 2017). In the same year, 63,632 total drug 
overdose deaths were observed, 66% of which were from opioids (CDC, 2017). In the USA, it 
is estimated that nearly 40% of heroin-related deaths involved fentanyl, and in studies 
examining non-fatal cases, many users had been unaware that fentanyl was what they had 




fentanyl was the most common substance involved across all overdose deaths (57% of 
deaths) in 2017 (NYC Department of Health and Mental Hygiene, 2018). Fentanyl is also sold 
as ‘ecstasy’ or as counterfeit versions of OxyContin®, alprazolam and hydrocodone, among 
others (see section on Pharmaceutical Opioids for further detail on this).  In relation to heroin, 
the increases in overdose deaths were 119% between 2012 and 2015, 23% between 2014 
and 2015 and 21% between 2015 and 2016 (CDC, 2017). Overdose deaths from prescription 
opioids (other than methadone) have stabilised over the last four years, although they are still 
at a very high level (CDC, 2015; Compton, Jones, & Baldwin, 2016). This is thought to be 
driven by the prescription monitoring programme and prescribing guidelines.  
 
In Canada, British Columbia has seen the highest overdose death rate at 285 per million 
population aged 15-64 years. This is in fact higher than the rate seen in the USA (246 per 
million). This represents a 79% increase from 2015 and a 240% increase from 2012. Similarly, 
fentanyl accounts for a large proportion of these deaths (British Columbia Centre for Disease 
Control (BCCDC), 2017).  
 
1.3.2 Europe 
Overall in Europe, opioid users are five to 10 times more likely to die than people of the same 
age and gender who do not use opioids (EMCDDA, 2017). Cohort studies of high risk drug 
users show mortality rates to be around 1 to 2% per year (EMCDDA, 2017). Other causes of 
death indirectly related to drug use (infections, accidents, violence and suicide) are also 
important. The EMCDDA states that chronic, pulmonary and liver conditions commonly occur 
in this population and also account for some of the increase in deaths amongst older and 
chronic drug users (EMCDDA, 2017).  
 
Mortality rate due to overdose in Europe is 20.3 deaths per million, and there is a large 
discrepancy between males and females, with 32.3 deaths, and 8.4 deaths per million seen, 
respectively (EMCDDA, 2017). With regards to age, the peak age group for males is 35-39, 
and for females it is 30-34. Mean age is actually lower in males at 38, compared to 41 years 




European countries reported rates of over 40 deaths per million, with the highest being 
reported in Estonia (103 per million), Sweden (100 per million), Norway (76 per million) and 
Ireland (71 per million) (UNODC, 2017). 
 
Three-quarters (78%) of people dying from overdose in Europe are male. However, caution 
should be taken when interpreting some of the data because of issues such as underreporting 
and reporting delays in coroners’ reports and death registration. The mortality rates should be 
considered as ‘provisional minimum values’ (EMCDDA, 2017).  
 
The UK accounts for the largest proportion (36%) of the total number of overdose deaths in 
Europe (EMCDDA, 2016). The combined impact of mortality rates that Germany and the UK 
have in Europe is partly related to the size of the population and also due to underreporting in 
other countries. In addition to the UK, increases in overdose deaths are being reported in 
Spain, Lithuania, as well as Germany and the Netherlands. Turkey is also reporting increases 
but this is thought to be due to improved methods in data collection and reporting (EMCDDA, 
2017). 
 
1.3.3 United Kingdom  
In England and Wales, the number of deaths involving heroin and/or morphine more than 
doubled between 2012 and 2017 and have been at the highest on record since 2016 (Figure 
1-1) (ONS, 2018). Over half (53%) of all deaths related to drug poisoning in 2017 involved an 
opiate (mainly heroin and/or morphine where there were 1,164 cases) (ONS, 2018). Deaths 
involving heroin and/or morphine remained relatively stable between 2016 and 2018, with only 
slight fluctuations (ONS, 2018). The latest figures appear to show a slight decrease by 45 
cases which is the first decrease since 2012, and is related to the decrease seen in the number 
of male drug misuse deaths (ONS, 2018). However, female deaths have increased year on 
year and is also the highest level reported since records began. Mortality rates for 
heroin/morphine were 33.1 deaths per 1 million population for males and 9.5 deaths per 1 




the group with the highest level of mortality. Previous years saw the 30-39 age group having 
the highest levels (ONS, 2018).   
 
Deaths involving heroin/morphine had declined between 2008 and 2012, with a particularly 
sharp fall between 2009 and 2011. The recent reversal means the mortality rate in 2015 and 
2017 was the highest since records began in 1993 and now exceeds the previous peak in 
2008, which occurred before the ‘Heroin Drought’ (see following section). The number of 
reported deaths involving heroin/morphine is actually likely to be an underestimate, as some 
coroners simply record ‘opiate overdose’ on the death certificate and do not specify which 
opiate drug was involved (ONS, 2016).  
 
Additionally, National Records of Scotland (NRS) data show that Scotland has seen an 
increase of 23% from 2015 to 2017, which is now the highest since comparable records began 
in 1996 (NRS (National Records of Scotland), 2018). Opioids contributed to 88% of these 
deaths with methadone deaths also at a peak (42% of all drug-related deaths) (NRS (National 
Records of Scotland), 2018). In Northern Ireland, although figures are small, creating difficulty 
in comparison with the rest of the UK, increases in drug-related deaths have also been 
observed (ACMD, 2016). It has been reported that there was an increase by almost three 
times between 2000 and 2013 (NISRA, 2016) and there appears to be particular concern 





1.4 Why Has There Been a Recent Increase in Overdose Deaths in 
England and Wales?  
There are many factors that have been suggested to be responsible for the recent increase in 
overdose deaths observed in England and Wales. Reports related to this rise in deaths state 
that they have been mostly driven by increases in heroin purity and availability, as well as an 
ageing cohort of heroin users who have a range of medical conditions attributed to long-term 
drug use. Purity as a pharmacological risk factor for overdose is analysed more extensively 
from the pharmacological perspective in chapter 3. This chapter focusses on the illicit drug 
market, and purity fluctuations therein, as the reason for the increase in deaths. The 2016 
ONS report on drug-related deaths had the most detailed explanations for these increasing 
trends (ONS, 2016). These were centred on purity and the ‘Heroin Drought’ of 2010/11.  
 
1.4.1 Heroin Drought and Purity Changes  
Heroin droughts/shortages have occurred at various time points around the world (e.g. in 
Australia and Canada in 2001). In the UK, when a surge of drug-related deaths was first 
reported in the ONS report of 2014, it was suggested that the increase in heroin-related deaths 
may have been as a result of a 5% to 10% increase in the purity of street heroin. The report 
stated: 
This increase in street purity after a time of lower purity may partly or wholly explain the 
increase in heroin related deaths in 2013, as users may have had reduced tolerance to the 
drug. (ONS, 2014) 
Subsequently, in relation to the 2015 data, the ONS stated:  
The heroin drought affected the purity of “street” heroin, which fell from 46% in September 
2009 to 17% in mid-2012, but then increased again in each of the last 3 years reaching an 
average of 44% in 2015 (ONS, 2016 based on Serious Organised Crime Agency (SOCA), 
2011).  
However, there is currently not enough of a consistent relationship between purity and 
overdose in fatal toxicological reports. Deaths occur most commonly in people in their 30s and 
40s, who are dependent, tolerant, long-term injecting users, and thus, purity variations would 
not greatly impact this group of people (Bauer et al., 2008; Bird, Hutchinson, Bird, & 




Degenhardt et al., 2011; Stenbacka, Leifman, & Romelsjo, 2010). Detailed discussion of purity 
and its relation to risk of overdose death is discussed in chapter 3.  
A previous explanation by the ONS has suggested that there is sufficient evidence to state 
that overdoses are associated with higher drug purity, citing a cross-sectional study on non-
fatal overdose deaths in Malaysia (Bazazi et al., 2015). While this paper relays an important 
finding on the high prevalence of non-fatal overdoses amongst injecting drug users, the study 
does not compare different purities of heroin, thus it is inappropriate to draw parallels to purity 
and overdose deaths. The ONS also concluded that the increase in user-level purity, and the 
changes in price, may partly explain the increase in heroin-related deaths since 2012 (ONS, 
2016). However, it would seem that data on purity appear more fluid and fluctuating than is 
suggested by the ONS.  
 
The Serious Organised Crime Agency’s (SOCA; now replaced by the National Crime Agency 
(NCA)) used to report on the national purity data from seizures from import to street level in 
their annual reports. Their report of 2014, from which these references to purity are made, 
states:  
Purity levels of heroin detected at the UK border remained at around 50%, while purity at 
street dealer level remained at around 25% (SOCA, 2014). 
Further, focusing on the SOCA figures for 2009 to 2013, the period of time in which the ‘Heroin 
Drought’ had occurred, firstly, there is a clear sign that the ‘Heroin Drought’ was a real 
phenomenon, with ‘street’ purities dropping from a reported 46% in 2009/10 to 19% in 
2011/12. It appears that the levels only began to re-stabilise a couple of years after this period, 
with SOCA stating in 2012/13 that “at street dealer level the purity of heroin was mostly 
between 15 and 20%” (SOCA, 2014). The report suggests that purity levels had slowly been 
recovering from the teens to low twenties to around 25% in 2014, rather than the jump 
suggested by the ONS report (ONS, 2016).  
Eurofins Forensic Services (formerly LGC Forensic Group) is a national laboratory that runs 
drug-testing services on seizures from law enforcement agencies in England and Wales. 
During the same time period, January to March 2013, the reported overall average heroin 




availability of purity data becomes sparser and much of the existent data on purity since this 
time have not been publicly available. Fortunately, I have been given permission from Eurofins 
Forensic Services to incorporate purity data over a 10-year period into this thesis (Eurofins, 
2018) (Figure 1-2). The data exist as percent purity every quarter and are compiled from 
various locations in England and Wales and from over 2,000 samples per quarter (Eurofins, 
2018). While it is not possible to differentiate between street and import level from the data, it 
provides an overarching picture of the fluctuations that have been seen during this 10-year 
period. As stated previously, these data also support the abovementioned purity levels. There 
was a peak purity level of 44% in the second quarter of 2015, which was reached after a 
steady rise from the nadir of 16% observed during the drought between 2010 and 2011. 
Across the same time periods (until 2015), increases in heroin/morphine-related deaths were 
being observed year on year in England and Wales. It has since stabilised (ONS, 2018). This 
suggests that perhaps purity levels are more fluid and fluctuating than has been previously 
acknowledged, and that the ‘recovery’ from the drought was more of a gradual process that is 
unlikely to have had a big impact on the experiences of regular users.  
There are, however, some limitations to these purity data from Eurofins. As stated earlier, it is 
not possible to differentiate between street and import level samples from the data that were 
received. Additionally, these data are averages for each quarter, and it has not been possible 
to obtain ranges or standard errors for each data point. Eurofins also compile data from 
contracted regions of the country, which has a twofold impact: 1) it does not cover every region 
of England and Wales (and none of the rest of the UK); and 2) contracts can stop and start 
and thus, some regions have not been consistent throughout this time period. It is also 
uncertain whether the date stated is the date of seizure or the date of receipt of the sample. 
Nevertheless, these are very important data and there are a great number of samples to draw 
from. It would be of huge interest to examine these data in more detail but that is beyond the 
scope of this thesis.  
Interestingly, an additional finding from the Eurofins purity data is that a second sharp 
decrease in purity was seen in between the fourth quarter of 2016 and first quarter of 2017. 




of 44% after three further quarters in 2017 (with a 5% rise in the subsequent quarter). This 
has not been publicly documented, and thus, there is no discussion of it in the literature. A 
change of 10% is perhaps not a considerable one, however, the fluctuations observed during 
the ‘Heroin Drought’ of 2010/2011 instigated an explanation based on rises of, at most 5% 
and at least 1% per quarter, and thus, it does appear that more attention should have been 
given to this ‘drought’ of 2016/2017. 
1.4.2 Gender 
The increases in deaths have affected both genders with a sharper increase being observed 
amongst males, and a steady increase or stable rate being seen amongst females for the last 
two decades. In fact, female opioid-related mortality has seen a steady increase in recent 
years; the latest figures show a 12% increase from the previous year in heroin/morphine 
deaths specifically for females (ONS, 2017). This covers the period of the ‘Heroin Drought’ 
(M. Harris, Forseth, & Rhodes, 2015), where a purity decrease was seen, and therefore, 
somewhat contradicts the explanation that a 5% to 10% increase in purity played a role in the 
rising number of deaths.  
 
In order to address the issue, the ONS states that the reason for the differences between 
genders is due to the fact that female deaths are more likely to be suicides rather than 
accidental overdoses, which are less likely to be impacted by the changes in purity. They state 
in their 2016 report: 
A more detailed analysis of the data suggests that a greater proportion of female deaths 
included in this section involve morphine rather than heroin – less than 40% of female 
heroin/morphine deaths actually mention heroin on the death certificate compared with more 
than 60% of male deaths. This means that female deaths are less likely to be affected by 
changes in the heroin market in England and Wales. (ONS, 2016) 
Much of the focus on fluctuations and increases of drug-related deaths has been on male 
deaths, primarily because these are much higher and presumed to be more influenced by 
changes in the illicit drug market. Whilst some argue that female deaths have a different profile 
(e.g. greater number of suicides and greater use of pharmaceutical drugs), very little 










Figure 1-2: Quarterly average purity data for heroin, 2009-2018. Reproduced with permission from 






1.5 The Issue of Prescription Opioids  
Non-medical use of drugs is defined as ‘using medications that were not prescribed for a 
patient or were taken only for the experience or feeling that they caused’ (Lipari & Hughes, 
2017). Use of pharmaceutical opioids is involved in acute and chronic pain management, for 
the treatment of opioid use disorders, as well post-surgical care, and palliative therapy. 
Prescription opioids, pharmaceutical opioids and synthetic opioids are usually referred to 
interchangeably. These include drugs such as oxycodone, hydrocodone, hydromorphone, 
fentanyl, as well as methadone and buprenorphine.  
 
Interestingly, in the last year in Europe, methadone deaths exceeded heroin-related deaths in 
Croatia, Denmark, France and Ireland (UNODC, 2017). In the UK, fentanyl deaths rose by 
29% between 2016 and 2017 (ONS, 2018). It is thought that the cause of these increases is 
related to the issue of legal alternatives to heroin (Griffiths et al., 2014). Australia has also 
seen a high level of prescription opioid use. However, it is impossible to discuss prescription 
opioid use and mortality without focussing on the USA which has dominated the discussion 
on this topic.  
 
1.5.1 Prescription Opioid Use in the USA  
Hospital emergency visits involving the misuse of prescription opioids have increased by 
153% between 2004 and 2011 (Center for Behavioral Health Statistics and Quality, 2013). 
The number of admissions to treatment clinics linked to opioids has also seen a four-fold 
increase between 2002 and 2012 (SAMHSA, 2014). Rates of death increased four-fold 
between 2000 and 2014 due to prescription opioid overdose. Although a reduction was seen 
in 2012 and 2013 from 2011’s peak, the 2014 data shows an all-time peak, greater than 
previous records (Figure 1-3). It is thought that the policies that are used to reduce the 
prescription opioid epidemic are causing some of these increases in mortality rates. There 
was a 145% increase in heroin use in from 2007 to 2014, and mortality from heroin overdose 





Figure 1-3: Age-adjusted rates of deaths in relation to prescription opioids and heroin in the USA, 
2000-2014 (CDC, 2015). 
 
1.5.2 Causes of Prescription Opioid Misuse and Mortality  
Different driving forces are thought to play a role in high levels of prescription opioid misuse 
around the world. High level of misuse of prescription opioids (not including methadone) have 
been seen in the USA and Australia where opioids are fairly easy to access, however, having 
easy access to opioids does not always lead to their misuse or addiction. In some cases, even 
the opposite is true, where there is restricted access to opioid painkillers, but high levels of 
misuse of these substances (Degenhardt  et al., 2007; Fischer, Gooch, Goldman, Kurdyak, & 
Rehm, 2014).  
 
In the USA the issue of prescription opioid misuse is thought to be primarily shaped by the 
health system. The misuse of prescription opioids in the USA has been on the increase since 
1997 by the medical practice of prescribing more and higher doses of opioids (King, Fraser, 
Boikos, Richardson, & Harper, 2014). From 2007 an increase in heroin was also observed 
and was attributed to the availability of pure and cheaper heroin on the market (Hughes et al., 
2016). This is somewhat different to the arguments provided in the UK; heroin was not a new 
drug in the UK, and the claims were made around a sudden increase in purity after a drought 
where lower quantities of heroin were available, as mentioned previously. In the USA, it has 
been seen that a $100 decrease in the price per pure gram of heroin resulted in 2.9% increase 




2014). Also, current heroin users are more likely to have used prescription opioids and then 
switched to heroin use (Kolodny et al., 2015; UNODC, 2017). Overall, the evidence seems to 
suggest that the non-medical use of prescription opioids is not related to the initiation of heroin 
use and other factors have contributed to the increase in heroin use and related mortality 





1.6 Problems with Interpreting Global Drug-Related Deaths Data 
The difficulties of studying overdose are substantial. It is difficult to conduct controlled trials on 
overdose as they are usually either observational or post-mortem (Frisher et al., 2012), with 
some exceptions including the N-ALIVE trial of take-home naloxone provision, post-prison 
release. Furthermore, it is also difficult to compare studies of differing drug use patterns and 
responses to overdose which vary from country to country. Cultural and legal factors 
influencing the study, populations and outcomes may also play a role here. In terms of 
recording deaths, general mortality registries do not always accurately represent deaths with 
an ‘unknown’ or insufficiently specified cause, which might actually be overdoses (EMCDDA, 
2009).  
 
Furthermore, importantly, it is reported that many countries actually underestimate the drug-
related death rates (Buchanich, Balmert, Williams, & Burke, 2018; Goldberger, Maxwell, 
Campbell, & Wilford, 2013; ONS, 2018). In some reports, statistical coding excludes those 
deaths where a specific drug is not reported, rather it is focussed solely on coding relating to 
‘opioid-related’ deaths. In the USA, one analysis indicates that more than 70,000 unspecific, 
unintentional overdose deaths (over a 17 year period) could be opioid-related (Buchanich et 
al., 2018).  
 
Thus, any comparisons between countries should be made with caution due to the differences 
in reporting methods (UNODC, 2017). Even within the UK, there are issues with the 
comparison of trends between England/Wales and Scotland which have differing definitions 





1.7 What About Other Fields?  
This issue is not only capturing the attention of concerned users, family and friends, clinicians 
in mental health, acute care, as well as global agencies, governments and public health 
officials, but also other allied health fields. There is an increase in attention across disciplines 
that deal with chronic pain (non-cancer particularly), palliative care, anaesthesiology, 
respiratory medicine and sleep medicine. Further, these fields are not simply discussing the 
issues around opioid use within their standard clinical practices but wider issues pertaining to 
addiction. 
 
One pertinent example is in the field of anaesthesia. In 2006 and 2011, American 
multidisciplinary conferences were organised to address the issue of opioid-induced 
respiratory impairment. In the last two to three years, the issue is more prominent in 
anaesthesia literature and there is an obvious increase in concern given the recent crisis. The 
issue for this field has been the inconsistent recording of the physiological measures of 
overdose, and respiratory depression. The literature states that taxonomy and outcome 
measures need to be standardised, and monitoring tools and measures need to be determined 
as appropriate for reducing opioid-induced respiratory depression (Gupta & Edwards, 2018). 
 
Opioid-induced respiratory depression is challenging to measure reliably. There are also 
evident difficulties in testing new monitoring techniques or technologies. Comparison to other, 
previous studies is also a challenge because respiratory depression is defined differently 
(Gupta & Edwards, 2018; Jungquist, Karan, & Perlis, 2011). The conclusions of these 
meetings were that, until a more reliable tool existed, the simplest method, continuous pulse 
oximetry, would be implemented. This is related to one of the most critical questions that 






With global upward trends and new record figures in some countries, the issue of drug-related 
deaths requires attention. The USA is experiencing the most severe crisis, with drug overdose 
appearing to be the leading cause of death for people under the age of 50, and with 91 deaths 
per day (Rudd et al., 2016). The UK has seen a distinct rise in recent years, with Scotland 
now leading the number of deaths per capita in Europe, at 160 deaths per million (NRS 
(National Records of Scotland), 2018). Unfortunately, there does not appear to be any sign 
that these figures will diminish any time soon. This thesis intends to explore some of the risk 
factors thought to play a role in opioid overdose using novel and physiological techniques. 
The work presented in this thesis should serve as the foundation for future studies that could 






2 Heroin Through History 
 
2.1 Preface 
The UK has a long history of prescribing pharmaceutical heroin (diamorphine). In fact, 
diamorphine prescribing was one of the main forms of treatment for heroin addiction in the UK 
(the 'British System'), particularly after the late 1950s and up until the mid-1970s. Thereafter, 
the growing reputation of oral methadone led to its dominance from the late-1970s onwards. 
Within the context of this thesis, has the UK always had high mortality rates from heroin 
overdose? 
 
This chapter will guide the reader through the history of diamorphine prescribing practices and 
focus on reports on mortality rates through this period and subsequently to comparable studies 
in the present day. As is often debated within the addictions and drug policy fields, a key 
question arises: do pharmaceutical, prescribed drugs increase safety for the user compared 
to illicit drugs of unknown purity? This will be explored in the chapter and represents an 
opportunity to uncover data that exist in this unique time period. This chapter also describes 
the special opportunity that the UK provides in studying opioid overdose and contextualises 
the history of mortality data and opioid overdose research. 
 
I presented some of the data in this chapter at the 1st Lisbon Addictions conference in 
September 2015 as well as at the Institute of Psychiatry, Psychology & Neuroscience PhD 
symposium in May 2015. It is planned that a version of this chapter will also become a journal 





Table of Contents 
2 HEROIN THROUGH HISTORY ................................................................................. 40 
2.1 PREFACE .................................................................................................................... 40 
2.2 BACKGROUND ............................................................................................................. 42 
2.2.1 What is the ‘British System’ and When was it Truly Active? .............................. 42 
2.2.2 1960 to 1975 .................................................................................................... 42 
2.2.3 Opening of Clinics ............................................................................................ 44 
2.2.4 What was the Mortality Rate During the Era 1960 to 1975, During the British 
System? .................................................................................................................... 44 
2.2.5 After the Mid-1970s .......................................................................................... 45 
2.3 METHODS ................................................................................................................... 47 
2.3.1 Data sources and search strategy .................................................................... 47 
2.3.2 Data extraction and synthesis .......................................................................... 47 
2.4 RESULTS .................................................................................................................... 48 
2.4.1 (A) Raw Data on Mortality Rates at Follow-up .................................................. 48 
2.4.2 (B) Calculations of Annualised Mortality Rates ................................................. 49 
2.5 DISCUSSION ................................................................................................................ 54 
2.5.1 Annual mortality rates ...................................................................................... 54 
2.5.2 Explanations for mortality rates and wider implications ..................................... 54 
2.5.3 After the Mid-1970s .......................................................................................... 55 
2.5.4 Present Day ..................................................................................................... 57 
2.5.5 Strengths and Weaknesses of the Evidence Examined in this Chapter ............. 57 
2.6 IMPLICATIONS FOR THESIS............................................................................................. 59 
2.6.1 The UK’s Special Position in the Study of Opioid Overdose .............................. 59 







2.2.1 What is the ‘British System’ and When was it Truly Active? 
The ethos of the British approach to pharmaceutical heroin prescribing, which became known 
as the ‘British System’, was confirmed by the Rolleston Committee recommendations of 1926. 
The Rolleston Committee concluded that addiction should be considered a medical problem 
rather than a criminal and moral one, with doctors permitted to treat and maintain patients with 
diagnosed opiate addiction, i.e. to prescribe medicines such as morphine or heroin to prevent 
the emergence of withdrawal symptoms and to continue this prescribing if withdrawal of the 
medicine led to ongoing distress (Rolleston Committee, 1926).  
 
The British System approach continued for decades. The Second Report of the Brain 
Committee (1965), and the subsequent changes to the drug laws in 1968 continued to allow 
doctors to prescribe (injectable) heroin for the treatment of addiction although the 1968 
legislation restricted the medical authority to prescribe pharmaceutical heroin to the new cadre 
of doctors working in the newly established drug dependence clinics. Further, a new system 
of notification1 of addicts to the Home Office by doctors became mandatory after 1968, 
modelled on systems of compulsory notification of infectious diseases (Ghodse et al., 1985). 
2.2.2 1960 to 1975 
In the decades leading up to the 1950s, in the UK, the number of opiate addicts was modest 
at around 400-600 in any one year and they were almost all considered ‘therapeutic addicts’, 
because they had become addicted whilst being treated for pain from a physical disorder 
(Spear, 1969). This group also included doctors or other professionals (e.g. pharmacists) who 
had access to these opioid drugs. Only a small proportion were addicted to heroin, and all 
were middle-aged or over (Spear, 1994; Connell & Strang, 1994).  
 
                                                   
1 The Addicts Index was a notification system of addicts as a method of the Home Office keeping track 




After 1951, a new group of heroin addicts began to emerge, mainly in London (Spear & Glatt, 
1971; Spear, 1969). These heroin users had begun their heroin use by buying diverted or 
stolen supplies of pharmaceutical heroin (Spear, 1994). Many of these new heroin users were 
young and also sometimes engaged in delinquent behaviours. Between 1960 and 1968, a 
small number of doctors in the inner London area (probably never more than half a dozen at 
any single point in time) were prescribing significant amounts of heroin for what might be 
considered non-therapeutic purposes or solely for treatment of their patients’ addiction (i.e. to 
‘non-therapeutic addicts’) (Leech, 1981; Spear, 1994). The number of known heroin addicts 
was only 62 in 1958 but grew to 324 by 1964. The pattern of prescribing (i.e. high doses) by 
these doctors was described at the time as “lunatic generosity” (Brain Committee, 1965) and 
created a considerable illicit market from the surplus doses prescribed. However, this illicit 
market, along with all heroin in the UK, was comprised of pharmaceutical diamorphine (heroin) 
exclusively (Cooke, 1962; Frankau, 1964) (i.e. no illicitly-imported heroin). This did not 
substantially change until the mid/late-1970s when significant amounts of imported heroin 
from the Middle East region became available in the UK for the first time.  
 
Injectable prescribing continued as the first-line treatment for heroin addiction until its peak in 
the mid-1970s (Strang et al., 1994), and then tapered off through the late 1970s, 1980s and 
thereafter (Strang & Sheridan, 2006). This can be evidenced by gradual changes in the actual 
quantities of prescribed injectable heroin, injectable methadone and oral methadone during 
this time period (Mitcheson, 1994; Strang et al., 1994). This shift in prescribing patterns was 
also discussed by Hartnoll and colleagues in their trial on the acceptance of two types of heroin 
addiction treatment: injectable heroin maintenance versus oral methadone maintenance 
(Hartnoll et al., 1980). Consequently, in this chapter, 1975 is the cut-off date for the end of the 
study period of this distinctive era of dominance of pharmaceutical diamorphine as the 
available form of heroin in the UK.  
 
Over this period (from early 1960s to mid-1970s), diamorphine prescribing was the mainstay 
form of treatment for heroin addiction. Furthermore, there was a low threshold for patients to 




maintenance was the preferred and most acceptable method of dealing with heroin addiction 
(Spear, 1994; Strang et al., 1994).  
 
2.2.3 Opening of Clinics 
Plans for the opening of new clinics started in 1967 by the Ministry of Health. The aim of the 
new clinics was to “contain the spread of heroin addiction by continuing to supply the drug in 
minimum quantities where this is necessary in the opinion of the doctor, and where possible 
to persuade addicts to accept withdrawal treatment” (Ministry of Health, 1967).  
 
Fifteen new outpatient clinics first opened across London. A smaller number opened up in the 
Home Counties and few specialist clinics existed elsewhere in the UK.  Whilst a degree of 
freedom existed, at least compared to today’s standards, in terms of take-home supplies, 
injectable drugs and fixing rooms with free equipment, the level of control introduced was 
definitely intensified (Connell & Strang, 1994). These were as follows:  
• Necessity to attend weekly or fortnightly appointments at the clinic; 
• Requirement to collect drugs on a daily basis from a local community pharmacist. 
The main complication was the necessity to balance competing responsibilities: good quality 
treatment of the individual patient versus the concern about the broader social and public 
health perspective. The main premise of these changes was to prevent the extra supply of 
heroin on the black market. Additionally, there was still only a small amount of oral methadone 
initially.  
2.2.4 What was the Mortality Rate During the Era 1960 to 1975, During the British 
System? 
The mortality rate during this period of readily available pharmaceutical diamorphine (with only 
very rare appearance of illicitly manufactured, imported heroin) is thus of interest. We are able 
to examine mortality data through the case studies and reports from clinics from a time that 
has now ceased to exist in the UK, and the rest of the world. It is a distinctive opportunity to 
examine this prescribing practice which is still being discussed today. Hence, the information 




2.2.5 After the Mid-1970s 
The mid-1970s was the time point at which, for the first time, more oral methadone was 
prescribed than injectable heroin. Total quantities of prescribed injectable heroin, injectable 
methadone and oral methadone reveal a gradual transition from the late 1960s onwards. In 
1970, 17kg, 11kg and 3kg of injectable heroin, injectable methadone and oral methadone, 
respectively were being prescribed. This became 15kg, 21kg and 8kg, respectively by 1974, 
and then 9kg, 14kg and 17kg by 1978 (Figure 2-1, Strang et al. 1994). Calculations of a mean 
dose of opiates per patient were collated for each clinic during the period of 1968 and 1980. 
This further supported the observation that there was, over this period, a gradual shift of 
prescribing patterns particularly during the early 1970s.  
 





The data presented in this chapter focus on the mortality rates of heroin users who received 
diamorphine maintenance treatment during the time period of 1960 to 1975 (Appendix A-1), 
as described in cohort studies from the various clinics, mostly in London. The focus of the 
original studies was not specifically on mortality but rather was more usually a follow-up or 
evaluation study of a cohort of patients from the clinics, or of patients registered as addicts 
with the Home Office. Some of these studies included mortality data as part of their follow-up, 
and thus re-examination is meaningful. By examining the literature for this time period, the 
prescribing of pharmaceutical diamorphine, and its potential impact on mortality in the treated 





2.3.1 Data Sources and Search Strategy 
Searches were performed of the English-language literature indexed in Embase, Medline and 
PsycINFO (1960-1978). A wide year range was set in order to ensure capture of studies that 
recruited within the period of interest of between 1960 and 1975. Furthermore, a wide-ranging 
set of terms was used in order to maximise sensitivity. Combinations of keywords included 
‘heroin dependence’, ‘drug dependence’, ‘opiate addiction’, ‘opiate maintenance’, ‘heroin 
treatment’, ‘heroin’ or ‘opiate’, ‘follow-up’, ‘observation’, ‘mortality’, and ‘death’.  
 
A full list of search terms and sequence of queries is listed in the appendix (Appendix A). 
Historical papers are not always reliably tagged with keywords nor do they always include an 
abstract, and thus, a broad search was required in order to ensure that all potentially relevant 
records were captured. Hand-searches of the personal libraries was also made of several 
experts in the field were made to check against bibliographies of articles, which were also 
examined for citations. Key informant enquiries were also made with experts within the field. 
The types of articles that met the inclusion criteria (see appendix: A-3) were observational, 
follow-up and case reports of clinical data. Papers that focused on heroin users in any form of 
treatment were reviewed.  
2.3.2 Data Extraction and Synthesis 
Duplicates and non-English language papers were removed. Papers were then subject to a 
review by title. A further review was based on abstracts. Full-text articles were then examined, 
and relevant papers and data were extracted (see appendix: A-2).  
 
Extracted data included recruitment years, study length (or follow-up period), mortality in 
absolute numbers (or percentage), type of treatment available and other demographics (if 
available). Annual mortality rates were calculated using the mortality figures listed in the paper 
but normalised across all papers to calculate a mortality rate per year, based on the period of 




2.4 Results  
Database and hand searches resulted in 4,679 records in total, from which 15 relevant 
publications were identified (Table 2-1). Out of these 15 publications, some reports were 
related to the same cohorts. Four publications related to a cohort study originally reported by 
Stimson and Ogborne (1970). Two publications were related to one cohort (Chapple, Somekh, 
& Taylor, 1972b) and two reports related to a separate cohort from d’Orbán (1973). All seven 
other reports were from cohorts of patients.   
 
All 15 reports described patients recruited from clinics, hospitals and surgeries based in 
London or near to London (only one study was based outside, but near, London, in Surrey 
(Beckett & Lodge, 1971)). At this time, these types of clinics were limited in areas outside of 
London.  
2.4.1 (A) Raw Data on Mortality Rates at Follow-up 
The paper at the start of this time period, Frankau (1964), was a report of follow-up of a total 
of 50 Canadian addicts from a clinic in West London. After an initial stabilisation period, 
withdrawal treatment occurred. Ten of 50 had become addicted whilst in Europe and were 
financially stable. Forty of the patients came to England specifically to seek treatment for their 
heroin addiction. Of these 40, one died and the status of four could not be ascertained. Thus, 
a minimal mortality rate for this study was 2% over the study period of 5 years.  
 
Two studies from a cohort of female addicts in prison followed up at 12 and 48 months showed 
mortality rates of 3% and 15% respectively over the study periods (d’Orbán, 1973;  d’ Orban, 
1970).  
 
The highest mortality rate was seen in the earlier studies during the recruiting period of 
interest. In one study which provided follow-up at 6 months, there was a 15% mortality rate 
(thus 30% as an annual mortality figure), albeit in a very small cohort of 33 patients (Bewley, 
1965). They were recruited from various London hospitals and were considered by the author 




However, a similar cohort of heroin addicts admitted to ‘mental’ hospital as inpatients actually 
reported no deaths in their 7 to 19 month follow-up (Beckett & Lodge, 1971). An additional 
study of adolescents who were referred to a special treatment unit and followed up for 12 
months also reported no deaths (Boyd, Layland, & Crickmay, 1971).  
 
Studies on hospital admissions related to patients for whom heroin prescribing was the 
dominant form of treatment had a variety of high mortality rates. Bewley & Ben-Arie (1968) 
reported an average mortality of 9.5% after 20 months, and the Chapple studies (Chapple et 
al., 1972a; Chapple et al., 1972b Table 2-2) reported 8% at 1 year, 16% at 5 years and 18% 
at 6/7 years.  
 
Outpatient treatment centres appeared to have a more consistent outcome on mortality. The 
four studies associated with Ogborne & Stimson (Table 2-2) showed mortality of 4%, 6.2%, 
9% and 12% when followed up at 1, 3.5/4, 6 and 7 years, respectively (Stimson, 1973; 
Ogborne & Stimson, 1975;  Thorley et al., 1977; Stimson et al., 1978). Bewley et al. (1972) 
followed up 397 patients after 1 year and found a mortality rate of 2%.  
 
Another study by Bewley et al. followed up 259 newly notified addicts through the Home Office 
Addicts Index (Bewley et al., 1968) and found a mortality rate of 3% over the 12 months of 
study.  
2.4.2 (B) Calculations of Annualised Mortality Rates 
For the next step in this examination, I have calculated the average annual mortality rate. 
Whilst statistical weaknesses need to be acknowledged (since this assumes constant risk over 
time and also through different stages of addiction and of treatment), it nevertheless allows an 
overall examination, across studies, of the range of mortality rates observed. Estimated annual 
mortality rates, calculated with respect to the follow-up period, varied greatly. The follow-up 
was often conducted over a period of time, over a span of a year in some cases, thus the 
annual mortality rates in these cases have been provided also as a range. The majority (13) 




Lodge, 1971; Bewley et al., 1968, 1972; Boyd et al., 1971; Chapple et al., 1972a, 1972b; 
Frankau, 1964; Ogborne et al., 1975; Stimson et al., 1978; Stimson, 1973; Thorley et al., 
1977). The remaining two had 9.5% and 30% (Bewley, 1965; Bewley & Ben-Arie, 1968). The 
median annual mortality rate of the 10 reports2  for this time period was 2.4% and the average 
was 5.4%.  
 
For studies which reported at more than one point in time, it was also possible to examine 
how mortality rate in a cohort might change over time. These studies of the same cohort saw 
a progressive reduction in mortality rate over time. An estimated annual mortality rate of 8% 
was seen in the first year of the Chapple study. By the 5-year follow-up observed, the annual 
average had reduced to 3.2%, and by the 6/7-year follow-up, the figure was 2.8%, as an 
average (Chapple et al., 1972a, Table 2-2). Furthermore, the Stimson & Ogborne cohort 
studies found an initial 4% annual mortality rate after the first year of follow-up and then a 
fluctuating rate of between 1.5% and 2% at every subsequent time point (Table 2-2).  
However, in contrast, the d’Orban studies that followed up female addicts in prison at 1-year 
and then 4 years saw annual mortality figures of 3% and 3.8%, respectively (Table 2-2).  
 
There were two additional papers that were excluded from the main studies because they 
extended outside the selected 1960-1975 era; however they still had overlapping recruitment 
periods with the time period of interest of this study (Table 2-3). Oppenheimer (1994) re-
examined the Ogborne & Stimson cohort 22 years later (see also Table 2-2) where it was 
found that 38% of the whole cohort had died by the 22-year mark. The second paper was 
James (1967) which showed that, of the 450 addicts notified to the Home Office, 35 died within 
the years 1955 to 1965 resulting in a 9% mortality of the cohort and an estimated annual 
mortality rate of 0.9%. However, part of the recruitment period is not relevant for this study 
and thus is not analysed further.
                                                   
2 Where multiple publications from the same cohort exist, only the most recent publication is included, 




Table 2-1: Studies included for examination. Additional publications of the same cohort in italics. Only most recent publications of each cohort are included in the 
calculation of annual mortality rates (as indicated by *). 
 
Study Sample Size Years Recruited Follow-up period 
in months 
Mortality % Annual 
Mortality % 
(range) 
Type of Treatment 
Frankau (1964)* 50 1959-64 60 2 0.4 Private practice. Follow-up of 
Canadian addicts in London 
Bewley (1965)* 33 1964-65 6 15 30 Admissions to a number of London 
‘mental’ hospitals - considered as 
'difficult to treat' 
Bewley & Ben-
Arie (1968)* 
100 1964-66 12 to 27 13 9.5 (13 to 6) Patients discharged from South 
London hosp. 
Bewley et al 
(1968)* 
259 1965 12 3.4 3.4 Follow-up of newly notified addicts 
Beckett and 
Lodge (1971)* 




78 1968 12 0 0 Adolescents referred to a special 
treatment unit 
Chapple et al 
(1972a) 
108 1963-65 60 (12) 16 (8) 3.2 (8.3) Several hospitals. Includes 'therapeutic 
prescribing' as treatment (12-month 
data). 
Chapple et al 
(1972b)* 
108 1963-65 72 to 84 18 2.8 (2.5 to 3) Same as above. 
Bewley et al 
(1972)* 
397 1968-69 12 2 2 Outpatients at 3 London hospitals. 
Stimson (1973) 101 1969 12 4 4 Cohort at London Drug Dependency 
Treatment Centres. Patient status from 
Home Office Records. Original cohort 
(n=128) in Stimson & Ogborne 1970. 
Ogborne & 
Stimson  (1975) 
128 1969 42 to 48 6.2 1.7 (1.6 to 1.8) Same as above. 
Thorley et al 
(1977) 
128 1969 72 9 1.5 Same as above. 
Stimson (1978)* 124 1969 84 12 2 Same as above. 
d’Orban (1970) 66 1967-68 12 3 3 Female addicts in prison 






Table 2-2: Results from the three cohort studies. 
 









Results from the 1969 Stimon & Ogborne cohort (1970): 
Stimson (1973) 101 1969 12 4 4 Status of patients from Home 
Office Records. 101 (of sample of 
128) interviewed 1 year later. 
Range of dose 10-1140mg 
Ogborne & Stimson  
(1975) 
128 1969 42 to 48 6.2 1.7 (1.6 to 1.8) Follow-up 3.5 to 4 years after 
initial interview 
Thorley et al (1977) 128 1969 72 9 1.5 6-year follow-up  
Stimson (1978) 128 1969 84 12 2 7-year follow-up 
Oppenheimer 
(1994) 
128 1969 264 38 1.8 22-year follow-up 
Results from the Chapple et al cohort (1972): 
Chapple et al, 
(1972a) 
108 1963-65 60 16 3.2 Also mentioned within this paper: 
1-year follow-up presented with 
mortality level of 8.3% 
Chapple et al 
(1972b) 
108 1963-65 72 18 3 6-year follow-up 
Results from the d’Orban cohort (1973):  
d’Orban (1970) 66 1967-68 12 3 3 Full cohort sample 
d’Orban (1973) 60 1967-68 48 15 3.8 After 1-year follow-up, 6 
participants were omitted as they 










































From the 1960s to the mid-1970s, take-home heroin prescribing was the main form of 
treatment for heroin addiction in the UK (the 'British System'). Retrospective analysis of 
mortality of treated cohorts over this period is possible due to the existence of observational 
and follow-up studies of clinics in England at this time. Data from these studies showed that 
the heroin-prescribed population during the late-1960s to mid-1970s of the ‘British System’ 
had substantial mortality. However, this varied greatly; in some clinics there were few or no 
deaths at all, whereas in other clinics, much higher mortality rates were seen.  
2.5.1 Annual Mortality Rates  
Exploring this annually, the figures differ as the duration of the studies vary. The majority of 
studies (nine) had an annual mortality rate of between 2% and 4%. The Bewley (1965) study 
is an outlier with an annual figure of 30%. However, this study has the smallest cohort and the 
shortest recruitment period when compared with the other studies in this chapter, and this 
could explain the ‘outlier’ status of the observed mortality rate.  
 
The differences cited in annual mortality rates across studies with the same cohort are 
interesting to note. Chapple et al (1972) state the reason for the difference between their 1-
year and 5-year observations is because of the circumstances of referral; some patients 
included in the study had died during the initial hospital admission. The Ogborne & Stimson 
cohort (Table 2-2) was another interesting cohort. They also saw an initially higher mortality 
rate but it remained at below 2% after the 1-year mark. This cohort was also followed up much 
later at which point it was found that the mortality rate remained at an average of 1.6% per 
year (Oppenheimer et al., 1994).   
2.5.2 Explanations for Mortality Rates and Wider Implications  
Some studies of that time make reference to the beginnings of imported heroin (from China) 
and promote this as a possible reason for drop-outs from treatment and death rates; the former 
due to easier access to the illicit market, and the latter due to adulteration. However, 




of reasons, not least because the imported heroin was only just beginning to enter the English 
drug market and was in a completely different form – as loose powder, compared with the 
pharmaceutical diamorphine which was mostly in tablet form.  
 
It is necessary also to consider mortality of heroin users at this time in other countries and 
global mortality figures of heroin users are available. The mortality rate described in the USA 
by an influential 20-year follow-up study was at around 10 per 1,000 per year, or 1% annually, 
during the 1960s (Vaillant, 1973). In New York, around 350 deaths were occurring among 
35,000 addicts (Helpern & Rho, 1966; Louria et al., 1967), again with an annual mortality rate 
of 10 per 1,000 (i.e. 1% annually). It is important to note that diamorphine maintenance was 
not available as a treatment in the USA and indeed there was very little medication-based 
treatment of any type in the USA, at that time, and certainly no maintenance treatments. 
Comparing the UK figures with these mortality figures is interesting. A difference of 1% and 
5.4% is notable. Certainly the ‘British System’ of heroin prescribing did not seem to prevent 
the high annual mortality.  
2.5.3 After the Mid-1970s 
After the period examined in this chapter, there was a dominance of methadone maintenance 
treatment in the UK, and death rates were generally lower but still varied (Oppenheimer et al., 
1994). Studies outside the UK after this time seemed to show that death rates depended on 
the type of treatment. Detox treatments and restrictive treatments (such as those that expel 
people from treatment for violating the regime) appeared to show higher rates of mortality, for 
example, in Sweden and the USA (Gronbladh et al., 1990; Gearing et al., 1977; Fugelstad et 
al., 1989). In the UK, an excessive death rate was observed in the mid-1980s (Table 2-4 and 
Figure 2-2) and it was suggested that this was connected to the import of heroin on the black 
market and when clinic policy became ‘less generous’ (Oppenheimer et al., 1994). A large 
proportion of these deaths were overdoses, and it remains a possible explanation that the 
mortality figures may have been affected by treatment regimes (Oppenheimer, 1994).  
 




Stimson cohort, between 1969 and 1991. They examined the excess mortality ratios which 
were calculated based on the ratio of the number of deaths observed to the numbers expected 
to die in an age- and sex-matched sample of the general population over a similar period. Of 
those who were recruited in 1969, 38% had died by 1991. 58% of those who died were most 
likely using at the time of their death, and overdose was by far the largest single category of 
death. Only 22% of the overdose cases mentioned an opiate as the only drug on the death 
certificate, and 55% contained multiple drugs. There were no deaths in this cohort from 
HIV/AIDS.  
 
Table 2-4: Mortality rates over the period 1969 to 1991(Oppenheimer et al., 1994). 
Years Time in study Deaths 
(cumulative) 
Years at risk Mortality rate per 
annum (%) 
1969-1970 2 4 2262 2.12 
1971-1976 6 15 8526 1.55 
1977-1982 6 25 7755 1.55 
1983-1988 6 40 6830 2.64 
1989-1991 3 43 2612 1.38 
 
 
Figure 2-2: Mortality in 128 heroin addicts 1969-1991 rates per annum (average over 3 years)  
…+… observed mortality; ◼ excess mortality ratio;  actual deaths (Oppenheimer et al., 1994). 
 
This demonstrates that from the 1970s onwards, it became more complex and difficult to 
unpick the underlying causes of opioid-related mortality. Historical data allows us to highlight 
periods of time where potential confounding factors such as the illicit drug market fluctuations 




2.5.4 Present Day  
Current heroin maintenance treatment is mostly conducted in supervised heroin clinics and 
has now been extensively studied in randomised controlled trials (Strang et al., 2012). In 
contrast to the mortality rates evident in the much earlier studies of unsupervised heroin 
prescription of the ‘British System’ of the 1960s and early 1970s, the new generation of 
supervised heroin clinics have extremely low rates of mortality compared to the majority of the 
studies presented here. In a recent systematic review of randomised controlled trials of 
existing studies, total mortality events was found to be 0.7% across all the trials that were 
examined (Strang et al., 2015). This is much lower than the rates seen in the publications 
presented in this chapter, even though the patients recruited to the new supervised heroin 
clinics are specifically selected as ‘difficult to treat’. The story of mortality rates outside of this 
small refractory-treated population is remarkably different, as addressed in chapter 1.  
2.5.5 Strengths and Weaknesses of the Evidence Examined in this Chapter  
This chapter uniquely examines a time period where diamorphine prescribing was the 
prevailing form of treatment of heroin addiction in the UK. The prescribing habits of that time 
have ceased to exist, and yet, discussion of heroin prescribing as a maintenance treatment 
continues. The mortality data presented here can contribute to this debate and expand our 
understanding of diamorphine prescribing and to opioid overdose mortality. However, caution 
should be exercised in generalising these mortality data. A reliable and comparable cohort of 
non-treated addicts, i.e. addicts who did not enter treatment and were not prescribed 
pharmaceutical heroin for maintenance treatment of heroin addiction, does not exist from this 
time period. As described previously, registration of addicts by the treating clinic or hospitals 
to the Home Office existed throughout this time period (and as a legal requirement from 1968 
onwards), and the numbers of non-registered addicts was very few (Frankau, 1964; Spear, 
1994). Thus, care should be taken when extrapolating the findings presented to other contexts 
and other points in time. Nevertheless the data, and consideration of their implications, give a 
valuable point of reference.  
 




illicit and licit forms of pharmaceutical heroin have been the source of numerous contentious 
debates. The data presented in this paper should be considered as an opportunistic re-
examination of the relationship between heroin and mortality, and should be deliberated upon 
with curiosity and caution, alongside the interest. 
 
The heroin being used in the UK over the period of focus of this chapter was pharmaceutical. 
The surprising finding, with regard to mortality, is that the proportion of heroin-related mortality 
which occurred in the treated population during the 1960s to mid-1970s of the 'British System' 
was comparable to, or greater than, the mortality rates reported in the international literature 
for the untreated population and substantially greater than the currently reported <1% annual 





2.6 Implications for thesis  
2.6.1 The UK’s Special Position in the Study of Opioid Overdose  
For most of the 20th Century, after the closure of heroin clinics in the USA in the early 1920s, 
the UK was the only country in which heroin was prescribed, up until the establishment of the 
new form of supervised heroin treatment centres in Switzerland in the 1990s. By 2015, there 
were eight countries in the world that provided diamorphine treatment as maintenance 
treatment for heroin addiction: Switzerland, The Netherlands, Spain, Germany, Belgium, 
Denmark, Canada and England (Strang et al., 2015). Except Spain, all of these countries still 
continue to provide injectable diamorphine or injectable opioid treatment as part of continued 
research trials or as part of their health service to patients.  
In England and the UK, the new form of supervised heroin treatment was the subject of study 
in the Randomised Injectable Opiate Treatment Trial (RIOTT). Following the trial, central 
government funding was provided for this supervised heroin treatment from three centres, but 
central funding was not continued beyond 2014 and local funding was not provided: 
consequently, these clinics closed in 2015. Nonetheless, a small amount of diamorphine 
prescribing still continues in the UK in the older unsupervised approach, and there is 
discussion, or implementation, of supervised diamorphine-maintenance clinics in Scotland 
and the North East of England (Alderson, 2017; Siddique, 2017). In 2017, over 100,000 items 
of diamorphine were dispensed3, however, these included diamorphine for the use in non-
addiction treatment practices such as operative and palliative cases, and so it is difficult to 
gauge the extent of heroin treatment for addiction across the UK – it is thought to be less than 
100 patients in total.  
                                                   
3 Data for this are provided by Open Prescribing (OpenPrescribing, 2017) which provides data on 
prescribed medication by the NHS.  It is currently not possible to determine how many of these 
diamorphine items were prescribed for the use in heroin addiction treatment.  
NB: Open Prescribing define ‘item’ as follows: ‘A prescription item is a single supply of a medicine, 
dressing or appliance written on a prescription form. If a prescription form includes three medicines it is 
counted as three prescription items. Item figures do not provide any indication of the length of 





Out of the eight countries that prescribe diamorphine for heroin addiction, the UK is actually 
the only country that gives diamorphine full approval as a medicinal product, i.e. it is used in 
addition to maintenance treatment medication and has been for many decades. The majority 
of other countries (Germany, Switzerland, Canada, The Netherlands, Belgium and Denmark) 
approve diamorphine specifically as a medicinal product for ‘treatment-refractory’ heroin 
dependence (Strang et al., 2015). Further, Spain and Belgium approved diamorphine as a 
specific investigational medication for use in research trials. All other countries in the world 
completely prohibit the use of diamorphine for use in treatment and/or have blocked or not 
granted heroin-prescribing research trials, such as is the case in the USA, Australia and 
France (Strang et al., 2015). 
With the limited number of clinics and legislations that allow use of diamorphine as part of 
heroin addiction treatment, there are very few opportunities to study opioid overdose with 
people who are actually taking diamorphine in a manner that is safe and ethically sound. While 
there are discussions of new clinics and trials emerging, even in regions of the world where it 
was never thought possible, e.g. the USA4, this is still an extremely limited form of heroin 
addiction treatment. It is clearly a unique position that the UK is able to provide such an 
opportunity for special study of the effects of diamorphine administration.  
2.6.2 Study of Opioid Overdose Through History  
As with most studies of drugs that have potentially lethal adverse effects, the clinical study of 
opioid overdose is experimental and requires attention to reduce risk. However, this thesis 
investigates what causes respiratory depression, and why some people appear to be more 
vulnerable than others. These questions are not in and of themselves novel, these issues 
have arisen before, in crises and epidemics around the world. The question that is important 
but rarely considered is why have there been so few similar studies to date? The likely answer 
is that they have not been examined precisely because of the very nature of the drug being 
studied (i.e. heroin). There is something circular and counter-productive about this situation. 
                                                   
4 In the USA, there is only yet discussion of this topic. The RAND corporation are currently conducting a 




Because of public and regulatory concerns about heroin, it is, for example, almost impossible 
for researchers in the USA to study the effects of diamorphine. Indeed, in the statement from 
the independent scientific committee at the UNODC 61st Committee on Narcotic Drugs 
meeting of 2018, a recommendation was recently made that:  
Facilitating research with controlled substances, including synthetic opioids, to generate new 
knowledge on how to use these substances to revert overdoses or adverse effects. As stated 
in the UN Conventions, controlled substances should be available for medical and scientific 
purposes, thus barriers to conducting such research should be removed. 
Historically, trends of drug use and mortality in the USA have often been focused on because 
of the potential influential effect on the UK. However, while similarities have been seen 
previously, particularly amongst heroin use in the 1960s onwards (Gfroerer & Brodsky, 1992), 
this has not always been the case. At this point in time, there is growing concern amongst 
those in the field about the influx and dangers of fentanyl which stems from the considerable 
increase in deaths observed in the USA in the last two years that have been, in large part, 
attributed to fentanyl and its synthetic analogues/derivatives (Hedegaard et al., 2017; Seth et 
al., 2018). While it is difficult to predict whether the UK will have the same fate – there have 
only been a small number of deaths from fentanyl reported so far (UNODC, 2017) – there is 
good reason to be cautious. However, this should provide the impetus for further debate and 
further research above all else.  
 
This chapter has provided the opportunity to examine historical data not simply as a 
retrospective opportunity to re-examine data but to reflect on trends and concerns that have 
been raised previously and to learn from them. It is with great hope that in a further 50 years 
progress will have been made of the kind that takes our understanding beyond the stagnation 
that has characterised the field over the past half century. We will most likely never observe 
the situation that existed prior to the 1970s in the UK and hence it is vital to learn as much as 
possible from retrospective examination of data from this earlier era and to consider their 







3 An Overview of Overdose Mechanisms and Respiratory 
Physiology 
3.1 Preface  
This chapter reviews the literature on opioids and opioid-related overdose and the current 
understanding of overdose mechanisms, respiratory physiology and relationship with lung 
disease. In addition, it raises some of the questions that are driving future research. 
Demographic and epidemiological data on overdose are extensive and valuable, however, 
clinical data are still lacking in certain areas. The potential dangerousness of opioid drugs is 
evident in the effects on the respiratory system. Overdoses are obviously complex but 
investigations into the mechanisms of fatalities and near fatalities are vital in the future 
prevention of overdose deaths.  
 
Part one provides an overview of pharmacodynamics (how opioids affect the body and their 
mechanism of action) and pharmacokinetics (the movement of the opioid drugs through the 
body). Part one also discusses the evidence for risk factors of opioid overdose from robust 
epidemiological studies and proposed contributory mechanisms. Part two details the 
physiological aspects of the respiratory system and its functioning, from a broad description 
of the anatomy and function of the respiratory system and subsequently, the relevant details 
involved in the mechanisms surrounding breathing and the effects of opioids on these 
mechanisms. Part three describes the overarching public health issues that this thesis is 
concerned with. Finally, part four ends on how respiratory depression can be measured and 
provides rationale for the various criteria that are used throughout this thesis. 
 
The respiratory system is a central aspect of this thesis and the purpose of this is in relation 
to the techniques that are used to detect acute overdose in this PhD. These techniques involve 
novel and accurate measurements of respiratory function and of respiratory muscles. An 
understanding of the function of the normal respiratory system is also central to understanding 
the relationship between overdose risk and underlying respiratory disease, a relationship that 





I had the opportunity to author a chapter within the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) Insights report on ‘Preventing Opioid Overdose Deaths with Take-
Home Naloxone’. This chapter incorporates the content from my co-first-authored initial 
chapter of the report (‘Pharmacology and physiological mechanisms of opioid overdose and 
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Part 1: A Recipe for Overdose.  
3.2 What are Opioids? 
The terms ‘opiate’ and ‘opioid’ are sometimes used interchangeably, but, in pharmacology, 
the term ‘opiate’ describes any of the opioid analgesic chemicals found as natural products in 
the opium poppy plant, Papaver somniferum (Shook, 1990). Both opiates and opioids have 
been used medicinally predominantly for pain relief, but also for their strong sedative (sleep 
disorders), anxiolytic (reducing anxiety), anti-tussive (cough suppressant) and anti-diarrheal 
properties. Since the nineteenth century, it has been possible to obtain opiate products 
through the chemical isolation and extraction of the active ingredient from the opium poppy 
plant (Berridge, 1999). Major opium alkaloids are morphine, codeine, and thebaine, of which 
morphine and codeine have analgesic properties and depressant effects, while thebaine has 
no direct therapeutic effect.  
 
Heroin, which has the chemical name diacetylmorphine (also called diamorphine) is produced 
by a simple chemical reaction from morphine. The chemical processes of converting opium 
into diacetylmorphine (i.e. diamorphine or heroin) involve processing opium into morphine 
before acetylation to produce heroin (Lerner & Mills, 1963). Heroin was originally discovered 
in St Mary’s Hospital, London, by Wright and Beckett. In their 1874 and 1875 papers 
describing a series of experimental studies on natural alkaloids, diamorphine is referred to as 
‘tetra acetyl-morphine’, an acetylated version of morphine (Beckett & Wright, 1875; Wright, 
1874). This discovery did not develop any further and around 20 years later, diamorphine was 
re-synthesised in Germany, and marketed in 1898 by the chemical company Bayer under the 
trade name ‘Heroin’.  
 
The term opioid is a wider term that includes the semi-synthetic analogues such as methadone 
and buprenorphine and also, heroin. The term opioid also encompasses the endogenous 
opioids, naturally occurring opiate and opiate-like drugs, including molecules that are very 
different from natural opiates but which nevertheless activate the opioid receptors in the 




With regard to effects of opioids, some people experience a euphoric reaction to opioid 
medications, as opioids also affect the areas of the brain involved in the reward system (NIDA, 
2014). Their potent medicinal effects as well as their euphoric properties may explain why the 
opioids are among the most commonly used groups of drugs for recreational and self-
medication purposes. The distinct properties of opioids that will be explored in this chapter 
can lead to physical and psychological dependence, and also carry a high risk of overdose. 
 
Most of the heroin currently found illicitly in Europe is in the form of a brown powder (base) 
which originates from South-West Asia (Ciccarone, 2009). The base is not water-soluble but 
is suitable for vaporisation with heat (known as ‘chasing’ but sometimes also called ‘smoking’, 
although no combustion of heroin takes place). It requires an acidifier (e.g. vitamin C) and 
heat to dissolve it in water and allow it to be injected. The white powder (salt) form of heroin, 
traditionally originating from South-East Asia, is soluble in water and can more easily be 





3.3 How do Heroin and Other Opioids Work? 
Heroin and the opioids affect several different areas in the human body. The primary areas of 
action are the brain, spinal cord and gastrointestinal tract, where the opioids bind to receptors 
in the nervous system and produce their actions through processes of activation or inhibition. 
Opioid receptors act in controlling physiological and psychological responses such as 
analgesia (pain reduction), sedation, euphoria, reduced breathing (respiratory depression), 
drowsiness, constricted pupils, and nausea. The physiological and psychological effects differ 
depending on the particular opioid and the type of receptor that is activated or inhibited.  
3.3.1 Opioid Receptors 
Opioid receptors are located in various locations of the brain that are implicated in the control 
of breathing and respiration, euphoria and pain control (Brunton, Buxton, & Parker, 2008; 
Eddy, Howes, & Arbor, 1935). They are also located in peripheral regions such as the 
intestinal tract (Brunton et al., 2008), and in areas relating to respiratory feedback drive, for 
example in the carotid bodies and the vagi (Pattinson, 2008) (further details in part 2 of this 
chapter). 
 
There are three main groups of opioid receptors: mu (μ), delta (δ) and kappa (κ). All three 
produce analgesia when activated, but differ in other effects (Brunton et al., 2008). The mu-
opioid receptor is the most widespread opioid receptor in the body and the primary target for 
a great variety of therapeutic drugs. However, mu-opioid receptors can also produce 
undesirable effects such as respiratory depression and constipation (Pasternak, 2006). The 
group of mu-opioid receptor agonists includes heroin, morphine, oxymorphone, methadone 
and fentanyl. The effect of other opioid receptors on respiration is less well understood. The 
delta-opioid receptors appear to have some inhibitory action on respiration and kappa-opioid 
receptors have little or no effect on respiration (Shook et al., 1990).  
3.3.2 Heroin Pharmacology 
Heroin is regarded as a powerful opioid. In its pharmacologically purest form it is more 
powerful than morphine weight for weight. If consumed orally, it crosses from the 




considerable proportion becoming deactivated (Way, Kemp, Young, & Grassetti, 1960). 
However, if injected intramuscularly or intravenously, it enters straight into the bloodstream 
and crosses the blood brain barrier (BBB), a cellular system that exists to protect the brain 
from potentially toxic molecules. The effect of heroin peaks within 20 seconds of an 
intravenous injection, and slightly later following intramuscular administration (Electronic 
Medicines Compendium (eMC), 2013; Klous, Van den Brink, Van Ree, & Beijnen, 2005). 
Heroin rapidly crosses the BBB but is also rapidly broken down into the active metabolites 
morphine, morphine glucuronide and 6-monoacetylmorphine (6-MAM) (Inturrisi et al., 1983). 
Heroin could therefore be considered not only as a drug in its own right but also as a pro-drug5 
for morphine (Sawynok, 1986). A key feature of heroin is that its chemical structure allows it 
to cross the BBB more easily than most other opioids. As a result, heroin has a very fast onset 
of action for brain effects and associated euphoric effect, which contributes to its high potential 
for addiction relative to other opioids.  
 
Heroin is a strong agonist for opioid receptors, with particular affinity for the mu-opioid 
receptor: the heroin metabolite occupies the receptor until it loses its ability to bind. Figure 3-
1 demonstrates the binding fit of a heroin metabolite (or any other opioid agonist) onto an 
opioid receptor. 
Figure 3-1: illustration of the heroin or metabolite (blue) attaching to an opioid receptor (grey triangle). 
This simplified illustration represents the metabolites of heroin, 3-monoacetylmorphine, 6-
monoacetylmorphine and morphine (McDonald & Strang, 2016). 
3.3.3 Other Opioids 
Opioids differ greatly in their duration of action, and this is influenced by their elimination half-
life, i.e. the amount of time it takes for half of the drug to be eliminated from the body. The 
                                                   
5 A pro-drug is an inactive substance that becomes active in the body by a metabolic 




half-life of a drug does not necessarily equate to its peak effects or its concentration at the 
relevant receptors, and in fact all drugs will continue to produce some effects after the stated 
half-life duration. Table 3-1 summarises some of the more commonly used opioids and their 
approximate half-life.  
Table 3-1: Opioids along with their respective half-life approximations (Pasternak, 2006). 
Drugs Approximate Half-life 
Heroin (Diamorphine) 6 minutes 
Morphine 120 minutes 
Hydromorphone 150 minutes 
Oxymorphone  150 minutes 
Codeine 180 minutes 
Fentanyl 220 minutes 
Tramadol (immediate release) 6 hours 
Methadone 24 hours 
Buprenorphine 37 hours 
3.3.4 Heroin/Opioid Metabolism 
Heroin breaks down into 6-monoacetylmorphine (6-MAM) and then into morphine, and thus, 
heroin as a drug lasts for much longer than the figure stated in the table above. There are two 
mechanisms by which opioids are metabolised in the liver: (1) via the enzymes known as the 
cytochrome P450 system6, and (2) via other types of reactions, most commonly by a reaction 
known as glucuronidation7. Some opioids (e.g. methadone, tramadol and fentanyl) undergo 
only the former process and some (e.g. heroin and morphine) only undergo the latter process. 
If taken orally, heroin undergoes extensive metabolism as it enters the liver and consequently 
does not reach the systemic circulation. In this instance, heroin is largely converted to 
morphine before it reaches the general circulation (and hence before it reaches the brain). 
Heroin absorbed by the gastrointestinal tract travels directly to the liver where this conversion 
occurs (known as hepatic first-pass metabolism). Consumption through the intranasal, 
inhalatory, intramuscular and intravenous routes bypasses this initial stage in the liver, and 
                                                   
6 This is one of two systems of enzymes (the other, less significant, group is known as UGTs (UDP-
glucuronosyltransferases) involved in the breakdown of opioids and has gained great attention since 
we have developed a stronger understanding of the genetic influences on the effectiveness of the 
breakdown pathway  (Holmquist, 2009). 




therefore produces more prominent brain effects compared to the oral route (Brunton, 2008; 
Smith, 2009).  
3.3.5 Toxicological Analysis of Fatal Heroin Overdose Deaths  
Toxicological advances mean that post-mortem examinations of fatal overdose cases are 
potentially able to give us a greater insight into the precarious stages before death. There are 
many studies examining the (often perplexing) discoveries, of metabolites of heroin found 
post-mortem. In some cases, these metabolites are lower than one would expect, suggesting 
that the term ‘heroin overdose’ is in itself is a misnomer (see section 3.5.2 on Unknown Purity 
for further details on this), Notwithstanding, with regards to novel research into post-mortem 
examinations, one study in particular stands out. Darke et al. (2016) analysed heroin 
metabolite concentrations to establish this as a proxy for survival times and estimated survival 
times in heroin-related mortality cases. Heroin is known to ‘deacetylate’ to 6-MAM within an 
average of 3 minutes after administration. Darke et al. found that the presence of the 
metabolite 6-MAM in post-mortem examinations could be used to distinguish between 
overdose cases that had survival times above 20-30 minutes subsequent to heroin 
administration and overdose cases below this time. The slight majority of cases (57%) were 
6-MAM-absent and such the survival would have been at least 20-30 minutes. A large 
proportion of cases (43%) were 6-MAM-present meaning that the survival time would have 
been less than 20-30 minutes. Amongst these cases, a quarter had experienced 
bronchopneumonia (inflammation of the lungs) and authors reported that these cases were 
significantly more likely to test 6-MAM-negative, suggesting that survival time was over 20-30 
minutes, an insidious overdose situation (description of overdose typology is in section 1.3 of 
this chapter) (Darke & Duflou, 2016). Whilst this piece of work is yet to be replicated, it is a 





3.4 Typology of Overdose Deaths  
As described in Chapter 1, there is often disparity regarding definitions of drug-related deaths. 
Here, an overview of definitions related to overdose specifically is described. Whilst there is a 
clear understanding that overdose is a serious public health problem, and that opioids have a 
negative impact on the respiratory system, an accurate monitoring of overdoses requires 
reliable definitions, categorisations and technological advances.  
 
The EMCDDA (2010) defines drug-related death as a death:  
[…] directly due to use of illegal substances, although these often occur in combination with 
other substances, such as alcohol or psychoactive medicines. These deaths occur generally 
shortly after the consumption of the substance and are therefore considered ‘directly caused 
by drugs’. (EMCDDA, 2010) 
 
According to the ONS in the UK, a similar definition of drug-related deaths is as follows: 
Death where underlying cause is drug abuse or drug dependence and deaths where 
underlying cause is drug poisoning and where a substance controlled under the Misuse of 
Drugs Act 1971 was mentioned on the death certificate (Christophersen, Rooney, & Kelly, 
1998).  
 
Drug-related deaths are also known as ‘drug-induced deaths’ (a term used in the USA and 
increasingly in the EU), as ‘poisonings’ (which corresponds to the terminology used in the 
International Classification of Diseases) or in more common language as ‘overdoses’. 
3.4.1 What is an Overdose Death? 
Overdoses are generally considered to be either accidental or with clear suicidal intent. 
However, the vast majority of overdoses in the drug misusing population are in the category 
of accidental drug overdoses (Farrell, Neeleman, Griffiths, & Strang, 1996). It is considered 
that some overdose deaths may fall into an overlap category where there is an absence of 
suicidal intent but nonetheless an overt lack of regard to personal safety (Vingoe et al., 1999).  
 
Overdoses themselves can further be categorised into sudden- and slow-onset cases. 
Sudden-onset (or catastrophic) overdoses, when the victim loses consciousness with the 
needle in situ, often occurs after intravenous heroin administration. Slow-onset (or insidious) 
overdose deaths occurs over a longer period of time; often the victim is thought to be sleeping, 




they are drifting into a coma and it is typically caused by longer-acting oral pharmaceutical 
opioids, e.g. oral methadone (McDonald & Strang, 2016).  It is thought that instant death, or 
catastrophic overdose, occurs in around 15% of cases (Lenton & Hargreaves, 2000; Sporer, 
1999).  
 
3.4.2 Non-fatal Opioid Overdoses 
Non-fatal overdoses, historically known as ‘near-miss overdoses’, are regarded as strong 
predictors of fatal overdose (Coffin et al., 2007; Linn Gjersing & Bretteville-Jensen, 2015; 
Stoove, Dietze, & Jolley, 2009). They are purported to occur in over half of opioid users but 
the overall figure per year is difficult to quantify as definitions of ‘non-fatal’ vary greatly 
(EMCDDA, 2010; Sporer, 2003). Darke et al. (2003) examined several longitudinal and self-
reported studies that had investigated fatal and non-fatal overdoses and attempted to 
establish a ratio between these two events. Overall, they found that an average annual fatal 
overdose rate of 0.8% and a non-fatal rate of 25% amongst heroin users is a reasonable 
prediction (Darke, Ross, & Hall, 1996; Darke, Ross, Zador, & Sunjic, 2000). This relates to an 
approximation that 3% of overdose events result in death. This is validated by emergency 
services call-out rates, in that not all overdoses result in ambulance attendance. It was 
estimated that ambulance attendances were around 51% with 12 attendances to every one 





3.5 Risk Factors of Fatal Overdose 
There are many factors that contribute to the risk of overdose in general and to fatal overdose 
in particular. Non-fatal overdoses are more common than fatal but the risk factors for both are 
the same. Incorporating the diverse range of studies available, it is possible to outline a 
complex set of factors and indicators that are involved in every drug using session, adapted 
from previous reviews (Rome et al., 2008; Frisher et al., 2012) (Table 3-2).  
 
Generally speaking, it is likely that the more that these risk factors are cumulatively present, 
the greater the likelihood that the overdose will be fatal (Frisher et al., 2012). However, it is 
important to note that:  
while significant risk factors for opioid overdose fatality are clearly recognised, the 
mechanism of death is still poorly understood (Warner-Smith et al., 2001,p.1121). 
This is still applicable today. Demographic data are extensive and valuable but clinical data 






Table 3-2: Risk factors of opioid overdose. 
Risk Factor/Indicator Reference(s) 
Type of opioid/drug (Bartu et al., 2004; Stenbacka et al., 2010)  
Bioavailability, route of administration, 
injecting site 
(Darke & Ross, 2000; Degenhardt et al., 
2011; Stewart, Gossop, & Marsden, 2002; 
Darke, Ross & Kay, 2001)  
Purity and dose (Darke, Hall, Weatherburn, & Lind, 1999; 
Desmond, Maddux, & Trevino, 1978; 
McGregor, Darke, Ali, & Christie, 1998)  
Concurrent use of other drugs, especially 
other depressants 
(Dietze, Jolley, Fry, & Bammer, 2005; 
Gossop, Stewart, Treacy, & Marsden, 
2002; Martyres, Clode, & Burns, 2004; 
Zador, Sunjic, & Darke, 1996) 
Age and gender (Bartu et al., 2004; Darke, Kaye, & Duflou, 
2006; Warner-Smith et al., 2001) 
Duration of use (Brugal et al., 2005; Hser, Hoffman, Grella, 
& Anglin, 2001) 
Tolerance due to:  
- current status of individual, e.g. in 




- post-prison release  
 
 
(Bell & Zador, 2000; Buster, van Brussel, & 
van den Brink, 2002; Thiblin, Eksborg, 
Petersson, Fugelstad, & Rajs, 2004; Wolff, 
2002)  
 
(Bird & Hutchinson, 2003; Darke, 
Williamson, Ross, & Teesson, 2005; 
Digiusto et al., 2004; A Fugelstad, 
Stenbacka, Leifman, Nylander, & Thiblin, 
2007; Oliver & Keen, 2003; Stewart et al., 
2002) 
Genetic and metabolic differences (Kosarac, Fox, & Collard, 2009) 
Underlying pulmonary diseases & other 
physical health problems (e.g. 
cardiovascular, liver) 
(Jolley, Bell, Rafferty, Moxham, & Strang, 
2015b; Warner-Smith, Darke, & Day, 2002; 
Warner-Smith et al., 2001) 
Recent life problems/psychological 
distress  
DORIS study (Neale & Robertson, 2005; 
Stewart et al., 2002) 




- using alone  
 
- fear of potential police involvement  
 
- using outdoors (e.g. street injectors) 
 
(Gerevich, Bacskai, Farkas, & Danics, 
2005; Siegel, Hinson, Krank, & McCully, 
1982) 
- (Best et al., 2002; Dietze et al., 2002; 
Tracy et al., 2005) 
- (Pollini, McCall, Mehta, Vlahov, & 
Strathdee, 2006; Tobin et al., 2005) 
- (Anoro & Ilundain, 2003; L Gjersing et 
al., 2013; Hunt, 2006)  
Lack of naloxone availability (Baca & Grant, 2005; Strang, Darke, Hall, 
Farrell, & Ali, 1996; Strang, Grifiths, Powis, 




3.5.1 Route of Administration and Relevant Risk of Overdose 
A high bioavailability (the proportion of the actual drug that reaches the systemic bloodstream) 
usually equates to a higher rate of absorption and increased risk of overdose. Bioavailability 
is considerably affected by the route of administration, which determines what type of 
metabolism (breakdown) the drug undergoes, but also by the dose taken and the purity of the 
drug. The combination of the latter two factors will determine the total amount of active 
substance consumed. 
 
In Table 3-3 below, routes of administration are listed in order of increasing risk of overdose, 
assuming that dose and purity are constant. 
 
Table 3-3: Risk of overdose by route of administration (descending order) (McDonald & Strang, 2016) 
Route Description 
1. Intravenous  
(injecting into vein) 
Powder or crushed tablets prepared for injection usually using 
water and an acidifier (e.g. heroin, crushed pharmaceutical 
opiate drugs) which is typically self-administered (or given by 
fellow drug user) as a bolus, thus delivering full sudden onset 
of drug effect when the bolus of drug reaches and crosses the 
blood-brain barrier. By virtue of the instant delivery following the 
pushing of the syringe-plunger, there is no scope for reducing 
the dose if the effect of the heroin is greater than expected. 
Heroin through this route has 100% bioavailability.  
2. Intramuscular  
(injecting into muscle) 
This is similarly typically self-administered quickly but, by virtue 
of being injected into muscle (instead of into a vein), it is 
absorbed more slowly and so, even if eventually fully absorbed, 
it does not produce the same front-end bolus effect as 
intravenous use. As with intravenous use, there is no scope for 
reducing the dose if the effect of the heroin is greater than 
expected. Bioavailability is slightly lower than that of 
intravenous (Girardin, 2003). 
3. Inhalation  
(smoking, ‘chasing’) 
Vaporising heated heroin base (brown powder), usually on foil, 
is known as ‘chasing the dragon’. By utilising the vast surface 
area of the lungs (as with cigarette smoking), ‘chasing’ 
produces rapid absorption and hence rapid brain effect. 
However, the technique of ‘chasing’ involves running the 
melted heroin up and down the heated tinfoil and inhaling the 
sublimate in the vapours – and this technique is not instant in 
the same way as pushing a syringe-plunger and, consequently, 
does not produce the rapid bolus effect. Hence inhalation 
results in an effect of slightly slower onset which thereby gives 
opportunity to reduce dose if the effect is larger than expected.   
4. Intranasal  
(snorting) 
Whilst not common, the white powder (salt) form of heroin 
occurs in some countries and communities. Snorting results in 




Heroin bioavailability intranasally is approximately half of the 
intramuscular route (Cone, Dickerson, Paul, & Mitchell, 1993). 
5. Oral Ingesting orally any drug as a tablet/capsule/liquid (e.g. 
methadone, morphine sulphate (MST), dihydrocodeine) is likely 
to produce a slow-onset effect as it is gradually absorbed from 
the stomach or further down the alimentary tract. The extent to 
which it then produces effects on the brain varies greatly 
between the different opiate drugs, and is markedly affected not 
only by how comprehensively it is absorbed, but also, crucially, 
by the extent of first-pass metabolism. Thus, there is no 
opportunity to reduce dose if the effect is larger than expected, 
but there is also no sudden-onset bolus effect. Heroin has 
<35% bioavailability when taken orally (Rook et al., 2006) 
3.5.2 Unknown Purity as a Risk Factor 
Much of the relationship between, and relationship of, heroin purity and mortality rates in the 
UK has been described in Chapter 1. This section focusses on the concept of purity and dose 
as a risk factor for opioid overdose. The classical depiction of a fatal overdose is of that 
deriving from a quantity or quality of the drug in excess. In the 1970s, Desmond and 
colleagues were the first to comment on the ‘pharmacologic overdose’ hypothesis, which 
states that there is a correlation between potency and of frequency of heroin overdose deaths 
(Desmond et al., 1978). Their paper in 1978 focussed on deaths in Texas, USA over a 5-year 
period and the mean dose of heroin in street packages (ranging from 1mg to 196mg). There 
was a low, non-significant correlation between monthly average heroin dose (relevant to 
potency) and monthly number of overdose deaths during that time (Desmond et al., 1978).  
 
This was following two studies in the USA which had found a positive correlation between 
heroin overdose deaths and the pharmacologic dose hypothesis (Garriott & Sturner, 1973; 
Greene et al., 1974). Since this time, the evidence supporting or disproving this correlation 
has been mixed (see Appendix B for a list of publications and the relative evidence).  
 
This confounding evidence consistently contributes to simplistic media reports which 
inaccurately report on drug-related deaths. In many media reports deaths are linked to 
contaminated or ‘killer’ batches of heroin that are often embellished or simply false (Bammer, 




experiencing non-fatal overdoses believed that the main reasons were related to the quantity 
or strength of the heroin (Darke et al., 1996; McGregor et al., 1998). 
 
It is true to state that ‘street’ heroin is subject to unpredictable variations in drug purity and 
may contain a variety of adulterants or contaminants mixed in, making it difficult for the user 
to determine the amount of active substance to use. However, the picture is far from clear cut, 
as large numbers of fatal overdose cases have low blood morphine concentrations, often 
below, or similar to, those of living intoxicated heroin users or of heroin users who died from 
other causes (Darke, Duflou, & Torok, 2010; Darke & Farrell, 2014; Davidson et al., 2003). 
Additional factors may have a stronger contribution to fatal cases (Table 3-2), e.g. the level of 
tolerance of the individual, consumption of other depressants, or organ (lung, liver) failure. In 
addition, an important point to consider is that harmful contaminants that may have contributed 
to the fatal outcome of the overdose may often not be detected in toxicological analyses of 
blood, drugs and used syringes (Darke et al., 2010). 
 
The idea that purity plays a role in overdose is further challenged by the observation of 
overdoses in clinical settings as well as in an illicit drug market scenario, most strikingly in a 
heroin-assisted treatment clinic. Even where a pharmaceutical and titrated dose is 
administered, though rare, overdose events still occur (Oviedo-Joekes et al., 2009; Strang, 
Metrebian, et al., 2010). 
 
To provide further context to this, in the UK, the Randomised Injectable Opiate Treatment Trial 
(RIOTT) compared supervised injectable heroin or injectable methadone versus oral 
methadone as treatment for chronic heroin addiction. Treatment was provided for 26 weeks 
and the rate of overdose (non-fatal) was reported to be around 1 in every 6,600 diamorphine 
injecting events (Strang, Metrebian, et al., 2010). These overdose events were immediately 
after injection, and in patients who had consecutively been taking the same daily, titrated dose. 
In a similar trial in Canada, the North American Opiate Medication Initiative (NAOMI) clinic 
saw a figure of around 1 per 8,300 injecting events (Oviedo-Joekes et al., 2009). In both of 




similar related work, the level of participants’ regular dose of diamorphine showed significant 
changes in oxygen saturation (blood oxygen level) in half of all testing sessions (Dursteler-
Mac Farland et al., 2000; Stoermer et al., 2003; Stohler et al., 1999; Mitchell et al., manuscript 
available on request). 
 
In Australia, a recent study into the supervised injectable drug clinic, the Medically Supervised 
Injectable Centre (MSIC) in Sydney, examined a total of 2,860 opioid overdoses (either heroin 
or oxycodone) between 2007 and 2014. Approximately two-thirds of all opioid overdoses were 
heroin-related, 12.7 overdoses per 1000 injections. Severe overdose/respiratory depression 
was reported significantly more in the overdoses related to heroin compared to oxycodone. 
Interestingly, no differences were reported across the groups with regards to concurrent use 
of depressants, reduced level of tolerance or using a larger quantity than usual (Roxburgh, 
Darke, Salmon, Dobbins, & Jauncey, 2017). Clearly, overdoses can occur without variation in 
administered heroin doses. 
3.5.3 Concurrent Use of Other Drugs 
There is an increased risk of heroin/opioid overdose if alcohol and other sedative drugs (e.g. 
benzodiazepines) are also consumed (CDC, 2017). This ‘cocktail’ of drugs and alcohol 
contributes to a great number of the overdose deaths. In the presence of other central nervous 
system depressant drugs, a usually well-tolerated dose of heroin can prove fatal. 
 
Polydrug use is possibly the most important risk factor in overdose deaths. A typical user is 
expected to have used at least ten different drugs in their lifetime, and at least six in one year 
(Darke, 2011) and higher levels of polydrug use appears to be associated with a higher risk 
of overdose, psychopathology and poor treatment outcome (Darke & Ross, 1997; DeMaria et 
al., 2000).  
 
Alcohol and benzodiazepines are the most commonly co-administered drugs. Alcohol is 
present in over half (Darke et al., 2000; Fugelstad et al., 2003; Ruttenber et al., 1990), and 
benzodiazepines in a quarter of fatal opioid overdose cases (Darke et al., 2010; Davidson et 




Outcome Research Study (NTORS) and the Drug Outcome Research in Scotland Study 
(DORIS), benzodiazepines were considered one of two major risk factors (the other being 
injecting route of administration) (Neale & Robertson 2005; Stewart et al., 2002). In another 
study, benzodiazepine use was shown to have increased the risk of overdose 28 fold (Dietze 
et al., 2005). 
 
Benzodiazepines are a class of drugs used for their anxiolytic, sedative and anticonvulsant 
properties. Benzodiazepines, like alcohol, represent a desirable combination for the heroin 
user. They are extensively abused by individuals in treatment for their addiction problems 
(Strang et al.,1994). In any one month, a third to half of heroin users will also use a 
benzodiazepine, for both clinically prescribed and recreational purposes, with quicker onset 
versions being preferred (e.g. diazepam and alprazolam) (Bargagli et al., 2006; DeMaria et 
al., 2000). 
 
Whilst most of the longitudinal, qualitative and observational studies discussed thus far show 
a great connection between the two drug groups, the direct pharmacological and physiological 
evidence is somewhat limited, particularly for the drug of greatest concern, heroin. In terms of 
the physiological effects, benzodiazepines have been shown to decrease oxygen saturation 
significantly in the presence of opioid substitution drugs such as methadone and 
buprenorphine (Lintzeris et al., 2007, 2006). Furthermore, according to Darke, co-
administration of a depressant greatly increases the likelihood of a fatal situation because it 
potentiates the respiratory depressant effects of heroin. In the presence of depressants, a 
normal dose of heroin may be fatal (Darke, 2011). However, whether this apparent increased 
risk of respiratory depression occurs via a potentiation of opioid effects or a synergistic action 
of more than one depressant is not well understood.  
3.5.4 Gender and Age 
It is understood that there is an increased vulnerability amongst older opioid users (Gao et al., 
2016; Pierce, Millar, Robertson, & Bird, 2018) and age is a risk factor for opioid overdose 
(Bartu et al., 2004; Warner-Smith et al., 2001). The basis of this is most likely related to the 




(Bartu et al., 2004; Hall, Degenhardt, & Lynskey, 1999; Langendam, van Brussel, Coutinho, 
& van Ameijden, 2001). A history of overdose is thought to increase the prevalence of high-
risk behaviours and most fatalities are thought to have had a number of overdoses prior to the 
fatal overdose (Warner-Smith et al., 2001). Therefore, it may be that increasing age is a 
marker for increasing overdose experience and consequent risk of fatal overdose.  
 
Males are consistently more likely to experience an overdose than females (Chen, Kuo, & 
Tsai, 2001; Gossop et al., 2002; Hall et al., 1999) and have even been shown to have a greater 
hazard of all-cause death compared to females (Bartu et al., 2004).  
3.5.5 Lung Disease and Overdose Mortality 
Warner-Smith et al., in their review of the causes and complications of overdose deaths stated 
that there was  
Biological plausibility of an association between pulmonary dysfunction and overdose 
mortality and the potential for substantial rates of pulmonary dysfunction among heroin users 
suggests that pulmonary morbidity may contribute to mortality from opioid overdose. 
(Warner-Smith et al., 2001, p.8).  
Seventeen years later, unfortunately, there is still very little experimental evidence that has 
investigated this link. Much of the literature on overdose risk in drug users is focused on 
injecting drug users and blood borne viruses such as HIV and infectious diseases. In the 
1990s there was a gradual trend towards smoking heroin (Smyth, O’Brien, & Barry, 2000; 
Strang, Griffiths, & Gossop, 1997). This was, in part, due to smoking (or inhaling) being 
perceived as ‘safer’. Currently, in the UK, smoking is still the more common form of 
administering heroin. Respiratory clinicians and researchers have increasingly been noting 
airways disease due to the effects of opioid smoking (Burhan et al., 2018; Lewis-Burke, Vlies, 
Wooding, Davies, & Walker, 2016; Palmer et al., 2012; Walker, Thwaite, Curtis, & Calverley, 
2015; Yadavilli et al., 2014). These studies have shown that there is a high prevalence of 
chronic lung diseases and significantly more drug users are diagnosed with lung diseases 
than controls. However, despite the few studies that have investigated obstructive lung 
disease in heroin smokers (‘chasers’) (Buster, Rook, Van Brussel, Van Ree, & Van den Brink, 
2002; Jolley, Bell, Rafferty, Moxham, & Strang, 2015a; Walker et al., 2015; Yadavilli et al., 
2014), very little is actually known of the link between heroin administration and lung disease, 




areas that requires investigation. The second part of this chapter will describe respiratory 
physiology in relation to lung disease in greater depth. 
3.5.6 Environmental  
Another factor that is thought to influence vulnerability to overdose is related to situation-
specific tolerance. This is based on work by Siegel et al. in the 1980s. In studies of rat models 
where morphine was administered, there appeared to be increased overdose signs in a 
differing environment to that which the effects originally took place/to where they had been 
accustomed to taking it. Rats that were given morphine in the same circumstances, on the 
other hand, had a smaller effect as if they had been ‘expecting’ its effect (Siegel, Hinson, 
Krank, & McCully, 1982). Siegel also interviewed heroin overdose survivors, and most had 
administered in an environment not previously associated with drug use (Siegel, 1984). 
Furthermore, O’Brien et al. showed that the anticipation and preparation in taking the drug 
appeared to act as a conditioned stimulus, reducing the action of the drug and contributing to 
the development of a corresponding tolerance (O’Brien, Childress, McLellan, & Ehrman, 
1992a, 1992b). This was seen in a study on the physiological effects of Hydromorphon dosing 
on differing occasions where participants were either give the opiate without prior indication 
or where they self-administered the opiate (O’Brien et al., 1992a).  
 
It is important to note that the issue of suicide as a risk factor is not discussed in this thesis. It 
is understood that there is a 14 times greater risk of suicide among heroin users than the 
general population (Harris & Barraclough, 1998; Wilcox, Conner, & Caine, 2004). It is likely 
that someone with a history of attempted suicide is more at risk of overdose due to an 
indifference of whether they ‘live or die’, but this is a complex phenomenon with different 




Part 2: The Impact of Opioids on Breathing Mechanisms  
 
To understand why heroin and other opioids are particularly dangerous, it is important to 
consider the fundamentals of breathing and lung physiology. This section will describe 
respiratory physiology provided in the subsequent part. 
 
3.6 Introduction to Respiration  
The lungs function to continually exchange oxygen and carbon dioxide with the external 
environment in order to maintain low concentrations of carbon dioxide and high concentrations 
of oxygen in the tissues of the body (Levitzky, 2013). Normal resting breathing is driven by the 
respiratory centres of the brain located in the medulla and pons regions of the brainstem. 
Sensors, also known as peripheral and central chemoreceptors (e.g. the carotid body) of the 
body and brain provide a precise self-regulating system. These receptors are sensitive to 
changes in arterial blood partial pressures of oxygen, carbon dioxide and acid-base status. 
The respiratory centres monitor the feedback from the peripheral sensors and send the 
appropriate stimuli to initiate pulmonary ventilation (breathing) (Figure 3-2).  
 
A build-up of carbon dioxide in the blood, and critically low oxygen levels are toxic. If not 
adequately expelled via the lungs, an accumulation of carbon dioxide can lead to the condition 
known as hypercapnia. This in turn causes a decrease in blood pH (known as acidosis, the 
accumulation of acid substances in the body) and is typically accompanied by a decrease in 
blood oxygen (hypoxaemia) and finally hypoxia (a condition in which oxygen is deprived from 
the tissue in a region of the body or the whole body). If this state of low oxygen and high 
carbon dioxide in the blood is prolonged for a period of time, or if it is rapid and profound, it is 





Figure 3-2: Respiratory Feedback Loop. PaO2: partial pressure of oxygen in arterial blood; PaCO2: 
partial pressure of carbon dioxide in arterial blood.  
 
3.6.1 Initiation of a Breath in Healthy Respiratory Function  
Initiation of respiratory muscles arise from the central brainstem region (medulla and pons) 
via spinal and cranial motor neurons (more details in Section 3.8). Respiratory muscles act to 
move air in and out of the lungs through their actions on the ribcage and are conventionally 
described as being inspiratory or expiratory. Inspiratory muscle contraction expands thoracic 
cavity (the space inside the ribcage), leading to a fall in the pressure between the thin fluid-
filled surrounding layers of the lungs (intrapleural pressure). The resulting pressure gradient 
across the lung and pleural space causes lung expansion, resulting in a fall in pressure in the 
airways and alveoli (airway pressure). Inspiratory flow begins when the airway pressure falls 
below atmospheric pressure. Expiration is passive in healthy individuals breathing at rest. 



















3.7 Respiratory Physiology: Structure & Function  
3.7.1 Definitions 
Table 3-4: Table of definitions in relation to respiratory physiology. 
Term Definition 
Afferent nerve fibre Carries impulses towards the central nervous system  
Efferent nerve fibre Carries impulses away from the central nervous system 
Tonic drive Tonic input adapts very slowly to a stimulus, in comparison to 
phasic input which responds very rapidly. Tonic inputs continue 
to produce action potentials over the time of the stimulus. It is 
often characterised by a steady state of action potential firing at 
a constant frequency. 
Phasic firing  Occurs after a neuron is activated, it is usually restricted to one, 
a few or a short burst of action potentials and will often rapidly 
return to the resting state.   
Alveolar ventilation The exchange of gas between the alveoli and the external 
environment 
Ventilatory frequency 
or respiratory rate  
The number of breaths taken per minute. Normal adult 
respiratory rate is between 12 and 20 breaths per minute.  
Minute ventilation/ 
minute volume  
Volume of gas inhaled or exhaled from the lungs per minute. 
Tidal volume Normal volume of air inhaled or exhaled when extra effort is not 
applied.  
Smooth muscle  Muscle tissue that contracts without voluntary control, having 
fine myofibrils but lacking transverse striations and found in the 
walls of internal organs, blood vessels and hair follicles.  
Skeletal muscle  A form of striated muscle tissue which is under the voluntary 
control of the somatic nervous system. Most skeletal msucles 
are attached to bones by tendons.   
pO2 Partial pressure of oxygen 
PaO2 pO2 in arterial blood 
pCO2 Partial pressure of carbon dioxide 
PaCO2 pCO2 in arterial blood 
 
3.7.2 Structural Anatomy of the Respiratory System  
The lungs are a pair of organs within the thoracic cage whose principal function is gas 
exchange. Atmospheric oxygen diffuses passively from the alveoli into the pulmonary capillary 
blood, down a partial pressure gradient. Carbon dioxide diffuses from the pulmonary capillary 
blood into the alveoli and is thereafter expelled into the atmosphere. The thoracic cage 
consists of the sternum and 12 pairs of ribs. The ribs slope inwards (inferiorly) and backwards 
(anteriorly) from the vertebrae. A combination of their sloping orientation with their elevation 
allows the ribcage move up and out (known as a ‘pump and bucket-handle motion’) (Hamid, 





The lungs are surrounded by serous membrane (visceral pleura) which folds in on itself to 
form a two-layer structure (Gray, 1918). The outer membrane (parietal pleura) is attached to 
the inside of the rib cage. The two pleural membranes are maintained close together (but do 
not touch) due to reciprocal repulsive forces and the existence of surface tension from the 
fluid present between the membranes, which opposes the elastic recoil of the parenchyma 
(functional parts of the organ) and prevents lung collapse (Hamid, Qutayba; Shannon, Joanne; 
James, 2005). 
 
3.7.3 Respiratory Muscles 
As previously described, pulmonary ventilation requires volume change of the lungs, which 
occurs as a result of contraction of the respiratory muscles (Ratnovsky, Elad, & Halpern, 
2008). The respiratory muscles work together to increase thoracic volume, expand the rib 
cage, to lower pleural and intrapulmonary pressures and cause air to flow into the lungs 
(Figure 3-3). Adequate gas exchange is maintained by appropriate functioning of the 
respiratory muscle pump which consists of inspiratory and expiratory muscles. The inspiratory 
muscles include the diaphragm and external and parasternal intercostal muscles as well as 
accessory muscles of the upper chest and neck. Expiratory muscles are the internal intercostal 
muscles and abdominal muscles.  
 
The diaphragm is the principal inspiratory (and skeletal) muscle and is involved in 70-80% of 
the work required for breathing in healthy individuals (Moxham & Jolley, 2009). The diaphragm 
is positioned at the interface of the thoracic and abdominal cavities and is innervated by the 
phrenic nerves. During contraction of the diaphragm, the muscular sheet flattens, compresses 
the abdominal region and causes the volume of the thoracic cavity to increase (Hamid, 
Qutayba; Shannon, Joanne; James, 2005). This increases intra-abdominal pressure and 
causes an outward movement of the lower part of the ribcage. The diaphragmatic muscle 
fibres are slow twitch, resistant to fatigue, oxidative fibres (De Troyer, Legrand, & Wilson, 
1996) (type 1 fibres, Table 5). 
 
Intercostal muscles consist of two thin layers of intercostal muscles each occupying the 




intercostals) have fibre orientations that are perpendicular to one another (De Troyer & 
Estenne, 1988). Both sets of intercostal muscles are innervated by the intercostal nerve and 
play an important role in respiratory function (De Troyer, 2005; Taylor, 1960). The internal 
intercostal muscles having a greater role in expiration, contracting to collapse the rib cage, 
whereas the external intercostals acting to raise the lower part of the rib, leading to an 
inspiratory effect. Between the sternum and costo-chondral junction (the joint between rib and 
costal cartilage on the front of the rib cage), the first five interspaces are replaced by flat broad 
tendons (fibrous aponeuroses), and the internal intercostals in these interspaces are known 
as parasternal intercostal muscles (Figure 3-3) (Han, Gayan-Ramirez, Dekhuijzen, & 
Decramer, 1993).  
 
The parasternal intercostal muscles are similar to internal intercostal muscles anatomically 
but not functionally. The parasternal intercostal muscles have a role in inspiration and are 
termed the ‘inspiratory intercostals’. These muscles are slow twitch and resistant to fatigue 
(De Troyer et al., 1996), similar to diaphragmatic muscle (Table 3-5). Contraction of the 
parasternal intercostal muscles increases specific regions of the chest wall (the lateral and 
anteroposterior diameters) (De Troyer, Kelly, Macklem, & Zin, 1985). There are many animal 
studies that have investigated the role of this group of muscles. Denervation of these muscles 
in anaesthetised dogs led to decreased tidal volume, minute ventilation and increases in 
partial pressure of carbon dioxide (pCO2) (De Troyer & Yuehua, 1994; Sugimori, Kochi, 
Nishino, Shinozuka, & Mizuguchi, 1993). Selective denervation of the chest wall in dogs 
showed that the parasternal intercostal muscles were responsible for around 80% of rib motion 
during resting breathing (De Troyer, 1991).  
 
Examining the changes to the intercostal muscle length using computed tomography (CT) 
scanning and cadaveric studies have shown that the parasternal intercostal muscles shorten 
during passive lung inflation, and it is said that these muscles have an inspiratory mechanical 
advantage, albeit less than that of the external intercostal muscles (De Troyer, Legrand, 
Gevenois, & Wilson, 1998; Wilson, Legrand, Gevenois, & De Troyer, 2001). Essentially, the 
mechanical advantage of parasternal intercostal muscles in humans is four-fold greater in the 




(Figure 3-3). This is relevant to measures of respiratory depression described further on in 
this chapter.  
 
Studies investigating activation of these muscles in isolation show that they do affect ribcage 
motion and volume change of the thoracic cavity, but their role in the fully intact system is 
dependent on their interaction with other muscle groups as well, in particular the external 
intercostal muscles and diaphragm (Decramer & De Troyer, 1984). Parasternal intercostal 
muscles act together with the diaphragm and they are consistently active during inspiration 
(only becoming inactive when the inspired volume is minimal) (Butler & Gandevia, 2008; De 
Troyer & Sampson, 1982; Easton et al., 2010; Gandevia, Leeper, McKenzie, & De Troyer, 
1996; Gandevia, Hudson, Gorman, Butler, & De Troyer, 2006).  
 
 
Figure 3-3: illustration of the location of intercostal muscles (Han et al., 1993). 
 
3.7.4 Respiratory Muscle Contraction and Physiology 
Respiratory muscles consist of skeletal muscle fibres, nerves and blood vessels bound 
together by connective tissue. A unit of a skeletal muscle is a single motor unit (motor neuron) 
and the group of muscle fibres that the neuron supplies. The neuronal cell bodies are located 
in the spinal cord. Muscle fibres themselves contain thread-like myofibrils that exist across the 
length of the muscle fibre. Mitochondria and a structure that stores calcium (sarcoplasmic 
reticulum) are also important components of muscle contraction. The outer cellular membrane 




project into the fibre, to the sarcoplasmic reticulum. They are defined by their functional 
properties; slow-twitch (type 1) or fast-twitch (type 2). Myosin is a protein that converts 
chemical energy into mechanical energy. Different forms of myosin are expressed in human 
skeletal muscle, and there are also various muscle fibre types which impact their function in 
the respiratory system. Table 3-5 represents the characteristics of different muscle fibre types. 
Table 3-5: Classification of muscle fibres (Scott, Stevens & Binder–Macleod, 2001) 
Characteristics Type I Type IIA Type IIX 
Contraction Time Slow Fast Very Fast 
Oxidative Capacity  High High Low 
Diameter Small Medium Large 
Resistance to Fatigue High Moderate Small 
Generating Force Small Moderate Very High 
 
3.7.5 Electrical activation of muscles 
An action potential that arises in the motor neurone supplies the motor unit and leads to a 
release of acetylcholine into the neuromuscular junction. Acetylcholine binds to its receptors 
allowing sodium ions to enter the cell and causing a depolarising excitatory postsynaptic 
potential that is above threshold and triggers an action potential. This travels along the 
sarcolemma and through the t-tubules, resulting in release of calcium ions from the 
sarcoplasmic reticulum (Tortora & Grabowski, 2000; Widmaier, Raff, & Strang, 2013) (Figure 
3-4). The number of active cross-bridges (i.e. the tension in the muscle) is a function of the 
calcium ion concentration. Each excitation of the muscle cell leads to an increase in 
intracellular calcium ion that is sufficient to bind all the regulatory protein complexes involved 
in contraction (troponin-tropomyosin), allowing the head of the myosin filament to attach to the 
actin filament (microfilament structure consisting of actin protein molecules within the 
cytoskeleton). A ‘power stroke’ follows whereby a new molecule of energy (adenosine 
triphosphate; ATP) is formed and binds to myosin releasing it from its attachment. The 
repeated actions of many actin-myosin complexes result in shortening of the sarcomere which 
produces either a contraction of the muscle or generation of tension depending on whether 





Figure 3-4: Diagrams of skeletal muscle, muscle fibre, myofibril to sarcomere (Marieb & Hoehn, 2013). 
 
3.7.6 Factors Affecting Muscle Contraction  
The force generated within a muscle during a contraction depends on the length of the muscle 
at the point of stimulation, the number of muscle fibres that are stimulated, the velocity of 
muscle fibre shortening and the frequency at which the fibres are stimulated. These are all 
closely related and rarely occur in isolation. This length-tension relationship is a product of the 
degree of overlap of the actin and myosin filaments.  
 
3.7.7 Load-Capacity Balance of the Respiratory Muscles  
The action of any muscle is dependent on the imposed load as well as its capacity (Ratnovsky 
et al., 2008). During resting breathing, the load on healthy human respiratory muscles is small. 
However, the variety of different pathophysiological changes that occur in lung disease can 
significantly alter the balance between the load imposed on the respiratory muscles and their 
capacity. In obstructive lung disease, there is an issue of increased airways resistance, 
hyperinflation and intrinsic positive end-expiratory pressure (PEEP)8 that place an additional 
load on the respiratory muscles. In addition to these, in emphysema (a type of chronic lung 
                                                   
8 Intrinsic PEEP is a positive pressure in the airways at the end of expiration, or put simply, an ‘incomplete 




disease; discussed further in Part 3), the diaphragm is flattened and fibres become shortened. 
The diaphragm is less able to generate tension, such that the metabolic requirements are 
greater for a given workload (Byrd & Hyatt, 1968). Thus, the actual neural input to respiratory 
muscles has to increase to compensate for this change in load-capacity balance and to 





3.8 Control of Respiration and Respiratory Drive 
The drive to respiration, or neural respiratory drive, is generated by the respiratory centres in 
the brainstem, specifically the medulla and pons (Feldman & Del Negro, 2006; Lumsden, 
1923; Pattinson, 2008). It is modulated by inputs from the cortex (Janczewski & Feldman, 
2006; McKay, Evans, Frackowiak, & Corfield, 2003) as well as central (brainstem) and 
peripheral (carotid and aortic bodies) chemoreceptors (Bruce & Cherniack, 1987; Richerson, 
2004) that sense changes in the blood. The respiratory centres act to control ventilation in 
order to maintain blood gas homeostasis.  
 
3.8.1 Respiratory Rhythm  
Rhythmic patterns and breathing movements are generated by the medullary and pontine 
respiratory networks which produce inspiratory and expiratory actions via spinal and cranial 
motor neurons to relevant respiratory muscles. A motor neuron has a cell body within the 
spinal cord, and an axon that projects out to organs or glands. The respiratory motor patterns 
are controlled by inputs within medullary neurons which exist as interconnected bilateral 
columns (Figure 3-5).  
 
Lumsden et al.’s work on decerebrate cats was seminal in establishing that the brainstem was 
essential for respiration (Lumsden, 1923). They showed that transections at varying levels of 
the pons and medulla produced differing effects on the respiratory rhythm. The majority of 
respiratory neurones are concentrated into four nuclei: 1) the dorsal respiratory group (DRG) 
within the nucleus tractus solitarius (NTS); 2) the ventral respiratory group (VRG), which 
contains the nucleus ambigualis (NA) and the nucleus retroambigualis (NRA); 3) the pre-
Bötzinger complex; and 4) the Bötzinger complex, located in and near the nucleus 
retrofacialis.  
 
The pre-Bötzinger complex in the ventro-lateral region of the medulla is a small area that can 
produce a respiratory rhythm in isolation, in vitro (Rekling & Feldman, 1998; Smith et al., 2000; 
Smith, Ellenberger, Ballanyi, Richter, & Feldman, 1991). However, whilst this has been 
confirmed in rodents, it has not been identified in humans. The pre-Bötzinger complex was 




with another group of nuclei called the Retro-trapezoid/parafacial respiratory group 
(RTN/pFRG) (Janczewski & Feldman, 2006; Onimaru & Homma, 2003) in oscillation. These 
coupled networks are strongly modulated by the pons (Smith, Abdala, Koizumi, Rybak, & 
Paton, 2007) specifically the Kölliker-Fuse nucleus, the parabrachial complex and the locus 
coeruleus (Figure 3-5).  
 
Figure 3-5: illustration of the nuclei involved in respiratory control (Benarroch, 2007). 
 
The Bötzinger complex is composed of expiratory neurones as well vagal and 
glossopharyngeal motor neurones (Taveira da Silva et al., 1983) (10th and 9th cranial nerves 
respectively). The NTS is the primary site that receives lung and peripheral chemoreceptor 
afferent input. The DRG consists only of inspiratory neurones which act immediately prior to 
the onset of inspiration and relay the activity to the phrenic nerves (involved in innervating the 
diaphragm) (Dobbins & Feldman, 1994). This activity lasts for around two seconds in adults 
and subsequently ceases to allow for passive expiration (Hamid, Qutayba; Shannon, Joanne; 
James, 2005). The DRG is responsive to differing afferents from the chemoreceptors and lung 
mechanoreceptors via cranial nerves and spinal cord, and also from descending afferents 
from higher brain regions. The DRG inspiratory neurones inhibit expiratory neurons of the 
VRG and pontine respiratory group (PRG) (Alheid & McCrimmon, 2008).  
 
The NA of the VRG contains premotor inspiratory neurones that supply the external and 




neurones (Subramanian & Holstege, 2009), and the parasympathetic input to the heart and 
bronchioles (Purves et al., 2001). The PRG counteracts the influence of the medullary 
respiratory centres. In studies that have examined the respiratory effects without any influence 
of the PRG have observed a slow, rhythmic, gasping breathing pattern (Wang, Ngai, & Frumin, 
1957). The PRG consists of a mix between expiratory neurones (in the medial parabrachial 
nucleus) and inspiratory neurones (in the lateral parabrachial nucleus and Kölliker-Fuse 
nucleus).  
 
In relation to cortical control, volitional control of breathing is influenced by descending input 
from the cerebral cortex to the medullary respiratory centres. Voluntary control bypasses the 
medullary and pontine respiratory centres and interacts with spinal respiratory motor neurones 
(Tortora & Grabowski, 2000). 
 
3.8.2 Respiratory Chemoreceptors and the Feedback Loops Which Control Breathing 
As briefly discussed previously in this chapter, chemoreceptors respond to changes in pH, 
pO2 and pCO2 in the blood. There are differences in how responses to these changes occur, 
and how sensitive the chemoreceptors are to each of these. Minor increases in pCO2 lead to 
significant and rapid changes in ventilation (Nattie, 1999), and contrastingly, decreasing pO2 
is hyperbolic in that large changes in pO2 are required to mediate a change in ventilation at 
first, but the increase in ventilation thereafter is rapid (Powell, Milsom, & Mitchell, 1998).  
 
Central chemoreceptors sense changes in pH, providing a tonic drive to the respiratory motor 
output. It is now understood that there are multiple chemo-sensing areas in the lower brain 
region, mainly in the brainstem, whereas classically it was thought that there were only three. 
These include the NTS, midline medullary raphe, pre-Bötzinger complex, and the RTN/pFRG 
in the medulla and locus coeruleus (Feldman, Mitchell, & Nattie, 2003; Oyamada, Ballantyne, 
Mückenhoff, & Scheid, 1998) as well as the fastigial nucleus in the cerebellum (Martino et al., 
2007). These areas are beyond the blood brain barrier and thus, do not respond to changes 
in blood gas levels, but rather changes to pH in cerebrospinal fluid (via changes in H+ 





Peripheral chemoreceptors are located in the carotid bodies at the joining (bifurcation) of 
carotid arteries, and in the aortic bodies, both above and below the aortic arch. The carotid 
body responds to changes in arterial pH, pO2 and pCO2 and the aortic chemoreceptors 
respond only to pH and pCO2. The carotid chemoreceptors exert more of an influence over 
respiratory control than those in the aortic bodies. Peripheral chemoreceptors are the only 
receptors that mediate change in ventilation in response to hypoxia (Lahiri et al., 2006), and 
complement the central chemoreceptors in responding to changes in pCO2 (West, 2008). 
Feedback from the carotid body to the respiratory centres is via glossopharyngeal nerves, and 
from the aortic body to respiratory centres is via the vagus nerve (Tortora & Grabowski, 2000). 
The peripheral chemoreceptors receive a high blood flow, which enables them to rapidly 
respond to changes in blood gas concentrations, albeit not as great a contribution of response 
to changes in pCO2 as central chemoreceptors (Smith, Rodman, Chenuel, Henderson, & 
Dempsey, 2006).  
 
3.8.3 Respiratory System Afferents 
Afferent feedback from receptors in the chest wall, respiratory muscles and lungs provides 
input to the brainstem respiratory centres via the vagus nerve as well as thoracic and cervical 
nerve roots (the initial segment of the nerve leaving the central nervous system). The 
receptors involved in respiratory feedback mechanisms are divided into three main types: 1) 
stretch receptors, 2) C-fibres (including irritant and ‘J’ receptors) and 4) proprioceptors 
(Widdicombe, 2009). There are slowly- and rapidly-adapting stretch receptors (SARs and 
RARs, respectively) that are located within the airway walls. SARs are large, myelinated fibres 
within smooth muscles of the airways (Schelegle & Green, 2001). Changes in lung volume 
and transpulmonary pressure stimulates SARs which has an influence on respiratory timing. 
SAR sensitivity is increased during bronchoconstriction, airway obstruction or reduced lung 
compliance, which is thought to be as a result of smooth muscle contraction (Davenport et al., 
1981). 
 
RARs are thinner, myelinated fibres that are widely distributed within and below the epithelium 
of the lower respiratory tract. RARs are sensitive to mechanical stimuli such as changes to 




as cigarette smoke, dust, pro-inflammatory chemicals or inhalable substances such as heroin 
or crack cocaine. They are also referred to as irritant receptors (Sant’Ambrogio & Widdicombe, 
2001). Stimulation of RARs leads to cough, airway vasodilation, mucous hypersecretion, 
hyperpnoea (increase in depth and rate of breathing), and other cardiovascular responses 
(Sant’Ambrogio & Widdicombe, 2001). 
  
J receptors are unmyelinated fibres that respond to chemical changes in the pulmonary and 
bronchial circulations. These receptors are triggered by chemical irritants such as capsaicin, 
histamine, prostaglandins and bradykinin (Widdicombe, 2001). Stimulation of these receptors 
causes an increase in respiratory rate, broncho- and laryngeal constriction and increased 
upper airway mucous secretion. There is great overlap between these receptors and RARs 
and in their responses to stimuli.  
 
Proprioceptors are sensitive to changes in muscle tension and length and are present in the 
tendon organs and muscle spindles of the respiratory muscles. When mechanoreceptors are 
activated, reflex inhibition of inspiratory activity is created in response to rib elevation (De 
Troyer, 1997). 
 
3.8.4 Impaired Gas Exchange 
Impaired gas exchange is the most common issue in any damage to the respiratory system 
through lung disease or injury to the lungs (including indirectly through consumption of 
opiates). An impairment to gas exchange causes hypoxaemia (abnormally low pO2 in arterial 
blood), and hypercapnia (increased arterial pCO2) if there is alveolar hypoventilation. The 
main causes of hypoxaemia are ventilation-perfusion inequality, shunt (whereby the air cannot 
reach alveoli that are adequately perfused by pulmonary capillary blood, i.e. the 
ventilation/perfusion ratio9 is zero) or hypoventilation. Reduced ventilation of alveoli, where 
gas exchange takes place, is termed alveolar hypoventilation. As described in the alveolar 
ventilation equation, there is an inverse relationship between alveolar ventilation and alveolar 
                                                   
9 The ventilation/perfusion ratio (V/Q ratio) is used to assess the efficiency and adequacy of matching 





PCO2. Consequently, when alveolar ventilatory rates fall, the rate at which carbon dioxide is 
eliminated by the lungs also decreases, thus yielding increased alveolar and arterial partial 
pressures of alveolar carbon dioxide (West, 2011). Hypoventilation is thus always 
accompanied by increased alveolar carbon dioxide values and in turn hypercapnia. As per the 
alveolar gas equation, an increase in the alveolar partial pressure of carbon dioxide result in 
a reduced alveolar partial pressure of oxygen (PAO2). A reduction in PAO2 will lead to a 
reduction in the arterial partial pressure of oxygen (PaO2) (West, 2011):  
PACO2 = VCO2/VA x K 
PACO2 = alveolar PCO2,  
VCO2 = CO2 output  
K = constant   
Many different conditions lead to hypoxaemia caused by hypoventilation and for many of 
these, the lungs are themselves normal. Opioid use leads to a blunted response to 
hypercapnic/hypoxaemic states (Weil, McCullough, Kline, & Sodal, 1975). Therefore, the 
hypercapnic ventilatory response of a chronic opioid user will be dampened and shifted to the 
right (Figure 3-6, line B) (Pattinson, 2008; Teichtahl et al., 2005; Weil et al., 1975). Specific 
description of opioid effect on respiratory control is discussed further on in this chapter. 
 
Figure 3-6: Carbon Dioxide Response Curve. 
Curve A represents the normal ventilatory response to carbon dioxide in an awake individual. Line B 
represents a 50% depression of the HCVR caused by opioid administration. Apnoea can occur here 
but PACO2 must rise to steady-state values (i.e. along the x-axis) for breathing to recommence (line B'). 
Curve C represents the carbon dioxide excretion hyperbola and demonstrates how changes in 
ventilation affect PACO2. Point X represents the awake state and point Y represents opioid-depressed 
breathing. Despite a 50% depression of the HCVR, the carbon dioxide changes only relatively 





The delivery of oxygen to tissues is the product of arterial oxygen content, and cardiac output. 
The oxygen content of arterial blood is mainly related to haemoglobin which greatly increases 
the oxygen-carrying capacity of the blood. When oxygen binds to deoxyhaemoglobin, the 
structure/conformation of the protein changes and is known as oxyhaemoglobin. When 
oxygen is unloaded, haemoglobin has a lower affinity (binding capacity) for oxygen (Thomas 
& Lumb, 2012). Hence the binding capacity changes with each additional oxygen molecule, 
and hence the saturation of haemoglobin is not a linear one. The well-known sigmoidal 
dissociation curve of oxyhaemoglobin represents the relationship between oxygen levels and 
haemoglobin saturation (Figure 3-7). The partial pressure of oxygen at which haemoglobin is 
50% saturated is known as P50. When the affinity to oxygen increases, the curve is shifted to 
the left, thus the P50 falls. Similarly, when affinity to oxygen reduces the curve is shifted to the 
right. The normal PaO2 is associated with oxygen saturation of around 98-100% (Thomas & 
Lumb, 2012).  
 
Figure 3-7: Oxygen-Haemoglobin dissociation curve (Thomas & Lumb, 2012). 
 
The term ‘respiratory failure’ is used to describe a syndrome in which the respiratory system 
fails in one or both of its gas exchange functions: oxygenation and carbon dioxide elimination. 
There are four different types of respiratory failure but the two most relevant types for this 
thesis depend on whether the failure stems from hypoxaemia/failure of oxygen exchange 




2003). Type III occurs during the perioperative period and Type IV results from hypoperfusion 
of respiratory muscles, when patients are in shock.  
 
An increase in arterial PCO2 causes an increase in blood carbon dioxide concentration, which 
will lead to a decrease in pH in the blood, i.e. a respiratory acidosis (Epstein & Singh, 2001). 
Hypercapnia and respiratory acidosis can occur with any disease process where there is an 
issue with the neural control of ventilation, mechanics of ventilation or alveolar gas exchange 





3.9 Opioids and Respiratory Control 
The opioid sensitive aspects of respiration are within rhythm generation. At low opioid doses, 
changes in respiratory pattern are observed over changes in tidal volume (Lalley, 2003). At 
higher opioid doses, tidal volume is shown to reduce, which may be due to decreased tonic 
inputs from opioid sensitive chemoreceptors. Opioid-sensitive chemoreceptors are partly 
compensated by increases in pCO2. There are suggested mechanisms of how opioids can 
cause an irregular respiratory pattern when administered (Bouillon, Bruhn, Roepcke, & Hoeft, 
2003; Lumsden, 1923).  
 
During inspiration the pre-Bötzinger complex is active and is inhibited by opioids, whereas the 
RTN/pFRG is active during expiration and is insensitive to opioids (Janczewski & Feldman, 
2006). This difference in sensitivity to opioids shows differing mechanisms of opioid-induced 
respiratory depression (Mellen, Janczewski, Bocchiaro, & Feldman, 2003). When the mu-
opioid receptor agonist DAMGO was applied to rat brainstem slices containing only pre-
Bötzinger complex, it gradually slowed the respiratory rhythm (Mellen et al., 2003). Further to 
this, when DAMGO was applied to a preparation with both RTN/pFRG and the pre-Bötzinger 
complex, the rhythm still slowed but with a change in the pattern. The breathing pattern 
became irregular due to the skipped inspirations and led to increased inspiratory periods. 
Subthreshold action potentials were observed during these periods of skipped breaths, which 
was thought to be caused by an intermittent reduction of the output signal from the pre-
Bötzinger complex (Janczewski & Feldman, 2006; Mellen et al., 2003). This pattern was 
labelled ‘quantal’.  
 
There is evidence that the Kölliker-Fuse and parabrachial nuclei of the pons also contribute 
to irregular respiration (Lalley, 2005). The Kölliker-Fuse is thought to regulate the transition 
from inspiration to expiration. There are also novel experimental receptor modulators (e.g. 
serotonin receptor subtype 4a agonists, or Dopamine D1 agonists) that have been used to 
investigate opioid-induced respiratory depression, however, none of these have yet to be 





In relation to opioid effect on chemoreceptors, literature related to peripheral chemoreceptors 
is better understood than central chemoreceptors, potentially due to the easier access for 
investigation. As described previously, depression of the hypoxic ventilatory response (HVR) 
and hypercapnic ventilatory response (HCVR) by morphine and other opioids is well-reported 
(Arita, Kogo, & Koshiya, 1987; Sarton et al., 2000; Weil et al., 1975) (Figure 3-6). With regard 
to central chemoreceptors, localised application of opioids in areas of the brainstem showed 
some depressant effects on respiration (Taveira da Silva et al., 1983), and mu-opioid receptor 
agonists have shown to affect chemoreception in the medullary raphe and the NTS (Poole, 





3.10 How do Opioids Cause Respiratory Depression? 
Heroin, morphine and other opioids with agonist activity at the mu-opioid receptor in the 
respiratory centre produce depressant effects soon after binding. As described, the activity in 
brain areas associated with inspiration is reduced by opioids, but the areas associated with 
expiration are unaffected, so the breathing rhythm becomes slow and irregular (Leino et al., 
1999). This causes hypercapnia (elevated carbon dioxide levels in the blood) and hypoxaemia 
(low levels of blood oxygen). An example of the acute effect of injected heroin on blood oxygen 
levels is demonstrated in Figure 3-8. 
 
In the absence of opioids, changes in arterial blood partial pressures of oxygen, carbon 
dioxide, and any resultant acid/base disturbance, which occur as a consequence of impaired 
control of breathing is sensed by central and peripheral chemoreceptors (sensors). These 
chemoreceptors relay information to the respiratory centres of the brain. Hypercapnia, 
hypoxaemia and arterial blood acidosis result in increased respiratory centre output to the 
respiratory muscles, to increase pulmonary ventilation and increase the rate of gas exchange 
in order to counter blood gas disturbance (see feedback loop mechanism in Figure 3-2). 
However, in the presence of opioids, this protective regulatory mechanism is blunted 
(Pattinson, 2008). If the ventilatory drive (or respiratory drive) is reduced for an extended 
period of time, the individual will hypoventilate, leading to impaired clearance of carbon dioxide 
in the arterial blood (hypercapnia), leading to respiratory acidosis. Vital organs and tissues no 
longer receive sufficient oxygen (hypoxia), ultimately leading to risk of organ failure, coma or 
death. In extreme cases, the individual will stop breathing (respiratory arrest). The severity of 
this respiratory depressant effect varies between opioids, but there is no opioid that does not 






















Figure 3-8: Oxygen saturation levels after intravenous opiate injection SpO2: peripheral capillary 
oxygen saturation (Latt, Conigrave, Marshall, Saunders, & Nutt, 2016) 
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Part 3: Why is Lung Disease Relevant to Opioid Users?  
This section will describe the relevance of lung disease to opioid users, the wider public health 
concerns and why it has become a problem that has recently received attention in the UK.  
 
3.11 What is Obstructive Lung Disease and Why is it a Problem? 
Obstructive lung disease is a category of respiratory diseases where the main feature is 
narrowing of the airways. Symptomatically, some of the common features of obstructive lung 
disease include coughing, excess mucus, persistent chest infections and breathlessness. 
Asthma and chronic obstructive pulmonary disease (COPD) are two of the most common 
chronic lung diseases in the UK. Around 1.2 million people in the UK have diagnosed COPD 
and around 5.4 million have asthma (BLF, 2016). Whereas asthma most commonly has an 
onset early in childhood, COPD (including emphysema) is most prevalent in later life (Mannino 
& Buist, 2007). Tobacco smoke remains the most important cause of COPD and the WHO 
estimates that between 40% and 73% of COPD mortality is related to smoking (Lopez, 
Mathers, Ezzati, Jamison, & Murray, 2006). Additionally, COPD morbidity and mortality 
increase with age as lung function declines in the third and fourth decades of life (Mannino & 
Buist, 2007). Other factors for COPD are exposure to dusts, chemicals, fumes in the 
workplace (Hnizdo, Sullivan, Bang, & Wagner, 2002), air pollutants (Lopez et al., 2006) and 
infections (Wedzicha & Seemungal, 2007).  
 
Generally, narrowing of the bronchial tree and can occur as a result of hyperactivity or 
hypertrophy of the smooth muscle, airway oedema, chronic airway remodelling or mucous 
hypersecretion (MacNee, 2006). Obstruction in airways lower down in the bronchial tree (distal 
airways) can result in their collapse during expiration. This can lead to gas trapping within the 
lung (lung hyperinflation), as well as causing positive end-expiratory pressure (PEEP) which 
needs to be overcome before air can be drawn into the airway down a pressure gradient from 
the atmosphere (i.e. PEEP is an inspiratory threshold load). Furthermore, hyperinflation 
imposes an elastic load on the respiratory muscles because of the added stretch on the lung 
tissues as a result of increased lung volume (see section 3.7.7). These changes increase the 




3.12 Opioid Users & Their Lungs  
From a clinical and public health perspective, the issue of underlying pulmonary morbidity in 
individuals who are at risk of opioid overdose is an additional concern. In general, it is widely 
understood that people with mental health conditions have increased risk of physical ill-health, 
delayed diagnoses and higher mortality rates. Moreover, those with physical as well as mental 
ill-health have poorer quality of life and increased mortality (Davies et al., 2014). At a national 
level, this is currently an area that is recognised by the Department of Health’s No Health 
Without Mental Health campaign (Health, 2012), and locally, by King’s Health Partner’s (KHP) 
Mind & Body Programme affirming the importance to ‘treat the whole person’ (KHP, 2017).   
 
People seeking treatment for drug and alcohol addiction are one of the most marginalised 
groups who struggle to access health care in both primary care and acute secondary care 
settings. An additional challenge is related to the premature deaths of individuals who are in 
treatment for drug/alcohol addiction, for example, patients seeking treatment for heroin 
addiction die 15 years earlier on average than the general population (Smyth, Fan, & Hser, 
2006) and drug-, and in particular, opioid-related deaths have been increasing (NRS (National 
Records of Scotland), 2018; ONS, 2018). A recent comprehensive inquiry into drug-related 
deaths highlighted that respiratory conditions contribute to these mortality figures and 
concluded that better pathways need to be enabled to screen for, and treat, health conditions 
including lung disease (PHE, 2017).  Considering the high number of people who smoke and 
use drugs, and the increasing numbers of ageing heroin users, it is unsurprising that illnesses 
caused by smoking play a significant role in the causes of death and may also increase the 
susceptibility to opioid overdose (Jolley et al., 2016; PHE, 2016b).  
 
Furthermore, respiratory clinicians have increasingly been noting airways disease due to the 
effects of opioid smoking (Jolley et al., 2016; Walker et al., 2015). A great deal of the existing 
literature relates to asthma and heroin inhalation (Cygan, Trunsky, & Corbridge, 2000; Hughes 
& Calverley, 1988; Krantz et al., 2003; Levine, Iliescu, Margellos-Anast, Estarziau, & Ansell, 
2005). These studies have reported acute to severe asthma cases in heroin smokers, some 




admissions occur in drug users (Canning, Kennell-Webb, Marshall, Wessely, & Peters, 1999). 
However, very little is actually known of the link between heroin administration and lung 
disease, let alone of overdose risk. A brief report on the prevalence of respiratory symptoms 
and lung disease in a community drug and alcohol treatment centre showed that 37% of clients 
(mixed sample of clients seeking treatment for drug and/or alcohol addiction) showed signs of 
COPD. Of the 112 clients that were tested 88% were smoking tobacco and 66% were heroin 
smokers (Jolley et al., 2015a). There are a further studies on COPD and heroin smoking 
(Burhan et al., 2018; Buster, Rook, et al., 2002; Lewis-Burke et al., 2016; Walker et al., 2015). 
They show that impairment of lung function (using either measures of Forced Expiratory 
Volume in the first second or CT scan of the lungs) is suggested to be related to smoking 
heroin.  
 
However, not all heroin users smoke heroin but despite this, it appears that many have 
pulmonary infections or diagnosed or undiagnosed lung disease, including COPD (Hind, 1990; 
Jolley et al., 2016; Scheidegger & Zimmerli, 1989; Walker et al., 2015). Tobacco smoking 
could play a role in the development of lung disease, and this is clearly a complex and 
multifactorial issue. Between 84% and 98% of opioid users smoke tobacco, which is the 
highest prevalence among all drug users (Bowman et al., 2012; Clemmey, Brooner, 
Chutuape, Kidorf, & Stitzer, 1997; Guydish et al., 2011; Pajusco et al., 2012; Tacke, Wolff, 
Finch, & Strang, 2001). Additionally, drug users who smoke have a heightened risk of 
premature death than non-smokers (Hser, McCarthy, & Anglin, 1994).  There is a great need 
to establish a stronger connection between clinical and experimental investigation of the 





3.13 Known Unknowns of Overdose Deaths 
For the past 40 years, a number of different studies have attempted to understand the 
contributing mechanism in fatal overdose (Cherubin, McCusker, Baden, Kavaler, & Amsel, 
1972; Darke & Duflou, 2016; Darke, Duflou, & Torok, 2010a; Darke, Mattick, & Degenhardt, 
2003b; Davoli et al., 2007; Force, Fisher, & Millar, 1973; Byers et al., 1975; White & Irvine, 
1999). Pulmonary oedema (fluid in the lungs) is considered the main factor and frequently 
observed in autopsy reports through histopathological evidence or congested lungs (Sporer 
& Dorn, 2001; White & Irvine, 1999).  
 
Pulmonary oedema in the heroin using population is considered to be the most common and 
widely reported complication of overdose (Duberstein & Kaufman, 1971; Hind, 1990; 
Schachter & Basta, 1973; Warner-Smith et al., 2001; White & Irvine, 1999). However, these 
findings are not specific to opioid-related deaths, but instead to deaths caused by respiratory 
failure. Additionally, pulmonary oedema and aspiration of vomit may not necessarily cause a 
fatality but may, in subsequent overdose events, lead to an increase risk of fatality (White & 
Irvine, 1999). Furthermore, opioids have an emetic effect and can also create the risk of 
aspiration of vomit (Henry, 1999). Whilst there can be a good prognosis and recovery from 
pulmonary oedema, it may leave impairment. In a study of 58 overdose survivors with 
pulmonary oedema (Duberstein & Kaufman, 1971), some showed lower vital capacity and 
total lung capacity after the non-fatal overdose event. Pneumonia also appears to develop 
after pulmonary oedema in some cases. Bacterial pneumonia is often as a result of aspirated 
vomit (Duberstein & Kaufman, 1971) but detailed studies on this are lacking as follow-up is 
inherently difficult (Darke & Duflou, 2016; Schachter & Basta, 1973). Moreover, there is also 
an issue related to the asymptomatic nature of certain conditions. Even after years of smoking 
tobacco, heroin and/or crack, emphysema may not be symptomatic enough for a user to seek 
treatment, however, autopsy reports often show that there is presence of undiagnosed 
pneumonia (Warner-Smith et al., 2001). This could be related to the respiratory depressant 





Part 4: How do we Measure Respiratory Depression in Opioid 
Users?  
This final section of the chapter will provide a justification of the measures used in this thesis. 
As there is no gold standard measure of respiratory depression it is important to provide good 
reason for inclusion of these varied measurements. This thesis incorporates a number of 
different parameters as it is ideally most effective to use multiple parameters at the same time 
to detect whichever indicator of respiratory depression may initially arise or is most effective 
at detecting changes (Gupta & Edwards, 2018).  
 
3.14 Justification of Physiological Measures  
3.14.1 Parasternal Intercostal Muscle Electromyography (EMGpara) and Neural 
Respiratory Drive (NRD) 
Neural respiratory drive (NRD) refers to the motor output from the central nervous system to 
the respiratory muscles acting on the chest and abdominal wall, generating respiratory 
movements necessary to pump air in and out of the lungs during inspiration and expiration. 
NRD differs according to the proportion of loads placed on the respiratory system and any 
changes in capacity of the respiratory muscle to respond to these loads (Moxham & Jolley, 
2009). Any increase in the load and/or reduction in capacity leads to increased NRD.  
 
It is not currently possible to accurately measure NRD using direct measures of the total 
brainstem respiratory neural output. Further, while it is possible to measure NRD as phrenic 
nerve activity in anaesthetised animals (Adrian & Bronk, 1928), this is not feasible in awake 
human participants. Pressure-based measures do exist but are restricted in their accuracy 
(Gaultier, Perret, Boule, Buvry, & Girard, 1981; Whitelaw, Derenne, & Milic-Emili, 1975) as 
they are reliant on patient motivation and cooperation as well as influenced by impaired lung 
mechanics, as occurs in disease such as COPD which are characterised by obstruction of the 
airways. These measures examine the respiratory pressures as indices of respiratory muscle 
tension (which indicate the activation of a muscle). Fortunately, there are other potential 
surrogates of NRD that can be measured relatively easily. These are highlighted in figure 3-




measured. Measurement of the neural input to selected and relevant respiratory muscles is 
possible and overcomes any limitation that may occur by use other ways of measuring NRD. 
NRD is able to reliably characterise the load imposed on the respiratory system relative to its 
capacity.  
 
Electromyography (EMG) is a technique that is used to measure electrical activation of 
skeletal muscle associated with muscle contraction (Lindstrom & Magnusson, 1977). EMG 
can be measured using surface electrodes placed over the muscle of interest, needle 
electrodes inserted into the muscle or catheter-mounted electrodes in the oesophagus. The 
magnitude of the EMG signal is directly related to the force generated by the muscle during a 
contraction. 
 
Details of the anatomy and neurophysiology relating to parasternal intercostal muscles are 
described earlier in this chapter. Between the sternum and costo-chondral junction (the joint 
between rib and costal cartilage on the front of the rib cage), the first five interspaces are 
replaced by flat broad tendons (fibrous aponeuroses), and the internal intercostals in these 
interspaces are known as parasternal intercostal muscles (Han et al., 1993) (Figure 3-3). The 
parasternal intercostals have a role in inspiration and are termed the ‘inspiratory intercostals’. 
Parasternal intercostal muscles are obligate muscles that activate in synchrony with the 
diaphragm and only inactive when inspired volume of air is minimal (De Troyer & Estenne, 
1988; De Troyer & Sampson, 1982; Gandevia et al., 1996; Taylor, 1960). There is also a well-
reported and strong agreement between EMG activity of the parasternal intercostal muscles 
and the diaphragm (Reilly et al., 2013, 2011; Wanke, Lahrmann, Formanek, & Zwick, 1992). 
EMG of the parasternal intercostal muscles (EMGpara) use in measuring NRD has also been 
shown to be reproducible (Gandevia et al., 1996; Murphy et al., 2011; Reilly et al., 2011; 
Steier, Jolley, Polkey, & Moxham, 2011). The parasternal muscles show less mechanical 
disadvantage than the diaphragm in the presence of lung hyperinflation (Decramer, Jiang, & 
Demedts, 1987) (an abnormally high volume of air remaining in the lungs at the end of 
expiration) and have greater mechanical efficiency at total lung capacity. It is suggested that 




preferentially recruited under conditions of increased and expiratory lung volume (Jiang, 
Deschepper, Demedts, & Decramer, 1989). 
 
EMGpara has been used in various different clinical settings and laboratories and has 
successfully been used to detect changes in respiratory load and NRD in a number of different 
patient populations (Gandevia et al., 1996; Murphy et al., 2011; Reilly et al., 2011; Steier, 
Jolley, Polkey, & Moxham, 2011), including opioid users (Jolley et al., 2015b). Two studies 
(Murphy et al., 2011; Reilly et al., 2011) examined the reproducibility of EMGpara in healthy 
young adults and showed strong correlation of values obtained across two occasions. 
Measuring EMGpara is a useful tool in discriminating between healthy subjects and those with 
respiratory disease. Greater levels of EMGpara (i.e. increased electrical activity of the 
inspiratory muscles) are observed in patients with COPD (Gandevia et al., 1996; Murphy et 
al., 2011), asthma (Steier et al., 2011) and cystic fibrosis (Reilly et al., 2011) compared to 
healthy subjects.  
 
EMGpara is thus widely accepted to be an indirect index of NRD, thereby providing an objective 
quantifiable index of the load on the respiratory muscles and the load-capacity balance of the 
respiratory muscle pump. The existing literature is in support of the use of EMGpara as a marker 
of NRD and load on the respiratory system. These observations support the use of EMGpara 
as a direct, reliable and sensitive measure of acute opioid-induced changes in NRD, as 






















Figure 3-9: A flow diagram outlining the physiological coupling of NRD to ventilation, indicating the 




This figure highlights the links between NRD, respiratory muscle activation, chest wall and 
lung mechanics as well as ventilation. It can also be seen here that the potential for 
‘uncoupling’ of mechanical output from NRD is increased with each move away from the 
central respiratory centre. The implication of this when measuring NRD in patients with 
respiratory disease, which applies to opioid users, is that the measures further away from 
respiratory centres such as ventilatory parameters become more unreliable measures of NRD 
in respiratory disease as the mechanical outputs are uncoupled from NRD.  
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3.14.2 Ventilation  
Although often used as a measure of NRD, ventilation is not a perfect measure of NRD 
because changes in the mechanical properties of the respiratory system will alter the 
relationship between NRD and inspiratory flow. This is crucial to the study of NRD in COPD 
where indices of NRD based on ventilation will unreliably underestimate the level of NRD 
(Cherniack & Snidal, 1956). Changes in the mechanical properties of the respiratory system 
alter the relationship between NRD and ventilation. This is important when studying NRD in 
people who have COPD, where indices of NRD based on ventilation are unreliable as they 
will underestimate the level of NRD (Cherniack & Snidal, 1956). 
 
Most studies that examine the neural control of respiration use ventilation as an outcome 
measure. Ventilation parameters are centred on measuring the volume and frequency of 
inspired and expired air as well as combinations of these. Usually these are conducted via a 
face mask or mouthpiece attached to a pneumotachograph10, which essentially allows an 
accurate and reliable type of flow measurement. Minute ventilation (VE) is the product of the 
tidal volume (VT) and respiratory frequency (breathing rate; Vf). As these can both be 
regulated separately, a more complete assessment of the impact of respiratory stimuli 
(anything that causes a change in the respiratory response mechanisms such as a decrease 
in oxygen or increase in stress) on NRD also requires assessment of both tidal volume and 
respiratory frequency) (Cherniack & Snidal, 1956; Milic-Emili & Grunstein, 1976).  
  
                                                   





3.14.3 End-tidal CO2 (ETCO2) and Transcutaneous CO2 
Capnography is a measure of carbon dioxide in respiratory gases and can be used to reliably 
measure different carbon dioxide outputs in a non-invasive manner. End-tidal CO2 (ETCO2) 
and transcutaneous CO2 (TcCO2) are two capnography measures incorporated in this thesis. 
The most reliable, and ‘gold standard’ measure of blood gases such as carbon dioxide and 
oxygen is via arterial blood gas tests (ABG) or by earlobe blood gas test (EBG), which is an 
arterialised capillary sample. However, its application has some limitations; arterial blood gas 
tests are invasive, time consuming, expensive and can be unpleasant and risky (Parker & 
Gibson, 2007; Yousuf et al., 2015).  
 
In addition, single measurements of partial pressure of carbon dioxide are unhelpful in 
predicting impending respiratory depression (Gross, 2003). Modelling of this interaction 
between carbon dioxide and opioids on breathing has shown that with gradual increase in 
opioid levels, progressive respiratory depression causes gradual hypercapnia. However, with 
a fast intravenous bolus injection of opioid, respiratory depression is reached until pCO2 
reaches its steady-state (Pattinson, 2008). This goes some way in explaining why drugs with 
slower binding to receptors (low affinity), e.g.  morphine, are considered safer than those that 
bind more quickly e.g. fentanyl. This modelling also demonstrates the inability of single point 
carbon dioxide measuring to reliably detect respiratory depression.  
 
End-tidal carbon dioxide (ETCO2) measurements refer to the peak carbon dioxide 
concentration or partial pressure of carbon dioxide recorded at end-expiration. ETCO2 
measurements uses infrared light passing over the gas sample within each exhaled breath. 
The presence or lack of carbon dioxide is inversely related to the amount of light that passes 
through the sensor (low levels are indicated by high amounts of light, and vice versa) (Bickler, 
2007). TcCO2 is another measure of carbon dioxide that uses continuous, instead of per 
breath measurements. Both have been shown to reliably detect hypercapnia but are not 
considered to be as accurate as PaCO2 (Won et al., 2016; Yousuf et al., 2015). 
 
Capnography can relay information on metabolism, perfusion and ventilation or even how 




immediate setting. An advantage of the ETCO2 method is that changes are detected and 
displayed breath-by-breath, allowing acute changes in alveolar (and hence arterial) CO2 levels 
to be measured. TcCO2 is more commonly used in polysomnography (sleep studies) where 
trends are reported over extended periods of time. Carbon dioxide is highly soluble in tissue 
and readily diffuses through the skin. TcCO2 uses sensitive sensors over the skin and is a 
well-validated surrogate marker for PaCO2 and is considered more reliable, in this sense, than 
ETCO2 (Gerdung, Adeleye, & Kirk, 2016). Additionally, in awake individuals the discrepancy 
between TcCO2 and ETCO2 is not as significant as during sleep (N. L. Jones, Robertson, & 
Kane, 1979; Won et al., 2016).  
 
3.14.4 Pulse Oximetry  
Measurement of arterial blood oxygen saturation and its physiological foundations are 
described in this chapter. Non-invasive assessments of arterial blood oxygen saturation 
(SpO2) by pulse oximetry is a simple and common monitoring tool used in almost every clinical 
setting. Strict guidelines exist within anaesthesiology and emergency medicine in the use of 
SpO2 to monitor for respiratory function during sedation, deep sedation or general 
anaesthesia, amongst other states. The detection of arterial hypoxaemia is crucial in these 
clinical areas (Becker & Casabianca, 2009). Hypoxaemia is distinct from hypoxia in that it 
occurs when ventilation is adequate but perfusion of the pulmonary alveoli is inadequate and 
there is a failure of oxygenation. Hypoxia is a more generic term encompassing reduced 
oxygen in inspired gas or any tissue, including blood. Pulse oximetry allows for a continuous, 
non-invasive method, again, as opposed to direct measurement of blood gases which require 
a sample of blood. However, a fall in SpO2 is a relatively late feature of hypoventilation, and 
reliance on SpO2 will therefore lead to under-recognition of respiratory depression in standard 
clinical settings (Dahan, Aarts, & Smith, 2010; Jolley et al., 2015b).  
 
It is also important to note that pulse oximetry and capnography are only ever an indirect, 





3.15 Current Experimental Studies on Respiratory Depression and 
Overdose 
A great proportion of our current understanding of overdose mechanisms is as a result of 
controlled trials of prescribed, injectable opioids, mainly heroin. These trials have incorporated 
physiological measurements as part of their safety protocols (Haasen et al., 2007; March, 
Oviedo-Joekes, Perea-Milla, & Carrasco, 2006; Perneger, Giner, del Rio, & Mino, 1998; 
Reimer et al., 2011; Strang, Metrebian, et al., 2010).    
 
There is a need to advance this type of experimental work further and develop better 
techniques and responses to overdose. The standard clinical practice of measuring 
hypoventilation involves monitoring pulse oximetry. As stated previously. it has been 
speculated that this approach may underestimate the true respiratory effects of the drugs 
(Jolley et al., 2015b). There are more sensitive approaches as well as novel, less invasive and 
reliable techniques that could be used to detect early indicators of respiratory depression. 
Transcutaneous or end-tidal carbon dioxide monitoring or direct measures of NRD via 
respiratory muscle EMG are more advanced, and potentially clinically useful techniques.  
 
My second supervisor, Dr Caroline Jolley, along with colleagues in the Addictions and 
Respiratory Medicine fields sought to investigate whether these other, more advanced 
techniques, could add value in detecting changes to the respiratory effects over oximetry alone 
(Jolley et al., 2015b). Participants (n=10) were monitored over a course of 150 minutes post-
administration of their usual diamorphine dose. EMGpara (a tool which assesses how hard the 
breathing muscles are working), pulse oximetry (measuring the blood’s oxygen levels), and 
measurement of carbon dioxide levels in exhaled breath were all measured. It was found that 
there was an increase in the level of carbon dioxide per breath in eight of the ten participants 
and a low blood oxygen level in only four out of the ten patients. Whilst there were varying 
degrees of respiratory depression found in all patients, pulse oximetry failed to detect some 
of these events. The study also found that simply talking to a patient raised awareness and 
resulted in resumed breathing – and thereby masked episodes where patient was breathing 





The findings of this work demonstrate that acute opioid-induced respiratory depression can 
be detected using advanced continuous respiratory monitoring techniques, but the question 
is: can the use of these advanced respiratory monitoring techniques reduce the risk of opioid-






Heroin is synthesised from morphine, the main active component of opium. Opioids are a 
particularly interesting group of drugs that have been used for centuries (in particular opium 
before morphine was originally isolated) for their pain-relieving, sedative, anti-anxiety and 
cough suppressant effects. However, they also possess a negative side effect that has been 
the crux of pharmaceutical development over many decades: respiratory depression, a 
dangerous reduction in breathing. Opioids act on a wide range of areas of the brain and body 
through molecules that elicit or inhibit effects (known as receptors).  
 
In healthy individuals, the intricately balanced network of respiratory muscles and control 
centres of respiration allow for adequate blood gas homeostasis. The extent of respiratory 
muscle activity is dependent on the load which is placed upon them, and simultaneously on 
their own capacity. Additionally, in the presence of opioids, this protective regulatory 
mechanism is stunted (Dahan et al., 2010; Pattinson, 2008). The effect on ventilatory 
frequency by opioids is well-reported in the literature (Bailey et al., 2000; Bouillon et al., 2003; 
Brunton et al., 2008; Ferguson & Drummond, 2006; Lumsden, 1923). Although mechanisms, 
or prevalence of assumed/documented mechanisms, of fatal overdoses are not fully 
understood (Sporer & Dorn, 2001), it is known that if the ventilatory drive is reduced for an 
extended period of time, the individual will eventually stop breathing causing respiratory 
failure. Furthermore, either through excessive build-up of carbon dioxide in the blood 
(hypercapnia), leading to respiratory acidosis or vital organs and tissues no longer receiving 
sufficient oxygen (hypoxia) or pulmonary oedema (fluid in the lungs), ultimately it leads to risk 
of organ failure, coma or death if hypoxaemia is profound. The severity of this respiratory 
depressant effect varies between opioids, but there is no opioid agonist that does not have 
this effect.  
 
There are numerous risk factors influencing the likelihood of an overdose, including, but not 
limited to, the type of opioid, strength and amount of the drug that is absorbed into the blood. 
Individual factors, such as tolerance, current health status, duration of use and genetic 




Opiate users usually smoke tobacco and are at risk of lung disease. In obstructive lung 
disease the pathophysiological changes to the muscles, tissues and airways disrupt this lung-
capacity relationship such that neural respiratory drive has to increase to adapt to this change 
in order to maintain homeostasis.  
 
It is possible to detect respiratory depression in individuals using reliable and accurate 
physiological measures. EMGpara is a feasible measure of NRD and is responsive to changes 
in respiratory load-capacity balance. Additionally, capnography is a reliable and non-invasive 
alternative to using classic invasive methods.  
 
This chapter has provided a detailed overview of the mechanisms, risk factors and 
physiological bases of opioid overdose and has explained the use of specific markers and 
measures of respiratory depression. The subsequent chapter leads on to discussing the 






4 General Methods 
4.1 Preface 
The clinical studies described in this thesis use physiological measures to examine respiratory 
depression and respiratory function amongst opioid users. Methods described in this chapter 
are traditionally-used clinical techniques as well as novel physiological techniques that are 
used as indices of neural respiratory drive (NRD), which is the motor output (signals from the 
brain and brainstem) to respiratory muscles. Methods involved in the subjective measures of 
drug effect are also stated in this chapter. A justification as to the use of these particular 
measures is described in the preceding chapter.  
 
I had the opportunity to be trained in the use of all of these methods with supervision from 
relevantly trained professionals. I also had the opportunity to attend regular research meetings 
with physiologists and critical care and respiratory clinicians which allowed me to resolve 
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4.2 Ethical Considerations  
All studies within the thesis were granted ethical approval by either the King’s College Hospital 
Research Ethics Committee (ref: 05/Q0703/82) or London South East Research Ethics 
Committee (ref: 16/LO/1765). All participants gave written, informed consent.  
 
4.3 Subjects 
Study 1, Respiratory Depression & Underlying Respiratory Disease in Opioid Users 
(described in Chapter 5): studies were performed in healthy participants, participant with 
opioid addiction and non-drug-dependent participant with obstructive lung conditions. All 
healthy subjects were free of respiratory or neuromuscular disease. All subjects gave their 
written, informed consent to participate and studies were performed within the Chest Unit of 
King’s College Hospital (KCH). Screening was conducted by Dr Caroline Jolley and 
anthropometric measures of height and weight as well as spirometry measures were taken by 
Chest Unit physiology technicians.  
 
Study 2, Acute Opioid Overdose Study (described in Chapter 8): study participants were 
opioid-dependent and receiving prescribed injectable diamorphine (pharmaceutical heroin) 
treatment. All participants gave their written, informed consent to participate and studies were 
performed within the NIHR/Wellcome Trust King’s Clinical Research Facility (CRF) at KCH. 
Screening was conducted by Addictions doctors and nurses and anthropometric measures of 
height and weight as well as spirometry measures were taken by clinical research nurses 





4.4 Pre-Protocol Procedures  
4.4.1 Respiratory Function Methods 
ARTP-trained11 respiratory physiology technicians within the KCH Chest Unit or clinical 
research nurses within the CRF at KCH conducted the pulmonary function tests in accordance 
with the American Thoracic Society and European Respiratory Society (ATS/ERS) standards 
(Miller et al., 2005). The technique was explained to each participant prior to commencement 
of testing. All participants were seated upright with head and neck in a neutral or slightly 
extended position, with a nose-clip and asked to seal their lips tightly around a mouthpiece. 
The participants were asked to breathe in rapidly and fully to full lung capacity, and then 
subsequently to perform a maximal forceful exhalation, until no more air could be expelled. 
Verbal encouragement was provided throughout each manoeuvre and repeated efforts were 
performed in order to obtain three acceptable maximal manoeuvres. Acceptable repeatability 
was considered when the difference between the largest and subsequent largest was no more 
than 5% (Miller et al., 2005).  
 
The FEV1 and FVC values are expressed in litres of volume of air as well as a percentage of 
the predicted normal for a person of the same sex, age and height. Percentage predicted 
values are based on a set of reference values that are collated by the Global Lung Function 
Initiative (Quanjer et al., 2012). A ratio of FEV1/FVC is used to determine what proportion of a 
person’s vital capacity they are able to expire in the first second of forced expiration.  
 
  
                                                   




4.5 Physiological Measurements  
There are obvious ethical implications in measuring respiratory depression and monitoring 
overdose in humans. Thus, a method of safely detecting respiratory depression in an acute 
setting appears a suitable approach in addressing this issue. A number of different traditional 
and novel measures can be used to detect acute respiratory depression. Rationale for the use 
of the particular measures relevant to this thesis are highlighted in the previous chapter 
(Chapter 3). This section describes the methods and procedures incorporated in this thesis.   
 
4.5.1 Electromyography of the Parasternal Intercostal Muscles (EMGpara) 
In the two primary clinical studies, parasternal electromyography (EMGpara) was conducted by 
me with supervision from Dr Caroline Jolley. Subjects’ skin was rubbed with an abrasive gel 
(NuPrep, Waver and Company, Aurora, Colorado, USA) and then followed by alcohol wipes 
prior to applying self-adhesive silver-silver-chloride electrodes (Kendall Arbo, Tyco 
Healthcare, Neustadt/Donau, Germany). Two electrodes to the second intercostal space 
(bilateral) were applied, 3cm from the midline (Figure 4-1), in accordance with existing 
literature (Maarsingh, Eykern, Sprikkelman, Hoekstra, & Aalderen, 2012; Murphy et al., 2011; 
Reilly et al., 2011). A reference electrode was placed on the acromion process of the scapula.  
 
Study 1 (Respiratory Depression in Opioid Users): EMGpara was recorded during resting 
breathing as participants were seated in a chair with their back supported, arms resting on the 
armrests and feet on the footrests. Participants were asked to remain still and quiet throughout 
the recording period. Recording of EMGpara was for a minimum of 30 minutes for each 
participant. Some participants necessitated longer recording periods due to movement, 
laughter or speech. Recording was taken with a minimum 15 minutes rest after spirometry 
testing to reduce any alteration of NRD due to forced expiratory manoeuvres.  
 
Study 2: EMGpara was recorded continuously over a 60-minute post-intervention period, plus 
a 3-minute baseline recording period. Participants were measured whilst seated in a semi-






Figure 4-1: Illustration of the positioning of electrodes (blue) on the 2nd intercostal space parasternal 


















Figure 4-2a: Sample showing raw EMGpara (red) and root mean square (RMS) (green) traces showing 







Figure 4-2b : 





































4.5.2 EMGpara Acquisition 
EMGpara signals were amplified (gain x1,000) and band-pass filtered between 10Hz and 
2,000Hz (using CED 1902, Cambridge Electronic Design Ltd, Cambridge, UK). EMGpara 
signals were acquired and digitised using a Powerlab analog-to-digital converter (Powerlab, 
ADInstruments, Sydney, Australia) and displayed on a laptop computer (Dell Inspiron 3000) 
running LabChart software (Version 8, ADInstruments Pty Ltd, Castle Hill, Australia). A 
sampling frequency of 4kHz was used during resting breathing and maximal inspiratory 
manoeuvres. Following post-acquisition band-pass filtering between 20Hz and 1kHz using 
LabChart software, the recordings were stored for off-line analysis (MacBook Air, Mac OS X 
Yosemite, Apple Inc., Cupertino, California, USA). A notch filter at 50Hz to minimise mains 
frequency interference (‘noise’) was implemented. It was accepted that there would be loss of 
EMGpara signals within the 50Hz region of the EMGpara frequency spectrum. 
 
4.5.3 EMGpara Interpretation  
Areas of increased EMG activity that were characteristic of inspiration were identified (Figure 
4-2a and Figure 4-2b). RMS was converted from the raw signal using LabChart. The maximum 
RMS value of EMGpara during 100ms subdivisions of each breath was determined by manually 
selecting signals falling between QRS complexes of the ECG artefact (Figure 4-2a). 
Subsequently, the mean maximum RMS EMGpara per breath over 1-minute subdivisions of the 
whole recording was calculated. EMGpara was expressed in microvolts (µV) and also, as a 
percentage of the peak RMS EMGpara value obtained during maximal respiratory manoeuvres 
such as inspiration to TLC (slow breath in all the way to maximum breath hold) (EMGpara%max) 
(Figure 4-2b). EMGpara from each minute of each recording was analysed. Periods of 
increased EMGpara activity characteristic of inspiration selected, manually selecting regions 
between ECG complexes (QRS) for analysis.  
 
Accurately measuring and representing EMG signals depends on a number of different 
factors; namely, quality of contact between the electrode and overlying tissue (muscle 
interaction factors), which includes electrode position in alignment with the area of the muscle 




as amplifier design, and conversion and storage of the EMG signal from analogue to digital 
form (i.e. A/D conversion). These factors influence the amplitude, time and frequency domain 
properties of EMG recordings. EMG signals are also affected and can be contaminated by 
ambient noise, transducer noise and biological noise.  
 
4.5.4 Sources of Noise  
Ambient noise is generated by electromagnetic devices such as computers and power lines, 
amongst others. Transducer noise is generated at the connecting point between the electrode 
and overlying muscle tissue. Electrodes convert the ionic currents that are generated in the 
muscle cell membrane into an electric current that can be stored as a voltage potential and 
be manipulated. There are two specific types of noise that are present in the transduction of 
the signal: Direct Current (D/C) Voltage Potential and Alternating Current (A/C) Voltage 
Potential. The D/C Voltage Potential is caused by differences in the impedance between the 
electrode and recording surface and by redox reactions occurring in the contact region 
between the electrode and conductive gel (‘contact gel’). The A/C Voltage Potential is 
generated by fluctuations in impedance between the conductive transducer and overlying 
tissue. Arranging the electrodes in a bipolar format suppresses the noise signals that are 
generated at the electrode-surface interface. In practice, the absolute electrode-surface 
impedance is not a critical factor because modern, high quality amplifiers have a high input 
impedance to reduce the differential pickup caused by mismatches in resistance as well as 
loss of voltage.  
 
4.5.5 Calculation of EMGpara%index 
All analysis was carried out offline using LabChart (version 8). The largest RMS EMGpara value 
was calculated by analysis of the block of EMGpara recordings. For each recording of interest, 
the mean maximum EMGpara per breath was calculated, and expressed as a percentage of 
EMG peak to obtain the mean EMGpara%max value. The ‘EMGpara%index’ or ‘NRDI’ was 
calculated by multiplying EMGpara%max with the respiratory rate (Vf) (Murphy et al., 2011). In 




manoeuvre are calculated as a percentage providing the EMGpara%max, which is then 
multiplied by the respiratory rate to provide the EMGpara%index or NRDI. 
 
4.5.6 Ventilation  
 
For study 1 (Lung Health study), flow measurements were calibrated prior to each study 
session/subject using a two-point calibration technique where two known flow rates were 
applied to the fine bore catheter pneumotachograph head. Zero flow was generated on one 
point, and on the second, a known flow rate was applied as measured by a rotatometer (KDG 
Mobrey, England, range 0-200l/min). The pneumotachograph was then connected to a 
pressure transducer (Validyne, Northridge, USA, range ±2.5cmH2O) and a test of linearity was 
conducted using stepwise increases in applied flow rates as shown in figure 4-3. Participants 
were asked to tightly seal their lips around the mouthpiece of the pneumotachograph and 
resting breathing was recorded over a minimum of 10 minutes with a break after 5 minutes. A 
noseclip was in place throughout the measurement.  
 
For study 2 (AOO study), a spirometer (AD Instruments) and calibration syringe (1L, AD 
Instruments) were used. Calibration involved connecting the pneumotachograph onto the 
syringe and subsequently, the flow head signal was set to zero. Once ensuring that there was 
no airflow through the pneumotachograph, the syringe was withdrawn at a steady rate to the 
full 3L, whilst ensuring that there was a negative deflection of flow on the trace. The acquired 
flow calibration signal was then calibrated through the Spirometer Flow function on the 
LabChart data acquisition software.  
 
Offline analysis allows calculation of Tidal volume (VT), measured in litres. The flow signal 
provides the volume of air that is inhaled and exhaled (Figure 4-4). The volume is obtained by 
integrating the flow signal on a breath-by-breath basis. Minute ventilation (VE) is a product of 




































































































































4.5.7 End-tidal carbon dioxide and Transcutaneous carbon dioxide 
 
Capnography was measured by end-tidal and transcutaneous measures. A Gas Analyser 
(Iworx capnograph) and a tube that attached to the nose. For measurement of end-tidal CO2, 
expired air was sampled continuously from the nasal orifices using an adapted nasal cannula 
in line with an Iworx (Figure 4-5). End-tidal carbon dioxide (ETCO2) was recorded as the peak 
% carbon dioxide per expired breath and converted to kPa (Figure 4-6). ETCO2 was recorded 
continuously and displayed in real time using Powerlab and LabChart (Figure 4-6) and was 
stored for offline analysis.  
 
 
Figure 4-5: Illustration of Nasal Cannula (BruceBlaus, 2017) 
 
Transcutaneous carbon dioxide (TcCO2) was measured using a transcutaneous capnograph 
(TOSCA TCM4, Radiometer Medical ApS, Brønshøj, Denmark) using an ear-clip sensor. 
TcCO2 uses sensitive sensors over the skin and is a well-validated surrogate marker for 
PaCO2 (Gerdung et al., 2016). TcCO2 uses continuous, instead of per breath measurements 
(Figure 4-7). 
 
The Radiometer TOSCA device uses earlobe sensors for TcCO2 measurement as well as a 
reflection sensor for pulse oximetry. The sensor is heated to 42⁰C in order to increase capillary 
arterialisation and improve measurements conditions once placed on the skin. The TOSCA 
consists of an automatically calibrated modus before it is attached to the earlobe, using a dry 
gas mixture. The sensor was placed according to instructions and data was collated after an 






Data were analysed offline using a laptop as above. All capnography data were analysed in 
kilopascals (kPa). TcCO2 data was acquired as millimetres of mercury (mmHg) and ETCO2 






























4.5.8 Pulse Oximetry  
 
Oxygen saturation (SpO2) is a simple and common monitoring tool used in almost every 
clinical setting. Strict guidelines exist within anaesthesiology and emergency medicine for the 
use of SpO2 to monitor for respiratory function. SpO2 was recorded by pulse oximetry 
(Ohmeda Biox 3700) and by earlobe sensor (TOSCA). The input to LabChart was calibrated 
with respect to the analogue output of the oximeter before each study session. The pulse 
oximeter was displayed and recorded continuously on LabChart in real time and stored for 
offline analysis. The measures of oxygen saturation were recorded continuously with the 
oximeters recording a percentage of blood oxygen saturation (SpO2%) every 5 seconds. 






4.5.9 Assessment of Shortness of Breath  
 
Shortness of breath, or dyspnoea, is a subjective experience. However, quantitative measures 
of dyspnoea are valuable. The standardised modified Medical Research Council (mMRC) 
Dyspnoea Scale (Hajiro et al., 1998; Mahler & Wells, 1988) uses a scale of 0 to 4 to measure 
a person’s functional limitation associated with breathlessness (Table 4-1). This scale was 
used in study 1 (Chapter 5) of the thesis.  
 
Table 4-1: mMRC Dyspnoea Scale used to describe breathlessness in Study 1 . 
Grade Description of Breathlessness 
0 I only get breathless with strenuous exercise. 
1 I get short of breath when hurrying on level ground or walking up a slight hill. 
2 On level ground, I walk slower than people of the same age because of 
breathlessness or have to stop for breath when walking at my own pace. 
3 I stop for breath after walking about 100 yards or after a few minutes on level 
ground. 






4.6 Indicators of Significant Respiratory Depression  
 
Several different studies were examined when determining the most appropriate cut-off as a 
representation of respiratory depression. Any presence of the markers and frequencies of dips 
or increases below/above certain levels were realised to be the most accurate representation 
of the data. Evidence of significant respiratory depression was recorded using a variety of 
physiological markers. Criteria and threshold levels are indicative of clinically-significant 
respiratory depression and were determined through Sleep Medicine and Anaesthesia 
literature (Dahan et al., 2010; Douglas, 2005; O’Driscoll, Howard, & Davison, 2008) and 
through discussions and advice from members of the respiratory medicine research group 
which included critical care consultants, respiratory medicine consultants, and other allied 
experts as well as academic supervisors and co-investigators.  
 
In study 1 (Chapter 5), an observational study where no intervention was implemented, 
respiratory depression was deemed to have occurred if any one of the following criteria were 
satisfied:  
• ETCO2 > 6.6kPa in one or more breaths, 
• Mean TcCO2 > 6kPa, 
• SpO2% <90% for longer than 10 seconds; 
• Absence of inspiratory airflow and/or parasternal intercostal muscle EMG activity for 
more than 10 seconds (apnoea). 
In the heroin study (Chapter 8), where the intervention was injectable diamorphine, the 
following indices of significant respiratory depression were recorded and used as evidence for 
respiratory depression: 
• Presence of oxygen saturation <90% for longer than 10 seconds or <80% for more 
than 1 minute, 
• ETCO2% per breath exceeding 6.6kPa or increases of 1kPa from baseline, 
• Mean above 6kPa TcCO2 or increases of 1kPa from baseline, 
• Absence of inspiratory airflow and/or parasternal intercostal muscle EMG activity for 




• Absence of response to verbal stimuli. 
As a comparison, the following values and ranges are considered to be ‘normal’ in healthy 
adults with healthy respiratory function during resting breathing:  
• SpO2 above 95%; 
• Mean TcCO2  between 5-6kPa; 





4.7 Subjective and Staff Rating of Drug Effect 
 
Subjective drug effect measures were calculated in the studies described in chapters 6 and 
8. The following variables were measured:   
• Staff rating of intoxication, 
• Staff level of consciousness,  
• Subjective drug effect (Chapter 8 only), 
• Subjective drug liking (Chapter 8 only), 
• Level of intoxication, 
• Pupil size, in mm. 
 
In Chapter 6 and 8, at 3 minutes prior to administration of the injectable opioid, and then at 3, 
8, 15, 30, 60 minutes each participant was asked to rate their subjective drug experience. At 
these times, pupil sizes were also recorded, and staff ratings of level of consciousness and 
intoxication were also documented against the Glasgow Coma Scale (GCS (Teasdale & 
Jennett, 1974)) (Table 4-2). 
 
In Chapter 6, the following ratings were used:  
Staff rating of intoxication was measured on a scale which follows the rating: 0 = no effect; 5 
= maximal effect. Staff rating of level of consciousness was assessed using a numerical rating 
scale, as follows: 1 = normal, 2 = visibly affected but alert, 3 = drowsy but responds to verbal 
stimuli, 4 = no response to verbal stimuli. Patients assessed their drug-related ‘high’ on a 
rating scale, which follows the rating as follows: Rating of intoxication 0 = no effect, 5 = 
maximal effect 
 







Table 4-2: Glasgow Coma Scale (Teasdale & Jennett, 1974). 
Behaviour Response Score 
Eye opening 
Response 
Spontaneously  4 
 To speech 3 
 To pain 2 
 No response 1 
Best verbal 
response 
Orientated to time, place and person  5 
 Confused  4 
 Inappropriate words 3 
 Incomprehensible sounds 2 
 No response  1 
Best motor 
response 
Obeys commands  6 
 Moves to localised pain  5 
 Flexion withdrawal from pain  4 
 Abnormal flexion  3 
 Abnormal extension  2 
 No response 1 
Total Score Best response  15 
 Comatose Client 8 or less 







Where appropriate, data were tested for normality and any ordinal data were presented as 
median (interquartile range) and non-parametric testing was used. In respiratory health study 
(Chapter 5), Kruskall-Wallis or Spearman Rank was used to assess the relationship between 
matched pairs of data and also, Mann Whitney U for differences between groups. Data 
analyses were performed using SPSS software v22 for Mac (SPSS Inc, Chicago, Illinois, 
USA). Significance was determined at values of p<0.05 level. 
 
In the heroin study (Chapter 8), differences between baseline, minimum and successive time-
points after drug administration were analysed using non-parametric repeated measures 
ANOVA (Friedman test). Friedman’s test, Kruskal-Wallis was used to test for differences 
between baseline, minimum/maximum or successive time-points for each measure after drug 
administration. In addition, post hoc analysis was conducted using Dunn’s Multiple 
Comparison Test. Differences between diamorphine dose condition (100% versus 110% 
versus 120% of the daily maintenance dose) was tested using Wilcoxon Signed Rank Test for 







The studies in this thesis use a variety of different physiological measures. Clinical 
assessments of lung capacity are used to assess disease severity and treatment decisions; a 
relatively novel technique is used to measure electrical signals that are required for muscle 
contraction relative to capacity; blood gases are measured through different techniques which 
have all been described here. The chapter also described the subjective measures of drug 
effect, breathlessness and outlines the criteria that have been identified as respiratory 
depression. Without a standard measure of respiratory depression, there are various 





5 Respiratory Depression and Underlying Respiratory 
Disease in a South London Drug Treatment Centre 
5.1 Preface 
This chapter explores the physiological and personal characteristic data from a sample of 
clients at a South London drug treatment centre. From January 2016 to January 2017, I had 
the opportunity to help assist my second supervisor Dr Caroline Jolley at the pop-up Lung 
Health Clinic at Lorraine Hewitt House. It was a great opportunity to observe the clinical 
application of a relatively novel health intervention and also to be able to recruit participants 
for the study described in this chapter.  
 
For the study, I was involved in (and responsible for) the study design, participant recruitment 
as well as data collection and data analysis of this study. Study recruitment is by and large 
unpredictable and can be frustrating. This is particularly the case in a population where 
participation in research for some individuals is a less significant priority.  
 
This chapter is divided into two parts; the first focusses on the descriptive and personal 
characteristic data of the opioid-dependent user (ODU) group; the second part of the chapter 
provides a comparative context to the ODU group data and delves into the novel area of 
respiratory disease and overdose risk crossover. Surprising though it may seem, the literature 
and general discussion of this crossover is relatively recent, and it has already proved 
important to guiding clinical practice and for paving the way to future research.  
 
I presented some of the results of this chapter at the 2nd Lisbon Addictions conference in 
Portugal as well as at the 27th International Congress of the European Respiratory Society in 
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5.2.1 Background & Rationale  
As described in chapter 3, opioids are mu-opioid receptor agonists with potent respiratory 
depressant properties. Opioids impact the control of breathing and cause fatal overdoses 
usually by respiratory failure as a consequence of a depressant and disruptive action on the 
regular breathing rhythm and respiratory drive. This can cause accumulation of high levels of 
carbon dioxide (hypercapnia) and low levels of oxygen (hypoxaemia) in the blood. A further 
complication of opioid overdose includes pulmonary oedema (Leino, Mildh, Lertola, Seppala, 
& Kirvela, 1999; Pattinson, 2008; White & Irvine, 1999). These opioid drugs act by binding to 
mu-opioid receptors which are present in the brain and brainstem respiratory centres. It has 
been shown that people on opioids (e.g. methadone or morphine) have a blunted ventilatory 
response to hypercapnia and hypoxaemia (Pattinson, 2008; Teichtahl et al., 2005; Weil et al., 
1975). 
 
The ability to take a breath depends on the balance between the load on the inspiratory 
muscles and their neuromuscular competence, i.e. their capacity. There is usually sufficient 
‘reserve’ available to allow for any increase in load. Opioids suppress neural respiratory drive 
(NRD) and reduce the increase in NRD that would usually occur in response to an increase 
in respiratory load (Bailey et al., 2000; Bouillon et al., 2003; Brunton et al., 2008; Dahan, Aarts, 
& Smith, 2010; Ferguson & Drummond, 2006). Furthermore, respiratory depression by opioids 
involves dose-dependent responses of reduced tidal volume, bradypnoea (slowed rate of 
breathing), impaired pulmonary gas exchange and blunted responsiveness to hypoxia and 
hypercapnia (Pattinson, 2008). In order to compensate for changes to the load-capacity 
balance and to maintain adequate ventilation for blood gas homeostasis, NRD has to increase. 
If this does not occur, respiratory failure can occur. Respiratory failure is a syndrome in which 
the lungs fail in one or both of their two key functions; oxygenation and carbon dioxide 
elimination. Chapter 3 provides a more detailed explanation of the underlying basis for this.  
 
In addition, there are a considerable number of risk factors that increase the risk of opioid 




oxygen desaturation (Jolley et al., 2015b), there are no studies to date that have investigated 
the overlap between risk factors of overdose with novel physiological tools measuring markers 
of respiratory depression. Older age and male gender (Darke et al., 2006; Warner-Smith et 
al., 2001; Bartu et al., 2004), longer duration of drug use (Brugal et al., 2005; Hser et al., 2001) 
and previous experience of overdose (Tobin et al., 2005) and higher dose (Darke et al., 1999; 
McGregor et al., 1998; Desmond et al., 1978) are all considered to be risk factors that underlie 
opioid overdose. Polydrug use is possibly the most important risk factor in overdose deaths, 
with higher levels of polydrug use appearing to be associated with a higher risk of overdose, 
psychopathology and poor treatment outcome (Darke & Ross, 1997; DeMaria et al., 2000).  
 
The data presented in this chapter allow examination of the relationship between opioid-
induced respiratory depression signs and symptoms and overdose risk in opioid-dependent 
users. This observational study examined physiological parameters in individuals who were 
maintained on opioid substitution treatment for their heroin addiction. Recorded parameters 
were compared to those measured in corresponding non-opioid-using controls with no history 





5.2.2 Aims & Hypotheses  
The overarching aims and hypotheses of this chapter were:  
 
Aim 1: to investigate the prevalence and severity of opioid-induced respiratory depression 
using specific respiratory depression criteria in long-term opioid-dependent users (ODU) and 
compare to corresponding non-opioid-using controls.  
• Hypothesis 1: ODU participants experience more severe respiratory depression 
than corresponding opioid-naïve controls.  
 
Aim 2: to examine the influence of personal, drug use and addiction treatment characteristics 
on the severity of respiratory depression.  
• Hypothesis 2a: older age, male gender and a previous history of overdose are 
factors that are related to more severe respiratory depression.  
• Hypothesis 2b: concurrent use of depressant drugs and injecting use of opioids 
are related to more severe respiratory depression.  
• Hypothesis 2c: higher dose of Opioid Substitution Treatment (OST) is related to 
more severe respiratory depression. 
 
Aim 3: to investigate the level of the NRD in ODU with particular focus on chronic obstructive 
lung disease compared to controls and whether there is an inappropriate suppression of NRD 
relative to the severity of lung disease. 
• Hypothesis 3: levels of NRD in ODU participants with co-existing chronic 
obstructive lung disease are lower than opioid-naïve subjects matched for lung 





5.3 Methods  
5.3.1 Ethical Approval  
The study was approved by the King’s College Hospital Research Ethics Committee (L/Rec 
reference number: 05/Q0703/82). It was conducted in accordance with the principles 
expressed in the Declaration of Helsinki. Written consent was provided by all participants prior 
to commencing the study.  
5.3.2 Study Design 
This was an observational study whereby the participant’s medication and clinical treatment 
were not altered. The study group were seeking treatment for their heroin/opioid addiction and 
were recruited for this study as a convenience sample. Each participant attended one study 
session. Comparisons were made within-subject and between-subject. Screening was 
conducted prior to study visit by review of medical notes. All participants underwent spirometry 
(as described in the Methods section), earlobe blood gas test (to aid clinical determination of 
lung disease), urine drug screen (AllScreen) and alcohol breathalyser (BACtrack©) prior to 
the testing session; methods for this are described in the Methods chapter.  
5.3.3 Setting  
Recruitment and data collection for all participants within the study commenced in January 
2016 and continued until April 2017. Participants were recruited from a South London 
Community Drug Treatment Centre (Lorraine Hewitt House). Potentially eligible participants 
were either approached through a regularly held Respiratory Clinic within the drug treatment 
clinic or through a researcher-led approach whilst the patient was in the waiting room. Testing 
was conducted at the Muscle Lab within King’s College Hospital in a climate-controlled room 
maintained at 23 degrees centigrade. All study participants underwent screening before each 






All ODU participants were undergoing opioid maintenance treatment (e.g. methadone or 
buprenorphine). The following criteria were adhered to when selecting subjects: 
 
Inclusion criteria: 
1. Patients undergoing treatment for their opioid addiction, e.g. opioid substitution 
treatment such as methadone or buprenorphine or heroin maintenance treatment, 
2. Age ≥ 18 years, no upper age limit, 
3. Capable of providing voluntary informed written consent, 
4. Clinician-determined diagnosis of an obstructive lung disease and no other 
potentially conflicting or impacting conditions (this is determined from clinical notes 
before the study and lung function results after the study).   
 
Exclusion criteria: 
1. Subjects suffering from severe respiratory insufficiency, 
2. Current psychiatric diagnosis of major depression with suicidal ideation, psychosis, 
bipolar disorder, or any psychiatric disorder that would compromise the subject's 
ability to complete the study, 
3. Female subjects who are pregnant or mothers who are lactating, 
4. Any other factor that in the opinion of the investigators would make the subject 
unsafe or unsuitable for the study. 
 
5.3.5 Control Participants  
Controls corresponding to the ODU participants with lung disease (ODU-LD) were selected 
based on age, gender, BMI and lung function results. Control subjects were recruited from 
existing laboratory studies on lung disease. These patients had been recruited either from an 
outpatient respiratory clinic or through word of mouth. Control participants were selected on 






Healthy control participants (Healthy Controls) were eligible for inclusion if they were aged 
over 18 years old and had no history of respiratory, cardiac, neurological disease, or drug or 
alcohol addiction problems. Any subject with abnormal spirometry was excluded.  
 
Lung disease control participants (Controls-LD) were eligible for inclusion if they were aged 
over 18 years old, had a clinician-determined diagnosis of a chronic, obstructive lung disease 
and no other potentially conflicting or impacting lung conditions such as bronchiectasis or lung 
cancer. Participants were excluded if they had co-diagnoses of cardiac or neurological 





5.3.6 Outcomes and Measurement 
All participants, of all groups, underwent a minimum total of 40 minutes of study testing (Table 
5-1).  
 
Table 5-1: Table of assessment, outcome, device and timing of each measure. 
5.3.7 Neural Respiratory Drive 
Neural Respiratory Drive (NRD) was determined using the parasternal electromyography 
methods described in Chapter 4. In brief, EMGpara was recorded transcutaneously using a 
bipolar pair of surface electrodes positioned bilaterally over the second intercostal space 3cm 
from the midline (Maarsingh et al., 2012; Murphy et al., 2011; Reilly et al., 2011). EMGpara 
signals were amplified and band-pass filtered between 10Hz and 2kHz and sampled at 4kHz. 
The raw EMGpara signal was converted to root mean square (RMS). The maximum RMS 
EMGpara per breath was determined and the mean peak EMGpara per breath for each recording 
block of interest was calculated. EMGpara%max was calculated by expressing mean peak 




Ventilation  Respiratory rate (Vf), 
tidal volume (VT) and 
minute ventilation 
(VE) 
Pneumotachograph  Total recording of 
minimum 10-mins 
with a break after 
5mins  
Pulse oximetry Average and 
minimum SpO2%  
Finger-clip oximeter  Continuous 






maximum of peak 















(Murphy et al., 2011; 
Reilly et al., 2013; 









blood gas meter 
Average and 
maximum TcCO2 
Ear lobe sensor Continuous 






inspiratory manoeuvres (total lung capacity and inspiratory ‘sniff’ manoeuvres). EMGpara%max 
was multiplied by respiratory rate to derive the individual’s Neural Respiratory Drive Index 
(NRDI) (Maarsingh et al., 2012; MacBean, Hughes, Nicol, Reilly, & Rafferty, 2016; Murphy et 
al., 2011; Reilly et al., 2011). More detailed description of the NRDI calculation is found in 
Chapter 4.  
5.3.8 Capnography  
Capnography was monitored by end-tidal and transcutaneous measures. All capnography 
data was measured and analysed as described in the Methods chapter.  With regard to end-
tidal carbon dioxide (ETCO2), this is a measure of the concentration of carbon dioxide at the 
end of an exhaled breath and was measured using a Gas Analyser (iworx capnograph) in line 
with an adapted nasal cannula as described in Chapter 4. ETCO2 was recorded as the peak 
percentage carbon dioxide (%CO2) measured in each expired breath and converted to kPa. 
Transcutaneous carbon dioxide (TcCO2) was measured using a transcutaneous capnograph 
(TOSCA TCM4, Radiometer Medical ApS, Brønshøj, Denmark) using an ear-clip sensor. The 
mean TcCO2 level was calculated in mmHg and then converted to kPa. Further details on the 
methods can be found in Chapter 4.  
5.3.9 Pulse Oximetry  
Oxygen saturation (SpO2) was recorded by finger pulse oximetry (Ohmeda Biox 3700) and by 
earlobe sensor (TOSCA). The pulse oximeter was calibrated as described in the Methods 
chapter. The oximeter recorded a percentage of blood oxygen saturation every 5 seconds. 
Recording started after attachment of the finger probe or ear-clip sensor on the participant. 
SpO2 was continuously displayed in real time on the pulse oximeter and on LabChart and was 
stored for offline analysis.  
5.3.10 Respiratory Flow and Volume Method  
Participants were asked to tightly seal their lips around the mouthpiece of the 
pneumotachograph (attached to a Validyne and to Powerlab). Airflow during relaxed, resting 
breathing was recorded over a minimum of 10 minutes with a short break after 5 minutes. A 
noseclip was in place throughout. Recording was continuously displayed on LabChart in real 




5.3.11 Breathlessness scale 
Breathlessness was measured using the modified MRC (mMRC) dyspnoea scale. There are 
four grades of breathlessness that individuals can experience, ranging from 0 to 4; these are 
highlighted in more detail in the Methods chapter. 
5.3.12 Personal, Drug Use and Addiction Treatment Characteristics  
Characteristics relating to personal, drug use or wider behavioural or addiction treatment 
related factors were obtained through a detailed medical history questionnaire at the start of 
the study session. These were asked by me or my supervisor Dr Caroline Jolley. These 
questions can be found in the appendix (C-8).  
5.3.13 Indicators of Respiratory Depression 
Physiological measures were represented as absolute values and also, the presence and 
frequency of pre-defined respiratory depression criteria (more details below). Evidence of 
significant respiratory depression was recorded using a variety of physiological markers. 
Criteria and threshold levels are indicative of clinically-significant respiratory depression and 
were determined through Sleep Medicine and Anaesthesiology literature (Dahan et al., 2010; 
Douglas, 2005) and through discussions and advice from members of the respiratory medicine 
research group which included critical care consultants, respiratory medicine consultants, and 
other allied experts as well as academic supervisors and co-investigators.  
 
Overall, four main measures were used to capture respiratory depression. Further, any 
presence of, or frequencies pertaining to, these physiological markers were used to establish 
the existence of significant respiratory depression: 
1. End-tidal carbon dioxide (ETCO2)  
a) Absolute value (kPa), 
b) ETCO2 > 6.6kPa per breath, 
c) Frequency of breaths above 6.6kPa. 
2. Neural Respiratory Drive (NRD) and Airflow 
a) NRD index (NRDI) value (min-1), normalised against respiratory rate and 




b) Any presence of NRD pauses or absence of inspiratory airflow of longer than 10 
seconds (apnoea), 
c) Frequency of pauses of longer than 10 seconds. 
3. Transcutaneous carbon dioxide (TcCO2) 
a) Absolute value (kPa), 
b) Overall average above 6kPa across the study session. 
4. Oxygen saturation (SpO2) 
a) SpO2 (%), 
b) Any presence of SpO2 below 90% for longer than 10 seconds. 
c) Frequency of dips below 90% for longer than 10 seconds. 
 
For each criterion, the actual values of each measure were initially recorded, and 
subsequently a dichotomous categorisation (e.g. any presence of a breath above 6.6kPa) as 
well as frequencies of each criteria (e.g. number of breaths above 6.6kPa in the whole 
session) were determined, with the except for TcCO2 where the marker was represented as 
a mean of the whole measurement. The absolute values of the measures along with 
categorised and frequency data were used to determine Aim 1. Aim 2 was analysed with the 
measures and frequency data to create a series of respiratory depression criteria against 
which each personal- and drug use-related characteristic was tested. Finally, Aim 3 was 
analysed using the measures of NRD along with each of the other physiological 
measurements.  
5.3.14 Study Size  
As a physiological study of n=20 (with equal n=20 corresponding controls), the sample size 
was considered sufficient to reflect variations in the population of interest, and also to allow 
for intensive study methods. Studies of this type have typically used sample sizes close to this 
number by utilising design of repeated measures with the same subjects, thereby obtaining 





5.3.15 Statistical Methods 
Where appropriate, data were tested for normality. Any ordinal data were presented as median 
(interquartile range) and non-parametric bivariate testing was used. Dichotomous 2x2 criteria 
or categorical data between groups were tested using Fisher’s exact test or Pearson’s Chi 
Square. Spearman Rank (Rs) was used to assess frequency data and the relationship 
between related continuous, scale data and also, Mann Whitney U (U-statistic) were used to 
test for differences between groups. Categorical data such as gender, smoking status and 
type of drug were compared only with the categorical physiological data, i.e. to whether there 
was any presence of certain physiological indices. Data analyses were performed using SPSS 
software v22 for Mac (SPSS Inc, Chicago, Illinois, USA). Significance was determined at 
values of p <0.05 level or at p<0.01. 
5.3.16 Opioid Substitution Treatment (OST) Dose Comparison 
Direct equivalent dose comparisons are difficult to attain for opioids. The comparisons are not 
exact conversions but are there as general guide to equivalence in order to allow comparison 
of doses between subjects. It is particularly difficult to compare doses above 80mg methadone 
and 16mg buprenorphine, which applies to three participants in this study. The Defined Daily 
Dose (DDD) is the assumed average maintenance dose per day for a drug used for its main 
indication and does not necessarily represent the recommended daily dose. It can be used as 
an estimate of consumption in a fixed unit of measurement, independent of price and 
formulation and is useful when comparing different opioids together (Strang, Hall, Hickman, & 
Bird, 2010; WHO, 2012). The calculation is: Drug usage (in DDDs) = items issued x amount 
of drug per item / DDD. 
 
All Opioid Substitution Treatment (OST) doses in this study were calculated according to this 
DDD for a given opioid. For example, for methadone the daily dose is 60mg and for 
buprenorphine it is 8mg because these are close to the average dose prescribed in the UK 
(BNF, 2018; H. E. Jones et al., 2007; NAABT, 2007) and are on the lower point of the 
recommended dose ranges. Thus, if a participant is on 60mg methadone, they would be 




5.4 Results  
The results are broken down into three subsections; firstly, I provide an overview of the general 
features of the opioid-dependent group, followed by the second part of the results focussing 
on respiratory function tests and wider personal and behavioural characteristics. The third part 
of the results focusses on comparison of the physiological results to controls.  
5.5 Part one: Overview of the Group 
5.5.1 Descriptive Data  
All participants completed the full duration of testing, however, in three sessions, the length of 
time was extended due to speech, movement or laughter which causes artefact on the 
measurement signals. Out of the 37 that were eligible for the study, 22 people were studied 
in full but 20 of these were considered acceptable and further analysed. Two datasets were 
rejected; one because of measurement artefact and the second because of the presence of 
restrictive lung disease. The total number of individuals who were recruited for the study as 
well as the number of drop-outs and reasons for these drop-outs are all stated in the flowchart 
(Figure 5-1).  
 
Twenty control subjects undertook the same protocol as the ODU participants. Thirteen 
control participants with obstructive lung disease were recruited for comparison with the ODU-
LD group, and seven matched healthy controls corresponded to the seven ODUs with no lung 
disease. Demographics, anthropometrics and lung function results are highlighted in (Table 
5-2). Significant differences were observed in the level of NRDI amongst the two control 
groups (Figure 5-5; p=0.001).   
 
Anthropometric, demographic and basic lung function and physiological data are represented 
for all participants of the study in Table 5-2 and Table 5-4 (and comparisons in Table 5-3) and 
full individual results for ODU participants are provided in Appendix C. The ODU group 
included four female and 16 male participants, with a median (IQR) Body Mass Index (BMI) 
of 26.5 (21.8-30.4) kg/m2. The median (IQR) age was 49 years old (44-55 years old). The 




age of first entrance into treatment for heroin addiction was 33 (24-40 years old). The median 
(IQR) duration of drug use was 27 years (19-32 years). Eleven participants of the 20 reported 
to have previously experienced an opioid overdose that required hospitalisation and/or 
reversal by naloxone. Twelve participants were prescribed buprenorphine or suboxone (two 
of whom took their dose via the sublingual route, the remaining via oral route), six were 
prescribed methadone (one of which was injectable), one was prescribed injectable 
diamorphine and one was prescribed oral diamorphine. With regard to cigarette smoking, 
three participants were ex-smokers, and the remaining 17 were current, and overall the 
median (IQR) smoking history was 15 (10-25) pack years. Eight of the 20 participants had 
taken their opioid substitution treatment on the day of testing. The majority (12) were 
prescribed buprenorphine or suboxone as part of their opiate maintenance treatment, and of 
these, eight had previously been in treatment on methadone. Two participants took their OST 
via injectable route (diamorphine and methadone), two others via sublingual route 
(buprenorphine), and the rest via oral route.  
 
Lung function measures varied greatly and two distinct groups within the opioid-dependent 
users were established: ODUs with no lung disease (ODU), and ODUs with lung disease 
(ODU-LD). The subsequent data will be presented with these distinct groups. Of the 20 opioid-
dependent users, 13 had obstructive lung disease by lung function and clinical criteria. Of 
these, only five had previously been diagnosed with a chronic lung disease and had been 
prescribed appropriate medication. The following medication (other than OST) was used by 
the participants: 5 benzodiazepines (temazepam, diazepam and alprazolam), 4 long-acting, 
anticholinergic bronchodilator (Tiotropium), 4 anti-psychotic, 3 anti-depressants (SSRIs & 
atypical), 2 short-acting -agonist inhalers, 1 antiviral medication for hepatitis C and 1 other 
was on a calcium channel blocker.  
 
Over half (55%) of ODU participants were not troubled by breathlessness as measured by the 
mMRC Dyspnoea Scale, and seven experienced shortness of breath when hurrying or going 
up a slight hill (mMRC grade 1 dyspnoea). Two ODU participants experienced moderate to 




breathlessness) (grade 2) or where they had to stop for breaths after a few minutes of walking 
(grade 3). All participants completed the full duration of testing, however, in three sessions, 
the length of time was extended due to speech, movement or laughter which causes artefact 
on the measurement signals.  
 
5.5.2 Other Drug Use 
Fifteen of the 20 ODU participants self-reported use of other drugs and/or alcohol. Seven 
participants reported using alcohol at quantities above the weekly recommended allowance 
(14 units). Six reported using cannabis, three of which were daily users. Five participants 
reported using benzodiazepines, two of which also reported high quantities of alcohol use. 
Dipstick urine drug screening showed presence of drugs in all except five cases. There were 
no notable differences in the physiological responses between these five cases compared to 
other participants who showed presence of a drug. The most commonly detected metabolites 
in the urine dipstick test were morphine (10) and methadone (eight). A positive alcohol 
breathalyser was detected in two of the 20 participants; their percentage blood alcohol content 
(BAC) measurements were 0.17% and 0.0026%.  
 

























20: not able to contact 
and/or no longer in 
treatment
37 total booked for 
study
- of these, 15 were no 
shows 
2 excluded after 
study (restrictive 
lung disease, or 
artefact)
46 excluded/ineligible
a) not seeking 
treatment for opioid 
use 








17: no longer interested
20 cases 
analysed




























Table 5-3: Between-group comparisons of lung function results and demographics of ODU-LD and their corresponding controls (top) and ODU without lung disease and their 
corresponding controls (bottom).  








All Groups Age 
(years) 










Median 48 30.0 96.1 99.7 74.7 2/5 




Median 50 26 100 108.1 75 1/6 




Median 49 23 77.1 106.7 60.2 2/11 




Median 66 27 60 104.6 52 3/10 
IQR 62-72 24.3-30 52.8-74.5 85.4-111.6 45-56.6 
 
Total (n=40) 
Median 49 26.5 82.9 105.5 62.9 8/32 
IQR  44.3-55 21.8-30.4 60.1-96.1 93.1-114.6 50.7-74.7 
 
 
Age BMI FEV1%pred. VC%pred. FEV1/VC%pred. Gender 
ODU and Controls: 
U-Statistic (p 
value) 
18.5 (0.44) 11 (0.90) 12 (0.11) 16 (0.28) 23 (0.85) 21 (0.53) 
ODU-LD and Controls-LD: 




5.6 Part Two: Results of Testing of Respiratory Function  
5.6.1 Prevalence and Severity of Respiratory Depression Amongst ODUs (Aim 1) 
At least one of the respiratory depression indicators was observed by all of the 20 participants 
and at least two of these indicators were observed in over half (11) (Table 5-6). The overall 
median (IQR) of SpO2% was 95.6% (94.0-96.8%) and the median (IQR) peak ETCO2 per 
breath was 5.8kPa (5.4-6.4kPa); the TcCO2 median (IQR) was 5.8kPa (5.0-6.2kPa). SpO2% 
was generally in the normal expected ranges, despite marked high levels observed in some 
of the participants’ capnography (ETCO2% and TcCO2) recordings (Table 5-4). 
 
Of the seven ODUs with no identified lung disease, five showed at least two indicators of 
respiratory depression. Of the ODU-LD participants, six showed at least two indicators of 
respiratory depression. Between the two ODU groups, there were no differences in severity 
of respiratory depression or NRDI (Χ2 1.7, p=0.19). 
 
A wide range of severity was observed with some participants displaying more severe 
physiological responses than others. In one ODU an apnoeic frequency of 1 pause per minute 
was observed. A sample of this is shown in Figure 5-2 with a comparison sample from an 
individual with a regular pattern of breathing and no opioid dependency.  
 
5.6.2 Individual and Wider Behavioural Features (Aim 2)  
Age was inversely correlated with NRDI (Rs= -0.43, p= 0.04); and smoking pack year history 
(Rs= -0.42, p=0.045) was inversely correlated with levels of SpO2% but there was no 
correlation with the measures of diffusing or transfer capacity of carbon monoxide, KCOc and 
TLCOc (Appendix: C-5). Gender, smoking status and BMI did not show any relationship with 
any of the physiological measures (Table 5-5).  
 
5.6.3 Features of Drug Use (Aim 2)  
The number of previous overdose events was correlated to ETCO2 (Rs= 0.42, p=0.04). 
Duration of overall drug use showed a significant relationship with TcCO2 (Rs= 0.45, p=0.04), 




(Rs= -0.44, p=0.05 (Table 5-5). Other features of drug use measured in this study did not 
show any relationship with the respiratory depression criteria. These included route of 
previous opioid use, OST consumption on the study day and co-use of other drugs.  
 
5.6.4 Features of Addiction Treatment (Aim 2)  
OST dose was correlated to ETCO2 (Rs= 0.57, p=0.009), ETCO2 frequency (Rs= 0.57, 
p=0.008) and frequency of NRDI pauses (Rs= 0.47, p=0.04). No other feature of addiction 
treatment, namely the type of OST, number of times in any type of opioid addiction treatment, 
the number of months in current treatment and the dosing regimen, was associated with 
























Figure 5-2: Sample of signal recording in two separate individuals.  
a) Opioid Dependent User with Lung Disease (ODU-LD); b) Lung disease control. 






 (µV), respectively. ODU-LD individual 
displays two respiratory pauses (apnoeic episodes) of 12 and 10 seconds (black arrows), 
respectively, within this 1-minute period, compared to regular pattern of breathing in the 
control. Similar severity of lung disease existed between both participants (FEV1%pred: 65.6% 




































































Table 5-4 a and b: Physiological measures (separated by a) blood gases & drive and b) ventilatory function) for all groups.  
Opioid-Dependent Users with no lung disease (ODU), their corresponding controls (Controls), Opioid-Dependent Users with Lung Disease (ODU-LD), Controls with 
Lung Disease (Controls-LD).  The bottom rows display all controls and all ODU. *Significant difference between medians, *p<0.05; **p<0.01, which was seen only 
between ODU-LD and Controls-LD in ETCO2, TcCO2 and NRDI (U-statistic: 19, 44 and 30, respectively).  
 
Table 5-4 a) Blood Gases and neural respiratory drive: 
Table 5-4 b) Ventilatory Function 
 
 SpO2 (%) ETCO2 (kPa) TcCO2 (kPa) NRDI (min-1) 
Median Min Max Median Min Max Median Min Max Median Min Max 
Groups ODU 95.85 93.90 98.53 5.93 5.18 6.48 5.77 4.67 6.75 87.62 51.67 115.30 
Controls 96.33 95.00 98.01 5.79 5.52 6.31 5.51 4.10 5.99 76.93 52.80 164.20 
ODU-LD 95.30 91.80 98.30 5.80** 4.58 7.15 5.68* 4.39 7.35 148.51** 34.99 172.62 
Controls-LD 93.80 89.44 95.90 4.58** 3.56 5.50 5.00* 3.46 6.10 217.02** 43.70 504.50 
All ODU 96.22 93.90 98.53 5.84 5.18 6.48 5.68 4.10 6.75 79.69 51.67 164.20 
All Controls 94.29 89.44 98.30 5.24 3.56 7.15 5.22 3.46 7.35 158.92 34.99 504.50 
 Respiratory Rate (breaths/min) Tidal Volume, VT (L) Minute ventilation, VE (L/min) 
Median Min Max Median Min Max Median Min Max 
Groups ODU 13.20 10.00 18.10 0.8 0.3 1.0 11.4 5.6 14.1 
Controls 13.00 6.00 16.20 1.0 0.6 1.5 12.1 8.7 19.0 
ODU-LD 13.60 6.60 15.50 0.7 0.1 1.9 9.2 1.9 18.0 
Controls-LD 15.47 7.00 25.71 0.9 0.3 1.8 12.3 4.9 18.7 
All ODU 13.60 6.00 18.10 0.74 0.13 1.88 9.52 1.91 17.95 





Table 5-5: Results of bivariate correlation (Rs) for personal and wider behaviour, drug use and opioid 




















Age  -0.30 -0.32 -0.43* -0.08 0.28 -0.28 0.17 
BMI 0.28 0.12 -0.10 0.22 -0.08 -0.30 0.37 
Smoking 
pack history  




Drug Use  
0.15 -0.14 -0.44* 0.51* 0.47* -0.04 0.06 
No. previous 
OD events 
0.42* 0.17 -0.16 0.23 0.14 0.13 -0.04 
OST dose 0.57** 0.57** -0.13 0.47* -0.09 0.07 -0.03 
No. opioid 
addiction Tx 








Table 5-6: Table displaying presence of respiratory depression criteria in all ODU and their 
corresponding controls.  
Fisher’s exact test was used to test for differences between criteria, both groups showed significant 
differences. ODU and controls p=0.021, and ODU-LD and Controls-LD p=0.0001.  
  
Number  SpO2     











Number  SpO2     











ODU (healthy): Controls (healthy): 
1         1         
2         2         
5         3         
8         4         
9         5         
16         6         
18         7         
ODU-LD: Controls-LD: 
3         1         
4         2         
6         3         
7         4         
10         5         
11         6         
12         7         
13         8         
14         9         
15         10         
17         11         
19         12         




Table 5-7: Comparison of severity of respiratory depression indices for all ODU participants and their 
corresponding controls.  
The average (range) number of indices/criteria exhibited by participants across 20 minutes of testing is 
shown, as well as U-statistic (p value) between the groups. Significant differences (Mann Whitney U test: 
U-statistic (p value)) between ODUs and controls were observed in both sets of groups across all 

















SpO2 dips 0.5 (0-3) None 1.6 (0-16) None 
U-statistic (p 
value) 
17.5 (0.28) 58.5 (0.03*) 
ETCO2 
increases 
31.6 (0-200) 0.3 (0-2) 66.1 (0-280) 0.3 (0-3) 
U-statistic (p 
value) 
10 (0.04*) 30 (0.002**) 
Resp. pauses  1.6 (0-4) 0 2.5 (0-20) 0 
U-statistic (p 
value) 




5.7 Part Three: Comparison to controls  
The next part of this chapter focuses on the comparison of the ODU group to relevant related 
controls.  
 
5.7.1 Severity of Respiratory Depression Amongst ODU Compared to Controls (Aim 
1) 
Controls were correlated based on age, BMI, gender and lung function values, smoking status 
(Table 5-3). Of the control group with no lung disease (i.e. healthy controls), only two 
participants observed one indicator of respiratory depression. A significant difference in the 
frequency of respiratory depression indicators was observed between the two groups (Table 
5-6; p=0.021). With regard to differences between the two groups for each criterion, all except 
SpO2% was significantly different (Table 5-7).   
 
All characteristics except age were significantly similar to the study group (Table 5-3). Only 
two participants in the control group showed an indicator of significant respiratory depression. 
Overall, the difference between frequencies was significant (Table 5-6; p=0.0001). For each 
criterion, the differences between frequencies of criteria were also significant compared to 
controls (Table 5-7).  
 
Overall, in comparison to control participants, there was a greater frequency of significant 
respiratory depression in all ODU than in all controls, across all groups (p=0.021, Fisher’s 
exact test). Furthermore, there were also significant differences between ETCO2, TcCO2 and 
NRDI between the ODU-LD and lung disease controls (Table 5-4).  
 
5.7.2 Level of NRDI in ODU with Lung Disease (Aim 3) 
Thirteen ODU-LD participants were compared with 13 controls with lung disease (Tables 5-4, 
5-6 & 5-7). ODU participants with moderate to severe COPD were compared to similar 
participants with the same severity of lung disease. NRD was observed to be significantly 
lower in the ODU-LD group compared to lung disease controls (Figures 5-3 & 5-6). None of 





There was no statistically significant correlation between FEV1%pred and NRDI in ODU-LD 
(Rs=0.43, p=0.14) but a non-significant trend towards an inverse relationship with FEV1%pred 
and NRDI in lung disease controls (Rs= -0.41, p=0.14) (Figure 5-4 & Table 5-8). Amongst the 
same two groups, there was no statistically significant relationship between NRDI and ETCO2 
(Rs= -0.19, p=0.5), TcCO2 (Rs=-0.19, p=0.7) and SpO2 (Table 5-8). 
 
Amongst ODU without lung disease and relevant control group, there was no statistically 
significant correlation between NRDI and ETCO2 (Rs=-0.57 and p=0.49) but there was no 






Figure 5-3a-f: Scatterplots of lung function measures of FEV1%pred and the FEV1/VC%ratio against 
the normalised index of Neural Respiratory Drive (NRDI). a) all groups, FEV1%pred; b) all groups, 
FEV1/VC%ratio; c) all ODU and ODU-LD, FEV1%pred; d) all ODU and ODU-LD, FEV1/VC%ratio; e) all 











Figure 5-4: Boxplot of NRDI values for healthy control and lung disease control (U= 10, p=0.005). 
 
 












Table 5-8: Table showing correlations coefficients, Rs (p value) of each blood gas and lung function 
measure against NRDI. Corresponding scatterplots in Figure 5-4. 
 ODU Controls ODU-LD LD Controls 
ETCO2 average peak per 














































5.8 Discussion  
5.8.1 Summary of Principal Findings  
The results of this study demonstrate that everyday respiratory depression is habitually 
present in opioid dependent users and is significantly more severe than related opioid-naïve 
controls. Furthermore, the results also show that certain personal, wider behavioural, 
treatment and drug use factors are related to chronic respiratory depression. In addition, the 
results also show that NRD appears to be significantly lower than that of controls in ODU with 
lung disease compared to non-ODU controls with lung disease.  
 
5.8.2 Respiratory Depression Indices in ODU  
It is important to acknowledge at the onset that there is no standard measure of respiratory 
depression. However, the criteria used in this study are widely accepted indices of respiratory 
depression, encompassing different aspects of the condition. Additionally, it has now been 
shown that, using continuous, advanced monitoring techniques, it is possible to detect opioid-
induced respiratory depression (Gerdung et al., 2016; Gupta & Edwards, 2018; Jolley et al., 
2015b). These criteria were observed to be consistently present throughout the study in ODU. 
Respiratory depression indices were significantly more frequently observed in both ODU 
groups compared to their corresponding controls. In fact, in some cases it was particularly 
severe, where apnoeas and peak ETCO2 per breath reached levels approaching thresholds 
that would be considered near-life-threatening under usual clinical circumstances in non-
opioid using individuals. The study presented in this chapter applied these techniques within 
an opioid-using population in a setting that aimed to capture realistic everyday physiological 
functioning. However, the question of whether attaining these criteria provides a clear 
indication of fatal or non-fatal overdose risk is to be discussed in the rest of this section. 
Nevertheless, the data presented in this chapter allow for further study and provide unique 
exploratory data to build upon. It is crucial to further study the health impact of this chronic 





5.8.3 Personal and Wider Behaviour Characteristics 
Some of the personal, treatment and medical features showed significant relationships with 
one or more of the respiratory depression markers. Male gender was not correlated to more 
severe respiratory depression. However, it must be noted that the number of female 
participants was particularly low in this study, and there may be other factors, outside the 
scope of this thesis, that lead to more males experiencing overdoses. Age was found to be 
inversely associated with NRDI, indicating that NRDI may be decreasing with age in ODU. 
There are differing findings in the literature, with variable suggestion that age may not 
significantly change at rest or may increase with older age (Jolley et al., 2015a, 2009). Others 
show that there might also be an inverse trend (MacBean, Hughes, Nicol, Reilly, & Rafferty, 
2016; Pollock et al., 2015). Chronic opioid use amongst older people is an issue that has 
raised much attention in recent years (Gao et al., 2016; RCPsych, 2011). With regard to data 
on physiological responses to opioids presented in this chapter, these data do not appear to 
show that age was related to more severe respiratory depression. As the youngest participants 
were not aged below 37 years old, with only four participants in their 30s, there are obvious 
difficulties in generalising these data. A greater and more varied sample size is required to 
test these findings further. There is more detailed discussion of age in connection to 
methadone users later on in this chapter.  
 
A higher smoking pack year history was related to lower levels of SpO2%. It is unclear whether 
this is in connection with current or recent use of cigarettes/tobacco or to the potential longer-
term effects of smoking. Pulse oximeters are not able to differentiate between carboxy-
haemoglobin and oxy-haemoglobin (Hampson, 1998) and so, often SpO2% records as normal 
even where there is a higher presence of carbon monoxide in the bloodstream of smokers, 
however, the literature on this seems unclear  (Glass, Dillard, Phillips, Torrington, & 
Thompson, 1996). Previous studies have shown that smoking does not have a relationship 
with lower SpO2 values or changes in mean (Kline, Nelson, Jackson, & Courtney, 2002; 
Witting & Scharf, 2008). The effects of long term cigarette smoking in relation to this population 
are probably most crucial to the increased risk of chronic respiratory diseases (ONS, 2016). 




and transfer capacity of carbon monoxide, KCOc or TLCOc (using true values and predicted 
values, Appendix: C5). These values reflect the efficiency of gaseous diffusion across the 
alveolar-capillary gas exchange interface. Changes to these values represent the signs of 
COPD progression, particularly for emphysema patients. In emphysema, there is a loss of 
alveoli and capillary bed which results in a lower surface area available for gaseous diffusion 
and a decrease in TLCO (Bailey, 2012; Owens, Rogers, Pennock, & Levin, 1984).  
 
5.8.4 Drug Use Characteristics  
The number of previous overdose events and the duration of drug use were associated with 
the two measures of carbon dioxide, ETCO2 and TcCO2. Both factors showed that the greater 
the overdose events, and the longer the period of drug use, the higher the levels of ETCO2 
and TcCO2. Hypercapnia is caused by alveolar hypoventilation and is a common effect of 
opioids. Further, the duration of drug use, similar to age, also showed an inverse association 
with NRDI and a positive correlation with the number of apnoeic pauses (lasting longer than 
10 seconds) and the high level of TcCO2. Thus, the longer the duration of use, the more 
episodes of respiratory depression were observed. Duration of drug use reported in this study 
did not take into account any periods of entry into drug treatment; it is a general measure of 
years of opioid use. Nonetheless, these results showed that there was a dampened level of 
drive, an increase in apnoeic pauses, and a higher level of carbon dioxide with a longer 
duration of treatment. It is certainly the case that an occurrence of these in combination is 
potentially fatal.  
 
5.8.5 Treatment Characteristics  
A higher dose of OST medication was associated with higher levels of ETCO2, greater number 
of ETCO2 breaths above 6.6kPa as well as a higher number of apnoeic pauses. It has been 
well-established that methadone and other opioid substitution treatments reduce the risk of all 
cause, and overdose, mortality, in some cases by a factor of 3-4 in opioid drug users 
(Degenhardt et al., 2009; NIH, 1998; Sordo et al., 2017). While it might be unsurprising that a 
higher dose of OST would be associated with higher levels of the stated criteria, it is interesting 




to four weeks of drug treatment is associated with a higher rate of mortality (Cornish, Macleod, 
Strang, Vickerman, & Hickman, 2010). Participants in this study had been in treatment for at 
least four weeks, but it would be interesting to investigate whether there is a similar association 
amongst individuals who are in the first few weeks of treatment.  
 
Contrary to hypotheses, the duration of current treatment was not associated with any of the 
respiratory depression criteria. There was a large variability with the distribution of duration of 
current treatment, ranging from one to 168 months (with a median and IQR of 12 months and 
2.5 to 51 months, respectively) across 20 participants. A larger sample size is required to do 
further analyses on this. Further, there was no association between the different types of OST 
and severity of respiratory depression. Buprenorphine is thought to have a lower risk of 
respiratory depression and overdose rates compared to methadone and other OST 
medication, showing a ceiling effect (Dahan, 2006; Strang et al., 2017; Walsh, Preston, Stitzer, 
Cone, & Bigelow, 1994). Buprenorphine acts as a partial agonist, where even with full 
saturation at receptor sites, there is less than maximal effect compared to full agonists. Dose-
response studies of buprenorphine have shown that there is a flattened or inverted U-shaped 
curve, demonstrating that at higher doses there is no greater or a decreased effect (Walsh, 
Preston, et al., 1994). However, there were no observed differences in the respiratory 
depression indices between users on methadone and buprenorphine in this study (Appendix: 
C-4 and C-6). Further discussion on this can be found later on in this chapter.  
 
Overall, a greater frequency of respiratory depressant markers can be observed as a greater 
severity of respiratory depression. However, the question still remains – does this equate to 
risk of actual overdose?  
 
5.8.6 Level of NRD in ODU with Lung Disease  
There were no differences in drive between the two ODU groups but there were significant 
differences between the ODU group with lung disease and their corresponding controls. ODU 
participants with lung disease showed significantly lower levels of drive compared to their 




COPD patients (Jolley et al., 2009; Murphy et al., 2011). In relation to this, however, the 
relationship between drive and measures of respiratory function and respiratory depression is 
uncertain. The levels of drive amongst ODU participants actually fell within the ranges seen 
in healthy adults (MacBean et al., 2016; Reilly et al., 2011), and were consistent with the 
previous study with a similar cohort (Jolley et al., 2015). A lower NRDI is evidently 
counterintuitive in the face of chronic use of opioids in combination with a higher likelihood of 
developing age-related diseases, including chronic respiratory disease where drive is required 
to increase to maintain adequate levels of blood gases. The data in this study therefore 
suggest that there is a chronic suppression of NRD by long-term opioid use, as demonstrated 
by a relatively inappropriately-low level of NRD relative to the severity of disease.  
 
Aside from an expected trend towards a relationship between ETCO2 and drive amongst the 
two control groups, no other respiratory marker or measure was correlated with drive in any 
of the groups. SpO2% did not show any relationship with NRDI, however, this was not 
unexpected because pulse oximetry may not be as reliable an indicator of respiratory 
depression as other measures and is only a surrogate indicator of the effects of a drug on the 
ventilatory control system (Dahan et al., 2010; Jolley et al., 2015b).  Even where baseline 
SpO2% levels are normal, there can still be presence of opioid-induced reductions in NRD or 
increased ETCO2% in line with opioid-induced hypoventilation (Jolley et al., 2015b) 
Additionally, several studies have reported hypercapnia in the presence of normal respiratory 
rates or oxygen saturation (Cronin et al., 2003; Dalchow et al., 2013; Herman et al., 1999; 
Jolley et al., 2015b; Kopka, Wallace, Reilly, & Binning, 2007)  or reductions in respiratory rate 
but little change in SpO2% or pCO2 (Clemens & Klaschik, 2007; Pinna, Clemens, Quednau, & 
Klaschik, 2008).  
 






5.8.7 Further Examination of Results and Relevance to Key Mortality Issues 
By focussing on the predominantly held mortality risk factors, it is possible to take a more in-
depth examination into the results from this study. Of all the risk factors noted in this chapter 
as well as chapter 3, there are some factors which are thought to be well-evidenced and most 
influential on opioid-related mortality. The type of drug, age and route of administration are 
considered to be fundamentally important in vulnerability to overdose, and cigarette smoking 
to wider respiratory impairment issues. The rest of this section delves into some of the 
commonly-held statements by reflecting on the data described in this chapter.  
 
Buprenorphine has less of a respiratory depressant effect than other opioids. It is a widely-
held view that buprenorphine does not cause respiratory depression. Despite this, 
buprenorphine overdoses can occur, often due to the co-ingestion of benzodiazepines 
(Hakkinen, 2015; Megarbane, Hreiche, Pirnay, Marie, & Baud, 2006). Buprenorphine is 
referred to as a partial agonist and sometimes as a mixed agonist/antagonist, with the agonist 
or antagonist effect varying by dose, by receptor and between individuals (Jacob, Michaud, & 
Tremblay, 1979).  
 
It is speculated that buprenorphine may be affected by other medication/drugs, particularly 
other depressants. The data in this study represented a good opportunity to find out whether 
there were any differences with people who were using buprenorphine with benzodiazepines 
or alcohol together. There were five ODU participants who used alcohol and were on 
buprenorphine and one person who used benzodiazepines as well as buprenorphine. Of the 
12 ODUs who were on buprenorphine, there were no differences in the respiratory depression 
criteria between ODU who were co-using buprenorphine and alcohol compared to those who 
were not co-using other drugs. Only one ODU was co-using buprenorphine and 
benzodiazepines. There is clearly a limitation of sample size with this particular study, and it 
is difficult to make any conclusive statements in relation to the combined, or additive, effect of 
other depressant drugs. The limited data in this study suggest that buprenorphine may have 
a respiratory depressant effect, independent from other drugs. However, the case of 




buprenorphine and norbuprenorphine, and a recent study (Strang et al., 2018) into its effects 
showed that the two metabolites may play opposing roles in respiratory depression, with 
buprenorphine appearing to antagonise the respiratory depressant effects of 
norbuprenorphine. This is also supported by animal studies (Ohtani, Kotaki, Nishitateno, 
Sawada, & Iga, 1997) but there is still very limited research into this.  
 
Methadone deaths are more common in older age. There does appear to be an increased 
vulnerability amongst older users specifically with methadone (Gao et al., 2016; M. Pierce et 
al., 2018). However, as previously mentioned, it is still unclear whether this is a sensitivity to 
opioids or whether there is an issue of underlying chronic physical ill-health. It is possible to 
examine the data on age in further detail by splitting the data by median age into ‘younger’ or 
‘older’ ODU. There were no differences between the two groups for any of the respiratory 
depression measures, except for basic lung function measure of FEV1/FVC% ratio (Appendix: 
C-6). It is expected that the lung function measures would be related to age as COPD is a 
progressive disease that is more common in older aged people, and also, predicted lung 
function values incorporate age as part of the prediction calculation (Quanjer et al., 2012). 
However, it is interesting that there were no differences between younger and older age, 
suggesting that other factors are more important.  
 
Injecting heroin is more likely to cause vulnerability to overdose than any other route of 
administration. According to reports, non-injection routes cause only 1% of heroin-related 
deaths (Darke & Ross, 2000). In terms of preferred and previous route of administration of 
heroin, there were no differences in the respiratory depression indicators between injectors 
(n=11), smokers (n=6) and both (n=3) (Appendix: C-6), except for ETCO2 level which showed 
a significant difference between the groups. The highest average criteria were seen in the 
injectors group, with an average of 2.3 respiratory depression criteria. Of note, according to 
self-reports, whilst the majority of injecting drug users were only previously injecting heroin, a 
smaller proportion were still currently using (29%). In addition to this, as urine test results 
showed (see subsequent section), a greater proportion of ODU showed a presence of 




enough to impact the measures obtained on the study day or whether previous route of 
administration really does show a particular vulnerability. The specific issue of route of 
administration is covered in Chapter 6.  
 
More severe cigarette smoking history means a greater vulnerability to respiratory system 
burden. Considering the high number of people who smoke and use drugs, and the increasing 
numbers of ageing heroin users, it is unsurprising that illnesses caused by smoking play a 
significant role in the causes of death and may also increase the susceptibility to opioid 
overdose (Jolley et al., 2015b; PHE, 2016b). Therefore, it is expected that the heavier the 
cigarette smoking history, the more likely the respiratory impairment. There were no 
differences in physiological responses amongst heavy, lighter and ex-smokers. The smoking 
pack history of the ex-smokers fell within the ‘heavier’ category, and thus, grouping the ex-
smokers within the heavier smokers category again showed no differences between ex-
smokers and current smokers in any of the respiratory function measures, encompassing the 
respiratory depression criteria, lung function measures and gas transfer (Appendix: C-6). This 
is relatively surprising, as one would expect that heavier smokers would show more severe 
respiratory impairment but the ability to draw definitive conclusions is again limited by the 
small sample size.  
 
Staying in treatment for longer is more protective. There has been very little research into the 
association between length of time in heroin addiction treatment and risk of opioid overdose 
death. The available literature is centred on users being in or out of treatment and shows that 
being in treatment is generally protective (Cornish et al., 2010) against all cause mortality 
compared to no treatment at all but that the initial four-week period of treatment (Buster, van 
Brussel, & van den Brink, 2002; Caplehorn & Drummer, 1999; Degenhardt et al., 2009; DOH, 
2017) and the immediate period after treatment ends are apparently vulnerable periods of 
time for users (Marina Davoli et al., 2007; Degenhardt et al., 2009). Based on cohort data, 
there is some evidence to suggest that mortality rates plateau after around the 50-week mark 
(Cornish et al., 2010). The question of whether the current duration of treatment has an actual 




a median split of the data (12 months of duration being the median) showed no difference 
between shorter and longer duration of treatment amongst the respiratory depressant 
measures. Longer duration of treatment could suggest an increased stability on OST 
medication and opioid drug tolerance, however, the study did not thoroughly examine other 
factors that are associated with addiction treatment.  
 
5.8.8 Veridicality  
Veridicality is defined as ‘the degree to which an experience, perception, or interpretation 
accurately represents reality’. The study measures incorporated questions on self-report 
additional drug and alcohol use, both on the study day and in more general. In addition, an 
alcohol breathalyser test and a urine test were used to examine presence of alcohol and seven 
drugs: Cocaine/Crack, Morphine (Heroin), Benzodiazepines, Methamphetamine, Cannabis, 
Methadone Amphetamine. A presence of morphine indicates use of morphine and/or heroin, 
usually within the last 2 to 3 days (Narongchai, Sribanditmonkol, Thampithug, Narongchai, & 
Chitivuthikarn, 2002; Standridge, Adams, & Zotos, 2010; Verstraete, 2004). In other words, if 
the only opioids taken are methadone and buprenorphine, it should not be present. Eight of 
the 20 ODUs had corresponding self-reports and urine analyses. Of the 18 subjects who were 
on buprenorphine or methadone, nine had a presence of morphine, indicating possible recent 
heroin use, and none of those declared any other drug use in the self-report question. Five 
ODUs had a presence of cocaine, and similarly did not report this. A presence of 
benzodiazepines, methamphetamine and/or amphetamine was detected in four ODUs where 
it was not self-reported.  
 
There are clear advantages of using self-report over urine analysis, notwithstanding the 
practical aspect. However, it seems it is possible for this to be improved upon, and further, the 
methods incorporated in the self-reporting questioning in this study are not without problems. 
A truly blinded questionnaire would have been a more reliable measure of self-report and will 





5.8.9 Additional Findings  
Whilst not part of the original aims of the study, there were also some important unintended 
findings from the study. 65% of the opioid dependent users showed readings that indicated 
chronic obstructive respiratory disease, and only 38% of these had knowledge of this prior to 
the study. This is in line with previous studies and is important in the context of an ageing, 
drug user population who are increasingly prone to respiratory disease and risk of overdose 
(Jolley et al., 2015b; Palmer et al., 2012; Yadavilli et al., 2014).  It has also previously been 
shown that respiratory diseases are prevalent amongst opioid users and in fact, can be 
considered more prevalent than matched controls (Jolley et al., 2015b; Palmer et al., 2012; 
Yadavilli et al., 2014).  
 
5.8.10 How Does this Translate to Overdose Risk? 
All measures examine respiratory depression differently. There is no gold standard of 
measuring respiratory depression, and the reasons for this are twofold: 1) that there are many 
potential mechanisms of respiratory depression (bradypnoea, reduced tidal volume as well as 
reduced responsiveness to hypercapnia caused by alveolar hypoventilation and hypoxaemia), 
and 2) technology and bioengineering is continually in development with regard to better and 
more reliable measures. It is for certain, however, that point measurements (one 
measurement of either SpO2 or CO2) are not sufficiently reliable to detect risk of respiratory 
depression (Dahan et al., 2010; Pattinson, 2008). The benefit of having all of these measures 
is the ability to extract the most suitable parameters for overdose detection. Using both end-
tidal and transcutaneous capnography measures together simultaneously allows one to 
observe both the overall trends and breath-by-breath analyses. The benefit of measuring 
SpO2 is its practical methodology as well as larger applicability in clinical and ambulatory 
settings. However, a change in SpO2 is one of the final physiological effects that occur in 
respiratory depression. Oxygen saturation is a measure of gas exchange in the lung rather 
than a direct indicator of ventilatory efficiency (Dahan & Teppema, 2003; Dahan, van Dorp, 
Smith, & Yassen, 2008). In addition to this, SpO2 is a peripheral measure of oxygen saturation 
and in clinical practice,  it is a simple measure used to indicate a serious opioid-induced 




breathing frequency and sedation (Dahan et al., 2010). Meanwhile, observed changes in 
NRDI is a measure of changes to the respiratory system prior to the occurrence of this said 
final result. Thus, NRDI is the most reliable of these to detect changes to the respiratory 
architecture.  
 
There is a multifaceted and complex network of activity that underlies the components of an 
opioid overdose. An impairment in respiratory mechanics in comorbid lung disease impairs 
neuromechanical and neuroventilatory efficiency. Thus, the impact of respiratory depression 
by opioids is further compounded which may be relevant to overdose risk. Opioids cause a 
blunted responsiveness to ventilatory demand, hypercapnic ventilatory response, hypoxic 
ventilatory response, and, as I have shown, neural respiratory drive, which are the body’s 
crucial signalling systems. Therefore, the greater the suppression of the neural drive to 
breathe, in combination with increased severity of lung disease, the greater the potential for 
respiratory depression, respiratory failure, and fatal overdose. This needs crucial further 
investigation. Studies examining this area have a difficult task because the reality of detecting 
whether indicators lead to fatal overdose is an obvious ethical obstacle and is very difficult to 
predict in live human studies. It is impossible to conclude with these data whether a summative 
effect is being observed, and this may well be an underlying factor.  
 
5.8.11 Weaknesses of the Study 
Age was not statistically matched and remained higher in the ODU-LD group when compared 
to the corresponding control group. One of the reasons for this was related to the fact that 
control samples were not specifically recruited for this study but had been selected from 
existing laboratory studies. However, one would expect that an older cohort would attain 
greater frequencies of respiratory depression due to the effect of the respiratory lung 
mechanics and lung function, but this does not appear to be the case. COPD is most 
commonly diagnosed in people over the age of 40, and crucially amongst those who smoke 
or are exposed to air pollutants and chemicals (BLF, 2016; Ramsey & Hobbs, 2006). Levels 
of oxygen saturation decrease in older age in healthy adults, and with a combination of COPD, 




In relation to this, FEV1%predicted values are based on age (as well as gender and height). 
The levels of FEV1%predicted between the ODU-LD and controls-LD groups were not 
significantly differing, with some overlap between IQR (ODU-LD: 67-90%; Controls-LD: 53-
75%). This suggests that the predicted values can actually account for differences in age 
between the two groups. 
 
Further, as this was a convenience sample, the ratios between participants with and without 
lung disease, or between male and female participants, were not controlled for, which led to 
a smaller number of healthy ODU participants and also fewer female participants. Also, more 
generally, the sample size was too few to conduct more detailed statistical tests. Despite this, 
the data presented in this chapter were sufficient to fulfil the aims of the study.  
 
5.8.12 Strengths of the Study  
The findings of this study are important because there are currently no distinct data on the 
overlap between those with chronic respiratory disease, risk factors of overdose and 
measures of respiratory depression. There are obvious ethical considerations in studies such 
as these but this type of study methodology is practical and informative. It has shown that an 
investigation into chronic, everyday respiratory depression can be observed without disrupting 
the individual’s treatment pattern or using pattern. Data presented in this chapter illustrate the 
ease of detection of respiratory depression and the need to explore the potential relationship 
with the suppression of NRDI and lung disease in ODU.   
 
5.8.13 Possible Mechanisms and Implications for Clinicians  
Using these types of intricate, detailed physiological measurements, we can identify markers 
that could be used to identify ‘at-risk’ patients. Reliable markers that are convenient, practical 
and immediate would be most useful for this but current techniques are not advanced enough 
for this to exist. SpO2% is perhaps the most practical clinical measure but as demonstrated 
there are flaws in its clinical application (Dahan, 2006). It is feasible that these measurements 




of providing opioid users with better information on which to choose their treatment. These 
methods require validation in a larger scale, prospective study.  
 
Further, more robust interventions need to exist in better identifying chronic respiratory 
diseases in this community. Even if overdose is not a potential risk/consequence, there is a 
clear requirement for this from the perspective of general health and well-being of this often 
multi-morbid population.  
 
Most importantly, the greatest implication for clinicians and the wider public health domain is 
in the context of where these data can drive technology and allow for an early detection of risk 
of opioid overdose. The eventual aim would be to create a tool or a checklist to enable the 
understanding of opioid overdose liability, and for these tools to be implemented in a method 
that is fast-responding and life-saving. The next section will outline the future work that should 
be taken forward with these data.  
 
5.8.14 Questions for Future Research  
Deaths from opioid overdose could be prevented if the onset of the overdose could be 
detected. Informing future research into practical wearable versions of these measures in 
order to reliably monitor and ultimately prevent fatal overdose events is crucial.  
 
Collaborating with other interested stakeholders and experts in bioengineering, mobile 
technology and physiology, these novel tools can be used to develop an experimental model 
of an acute, realistic overdose scenario. It would inform the development of devices that could 
detect overdose onset and trigger an emergency response. Future studies need to 
concentrate on taking this model further, i.e. how can we predict vulnerability to a fatal 
overdose? Determining physiological indices that are most suitable for mobile monitoring is 







Conducting detailed physiological studies in a hard-to-reach population is a challenging task. 
However, being able to investigate such a group provides a great deal of detailed physiological 
information. Everyday respiratory depression exists within opioid-dependent users with and 
without lung disease. Compared to controls, there is a significant respiratory system ‘burden’ 
of lung disease. Being able to elicit these data by means of a simplified, practical method 
shows that it can be taken further into a clinical setting or inform further technological 







6 Exploration into the Effects of Differing Routes of Heroin 
Administration  
6.1 Preface  
Route of administration as a factor for opioid overdose has been addressed from many 
different perspectives. Whilst deaths can, and do, occur through non-injecting routes of 
administration of heroin (i.e. smoking, snorting and swallowing), the substantial majority of 
overdose deaths are still the result from injection of heroin (Darke & Hall, 2003). The 
understanding of the pharmacokinetic differences between different routes of administration 
are well-established and is the basis of much of pharmaceutical research and development. 
However, there is little understanding of whether, and why, the differing injecting routes of 
administration amongst heroin users actually relate to a higher risk of opioid overdose.  
 
In the wider scope of my PhD studies, I had the opportunity to conduct secondary analyses 
on data that were collected by colleagues during a previous study which enabled me to 
examine the acute effects of injection heroin administration (these data were from an earlier 
study by my supervisors and colleagues (Jolley et al., 2015b). The data were not originally 
collated in order to examine the differences between routes of administration. The study aimed 
to investigate the acute respiratory depressant effects after a normal dose of diamorphine in 
patients who receive diamorphine as part of their maintenance treatment for their heroin 
addiction. However, as will be discussed in this chapter, the participants presented with a 
varied set of heroin use history and, therefore, the range of doses and routes presented in this 
chapter can be considered as reflective of the wider, long-term injecting heroin using 
population in the UK. Re-visiting this type of study was valuable in informing the future work 
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6.2 Introduction  
Many long-term heroin users have peripheral veins that have been destroyed by repetitive 
injecting and consequent phlebitis, whereby the veins become inflamed. This is usually 
caused by blood clotting inside the vein or by damage to the vein walls. In this condition, users 
are usually left with finding alternative injecting routes of administration, such as intramuscular 
or subcutaneous, or non-injecting routes, such as intranasal or smoking (‘chasing’) (Girardin 
2003). The pharmacological and subjective effects of intravenous and intramuscular routes 
differ in their absorption and initial onset. The different metabolites have different actions. It is 
known that the initial effects of heroin are attributed to 6-MAM and heroin effects after the 
initial drug effect are attributable to morphine. Intramuscular injection results in lower and 
delayed peak onset of the concentrations of the heroin metabolites 6-MAM and morphine 
(Girardin 2003). The peak effects of intramuscularly and intranasally administered heroin 
occur in 3 to 5 minutes (Skopp et al., 1997). Intravenous on the other hand, peaks in less than 
1 minute.  
 
Most fatal and non-fatal heroin overdose cases occur when heroin is administered 
intravenously. A case series on overdose fatalities in an emergency department in California, 
USA reported that the intramuscular route accounted for only 0.5% of non-fatal heroin 
overdoses (Sporer, 1999; Sporer, Firestone, & Isaacs, 1996). It is not clear whether this 
translates to a lower risk of overdose or whether there is just much lower prevalence of the 
use of intramuscularly administered heroin and subsequent overdoses. From the relatively 
limited literature that exists, there is a belief that the intramuscular route is a safer way to inject 
heroin. This route involves extensive peripheral hydrolysis and therefore, limits toxicity 
compared to that seen in intravenous administration (Way et al., 1960). Although it must be 
noted that any injection route carries risks, e.g. non-intravenous injection (particularly 
subcutaneous) may increase the risk of soft tissue damage (White, 1973).  
 
Previous chapters have addressed the background of diamorphine maintenance treatment or 
heroin-assisted treatment (HAT). Safer heroin dosing in the patients who attend these clinics 




Generally, this is also applicable to advice and clinical recommendations to injecting heroin 
users in other types of clinics as well. Whilst encouragement to transition to less risky routes 
have been incorporated into clinical practice, to date, there has not been a clinical study that 
has compared the respiratory depressant and subjective effects from differing routes of 
administration of a single dose of pharmaceutical heroin. 
 
In principle, the intramuscular route of administration should confer a lower risk of opioid 
overdose compared to intravenous administration which is more direct and has a more rapid 
and higher absorption of metabolites in the blood after injection. IV should also confer a higher 
subjective feeling of drug high because of the greater initial absorption and effect. Data in this 
chapter represent a secondary data analysis on a dataset from a study examining the acute 
respiratory depressant effects of a dose of injectable diamorphine. This chapter describes an 
exploration into the physiological and subjective effects between two common injecting routes 
of administration amongst long-term heroin users on diamorphine maintenance treatment.  
 
6.3 Aims & Hypotheses 
Aim 1: Is there any difference in physiological and subjective effects between an intravenous 
(IV) and intramuscular (IM) administration of heroin?  
• Hypothesis 1: IV administration of heroin produces a more severe respiratory 
depressant effect and greater subjective experience of ‘drug high’ compared to 
IM administration.  
 
Aim 2: Does IV administration produce more pronounced physiological and subjective effects 
in the initial first few minutes compared to IM administration? 
• Hypothesis 2: IV administration produces more pronounced immediate and 
short-term (within the first minutes post-dose) physiological and subjective 







6.4.1 Study Design  
The sample of all analyses in this chapter was drawn from a previous study on acute heroin 
administration within a clinic that provided a stable maintenance dose of diamorphine. Any 
personal information pertaining to the participants had already been anonymised at 
recruitment stage of the study. The methods of this study were detailed in the 2015 publication 
by Jolley and colleagues (Jolley et al., 2015b). All participants were receiving injectable opioid 
treatment for heroin addiction within South London and Maudsley NHS Foundation Trust and 
had been on a stable dose for at least two weeks.  
 
In total, 10 participants took part in the study and attempt was made to monitor all participants 
for 150 minutes post-dose administration. At 3 minutes prior to opioid drug administration, and 
then at 3, 8, 15, 30, 60, 105 and 150 minutes post-administration, participants were asked to 
rate their drug high, and their pupil size was recorded. All participants completed 30 minutes 
of recording after administration of their injectable heroin, and all underwent the following 
physiological measures: 
• Parasternal intercostal muscle electromyogram recordings (EMGpara) providing 
an indication of the neural respiratory drive index (NRDI). 
• Ventilation: respiratory rate, tidal volume and minute ventilation  
• SpO2% and ETCO2%  
 
6.4.2 Indicators of Significant Respiratory Depression 
The following respiratory-related indices were used in the study as evidence for significant 
respiratory depression:  
• Absence of inspiratory airflow for more than 10 seconds 
• SpO2 < 90% for more than 10 seconds  
• ETCO2 % per breath exceeding 6.5%  





6.4.3 Subjective Drug Effect 
Participants rated their drug high on a scale of 0 (no effect) to 5 (maximal effect). The staff 
rating of intoxication was measured on the same scale of 0 (no effect) to 5 (maximal effect). 
Staff level of consciousness was assessed using rating scale of 1: normal; 2: visibly affected 
but alert; 3: drowsy but responds to verbal stimuli; 4: no response to verbal stimuli.  
 
6.4.4 Statistical Analysis 
The participants were divided into those that had administered their heroin dose 
intramuscularly and those that administered intravenously. Non-parametric bivariate testing 
was used to assess the differences between the participants. Examination of within-subject 
differences used Friedman’s Test to test for differences between baseline and successive 
time points for both groups (IV and IM). Kruskal-Wallis test was used to identify differences 
between groups at each time point and Mann Whitney U Test (U-statistic) was used to test for 
differences between groups at specific time points. Data analyses were performed using 
GraphPad Prism 7 for Mac OS X (GraphPad Software, Inc) or SPSS software v22 for Mac 







6.5 Results  
6.5.1 Demographics  
The median (and interquartile range) age of the participants was 49 years (42 to 58 years) 
(Table 6-1). Three of the participants took their diamorphine took via intravenous route and 
seven took their dose via intramuscular. Doses ranged between 50mg to 100mg for 
intravenous, and 90mg to 200mg for intramuscular. Nine of the 10 participants had COPD as 
measured by spirometric and clinic criteria.  
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6.5.2 Physiological and Objectives Measures of Respiratory Depression 
 
6.5.2.1 Pulse Oximetry 
The median (IQR) SpO2% amongst participants in the IV group was 95.3% (92% to 95.7%). 
The IM group had a median (IQR) SpO2% of 96.4% (94.8% to 98%). Neither IV nor IM groups 
showed significant changes from baseline to successive time points post-dose (Q=7.5, p=0.1 
and Q=7, p=0.1, respectively). There was no statistically-significant difference between the 
two groups across the 30-minute recording as well as within the initial first few minutes post-























Figure 6-1a-d: Results for pulse oximetry (SpO2%) over time.  
a) three IV participants; b) seven IM participants; c) bar graph of the differences between IV and IM 
administration at each time point: 0, 3, 8, 15, and 30 minutes post-dose; d) all participants, IM (blue) and 



















































































6.5.2.2 End-tidal carbon dioxide 
The median (IQR) ETCO2% was 4.65% (4.4% to 5.2%) in the IV group, and 5.4% (4.8% to 
5.9%) in the IM group. A significant change from baseline to successive time points post-dose 
was seen in the IM group (Q=11, p= 0.03), but not in the IV group (Q=6.7, p=0.2). In the initial 
first few time points post-dose, ETCO2% was higher in the IM group compared to the IV group, 
but this was not significant (H-score=13.9, p=0.13). Overall there was no statistically 

















Figure 6-2a-d: Results for end-tidal carbon dioxide (ETCO2%) over time.  
a) three IV participants; b) seven IM participants; c) bar graphs of the differences between IV and IM 
administration at each time point: 0, 3, 8, 15, and 30 minutes post-dose and d) all participants, IM (blue); 
IV (red).






















































































6.5.2.3 Respiratory Rate  
The median (IQR) respiratory rate was 8.95 breaths/minute (7.85-9.63breaths/min) in the IV 
group, and 10.27 breaths/minute (8.92-13.25breaths/min) in the IM group. Neither IV or IM 
group showed significant change from baseline to successive time points (Q=0.5, p=0.9 and 
Q=6,p=0.2). Generally, the respiratory rate was higher in the IM group compared to the IV 
group at each time point, but this was not significant. Overall there was no statistically-













Figure 6-3a-d: Results for respiratory rate over time:  
a)  three IV participants; b) seven IM participants; c)  bar graphs of the differences between IV and IM 
administration at each time point: 0, 3, 8, 15, and 30 minutes post-dose and d) all participants, IM (blue); 
IV (red).  
 
 
























































































6.5.2.4 Neural Respiratory Drive Index (NRDI) 
The median (IQR) NRDI was 68.73 min-1 (56.77-161.99min-1) in the IV group, and 107.33 min-
1 (76.14-129.22 min-1) in the IM group (with a median of 75.4min-1 and 120min-1 at baseline, 
respectively). There were no differences from baseline to successive time points post-dose 
for either IV or IM groups (Q=3, p=0.6 and Q=7,p=0.4). Overall, NRDI was higher in the IM 
group compared to the IV group at each time point, but this was not significant. Overall there 













Figure 6-4a-d: Results for EMGpara%index (NRDI) over time:  
a) three IV participants; b) seven IM participants; c) bar graphs of the differences between IV and IM 
administration at each time point: 0, 3, 8, 15, and 30 minutes post-dose and d) all participants, IM (blue); 
IV (red). 

















































































6.5.2.5 Tidal Volume (VT) 
The median (IQR) VT was 1.02L (0.78-1.42L) in the IV group, and 0.92L/min (0.71-1.01L) in 
the IM group. There were no differences from baseline to successive time points post-dose 
for either IV or IM (Q=6, p=0.3 and Q=3,p=0.5). There were no statistically-significant 
differences between the two groups with regard to tidal volume (H-score=6.6, p=0.7).  










Figure 6-5a-d: Results for tidal volume (VT) over time:  
a) three IV participants; b): seven IM participants; c) bar graphs of the differences between IV and IM 
administration at each time point: 0, 3, 8, 15, and 30 minutes post-dose and d) all participants, IM (blue); 



















































































6.5.2.6 Minute Ventilation (VE) 
The median (IQR) VE was 9.35L/min (6.84-12.44L/min) in the IV group, and 8.52L/min (6.71-
12.53L/min) in the IM group. There was a significant change from baseline to successive time 
points in the IM group post-dose (Q=13, p=0.01), but not the IV group (Q=2,p=0.8). Overall, 
there were no significant differences between minute ventilation amongst the two groups. 
There did appear to be a higher minute ventilation in the intravenous group at 15 and 30 








Figure 6-6a-d: Results for minute ventilation (VE) over time:  
a) three IV participants; b) seven IM participants; c) bar graphs of the differences between IV and IM 
administration at each time point: 0, 3, 8, 15, and 30 minutes post-dose and d) all participants, IM (blue); 
IV (red).  
  
















































































6.5.2.7 Pupil Size  
The median (IQR) pupil size was 2mm (2-2.75mm) in the intravenous group, and 3mm (3-
4mm) in the intramuscular group (3.5mm and 4mm, respectively, at baseline). The IV group 
did not show any difference from baseline to successive time points (Q=8, p=0.07) whereas 
the IM group showed significant difference at 8 minutes post-dose (Q=14.9, p=0.02). 
However, the IV group showed significantly more constricted (smaller size) pupils at the 3-










Figure 6-7a-d: Results for pupil size over time:  
a) three IV participants; b) seven IM participants; c) bar graphs of the differences between IV and IM 
administration at each time point: 0, 3, 8, 15, and 30 minutes post-dose and d) all participants, IM (blue); 
IV (red). 
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6.5.3 Subjective Measures of Drug Effect 
 
6.5.3.1 Level of Consciousness  
The median (IQR) Level of Consciousness (out of 4) was 1 (1 to 1.5) in the IV group, and 1 in 
the IM group. Neither the IV or IM group showed a significant change from baseline to 
successive time points (Q=4, p=0.9 and Q=8, p=0.1). Overall there was no significant 












Figure 6-8a-d: Results for level of consciousness over time:  
a) three IV participants; b) seven IM participants; c) bar graphs of the differences between IV and IM 
administration at each time point: 0, 3, 8, 15, and 30 minutes post-dose and d) all participants, IM (blue); 
IV (red).  
 



































































































6.5.3.2 Subjective High  
In the IV group, the median (IQR) of the subjective rating of drug high was 2 (1.5-2.25) out of 
the maximal effect of 5. In the IM group, participants rated their high at 2 (1-2) out of 5. Both 
IV and IM groups showed significant differences from baseline to successive time points post-
dose (Q=11,p-0.002 and Q=25,p=0.0001, respectively). At the 3-minute post-dose time point, 
the IV group showed a significantly higher rating of drug high compared to the IM group (U-
statistic=0, p=0.017). Other time points did not show any difference in subjective high.  
















Figure 6-9a-d: Results for subjective high over time:  
a) three IV participants; b) seven IM participants; c) bar graphs of the differences between IV and IM 
administration at each time point: 0, 3, 8, 15, and 30 minutes post-dose and d) all participants, IM (blue); 













































































































6.5.3.3 Staff Rating of Intoxication  
The median (IQR) rating of intoxication (out of 5) was 1 (0 - 3) in the IV group, and 1 (0 to 2.5) 
in the IM group. Neither group showed a significant change from baseline (Q=5, p=0.3 and 
Q=8, p=0.1). At 3 minutes post-dose, the IV group showed a higher level of intoxication 
compared to the IM group, but this was not significant. Overall there was no significant 
difference between the two groups (H-score= 13, p=0.2).  








Figure 6-10-d: Results for staff intoxication over time:  
a) three IV participants; b) seven IM participants; c) bar graphs of the differences between IV and IM 
administration at each time point: 0, 3, 8, 15, and 30 minutes post-dose and d) all participants, IM (blue); 
IV (red).  
  































































































6.5.4 Indicators of Respiratory Depression 
One participant was found to have all of the indicators of respiratory depression, which was 
previously reported (Jolley et al., 2015b). This participant had administered IV and this dose 
was the highest IV dose amongst the IV group (100mg). The other IV participants did not show 
any of the indicators of respiratory depression; their doses were 50mg and 60mg.  
 
Amongst the IM group, there were two participants who administered the same 100mg as the 
IV participant stated previously, however, only one of the IM participants showed one of the 
indicators of respiratory depression (respiratory pause for longer than 10 seconds). Out of the 
other five IM participants, three experienced two indicators of respiratory depression, and two 
experienced one indicator.  
 
6.5.5 Changes from Baseline  
Similar diverse observations were noted for physiological changes from baseline. In the IV 
group, the relative % change from baseline to nadir was 1.1% to 4.3%. The IM group showed 
decreases in SpO2% from baseline of between 0.6% to 4.6%. The % change from baseline to 
peak ETCO2 also varied between the groups. The IV group saw a range of between 5.1% and 
39.1% relative change from baseline to peak ETCO2%, whereas the IM group saw a range of 
0.01% to 34% change. Respiratory rate saw a diverse range, from 7% to 48.8% and 4.9% to 
37% between the IV and IM group, respectively. EMGpara%index (NRDI) ranged between -





6.6.1 Summary of Results 
Results from the data presented in this chapter are of a varied physiological and subjective 
response to differing routes of heroin administration. The only statistically-significant 
difference between the IV and IM administration groups was in subjective effect and reduction 
in pupil size which were significantly more pronounced in the IV group compared to IM in the 
initial 3 minutes post-dose.  
 
6.6.2 Implications and Limitations of this Chapter  
The physiological responses that occurred in this study were an expected part of the opioid 
effect. However, the expected difference between IV and IM were not apparent in the data 
presented in this chapter. The reason for this is most likely due to the fact that the number of 
participants in each group are not sufficient to draw detailed conclusions on the data. 
However, age did not vary greatly in this group, and chronic lung disease was present in all 
except one participant. Additionally, these types of studies are notoriously difficult to recruit 
for, given the limited size of the population, but have a high level of within-subject design which 
provides in-depth physiological data for each participant.  
 
Pupil size showed a significant difference between the groups. Pupillary light reflex is a 
commonly used evaluation in medicine generally to detect injury to the central nervous system 
such as stroke, traumatic brain injury, etc. Opioids induce miosis (excessive constriction of the 
pupils) by causing contraction of the circular muscles that consequently constrict the pupil 
response to light (Ellis, 1981; Fountas et al., 2006). It is well-understood that the signs of an 
opioid overdose involve pinpoint pupils, i.e. pupils that are very small in diameter, and 
pupillometry is a validated and recognised diagnostic criterion of overdoses (Friedman & 
Manini, 2016; Larson, 2008; Stead, Stead, & Kaufman, 2006). This is usually combined with 
decreased level of consciousness and respiratory depression. Pupil size did appear to show 
a significant difference at the 3-minute post-dose time point between the IV and IM group 
which is consistent with previous literature (Rollins, Feiner, Lee, Shah, & Larson, 2014). This 
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finding warrants further and more detailed research to examine whether this relationship is 
consistent in a larger sample size.  
 
It is also interesting that pupillary responses were the only objective measure that showed any 
difference between the two injecting routes of administration and ventilatory responses were 
not. This may be due to the individual subject factors that influence ventilatory parameters and 
are difficult to control (e.g. talking, level of agitation, etc.), whereas pupillometry is a measure 
observed in a truly objective manner. It could also be related to the fact that pupil diameter is 
regulated by different regions within the brainstem compared to respiratory control. Opioid-
induced pupillary effects are caused by disinhibition of the pupilloconstrictor nucleus in the 
pretectal region of the brainstem (Larson, 2008). Other studies have noted the importance of 
using pupillometry over other measures as a marker of pain thresholds in anesthesia as it is 
shown to be more sensitive to noxious stimulation (Constant et al., 2006; Larson et al., 1993; 
Paulus et al., 2013) and in an experimental model of opioid antagonism developed in Norway 
(Skulberg et al., 2018).  
 
Finally, this study was a comparison between IM and IV. Whilst IM does occur, the more 
common non-IV route is smoking or ‘chasing’. Unfortunately, the participants recruited in this 
study were only on an injectable form of diamorphine and therefore, the study design was 
limited to these routes. An inhalable form of diamorphine does exist and is used in heroin-
assisted treatment clinics in the Netherlands (Blanken, Hendriks, Van Ree, & Van Den Brink, 
2010; Brink et al., 2003) but is not available in the UK. In the future, it would be relevant and 
important to also compare IV with chasing, and possibly even intranasal administration of 
heroin (which carries greater risk of overdose but is much less common) perhaps among an 
illicit heroin-using population.  
 
6.6.3 Additional Findings  
It is important to highlight that the participant who administered the highest IV dose (100mg of 
diamorphine) also showed the most significant impairment in the study. The oxygen saturation 
recording for this participant reached a low level of 73.6%. Considering the dips in SpO2% for 
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other participants did not surpass levels below 85.6%, this is a remarkably distinct response. 
The levels of other physiological responses also showed similar pronounced effect such as 
NRDI which was 26min-1 at nadir, when the median for the group as a whole was 109.5min-1, 
as well as respiratory rate which dipped to 3 breaths/minute at the 8-minute time point.  
 
An interesting point to note with this particular participant was that, as well as experiencing 
the most significant physiological changes post-dose, they also experienced the highest effect 
of drug high. This was not unexpected but it is interesting as these particular participants are 
long-term injecting heroin users who have been using diamorphine for, in most cases, many 
decades. In the case of this participant, the number of years of injecting drug use exceeded 
40 years. Despite this length of time injecting heroin, the drug effect is still pronounced. This 
drives the question of whether other subjective effects were also experienced, such as drug 
liking. This is an important issue in discussions about addiction treatment more widely and is 
beyond the scope of this thesis.  
 
In relation to the prolonged nature of the respiratory depressant effects, it is interesting that all 
participants showed sustained markers of respiratory depression throughout the monitoring 
period. There were two individuals who showed abnormally low levels of SpO2% before the 
dose was administered (below 95%, participants 1 and 10) and a further three participants 
showed abnormally low respiratory rates (below 10breaths/minute, participants 1, 4 and 7). 
None of other participants or measures showed abnormal levels pre-dose. However, those 
with abnormal pre-dose levels appeared to show the same levels of physiological markers 
post-dose as the other participants (Figures 6-1 to 6-10), i.e. they were not ‘more extreme’, 
and the pre-dose irregularity did not appear to cause more of an impact on their response to 
the IV and IM heroin dose.  
 
6.6.4 Wider Implications of Exploring Non-intravenous Routes of Administration  
Injecting routes of administration are highly reinforcing because of the initial rapid onset and 
greater bioavailability. Intramuscular is less intense than intravenous and may be less risky; 
this prompts the question, should users be encouraged to switch to intramuscular (Strang et 
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al., 1999; Swift, Maher, & Sunjic, 1999)? Previous literature has discussed the potential 
benefits of encouraging users to switch to non-injecting routes in order to reduce the related 
harms and risk of overdose (Darke & Hall, 2003; Hunt, Griffiths, Southwell, Stilwell, & Strang, 
1999). Literature on the practical application of the switching of routes within a clinical setting 
is limited. The Randomised Injectable Opioid Treatment Trial (RIOTT) protocol considered this 
in relation to implementing clinical practice of encouraging a move to IM. Clients within this 
trial were generally all IV users. However, as part of their trial, when IV administration was 
unsuccessful, it was established that the procedure would be addressed as follows: after three 
unsuccessful attempts at superficial vein injecting, and if no blood was in the syringe, the 
clients were asked to inject IM or subcutaneously (SC). If this was refused, or if a significant 
amount of blood is seen in the barrel of the syringe, then IM or SC would be not given, and an 
oral dose was issued instead. It was also stated that clients who repeatedly have difficulties 
injecting IV would be reviewed by their key worker or medical officer. This encouragement to 
change route of administration was not necessarily based on reducing risk of overdose but it 
is useful to reflect on the dynamics that this transition may represent for users in these types 
of settings. Indeed, this issue is one that concerns clinicians in the addictions field more widely. 
There is anecdotal information of clinicians encouraging IM use over IV, but evidence for how 
commonly this occurs or how effective this is still unknown. This further highlights the 
importance of exploring this area in future research.  
 
6.6.5 Questions for Future Research   
Heroin users clearly administer heroin intravenously for a reason. It gives users a greater rush, 
and higher peak effects. The data presented in this chapter show the need for further research 
into two areas: firstly, further analysis into the physiological and subjective differences 
between the two common injecting routes, and secondly, the qualitative aspect of why 
individuals chose to use heroin IM or IV.  
 
An important way forward from these data would be to expand this type of exploratory 
physiological and psychological study and examine whether variation of dose effect exists 
between IV and IM within the same subjects. In a controlled setting, this could be a strong way 
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of ensuring that the dose effect is in fact related to the route itself. The other question for future 
research is in the understanding of the experiences of users within the context of how and 
why differing routes of administration are chosen.  
 
The question remains whether people choose to IM simply because of limited/restricted 
venous access or whether there is a more nuanced aspect to this that should be explored. In 
a similar vein, it could be compared to choosing between a stronger %ABV such as whiskey, 
over a weaker %ABV such as beer on certain days, or in certain circumstances over others. 
Should we do qualitative analysis into why people who have chosen to IM and why they would 




Intravenous administration of heroin is the route most commonly observed in cases of fatal 
and non-fatal opioid overdose. Previous literature suggests that intramuscular administration 
may be less toxic and potentially safer option of injecting heroin. Data presented in this chapter 
cannot definitively support the hypothesis that IV heroin administration produces more 
pronounced respiratory depressant effects compared to IM heroin administration. However, 
the data represent valuable preliminary information for future studies and introduces further 
questions for exploration. Further, more detailed analysis into individual cases showed that 
the highest IV dose also produced the highest respiratory depressant response. These 
experimental studies are difficult and ethically challenging. Therefore, opportunities to 
examine previously conducted data must be pursued. It is important to develop these 
questions further in order to be able to determine safer alternatives that can be implemented 





7 Clinical Trial and Error  
7.1 Preface  
This chapter is focussed on describing and highlighting the preparatory work that was involved 
in setting up the clinical trial on acute opioid overdose or ‘AOO’. It is important to highlight the 
preparatory work as these particular types of experimental studies within academic settings 
are few and far between, probably for many good reasons. I start the chapter by describing 
the development of the study protocol which involved establishing a set of questions, guided 
by the qualitative Reader Dr Jo Neale. I consulted a number of former and current service 
users with these questions and held several discussions with experienced clinicians and 
academics in order to refine and develop the study design and protocol. It was crucial that we 
prepared the protocol in this way as it is important to enable this study design to be not only 
robust, but also, to be used as a model for future research studies.  
 
The latter part of this chapter delves into the administrative, procedural and, even at times, 
political obstacles that became part of the journey of this study. These steps took the better 
part of three years to undertake and have given me an incredible insight into real-world 
research that would not have been possible otherwise. It also, hopefully, strongly 
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7.2 Development of AOO Study Protocol  
Development of the study protocol involved a number of processes. This section will highlight 
the consultation process with former and current service users. The initial consideration was 
regarding the dose of the opioid, and how we determined the increase of 10% and 20% of 
normal maintenance dose. Other important considerations were of the randomisation and 
blinding processes, respiratory depression indices and the cut-off levels for use as the study 
parameters; the latter of which had to be established without jeopardising the safety of the 
patient or quality of the study.  
 
7.2.1 Dose Increases  
Several reputable studies that have conducted this type of increased opiate dose have 
successfully shown that an experimental study can be implemented without any serious side 
effects to the subjects. A Dutch group conducted a double-blind randomised study to address 
the pharmacological differences between inhalation and intravenous routes of heroin 
administration, taking patients from the Heroin on Medical Prescription Research Project in 
the Netherlands. Their regular doses alternated between 67%, 100% and 150% (Rook et al., 
2006). Other studies have looked at high dose effects of opiate substitution drugs, such as 
methadone or buprenorphine. Curran and associates focused on the craving effects of a 33% 
increase in oral methadone to patients who are on a daily dose of methadone (Curran et al., 
1999).  
 
From a risk assessment perspective, these were seen as increases with minimal harm. In this 
study, the proposed +10% and +20% of regular dose of diamorphine was expected to show 
significant changes but with minimal harm to the subjects and their treatment plans. Subjects 
were recruited from clinics where they were already receiving a dose of diamorphine. Patients 
in these clinics normally self-administered their dose separately throughout the day. This study 




7.2.2 Randomisation and Blinding 
In the original concept of the study, a study design resembling the 2x2 crossover design 
(Lintzeris et al., 2007, 2006) was to be implemented. This was when the study design included 
the element of co-use of diazepam. The design was based on a series of studies that had 
examined the pharmacodynamic effects of co-administering high dose methadone or 
buprenorphine with high dose diazepam. Participants in these studies were recruited from the 
Randomised Injectable Opiate Treatment Trial (RIOTT) clinic and a comparison of the effects 
of 100% and 150% of the maintenance dose, as well as 0mg and 40mg of diazepam, using 
physiological measures and Visual Analogue Scales were made (Lintzeris et al., 2007, 2006). 
The design for the AOO study was originally to include a placebo control for diazepam along 
with the diamorphine doses and thus, incorporated this 2x2 design. It was not deemed 
appropriate to include a placebo for diamorphine as the treatment regimen is such that it would 
potentially cause the user to destabilise, which was not the aim of the study. The protocol and 
study design were eventually revised and co-administration of diazepam was excluded from 
the study. While this research question is still crucial to investigate, it was thought that a focus 
on diamorphine would strengthen adherence rates and quality of the study and, as a result, 
this was prioritised. Other reasons that also influenced this exclusion are explored further on 
in this chapter. 
 
There were also plans to include double blinding, whereby only the trial pharmacist would be 
aware of the diamorphine dose levels and the sequence of randomisation. However, the cost 
of randomisation, but more significantly, the de-randomisation process were seen as 
obstacles for this to be implemented. The de-randomisation process is such that there could 
potentially be a delay in relaying the actual dose used in the session, and thus, in an 
emergency situation, it was deemed inappropriate to incorporate a full randomisation and 
double blinding strategy. In addition, the Ethics Committee and other specialists specifically 
enquired about the procedures in place for a potential situation in which a participant 
experiences a serious adverse event in one of the sessions, and whether they would be re-
invited for further sessions. We decided that a dose escalation was the most appropriate way 
to manage this. It is clearly unusual for a clinical trial of a product that has been around for 
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over a century to incorporate features that are more commonly associated with a Phase I 
study. However, it was still important to incorporate a form of randomisation and blinding for 
the purposes of study reliability. It was, therefore, decided that a single blind, single 
randomisation strategy would be established. The participants were told that a dose increase 
of 10% and 20% would be implemented, but that they would not know when these would be 
given, and the order, according to the participants, was randomised. Initially, it was conceived 
that the blinding would be implemented via over-labelled or masked syringes. However, this 
procedure was quoted at a prohibitively high cost. The final decision to add water per volume 
that was the same for each participant, according to their dose, was implemented in the final 
protocol. Ultimately, the study relied on relative flexibility to the study design to reflect the 
realistic using scenarios that it aimed to capture, and to guarantee the safety of the 
participants. As a result, some of the methods, while scientifically sound, were not usual. The 
quality and objectives of the study were maintained throughout all of the novel practical 
implementations.  
 
7.2.3 Consultation with Other Researchers and Clinical Specialists  
Discussions were also held with various clinical colleagues (Dr James Bell, Dr Ian Winston 
and Mr Rob van der Waal) working in the clinical team associated with RIOTT in order to 
ascertain over the degree to which an increase to a patient’s diamorphine dose is suitable, as 
well as the cut-off limits of the safety measures. Discussion of the safety measures, as well 
as respiratory depression indices, were held across multidisciplinary groups, with the advice 
of members of a respiratory medicine research group. Specialists in this group included critical 
care consultants, respiratory medicine consultants and other allied experts, alongside 




7.3 Consultation with Service Users 
Service users were consulted about the feasibility and acceptability of this study. At the time 
of the consultation, the plan was to include study sessions with co-administration of 
benzodiazepines, e.g. diazepam. However, for reasons stated earlier and to be stated in the 
latter part of this chapter, this particular section of the study did not go ahead as originally 
planned. It is an area that is expected to be explored in continuation of this study after the 
PhD, and therefore, is still included in the discussion of the protocol.  
 
Voluntary service users from the target population were recruited through a UK-based drug 
charity for consultation. The consultation took the form of one-to-one interviews, and Dr Jo 
Neale, a qualitative Reader in Addictions, provided the necessary guidance over the structure 
of these interviews. The aim of the consultation was to gather information on whether the study 
design was suitable and feasible, and to address the potential concerns of administering an 
increase to a maintenance dose. The consultation informed the methodology of the study 
protocol. The consultations were initiated with a brief description of the study. The description 
was verbally iterated along the following lines: 
The study is aiming to look at what happens in an overdose. It aims to address the myth that 
high dose heroin and, separately, that co-administration of benzodiazepines, are likely to 
increase the risk of overdose. We haven’t yet tested these things in a proper scientific setting 
but they are received wisdom in the medical field.  
A consultation of this type is to gather information about what is considered most acceptable 
and reasonable. It is open for you to comment and make any suggestions you think would 
be necessary.  
Some information about the study that we know so far:  
• Each study session will last a maximum of three hours.  
• People who are on diamorphine treatment will be asked to participate.  
• Two main questions will be answered: 1) is high dose heroin more likely to cause 
overdose; and 2) is co-use of benzos more likely to cause overdose? 
• In each session, each participant will take one placebo or active diazepam tablet 
AND diamorphine IV, either their normal or an increased dose.  
• Payment and travel reimbursements will be issued. 
 
Questions were asked in five separate sections, each addressing different components of the 
study design; ‘Increased Dose of Heroin’, ‘Co-use of Valium’, ‘Future Studies’, ‘Study 
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Conditions’ and ‘Recruitment’. The questions and summarised responses for each section 
have been described as follows.  
 
7.3.1 Increased Dose of Heroin 
1. Do you think it is reasonable to ask people to increase their dose by 10% for the 
purposes of this study?  
2. Do you think it is reasonable to ask people to increase their dose by 20% for the 
purposes of this study?  
3. Do you think it is reasonable to ask people to increase their dose by 50% for the 
purposes of this study?  
4. If there is an increase, is it acceptable to have a decrease? By 10%? 20%? How 
far do you think it could go either way?  
None of the service users stated that a 10% or 20% dose increase would be an issue, or that 
people would be reluctant to participate because of this dose increase. One user said that 
20% or 25% would be ‘much of a muchness’; and also, ‘50% would probably show some 
difference with intravenous, but perhaps not intramuscular users’. They all stated it would 
depend on the actual dose they are receiving. Finally, an increasing stepwise approach to the 
opioid dose was suggested by all users.  
 
7.3.2 Co-use of Valium (diazepam) or other sedatives  
1. People who are already using benzodiazepines will be excluded from the study 
because it will not be safe and will skew the results. However, what do you think 
about asking people who have had a history of benzo use? E.g. haven’t used for 
30 days. Do you think it is reasonable? 
2. Initial thoughts are to have a low dose of Valium (10mg) with the normal heroin 
dose. The daily recommended is 30mg. Do you think this is reasonable?  
3. What would be their reaction if a higher dose (20 or 30mg) of Valium was 
requested?  
4. What about adding an inactive benzodiazepine dose (placebo)?  
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None of the service users thought that it was unreasonable to include individuals who were 
on diazepam as well as diamorphine, and that it would be sensible to start at a low dose first 
before increasing. One user suggested including people who were using Temazepam as well.  
Ultimately, this aspect of the study was not continued any further, with the focus being 
maintained on diamorphine, and the aim to include co-administration of other depressants at 
a subsequent stage after the study.  
 
7.3.3 Future Studies 
1. Alcohol and heroin? Again, we will have to exclude people already drinking 
heavily, do you think this is reasonable? 
2. What about heroin at normal dose and alcohol at varying doses or vice-
versa?  
All the services users said that alcohol would more likely be the root of these problems in 
much the same way that benzodiazepines are. One stated that ‘alcohol seems to go hand in 
hand with heroin, especially with people who don’t know where or when their dose is coming 
from. Alcohol is definitely more commonly used’.  
 
7.3.4 Study Conditions 
1. Timing: do you think three hours is an unacceptable period of time? 
2. Would you be ok with taking your drugs in a laboratory setting?  
3. Would you be ok being wired up at the same time?   
The timing and study setting were not considered as unacceptable and it was thought that 
these particular participants would be used to taking their doses in clinical settings.  
 
7.3.5 Recruitment 
1. Do you think £60 supermarket vouchers are suitable payment/remuneration? 
2. What If I ask 20 people, how many do you think will agree? Why/Why not? 
3. What will be their biggest concern and what would be their reaction? 
4. What is the best way and best time to approach people? 
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When asked how much was to be given, all said that £60 would be insufficient. At the time of 
consultation, there were three sessions proposed, in the final version of the protocol, the 
number of sessions was increased as it was important to examine the effect of new settings, 
and particularly of new clinical settings. This meant that the amount of money given was also 
increased to £100 to reflect this. The method of providing an escalating scale of vouchers was 
used, and this was based on the research conducted by colleagues at the National Addiction 
Centre through its work on contingency management (Weaver et al., 2014). One of the larger 
scale studies examined the potential significance of providing financial incentives for Hepatitis 
B vaccinations amongst drug users in drug treatment and showed that adherence improved 
significantly. These findings around reinforcement and the emergence of the idea of a 
reinforcing ‘completion bonus’ informed the protocol and escalating voucher provision for each 
of the visits incorporated in this study.   
 
7.3.6 Summary of Service User Consultations 
Overall, one of the biggest challenges that was raised, and one which had a direct impact on 
the implementation of the study, was the issue of blood sampling. All of the consulted service 
users stated that people’s biggest concern and problem would be fear and paranoia about 
blood tests. It was noted that many of the potential participants approached for the study would 
be chronic injecting drug users, and whose venous access had been an issue in other settings, 
such as routine blood tests or liver function tests. The AOO study protocol did not include 
blood testing, and instead required participants to have had a liver function test prior to 
participation in the study. Most of the areas covered by the consultation were met positively 
by the service users and the consultation process was invaluable to establish the most 




7.4 Clinical Trial Process  
The clinical trial process, from initial conception to invitation of first participant, has been an 
arduous and complicated journey. Many aspects of this journey have seemed completely 
unexpected and, at times, even unbelievable. This particular study is without a doubt a 
challenging one, and for many people who interacted and assisted along the process it was 
unfamiliar territory. It would not be possible to cover all aspects of this process in this thesis. 
This section of the chapter reflects on some of the specific themes and obstacles that were 
observed within this unfamiliar situation. These reflect the interpersonal interactions, the 
challenging and hard-to-reach population and the often-difficult requests put upon the variety 
of people who were involved in the process. A timeline of events can be found in Appendix D.  
 
7.4.1 The Type of Study You Have Will Define the Next Three Years of Your Life 
The initial process of the study required the definition of the type of study, which caused much 
confusion. As it was a study examining a particular treatment but maintaining the same 
medication that patients had been using, it was unclear whether it would be classified as a 
standard clinical study or a clinical trial on a medication, officially termed Clinical Trial of an 
Investigative Medicinal Product (CTIMP). However, it was not a study on the treatment per se, 
but on the dose of the medication. These types of studies are most common in Phase I clinical 
trials, which are minimally available for diamorphine/heroin effect.  
 
In January 2015, an application as a non-CTIMP clinical study was initiated. This was initially 
questioned within the local Risk Assessment Committee (RAC), which assesses studies’ pre-
ethics applications. A RAC predominantly ensures that a study is generally acceptable and 
financially viable. In order to assess whether the study was a CTIMP or not, a summary of 
study was sent to the Medicine and Health Regulatory Authority (MHRA), which uses an 
algorithm to determine whether a study is a CTIMP. In the end, after several months of being 




7.4.2 Never-Ending Liaisons with the Clinical Trials Office  
As soon as a study is determined as a CTIMP, a Clinical Research Associate (CRA) is 
connected to a study. Usually, one CRA is assigned to each study prior to the relevant 
application processes and immediately prior to the ‘kick-off’ meeting. A kick-off meeting 
involves all relevant parties (funders, research, facilities and administrative staff) to meet and 
assign the required activities to relevant people; in reality, it took four months to set up this 
meeting due to the sheer number of attendees. Furthermore, a CRA assists with anchoring 
the study and the study documents to the legal and procedural requirements of all CTIMPs 
which are governed by national and European Union legislation. This particular study, in the 
end, involved two different CRAs, and a further three who covered or supervised the main 
CRA. However, CRAs generally do not work in one office, but instead, are based from home, 
and travel across the country on monitoring visits (CTIMPs require regular monitoring to 
ensure that all aspects of the study are in place). As a result, many of the discussions with 
CRAs were via email and some via telephone. This has, in many ways, been helpful to retrace 
many of the concerns, issues and obstacles that were raised throughout the study. The 
number of email exchanges reached quantities that has been impossible to quantify. The 
importance of having face-to-face meetings, however, has its own advantages in establishing 
a good connection and understanding between you and the CRA, and is important in the 
context of navigating the complex maze of conducting CTIMPs. Fortunately, in the later stages 
of the study, this was actually experienced with the final CRA that we were assigned.  
 
7.4.3 Unexpected Outcomes and Discussions with the Ethics Committee  
The main ethics meeting was conducted on 12th October 2016 and both my supervisor, 
Professor Sir John Strang and I attended this meeting. It was fully expected that questions on 
safety and participant recruitment would be a priority. The greatest concerns, however, 
appeared to be related to the justification of payment in vouchers and further clarifying the 
fatal risks in the participant information sheet. For example they stated: 
After the researchers had left the meeting, the Committee raised a concern regarding the 
£100 voucher that participants would receive. Although the voucher would be awarded in 
staged payments, the Committee requested written justification for this as they could be sold 




The particular issue of voucher payments is discussed in some more detail in the previous 
section. Moreover, in the meeting itself, we also met some unexpected questions from the 
Committee. One of the Committee members, a Clinical Pharmacologist, began his query as a 
very specific question about the scientific value of the study. He stated that the purity of street 
heroin had an enormous variability of strength, and that, because we would only be impacting 
a small dose range of diamorphine, he asked how we would be replicating the street doses 
without introducing too much risk. However, most interestingly, he asked whether we should 
just continue with the dose escalation until we felt uncomfortable. We responded by stating 
that we had also discussed this dilemma and we were aiming to maintain the correct balance. 
We stated that once we had explored the more ‘comfortable’ territory of a 10% and 20% 
increase, that we would consider investigating a higher dose increase of, for example, 40% in 
separate future studies.  
 
7.4.4 Your Clinical Research Associate Explains Your Study Better than You Can 
Once the CRA is assigned, the intricacies of the CTIMP world become ever more complicated. 
There are two site initiation visits, one for pharmacy staff, and another for the study site staff, 
which both involve meeting all relevant staff involved and introducing the protocol and the 
procedures to the relevant parties. While this is clearly a useful element of the process, the 
reality of conducting these types of meetings without a specific Trial Manager or Research 
Coordinator (I acted both roles) was a challenge. However, the establishment of good 
relationships with the CRA proved important. In one of these meetings, our CRA showed a 
keen interest in diamorphine prescribing: during her talk about her role and the regulations 
that, in reality, most of the staff had heard in one form or another on many occasions, she also 
incorporated a description about the study, and a very detailed overview about diamorphine 
prescribing, which surprised and impressed me. CRAs do not need to be informed about the 
details of the background of the study being implemented, but it was positive to hear the 




7.4.5 No More Heroin Anymore 
After initial ethics approval, there is an opportunity to reach out to recruitment sites and 
establish connections. This process was slightly complicated in this study. When the 
Randomised Injectable Opiate Treatment Trial (RIOTT) was officially closed down in 2015, 
due to the cessation of central government funding and a lack of local funding, there was 
immediate concern as to how the study would proceed. It was known that there would be a 
period of time in which the patients of RIOTT would slowly be re-integrated back into standard 
drug treatment and/or that their treatment would continue within standard drug treatment 
centres. It was always expected that there would be a sufficient pool of patients to draw from. 
However, when contact was made with relevant services in various regions of London and the 
South East of England, it became clear that the pool to recruit from had reduced and that it 
would be insufficient to recruit the required numbers. Fortunately, many of the services in 
these and other areas of the UK agreed to be included in the study. The first substantial 
amendment incorporated the addition of these services as ‘PIC’ sites (Participant Identification 
Centres).  
 
7.4.6 Top Deals and First-class Delivery 
With regard to the ordering and delivery of diamorphine and other drugs, there were some 
interesting discrepancies in the manner in which they were proposed. Diamorphine ordering 
was not an issue, and we did not observe any obstacles in the process, neither financial nor 
procedural. In fact, when the time came to order the diamorphine, the particular size of 
ampoules were ‘on contract’ and essentially were on offer (100mg x 5 vials = £18 plus VAT, 
The 100mg vials are usually £42.39 but are on contract at the moment). Not only was this the 
cheapest aspect of the study, the delivery of diamorphine was also almost immediate – within 
24 hours.  
 
When the initial project included diazepam, and its placebo control equivalent, quotes were 
obtained for pricing for the diazepam and placebo. Bizarrely, the quick-delivered, 
conveniently-priced diamorphine was not in any way comparable to the pricing for diazepam. 
The quote we received was based on 12 diazepam capsules, with 24 identical placebo 
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capsules and the total amount was four thousand, three hundred and fifty-one pounds, 
excluding VAT. The identical placebo capsules consisted of sucrose. 
 
7.4.7 Meet your RNs, the Driving Force 
Once ethics, MHRA and other local approvals had been received, the next step was to meet 
the research nurses (RNs) and the other clinical research facilities staff who would be involved 
in the study day to day. There were several meetings with potential research nurses. The 
career experience of research nurses is generally very varied, some have emergency 
medicine experience, others are mental health nurses by specialism. When explaining the 
details of the study to the research nurses, some of the nurses seemed surprised that such a 
study could go ahead, and others, for example, emergency nurses, were unfazed by the 
possibility to dealing with an emergency overdose situation, as they had seen many fatalities 
in their careers. It seemed that whoever the study was discussed with had a different 
expectation and understanding of the purpose of the study. It highlighted even further the 
importance of acquainting oneself with the people who would, in essence, be undertaking the 
day to day tasks of the study and upholding the integrity of the research.  
 
7.4.8 Do Not Pass Go, Do Not Receive Green Light 
Green light for recruitment is the final step that is required before the first participant can be 
recruited for the study. For this study, green light was obtained two months after the final 
approval was received. The reason for this delay was related to database validation. In all 
CTIMPs, there must be a specific type of database used throughout the study, one that is 
compliant with CTIMP rules and has very strict audit trail functions and enhanced security. 
The local Clinical Trials Unit has a fixed pricing system for their databases, which start at a 
minimum of £5,000, regardless of the number of participants. As this was not a realistic option, 
the opportunity arose to use a company that had recently been established as a user-friendly 
and regulatory approved database system. This required the database to be built by 
ourselves, from scratch, but was reasonably priced and as effective as other databases. Much 
of this was good news for the study, and despite the challenge faced in putting together a 
database from scratch, it was completed successfully. However, there was an aspect of the 
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database usage in the trial that no one had envisaged, including the CRA herself. As the 
database was new, and had never been used previously by other trials in the Clinical Trials 
Office, there had to be a validation process. Unfortunately, the validation process could only 
be conducted by one member of the Clinical Trials Office - the database manager - who was 
part-time and overstretched. For this reason, green light could not be provided, and a waiting 
game was played (from September to November 2017). Again, this revealed the reality of 





Preparation and development of these clinical trial protocols are generally time-consuming 
and lengthy and are required to comply to strict regulatory rules as well as adhere to upholding 
scientific value and rationale. Consultations were conducted with researchers and clinical 
colleagues, as well as service users. This chapter also delved into some of the clinical trial 
procedures that were involved in establishing the trial itself. It highlighted the reality of 
establishing a clinical trial, and the unexpected challenges that were experienced. In truth, 
studies that are not externally funded, such as this study, are not prioritised and administrative 
tasks are generally more delayed. These were obstacles that, unfortunately, occurred 





8 Heroin Overdose: Experimental Testing and Measurement 
in the Laboratory (AOO Study).  
8.1 Preface  
The concept of this study began at the initial commencement of my PhD studies. Risk factors 
and mechanisms of heroin overdose deaths have been discussed in detail in the earlier 
chapters of this thesis. As mentioned, there are many post-mortem examinations of overdose 
deaths that do not find particularly high levels of heroin. There also appear to be some cases 
where patients in heroin maintenance treatment experience significant changes in their 
physiological responses, despite being stable and tolerant.  
 
These findings have led to the need to examine this further. Why is this happening when there 
is not technically an ‘over’-dose? And yet ‘over’ doses and ‘killer’ batches of heroin that contain 
unusually high purity/dose are often identified as the cause of cluster of deaths in the 
community. Yet it is surprising that clusters occur if it is merely dose-related as one would 
expect the user community to adapt and reduce dose. Additionally, perhaps due to the 
celebrity persona associated with some of these deaths, there is also a great deal of media 
attention.  
 
Figure 8-1: selection of newspaper headlines on heroin overdose and the influence of purity. 
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This confounding evidence consistently contributes to simplistic media reports which are often 
inaccurately reported, often embellished or simply false (Bammer, Ostini, & Sengoz, 1995; 
Darke et al., 1999). 
 
Herein lays my first research question: Does more of the drug actually equate to more of a 
risk of overdose? To test this, we have, with ethical approval, given patients who were on a 
stable dose of diamorphine a small increment of 10% and 20% of heroin (i.e. a 110% or 120% 
dose) and observed a vast array of physiological responses, including airflow, oxygen, carbon 
dioxide and neural respiratory drive, and subjective responses of drug effect, drug liking and 
level of intoxication.  
 
The data presented in this chapter took much preparation and the initiation of the study itself 
experienced many obstacles. The issues and preparatory work are presented in Chapter 7: 
Clinical Trial and Error. The data presented in this chapter are still being collated. 
Nevertheless, there is still a strong opportunity to reflect on the data collated thus far as this 
type of study is difficult to conduct but has far reaching implications. 
 
I have presented the study methodology in this chapter at local and national meetings to 
colleagues in the Respiratory Medicine and Addictions fields. Some of the data in this chapter 
have been presented at a locally organised conference on Heroin on Trial in May 2018 and at 





Table of Contents 
8 HEROIN OVERDOSE: EXPERIMENTAL TESTING AND MEASUREMENT IN THE 
LABORATORY (AOO STUDY). ....................................................................................... 224 
8.1 PREFACE .................................................................................................................. 224 
8.2 INTRODUCTION .......................................................................................................... 228 
8.2.1 Background ................................................................................................... 228 
8.2.2 Objectives ...................................................................................................... 229 
8.3 METHODS ................................................................................................................. 230 
8.3.1 Trial Design ................................................................................................... 230 
8.3.2 Selection of Dose and Route .......................................................................... 231 
8.3.3 Participants .................................................................................................... 231 
8.3.4 Pharmacy Procedures .................................................................................... 232 
8.3.5 Study Procedure ............................................................................................ 233 
8.3.6 Outcomes ...................................................................................................... 234 
8.3.7 Assessments at Each Visit ............................................................................. 235 
8.3.8 Indicators of Significant Respiratory Depression ............................................. 235 
8.3.9 Drug Effect Measurements ............................................................................. 236 
8.3.10 Sample Size .................................................................................................. 236 
8.3.11 Blinding .......................................................................................................... 236 
8.3.12 Statistical Method........................................................................................... 237 
8.3.13 Recording of Injection .................................................................................... 237 
8.3.14 Brief Informal Interview .................................................................................. 237 
8.4 RESULTS .................................................................................................................. 239 
8.4.1 Participants & recruitment .............................................................................. 239 
8.4.2 Demographics & Screen ................................................................................ 239 
8.4.3 Case 1 ........................................................................................................... 242 
8.4.4 Case 2 ........................................................................................................... 245 
8.4.5 Case 3 ........................................................................................................... 248 
8.4.6 Primary Outcomes by Measure (Aim 1) .......................................................... 252 
 
 227 
8.4.7 Summary of Differences Between Baseline and Successive Time Points ....... 264 
8.4.8 Summary of Differences Between Doses ....................................................... 264 
8.4.9 Secondary Outcomes: Subjective Effects and Observer Ratings (Aim 2) ........ 265 
8.5 DISCUSSION .............................................................................................................. 271 
8.5.1 Summary of Principal Findings ....................................................................... 271 
8.5.2 Interpretation of Results ................................................................................. 271 
8.5.3 Case 1, Participant A ..................................................................................... 273 
8.5.4 Case 2, Participant B ..................................................................................... 274 
8.5.5 Case 3, Participant C ..................................................................................... 275 
8.5.6 Secondary Outcomes: Subjective & Observer Ratings ................................... 276 
8.5.7 Limitations ..................................................................................................... 277 
8.5.8 Strengths ....................................................................................................... 277 
8.5.9 Significance of Apnoeic Episodes ................................................................... 277 
8.5.10 The Effect of Repeat Dosing .......................................................................... 280 
8.5.11 Speed of Administration ................................................................................. 281 
8.5.12 Implications for Clinicians and the Community ................................................ 282 
8.5.13 Public Health and Policy-Related Implications ................................................ 284 
8.5.14 Future Research ............................................................................................ 285 





8.2 Introduction  
8.2.1 Background  
As mentioned in previous chapters, heroin and other opioids cause dampening on the regular 
breathing rhythm and respiratory drive. This can cause high levels of carbon dioxide 
(hypercapnia), low levels of oxygen (hypoxaemia) in the blood. A further complication of opioid 
overdose includes pulmonary oedema (accumulation of fluid in the lungs) (Leino et al., 1999; 
Pattinson, 2008; White & Irvine, 1999). It remains unclear why some people are more prone 
to experiencing hypercapnia and hypoxaemia than others. 
 
It is received wisdom that purity is a risk factor for opioid overdose (Darke, 2014; Darke & 
Farrell, 2014). However, several issues relate to why this remains unclear and requires testing; 
firstly, street heroin is not consumed at doses, purities and frequencies that show any clear 
correlation with a heightened risk of overdose. This is evidenced by, a) toxicological 
examinations, and b) demographic reports. Great numbers of fatal overdose cases have low 
blood morphine (metabolite of heroin that is tested) concentrations, often similar to, or even 
below those of living intoxicated heroin users, or of heroin users who died from other causes 
(Darke et al., 2010b; Darke & Farrell, 2014; Davidson et al., 2003). Demographic reports 
reveal that fatal overdose is most common among long-term, dependent, injecting drug users, 
often over the age of 30 (Bauer et al., 2008; Darke, 2011, 2014; Degenhardt et al., 2011). This 
bears no relevance to the inexperienced and intolerant (to variations in purity) user that one 
might expect.  
 
The idea that purity plays a role in overdose is blurred further when considering the opposing 
setting to this illicit drug market scenario, a heroin-assisted treatment clinic. Even where a 
pharmaceutical and titrated dose is administered, though rare, overdose events still occur 
(Oviedo-Joekes et al., 2009; Strang, Metrebian, et al., 2010) In the UK-based RIOTT clinic, 
the rate was reported to be around 1 in every 6,000 injecting events (Strang et al., 2010), and 
in the Canadian NAOMI clinic this figure was around 1 in 8,000 injecting event (Oviedo-Joekes 
et al., 2009). Clearly, respiratory depression can occur without variation in administered heroin 
doses. Previous work has shown that even regular doses of prescribed opioids show 
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significant changes in oxygen saturation (blood oxygen level) (Dursteler-Mac Farland et al., 
2000; Stoermer et al., 2003; Stohler et al., 1999). The onset and severity of respiratory 
depression is likely also affected by inter-subject variability and the factors underlying this 
susceptibility to overdose in certain individuals are poorly understood.  
 
To test this in a clinical laboratory setting, a higher-than-regular dose was used as a 
comparative marker to address whether changes in dose (equivalent to changes in purity) 
truly does increase respiratory depression. 
 
8.2.2 Objectives  
The primary aim of the research is to address whether there are changes in physiological and 
subjective responses to varied doses of injectable heroin. Specifically, this study aims: 
1: To investigate respiratory depression and hypoxaemic response to intravenous 
(IV) or intramuscular (IM) higher-than-regular doses of heroin as a marker for 
overdose.  
2: To investigate effect of variations in IV and IM heroin dose on subjective and 




8.3 Methods  
8.3.1 Trial Design  
The study was a single-blind, dose escalation, within-subject design with four testing sessions. 
Each session was comprised of an intravenous or intramuscular injection of 100% OR 110% 
OR 120% of the regular dose of diamorphine. The following sequence of doses was self-
administered (or administered by a doctor, if requested) with the patient blind to the dose on 
each study session: 
1. Diamorphine=100% (IV or IM) 
2. Diamorphine=110% (IV or IM) 
3. Diamorphine=120% (IV or IM) 
4. Diamorphine=100% (IV or IM)  
Each session consisted of 30 minutes of pre-monitoring analyses (drug test, breathalyser and 
pregnancy test, if applicable), 30 minutes for preparing the participant for monitoring and 60 
minutes of monitoring. Participants were not expected to remain at study facilities for longer 
than 120 minutes in total, per study day. However, in any case of adverse events, participants 
were not be discharged until symptoms were under control. There was a wash-out period of 
at least four days to ensure that there was no presence of excess metabolites. Between study 
visits, subjects were taking their treatment of diamorphine maintenance as per standard care. 
Additionally, after the trial ended, subjects were able to continue diamorphine maintenance 
treatment as per standard care. 
 
Serial measurements of subjective drug effects and physiological responses were made prior 
to, and for one hour following, drug administration. A fourth session was implemented with the 
same dose as the first session to measure whether there were any effects on respiratory 
measures due to the novel laboratory setting.  
 
Subjects on injectable diamorphine maintenance treatment, who were therefore on a stable 
titrated dose of diamorphine, were recruited for this study. As stated, a minimum of four days 
was the permissible window between study visits, and time from consent to first study session 
was a maximum time period of eight weeks.  
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8.3.2 Selection of Dose and Route  
Subjects normally self-administer their diamorphine in separate doses throughout the day. 
Subjects were screened prior to the first testing, and during this process, the frequency and 
dosing pattern of the subject’s usual daily dosing were established. For example, a patient 
who is on 300mg daily may take this in 3 equal parts, each consisting of 100mg doses or they 
may take it as a 1 x 120mg and then the remaining 60mg at night or many other patterns. The 
trial only examined one dose of diamorphine. This was determined at the screening visit. The 
affected dose was selected depending on circumstances of the individual patient. For 
example, where a subject was required to commute a longer distance to the CRF, it was more 
practical to affect their 2nd or 3rd dose of the day. In cases where the selected dose was not 
the first one of the day, subjects were asked to attend 4 hours after their previous dose. 
Diamorphine has a half-life of 2-3 minutes, but, because of the action of active metabolites 
such as morphine, its effects can last up to 3 to 4 hours (when injected), thus, the 4-hour time 
window was sufficient to prevent substantial interaction with the trial dose.  
 
Where participants varied daily diamorphine dose, and/or where IV or IM routes were used 
interchangeably, the decision of dose and route was determined at the screening session, 
incorporating discussion between participant, research medic and treating clinician, as well as 
examination of peripheral venous access. A combination of these allowed suitable decision 
about route and dose, with preference given to IV over IM, where possible. IV was preferred 
because of the reliably complete level of absorption into blood and relevance to the wider field. 
Once the decision on route and dose had been defined, the same route and 100% 
diamorphine dose was kept consistent across all dose sessions.  
8.3.3 Participants  
Relevant patients (in this case, patients who are on an injectable diamorphine prescription) 
were approached by clinical care staff associated with the patient. Patients were based within 
selected services/clinics that provide a specified injectable diamorphine treatment for injecting 
heroin users. These were within South London and Maudsley NHS Foundation Trust (SLaM) 
and other allocated Participant Identification Centres (PICs). All potential participants received 
exactly the same standard treatment within their treating clinic. Potential participants were pre-
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screened in the study site (Clinical Research Facilities; CRF) and all study procedures were 
also conducted at the CRF. All participants, whether within SLaM or within the PIC sites, 
continued with their normal treatment in between study sessions. Treating clinicians within the 
PIC site were updated upon participant consenting to take part in the trial. This was noted in 
the relevant site’s patient system.  
 
8.3.4 Pharmacy Procedures  
Diamorphine Hydrochloride powder (freeze-dried powder in pharmaceutical ampoules) for 
solution for Injection (100mg or 500 mg, any brand allowed) was the Investigative Medicinal 
Product (IMP) for this study. A white to off-white, sterile, freeze dried powder of Diamorphine 
Hydrochloride BP for reconstitution for injection.  
 
IMP dispensing was conducted by SLaM pharmacy. The diamorphine supplied for the 
purposes of this study was a licensed medicinal product that is available in the UK. 
Commercial stock was used for trial purposes. The IMP labelling complied with Eudralex 
Volume 4 annex 13 for the purposes of the trial. This was a single blind trial where dose was 
masked only to participant. This was conducted by making up each injection with water per 
volume to achieve same volume for each participant. All doses of diamorphine were made up 
to as close to a volume that the participant would normally use for their daily use, and was 
kept consistently for each session, thus preventing participants from being aware of what dose 
they were given. Two non-blinded nurses were required to bring the medication to the patient 
(the medication was stored and dispensed by the Maudsley Hospital pharmacy) and were 
responsible for preparing the diamorphine and supervising the self-administration of the 
injectable diamorphine. 
 
Diamorphine at 100% of the participant’s regular maintenance dose was used for the regular 
dose condition, 110% and 120% of the participant’s maintenance dose was used for the 110% 




8.3.5 Study Procedure  
Chapter 4 (Methods) highlights the methods for this study in detail. Essentially, each session 
consisted of 30 minutes of pre-monitoring analyses (vital signs, SpO2%, drug test, 
breathalyser, and pregnancy test, if applicable), 30 minutes of preparing the participant for 
monitoring and 60 minutes of monitoring. Serial measurements of subjective drug effects and 
physiological responses were made 3 minutes prior to, and for 60 minutes following drug 
administration. Participants were not expected to remain at study facilities for longer than 120 
minutes in total, per study day. This time was prolonged if adverse events occurred.  
 
Diamorphine was self-administered intravenously or intramuscularly on the study day. 
Participants were encouraged to self-administer the diamorphine in under 1 minute, and timing 
of diamorphine administration was measured by video by one of the trial staff. Delegated trial 
staff (nurse or doctor) was available for assistance, and also, if the patient chose not to self-





8.3.6 Outcomes  
Table 8-1 details the primary physiological outcome measurements that were taken during the 
study sessions. Please see Full Study Flowchart and Study Procedures by Visit for full list of 
procedures on the four study days in Appendix E-2.  
 







Ventilation  Respiratory rate 
(Vf), tidal volume 
(Vt) and minute 
ventilation (Ve) 
Pneumotachograph 




Pulse oximetry Average and 
minimum SpO2%  





maximum of peak 
%CO2 per expired 
breath (ETCO2%) 
Pneumotachograph 













(Murphy et al., 
2011; Reilly et al., 








blood gas meter 
Average and 
maximum TcCO2 




8.3.7 Assessments at Each Visit 
Table 8-2 displays the tasks that occurred during the three main stages of the study.  
 
Table 8-2: assessments at screening and at each study visit. 
Assessments at each visit  
Screening Visit Pre-testing on Study Day  During Study  










Airflow and ETCO2% (via 
face mask and pneumotach) 
Spirometry Breathalyser for alcohol  EMGpara (via sticky pads on 
top of chest) 
SpO2% (via finger pulse 
oximeter) 
Drug screen  TcCO2 (via earlobe sensor) 




Vital signs Pupil size 
Concomitant medication 
check  
SpO2% (via finger pulse 
oximeter) 
Subjective, and staff rating 
of, drug effects (via VAS 
response scale and GCS) 
Eligibility Assessment Pupil size Adverse Events check 
 
8.3.8 Indicators of Significant Respiratory Depression 
The following indices of significant respiratory depression were recorded and used as 
evidence for respiratory depression:  
• SpO2 of <80%; <90% for longer than 10 seconds, 
• ETCO2% per breath exceeding 6.5%, 
• absence of inspiratory airflow and/or parasternal intercostal muscle EMG activity for 
more than 10s (apnoea), 
• absence of response to verbal stimuli. 
Further criteria were also recorded and assessed for severity of respiratory depression:  
• frequency dips of SpO2<90% longer than 10seconds, 
• % time spent SpO2 <90% across the 60mins, 
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• frequency of breaths above 6.5% for ETCO2% and 6.6kPa for TcCO2 (equivalent to 
6.5%) for each time point, 
• % of time spent over 6.5% over 60mins, 
• frequency of pauses that were longer than 10 seconds. This value will be multiplied 
by 60 to produce the Apnoea Hypopnea Index (AHI) for each time point. A value per 
hour, 
• Frequency of pauses that were longer than 10 seconds, 
• % changes from baseline to peak or nadir for each of the measures.  
 
8.3.9 Drug Effect Measurements  
At 3 minutes prior to administration of the injectable diamorphine, and then at 0, 3, 8, 15, 30 
and 60 minutes participant were asked to rate their subjective strength of drug effect, drug 
liking and sedation using a visual analogue scale (VAS) (Nicholson, 1978). At these times 
pupil size was recorded, and a staff rating of level of consciousness (eye, verbal and motor 
responses as in the Glasgow Coma Scale (Teasdale & Jennett, 1974)) and intoxication were 
also documented using a VAS (previously used by: Comer et al., 2008; Kelly et al., 2005; 
Lintzeris et al., 2007; Sessler et al., 2002).  
 
8.3.10 Sample Size  
This study received ethical approval for 12 subjects, but there are only data available for three 
subjects in this thesis. The sample size of 12 is small study, but this is an exploratory study 
for which a power calculation was deemed not to be required. Studies of this type have 
typically used sample sizes close to this number by utilising design of repeated measures with 
the same subjects, thereby obtaining strength from within-subject trial design. For example, 
sample sizes of n= 4 to 12 (Dowling et al., 2008; Lintzeris et al., 2006; Lintzeris et al., 2007; 
Walsh et al., 1994; White et al., 2009). Measuring variations between individuals would involve 
a much larger study which is beyond the scope of this trial, and would not be without risk to 
the participants involved. 
8.3.11 Blinding  
The study incorporated a single-blind, dose escalation design with four testing sessions. This 
design was deliberately chosen to ensure safety with increasing doses of diamorphine, with 
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explicit decision that the sequence of the study sessions were not randomised. Furthermore, 
due to the regulations on diamorphine prescribing, i.e. that it cannot be prepared beforehand 
and that two healthcare professionals (e.g. two nurses) must be present, masking the research 
team members was not possible. However, in order to reduce expectation bias, participants 
were not informed of which dose they were self-administering. The drug was prepared by 
nurses and masked by making up to the same volume with water. Consequently, the same 
volume was self-administered by the participant on each of their four dose sessions and was 
thereby blinded to the true dose. 
8.3.12 Statistical Method  
The statistical aspects of the research were reviewed by a statistician (Dr Elizabeth Ryan) 
within the Institute of Psychiatry, Psychology & Neuroscience. The outcome measures were 
calculated offline and used for analysis. Friedman’s test was used to test for differences 
between baseline, minimum/maximum or successive time-points for each measure after drug 
administration (Friedman’s statistic, Q). In addition, post hoc analysis was conducted using 
Dunn’s Multiple Comparison Test. Where there were missing data, differences between 
diamorphine dose condition (100% versus 110% versus 120% of the daily maintenance dose) 
was tested using the Wilcoxon Signed Rank Test (W-score) for each paired dose session (e.g. 
100% versus 110%).  
8.3.13 Recording of Injection 
An anonymised video (with consent from the participant) was taken of the administration 
procedure. The purpose of this was to accurately relay the timing of injection, until plunger is 
pushed down all the way. The number of seconds that this process took was recorded after 
the study using the video as a guide.  
8.3.14 Brief Informal Interview  
At the end of each visit, participants were briefly asked about how the experience was, and 
whether the session and drug experience felt any different from the previous visits or from 
their usual experience. They were also asked about what dose they thought they had received. 
This was more of an informal dialogue between researcher and participant but was noted for 
each participant in their study notes. This was in the form of a ‘check-out’ process at the end 






























Figure 8-2: Clinical Research Facility. 
These two figures illustrate the setting in which the studies took place. This was within a clinical room of 




8.4 Results  
8.4.1 Participants & recruitment  
Recruitment began in January 2018 after green light for recruitment was granted. Data 
collection for the data presented in the thesis occurred between February 2018 and August 
2018. Three participants were screened, and all three were included in the study. With one 
exception, all participants attended all four visits. For one participant, the study team decided 
that a 20% dose increment was not appropriate, and unsafe due to the length of apnoeic 
episodes and shallow breathing (low tidal volume) observed during session two, the 120% 
dose session (session 3) was omitted and the sequence progressed directly to session 4, i.e. 
the final study at 100% dose. The results will be presented case by case initially and then 
overall group results will be described by measure.  
 
8.4.2 Demographics & Screen  
All three participants were male and had a similar age of 62, 63 and 59 years (Table 8-3). All 
three had a BMI in the normal range (19.6, 19.3 and 24.8 kg/m2). One participant was 
prescribed a dose of 30mg diamorphine that was injected IV or IM, once daily. The second 
participant had a prescribed dose of 400mg diamorphine that was injected three times IM 
daily, and on occasion, IV. The third participant had a prescribed dose of 630mg diamorphine 
that was injected IM, three to four times daily. Two of three participants were also prescribed 
doses of 450mg and 360mg morphine sulphate (MST) that was taken as an oral dose daily. 
Except for one participant who self-reported regular use of cannabis oil, none of the 
participants reported use of alcohol or other illicit drugs. Urine analysis and breathalyser 
results on the day of each study session confirmed absence alcohol and other drugs.   
 
Two of the three participants had diagnosed chronic obstructive pulmonary disease (COPD), 
and a third had spirometry results and history that was compatible with COPD with a FEV1 
level (65.8%) that would indicate a moderately-severe category of COPD. Two participants 
had hypertension. One participant was Hepatitis C positive and was being treated by a 
combination of antiviral medication (Ribavirin, Viekirax and Dasabuvir) at the time of the study 





















Figure 8-3a-d: A sample recording from Participant B. All boxes display airflow on the top trace, oxygen saturation in the middle trace and end-tidal carbon dioxide at 
the bottom and all are across 3 minutes.  
a) and b) 100% dose session of 100mg diamorphine, administered by study doctor, a) baseline (-3minutes) and b) 2 minutes post diamorphine administration.  

























































































































































































Figure 8-4a-c: A sample recording from Participant A in the same 100% dose session.  
All boxes display airflow (brown), oxygen saturation (red) and end-tidal carbon dioxide (pink) and are all 
across 5 minutes of recording. a) 5 minutes baseline; b) 5 minutes post diamorphine administration; c) 
























































































































8.4.3 Case 1 
Participant A is male with a 45-year injecting heroin use history. He started diamorphine 
maintenance treatment 12 years ago as part of RIOTT. The participant was reduced to 30mg 
four years ago and his previous dose was 150mg diamorphine daily. A standard week of use 
involves some days that may be higher in dose than others. However, if using IM, this dose 
increases to 50mg but his current IV dose was never more than 30mg on each administration. 
The route for the study was IV and dose was 30mg. This participant did not report use of any 
other drugs, including alcohol or benzodiazepines but did describe a previous history of 
alcohol use disorder. Results for participant A are displayed in Figure 8-5a-g. 
 
SpO2%: Participant A showed an average SpO2% of 93.6% across all doses, and a minimum 
SpO2% of 84.3% in the 100% dose session (similarly with the increased dose sessions, the 
minimum value was 84.6% and 84.9%). Participant A showed a percentage change from 
baseline of between 12.4% and 10% with the greatest drop in SpO2% being observed in the 
120% dose session. There was no significant difference between doses (Q=3.9, p=0.3). SpO2 
reached below 90% for longer than 10 seconds in every dose session for this participant. The 
percentage time spent under 90% across the 60 minutes of monitoring was 2.5%, 10.1%, 
10%, 13.9% in the four dose sessions, respectively.  
 
ETCO2%: Participant A observed varying averages of ETCO2 across the different dosing 
sessions with a range of 6.5% to 5.7%. The highest level was seen in the first 100% dose 
session. Further, a 2.9% average change from baseline to peak ETCO2% was observed, with 
the highest % increase in CO2 occurring in the 120% dose session. In terms of frequency of 
breaths above 6.5%, rates of 3.7, 1.4, 1.9 and 0.7 breaths per minute above 6.5 in the four 
dose sessions, respectively were observed. Additionally, percentage of total breaths above 
6.5% over the 60 minutes of monitoring started at 45.1% in the first 100% dose session and 
dropped considerably to 13.6%, 19.3% and 9.2% in the three subsequent dose sessions, 
respectively. Overall, there were significant differences between doses (Q=15, p=0.002), with 
significantly lower levels of ETCO2% being observed in the 110% and repeat 100% dose 
sessions (p= 0.003 and p=0.02, respectively).  
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TcCO2: Participant A had a range TcCO2 between 5.9kPa to 6.4kPa with the highest being 
observed in the first 100% dose session. Participant A showed the greatest change from 
baseline in the 110% dose session (18%) and the smallest change (6%) was seen in the first 
100% dose session. There was a significantly lower level of TcCO2 in the repeat 100% dose 
session compared to the first 100% session (Q=11.8, p=0.008).  
 
NRDI: Participant A showed an average range of between 77.7min-1 and 109.1min-1 with the 
highest level being observed in the 120% dose session. Participant A initially exhibited a 
26.7% reduction in drive from baseline to post-administration nadir. This change was at a 
lower magnitude in the repeated 100% dose where a reduction of 11.8% was seen. The two 
dose increases showed slightly greater reductions of 35% and 30.5% in the 110% and 120% 
dose sessions, respectively. Overall, differences between the doses were significant (Q=13, 
p=0.004), with a 20% increase in dose showing significantly higher levels of NRDI compared 
to both the 100% and 110% dose sessions (p=0.02 and p=0.006, respectively).  
 
Ventilation: Participant A showed a minimum respiratory rate of 5 breaths/minute in the repeat 
100% and an average of between 7.7 and 10.5 breaths/minute. The rate did not exceed 11.7 
breath/minute. Significant differences were observed across doses (Q=18, p=0.0005), with 
the 10% dose increase showing a significant decrease compared to the two 100% dose 
sessions (p=0.006 and p= 0.003). Tidal volume remained between 0.3L and 1.6L and was 
highest in the 120% dose session and significantly higher than usual dose (Q=11.2, p=0.006). 
Minute ventilation remained between 2L/min and 16.6L/min and again, was highest in the 
110% and 120% dose session which were both significantly higher than the usual dose 














































Figure 8-5a-g: Participant A one-minute averages for each dose session - 100% (dark blue); 110% 
(red); 120% (green) and 100%R (light blue): a) SpO2%; b) ETCO2%; c) NRDI; d) Vf respiratory rate; e) 
VT Tidal Volume; f) VE Minute ventilation; g) TcCO2. 
SpO2% = oxygen saturation; ETCO2% = end-tidal carbon dioxide; NRDI = neural respiratory drive index; 
TcCO2 = transcutaneous carbon dioxide.  
  














































































































8.4.4 Case 2 
Participant B is male and a predominantly intramuscular heroin user with a 38-year use 
history. Participant B used heroin once when 18 years old and became dependent in 
early/mid-1980s using Pakistani heroin by chasing and moved onto IV heroin in early 1990s. 
He was started on a diamorphine prescription in 2006 with occasional supervision. His dose 
increased to the current dose of 300mg daily in 2010 and has been on same dose since. In 
1990s, he had several overdoses and believed that on two occasions it was related to heroin 
of greater strength than he knew and on one occasion when he had mixed heroin with alcohol. 
He only drinks minimally now but can smoke cannabis up to 10 joints per day.  
When he used to take IV and IM, he would usually take the same dose, i.e. there was no dose 
adjustment for different route. His current routine is 100mg IM in early morning, 100mg an 
hour later and 100mg in the evening. On weekends, he receives a 3-day supply and 
sometimes has used 400mg, 450mg or even 500mg on a Saturday and then as little as 100mg 
on the remaining days. He does not use more than 100mg as his occasional IV diamorphine 
dose.  For the study IV dose of 100mg was chosen. Results for Participant B are displayed in 
Figure 8-6a-g.  
 
SpO2%: Participant B showed an average of 95.5% and 96.6% across all dose sessions, and 
a minimum of 84.3% being observed in the 110% dose sessions. The % change from baseline 
was between 6% and 14.8%, with the greatest change being observed in the 110% dose 
session. SpO2 reached below 90% for longer than 10 seconds in the 110% dose session. 
Percentage time spent under 90% over the 60 minutes of monitoring in this dose session was 
4.4%. There were no significant differences between doses (Q=1.1, p=0.6).  
 
ETCO2%: Participant B had an average of peak per breath of 6.7% and a maximum level of 
9.1% in the 110% dose session. A change from baseline average of 2% with the highest 
change being at the 110% dose session of 2.9%. There were also differences noted in the % 
of breaths above 6.5% across the 60 minutes of monitoring. In the first 100% dose session, 
Participant B showed an average rate of 5.4 breaths per minute above 6.5%, which was 70% 
of all breaths over the 60-minute monitoring period. In the 110% dose session, Participant B 
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showed an average rate of 4.9 breaths per minute above 6.5% which is equivalent to 56% of 
breaths across the 60-minute period. Finally, in the second 100% dose session, a lower level 
of 3 breaths above 6.5% per minute was observed. This was equivalent to 34% of all breaths 
in the 60-minute monitoring period. Overall, however, there were no significant differences 
between the doses (Q=4.6, p=0.1).  
 
TcCO2: Participant B had a range TcCO2 between 5.5kPa to 6.4kPa with the highest being 
observed in the first 100% dose session. Participant B showed the greatest change from 
baseline in the 110% dose session (21%) which was also the highest change amongst all 
participants for TcCO2. Overall, there was a significantly different level of TcCO2 between 
doses (Q=9.5, p=0.005) with a higher level in both 100% and 110% dose session compared 
to the repeat 100% dose session (p=0.02, p=0.04, respectively).  
 
NRDI: The average values for NRDI in the two dose sessions are 118.5 min-1 and 133.6min-1 
(100% and 110%, respectively). Participant B showed a 107% reduction in drive from baseline 
post-drug administration in the 100% dose session, and a less pronounced 63.3% reduction 
in the 110% dose session. A significant electrical noise issue led to difficulty in analysing the 
EMGpara recording in the repeat 100% dose, thus, the level of NRDI could not be attained for 
this dose session. There was no significant difference between the two doses for NRDI (W=20, 
p0.1).  
 
Ventilation: Participant B showed the highest respiratory rate in the 110% doses session (11.4 
breaths/minute) and an average between 7.7 and 8.8 breaths/minute across all sessions, 
there were no significant differences between doses (Q=2, p=0.5). Average tidal volume 
remained relatively equal at 0.3L to 0.2L across all sessions with the highest tidal volume 
reaching 0.5 in the first 100% dose session and a significantly lower tidal volume was seen in 
the repeat 100% dose session compared to the first 100% dose (Q=8.9, p=0.01). Minute 
ventilation was similar with an average range of 2.3L/min to 1.7L/min and a maximum level of 
4.7 seen in the first 100% dose session, but none of the doses showed any significant 



































Figure 8-6a-g: Participant B one-minute averages for each dose session - 100% (dark blue); 110% 
(red); 120% (green) and 100%R (light blue): a) SpO2%; b) ETCO2%; c) NRDI; d) respiratory rate; e) 
Tidal Volume; f) Minute ventilation; g) TcCO2.  
SpO2% = oxygen saturation; ETCO2% = end-tidal carbon dioxide; NRDI = neural respiratory drive index. 
  











































































































8.4.5 Case 3 
Participant C is male with a 30-year heroin-using history. His current prescription is 630mg 
daily, which is taken 200mg IM, occasionally IV in the morning, then 200mg in the afternoon, 
then 200mg in the evening and the final 30mg before sleep. He does not alter the dose when 
administering IV but only does this when a vein is accessible. In the study, peripheral venous 
access was deemed unsuitable and thus, IM with 200mg was chosen. This participant did not 
report the use of other drugs, including benzodiazepines and alcohol.  Results for Participant 
C are displayed in Figure 8-7a-g. 
 
SpO2%: Participant C showed an average of 95.3% and 96.1% across the dose sessions and 
a minimum of 92% observed in the 110% dose session. Participant C showed comparatively 
minimal % change of between 3.1% and 3.5% from baseline to nadir compared to the other 
two participants. This participant did not experience any dips of SpO2% below 90% for longer 
than 10 seconds. There were no significant differences between doses (Q=3.5, p=0.3).  
 
ETCO2%: Participant C had an average of 6.6%, 6.1%, 6% and 6.4% ETCO2% across all dose 
sessions with the highest level being observed in the first 100% dose session. A change from 
baseline to peak ETCO2% of 1.2% to 1.9% was observed. With regard to the frequency of 
breaths above 6.5% across the 60-minute observation period, 4.6, 1.4, 1.7 and 4.7 breaths 
per minute were observed. The % of total breaths above 6.5%, the figures were as follows 
43%, 13.6%, 15.5% and 45.8% in all of the dose sessions, respectively. Overall, there were 
significant differences between the doses (Q=17, p=0.0006), with the 10% and 20% increased 
doses showing a significantly lower level of ETCO2% compared to the 100% dose sessions 
(p=0.01 and p=0.006).  
 
TcCO2: Participant C had a range TcCO2 between 5.5kPa to 6.4kPa with the highest being 
observed in the first 100% dose session. Participant B showed the greatest change from 
baseline in the 110% dose session (21%) which was also the highest change amongst all 
participants for TcCO2. Overall, there was a significantly different level of TcCO2 between 
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doses (Q=18.4, p=0.0004) with a lower level in both 120% and repeat 100% dose session 
compared to the first 100% dose session (p=0.003, p=0.006, respectively).  
 
NRDI: Participant C showed an average of NRDI between 65 min-1 and 71.4min-1, with the 
lowest level of drive being observed in the 120% dose session (51 min-1). This participant also 
showed an 80.1% reduction from baseline to nadir post-dose in the first 100% dose session. 
Each dose increase appeared to show less of a reduction than the initial 100% dose session, 
with 61%, 44%, 39% respectively. Overall, significant differences were observed between 
doses (Q=15, p=0.002), with a 20% dose increase showing significantly lower levels of NRDI 
compared to usual dose and a 10% increase.  
 
Ventilation: Participant C showed the highest respiratory rate in the 120% dose session (13.4 
breaths/minute) and an average range of 10.2 to 11.1 breaths/minute). There were no 
significant differences between doses. Tidal volume was on average between 0.9L and 0.3L 
with the lowest tidal volume being observed in the 120% dose session (and was significantly 
lower than usual dose, p=0.003). The repeat usual dose also showed a significantly lower 
level of tidal volume than the first usual dose (p=0.01). Minute ventilation (VE) was observed 
to be between 0.8L/min and 2.9L/min on average, with the lowest VE being observed in the 
repeat 100% dose session (session 4), which was significantly lower than the first usual dose 
(p=0.006). The 120% dose session also showed a significantly lower level of minute ventilation 




Figure 8-7a-g: Participant C one-minute averages for each dose session - 100% (dark blue); 110% 
(red); 120% (green) and 100%R (light blue) a) SpO2%; b) ETCO2%; c) NRDI; d) respiratory rate; e) 
Tidal Volume; f) Minute ventilation; g) TcCO2. 
SpO2% = oxygen saturation; ETCO2% = end-tidal carbon dioxide; NRDI = neural respiratory drive 
index. 













































































































Table 8-3: Demographics and other clinical details for each of the three participants.  
BMI=Body Mass Index; MST= Morphine sulphate; COPD= chronic obstructive pulmonary disease; FEV1%predicted= % predicted of Forced Expiratory Volume in 1 

























Injected Speed of 
inject (secs) 











2 63 19.3 300 IM, 
occasionally 
IV 





77.3 91.9 Doctor 1) 4;direct IV 
2) 12;cannula 
3) 4; cannula 










8.4.6 Primary Outcomes by Measure (Aim 1) 
The focus for this section will focus on two overarching aspects: the observations within and 
between subjects, and amongst these the observations within and between different doses. The 
data are presented in the first instance by each respiratory measure separately.  
 
8.4.6.1 Oxygen Saturation (SpO2)  
The average SpO2% varied between 89.7% to 99.47% across all participants and doses (Figure 
8-8a-d). Overall, there were significant differences from baseline to successive time points across 
all subjects (Q=35, p-0.0001), with levels at 3- (p=0.01), 8- (p=0.0003) and 15-minute (p=0.01) 
time points significantly lower compared to baseline. There was no significant difference between 
doses (100%v110%=-69,p=0.2; 100%v120%=-7,p=0.9; 100%v100%R=-47,p=0.4). Figure 8-8a-
d shows the median values for each dose and the individual plots.  
 
None of the participants in any dose session displayed a dip below 80%, however, the average 
SpO2% for all participants was below 96% in all of the dose sessions. One of the three participants 
reached below 90% SpO2 for longer than 10 seconds in every dose sessions, and another 
reached this criterion in one dose session.  
 
The % oxygen desaturation from baseline in each session varied somewhat from 3% to 14.8% 
change in SpO2% from baseline to nadir. On average, the 110% dose session showed a greater 

















































Figure 8-8a-d: SpO2% results. 
a) median values for each session for all participants; b) one-minute averages of SpO2% for all participants 
at baseline (-3 minutes), 0, 3, 8, 15, 30 and 60 minutes after diamorphine administration; c) one-minute 
averages of SpO2% for each individual participant; d) % desaturation from baseline for each participant and 
dose session. SpO2% = oxygen saturation; 100%R = repeat 100% dose. Participant A = 1; Participant B = 
2; Participant C = 3   *p<0.05  
  






















































































8.4.6.2 End-Tidal Carbon Dioxide (ETCO2) 
Across all participants and doses the average of the peak ETCO2 per breath was between 5.98% 
and 6.6% (Figure 8-9a-d). Overall, there were significant differences from baseline to successive 
time points (Q=23.8, p=0.0006), with levels significantly higher in the 3- (p=0.02), 8- (p=0.0005) 
and 15-minute (p=0.03) time points (all p<0.05). ETCO2% was significantly lower in the 110% 
(W=-139, p=0.01), 120% (W=-103, p=0.0002) and the repeated 100% (W=-185, p=0.024) dose 
session compared to the first 100% dose session. 
 
ETCO2% per breath was above 6.5% in all participants in all of the dose sessions. The % change 
from baseline varied between an increase of 1.2% to an increase of 3.5%. The frequency of 
breaths in which ETCO2% per breath was above 6.5% ranged between 0.7 and 7.7 breaths per 
minute, this was equivalent to 9% and 70% of all breaths reaching 6.5% or above across the 60-
















































Figure 8-9a-d: ETCO2% results. 
a) median values for each session for all participants; b) one-minute averages of ETCO2% for all participants 
at baseline (-3 minutes), 0, 3, 8, 15, 30 and 60 minutes after diamorphine administration; c) one-minute 
averages of ETCO2% for each individual participant; d) % change from baseline for each participant and 
dose session. ETCO2% = end-tidal carbon dioxide; 100%R = repeat 100% dose. Participant A = 1; 
Participant B = 2; Participant C = 3   *p<0.05 
  























































































































8.4.6.3 Transcutaneous carbon dioxide (TcCO2) 
Average TcCO2 for all participants and all doses remained between 5.4kPa and 6.7kPa. Overall, 
there were significant differences between baseline and successive time points (Q=23, p=00008). 
There were significant increases in TcCO2 at 8- (0.03), 15- (0.0005) and 30-minutes (0.003) post-
dose compared to baseline (Figure 8-10a-c). There were significant differences between the 
100% and 120% dose sessions (W=-105, p=0.0001), the 100% and repeated 100% (W= -231, 
p<0.0001), the 110% and 120% dose sessions (W=-77, p=0.01) and finally, in the 110% and the 
repeated 100% dose sessions (W=-179, p<0.0001).  
 
There were no discernible differences between participants, although a slightly higher average 
was noted in Participant C. Participants A and C displayed breaths above 6.5kPa in almost all of 
the dose sessions, with the highest frequencies being noted in the 100% and 110% dose 
sessions. In terms of difference between baseline and peak TcCO2 the greatest difference was 






























Figure 8-10a-c: TcCO2 results. 
a) median values for each session for all participants; b) one-minute averages of TcCO2% for all participants 
at baseline (-3 minutes), 0, 3, 8, 15, 30 and 60 minutes after diamorphine administration; c) one-minute 
averages of TcCO2% for each individual participant. TcCO2% = transcutaneous carbon dioxide; 100%R = 
repeat 100% dose. Participant A = 1; Participant B = 2; Participant C = 3   *p<0.05 
 
  















































































8.4.6.4 Neural Respiratory Drive Index (NRDI) 
NRDI was varied between doses and participants. The highest level of NRDI was 166min-1 across 
all doses and participants (Figure 8-11a-d). Median values for the 100% dose sessions were 91.9 
min-1 and 82.9 min-1 respectively and 96.2 min-1 and 88.5 min-1 for the 110% and 120% dose 
sessions, respectively. Overall, there were significant changes between baseline and successive 
time points (Q=19, p=0.04), with significant reductions in NRDI at 3- (p=0.03), 8- (p=0.02) and 15-
minutes (p=0.002) post-dose. There were no significant differences in NRDI between doses 
(100%v110%=-39,p=0.9; 100%v120%=-13,p=0.7; 100%v100%R=-51,p=0.1). 
 
Notable differences between participants were observed in the % change of NRDI from baseline. 
For each participant, there was generally less of a pronounced change from baseline with each 
study session, although a greater reduction from baseline was observed in the 110% dose 


























































Figure 8-11a-d: NRDI results. 
a) median values for each session for all participants; b) one-minute averages of NRDI for all participants at 
baseline (-3 minutes), 0, 3, 8, 15, 30 and 60 minutes after diamorphine administration; c) one-minute 
averages of NRDI for each individual participant; d) % change from baseline for each participant and dose 
session. NRDI = neural respiratory drive; 100%R = repeat 100% dose. Participant A = 1; Participant B = 2; 



































































































































8.4.6.5 Respiratory rate and flow  
Overall, respiratory rate was between 5.2 and 13.4 breaths/minute across all doses and 
participants. Overall, respiratory rate was significantly different from baseline to successive time 
points (Q=23, p=0.0008), with significantly lower rates at 3- (p= 0.005), 8- (p<0.0001) and 15-
minutes (p=0.007) post-dose time points (Figures 8-12a-b and 8-13a). There were increases in 
breaths per minute between all of the dose sessions: 100% and 110% (W=101, p=0.0004), 100% 
and 120% (W=77, p=0.01), 110% and repeated 100% (W=-119, p=0.04) and 120% and repeated 
100% (W=-85, p=0.005). Additionally, a similar pattern was seen within each participant, where 
increases in respiratory rate were observed in the higher dose sessions.  
 
All participants experienced pauses of inspiratory flow in all dose sessions. The frequency of 
pauses (apnoea-hypopnea index, AHI) and % time spent with absence of flow across the 60-
minute monitoring varied greatly across participants (Figure 8-14). The number of pauses ranged 
from 9 to 65 per session and lasted on average between 1.7 minutes (2.9% of total time) to 25.8 
minutes (45.9% of total time).  
 
The length of apnoeas ranged from 10 seconds to 56 seconds. Pauses were present throughout 
each dose session and sometimes occurred from baseline, prior to diamorphine administration, 
until the last minute of recording. Apnoeic episodes were present with subsequent increases in 
levels of end-tidal carbon dioxide and desaturation in peripheral oxygen readings (Figure 8-14).  
 
With regard to tidal volume, overall, more varied changes occurred in tidal volume, with an initial 
decrease, and then increase in VT from 100% to 110% and 120%, respectively (Figures 8-12c-d 
and 8-13b). None of the changes from baseline to successive time points for VT were significant 
(Q=8, p=0.2). The median VT across all doses and participants was 0.5L with a minimum of 0.2L, 
0.2L, 0.1L and 0.1L being observed in the four sessions, respectively. There were no significant 
differences across the dose sessions (100%v110%=-71,p=0.2; 100%v120%=-15,p=0.7; 
100%v100%R=-99,p=0.09). 
 
Minute ventilation levels also somewhat varied across the doses (Figures 8-12e-f and 8-13c). 
Overall, there were significant differences between baseline and successive time points (Q=17, 




at 3- (p=0.005), 15- (p=0.01) and 30-minutes (p=0.02) post-dose. The median was 5.4L/min 
overall, with minimum levels reaching 1.5L/min, 1.3L/min, 1.6L/min and 1.2L/mins across the four 
doses, respectively. None of these changes were significant across the dose sessions 
(100%v110%=-25,p=0.7; 100%v120%=-3,p=0.9; 100%v100%R=-105,p=0.07). 
 



























Figure 8-12a-f: Respiratory rate and flow results. 
All graphs show median values across each dose session as well as one-minute averages at baseline (-3 
minutes), 0, 3, 8, 15, 30 and 60 minutes after diamorphine administration for Vf, VT and VE; a) Vf median 
values; b) Vf one-minute averages; c) VT median values; d) VT one-minute averages; e) VE median values; 
f) VE: one-minute averages. Vf= respiratory rate; VT= tidal volume; VE= minute ventilation; 100%R = repeat 
100% dose.  *p<0.05 
 










































































































































































Figure 8-13: % change from baseline for each participant and dose session for a) Vf, b) VT and c) VE. 
  
























































































































Figure 8-14a-b: Respiratory pauses. 
a) frequency of apnoeic pauses of longer than 10secs; b) % time with absence of breath across 60 minutes. 






















































































8.4.7 Summary of Differences Between Baseline and Successive Time Points  
Significant changes from baseline to successive time points were seen in SpO2, ETCO2, 
respiratory rate, VE as well as NRDI. These changes were especially between the 3 minutes prior 
to administration (baseline) and 3-, 8- and 15-minutes post-drug administration. Some of the 
measures continued to show significant difference from baseline at 30 minutes post-dose (VE and 
ETCO2). Almost all measures recovered back to figures that were seen in baseline, with the 
exception of ETCO2%. There were non-significant changes from baseline to successive time 
points in VT. These values alternated from baseline across the 60 minutes of monitoring and did 
not show a substantial increase or decrease overall.  
 
8.4.8 Summary of Differences Between Doses  
SpO2, NRDI, VE and VT showed some changes between doses but there were no significant 
differences between doses for these measures, including between the two 100% dose sessions. 
Three of the measures showed some significant differences between some of the doses. 
ETCO2% was significantly lower in the 110%, 120% and repeated 100% dose sessions compared 
to the first 100% dose session. Respiratory rate was significantly higher between the higher dose 
sessions compared to the both 100% dose sessions. TcCO2 was significantly lower in the higher 
doses and the repeated 100% dose compared to the first 100% dose session.  
 
Individually, Participant A showed significant changes across doses for all measures except 
SpO2%. Participant B showed significantly lower levels of VT between the two usual doses and 
significantly higher levels of TcCO2 between 110% and repeat 100% dose session, but no other 
significant changes. Participant C showed significantly lower levels of ETCO2, NRDI and TcCO2 





8.4.9 Secondary Outcomes: Subjective Effects and Observer Ratings (Aim 2) 
Aim 2: To investigate effect of variations in heroin dose on subjective drug effect. 
 
The second part of this chapter will focus on the various measures of subjective and observed 
drug effects. Each individual measure will be described separately. Measures of drug effect, drug 
liking and drug sedation as well as observer rating of intoxication were assessed at the seven 
successive time points post-administration. All were measured on a 100mm scale.  
 
8.4.9.1 Pupil Size  
Pupil size varied between 3mm and 1.5mm (Figure 8-15). Overall, across all participants, pupil 
size was significantly different from baseline to successive time points (Q=20.5, p=0.002). Pupil 
size was significantly lower in the 3- (p=0.04) and 8-minute (p=0.02) time points post-dose 
compared to baseline. Between doses, there was a significant decrease between both 100% and 
110% (W=-94, p=0.005) and 100% and 120% (W=-28, p=0.02) dose as well between the 100% 








   
Figure 8-15: Pupil size. 
Left: median values for each session for all participants for pupil size; right: one-minute averages of pupil 
size for all participants at baseline (-3 minutes), 0, 3, 8, 15, 30 and 60 minutes after diamorphine 
administration. 100%R = repeat 100% dose.  *p<0.05 
  
  






















































8.4.9.2 Drug Effects 
Overall, across all participants, the subjective drug effects ranged from 0 to 92mm (Figure 8-16). 
Overall, there were significant differences from baseline to successive time points (Q=37, 
p=0.0001) with significant increased responses being observed at all successive time points (3- 
(p=0.008, 8- (p=0.001), 15- (p<0.0001), 30- (p<0.0001), 60-minutes (p=0.0009)). However, there 
were no differences between any of the doses (100%v110%=21, p=0.7; 100%v120%=24, p=0.4; 
100%v100%R=-1,p=0.9). There was an average of 29mm, 34mm, 31mm and 44mm in each dose 
session, respectively.  
 
Participant A experienced the highest level of drug effect in the 110% and then subsequently with 
the 120%. The lowest experience was in the first 100% dose session. When asked which session 
was thought to be highest dose increase, the response was 110%. Participant C experienced the 
lowest level of drug effect of the three cases and the highest level was in the 110%.  
  
Figure 8-16: Drug effects. 
Left: median values for each session for all participants for subjective drug effects; right: one-minute 
averages of subjective drug effects for all participants at baseline (-3 minutes), 0, 3, 8, 15, 30 and 60 minutes 




























































8.4.9.3 Drug Liking 
This measure ranged from 0mm to 96mm with an average in each dose of 61mm, 60mm, 62mm 
and 87mm, respectively (Figure 8-17). Friedman’s test showed overall non-significant differences 
between time points but a significant difference between baseline and 30-minutes (Q= p=0.008) 
was observed. There were no significantly different results (100%v110%=-30, p=0.6; 
100%v120%=31,p=0.3), except for between the two 100% dose sessions (W=-114,p=0.04).  
 
 Individually, Participant A showed the highest level of drug liking amongst all participants and 
experienced the highest level in the repeated 100% dose session. Participants 2 and 3 showed 















Figure 8-17: Drug liking. 
Left: median values for each session for all participants for subjective drug liking; right: one-minute averages 
of subjective drug liking for all participants at baseline (-3 minutes), 0, 3, 8, 15, 30 and 60 minutes after 

















































8.4.9.4 Drug Sedation 
This measure ranged from 0mm to 91mm and an average across each dose session was 
observed as: 32mm, 42mm, 29mm and 47mm, respectively (Figure 8-18). Overall, significant 
changes occurred over time points, post-dose (Q=31, p<0.0001). A significantly greater level of 
sedation was experienced at all time points post-dose (p=0.03, p=0.002, p<0.0001, p<0.0001 and 
p=0.003, respectively). Increased levels of sedation were experienced in the 110% and repeat 
100% dose sessions, significant differences were observed between 110% and 120% doses only 
(W=-71, p=0.02), the rest were not significant (100%+110%=83,p=0.2; 100%+120%=26,p=0.3; 
100%+100%R=39,p=0.5).   
 
Individually, Participant A felt the highest level of sedation and showed a maximum of 90-91mm 
within the three latter dose sessions (110% to repeat 100%). Participant B experienced the 
highest level of sedation in the first 100% dose session and Participant C experienced the lowest 











Figure 8-18: Drug sedation. 
Left: median values for each session for all participants for subjective drug sedation; right: one-minute 
averages of subjective drug sedation for all participants at baseline (-3 minutes), 0, 3, 8, 15, 30 and 60 

























































8.4.9.5 Staff Rating of Intoxication  
This measure ranged from 0mm to 96mm and the average rating for each dose session was 
19mm, 26mm, 19mm and 44mm, respectively (Figure 8-19). Overall, significant differences were 
observed from baseline to successive time points (Q=38, p<0.0001). A greater level of intoxication 
was observed at 8- (p=0.0003), 15- (p<0.0001), 30- (p<0.0001) and 60-minutes (p=0.003) post-
dose compared to baseline. Increased levels of sedation were experienced in the 110% and 
repeat 100% dose sessions but these were not significant. 
 
Individually, ratings on the level of intoxication were greatly varied. Participant A had an observed 
highest level of intoxication in the repeat 100% dose session, followed by the 110% dose session. 
On average, the first 100% dose session was rated the lowest (6mm). Participant B showed the 
highest intoxication level at 110% dose session of 67mm but on average, the higher value was 
the first 100% dose session. Participant C displayed the lowest rating of intoxication at between 












Figure 8-19: Staff rating of intoxication. 
Left: median values for each session for all participants for staff rating of intoxication right: one-minute 
averages of staff rating of intoxication for all participants at baseline (-3 minutes), 0, 3, 8, 15, 30 and 60 
minutes after diamorphine administration. 100%R = repeat 100% dose.  *p<0.05 
 
  










































































8.4.9.6 Glasgow Coma Scale/Level of Consciousness 
There were little to no changes in the GCS scores across all participants and doses (Figure 8-
20). There were 3 time points in one dose session that showed a slightly lower score indicating 
less consciousness. This was in 3-, 8- and 15-minutes post-administration in the 100% dose 
session for Participant A as well as in the 110% dose session at the 3-minute time point for 
Participant B. 










Figure 8-20: Level of consciousness: 
Left: median values for each session for all participants for level of consciousness; right: one-minute 
averages of level of consciousness for all participants at baseline (-3 minutes), 0, 3, 8, 15, 30 and 60 minutes 



















































8.5 Discussion  
8.5.1 Summary of Principal Findings  
Overall, a severe respiratory depressant response was observed in all participants across all 
doses. However, a varied response was seen to increases in diamorphine dose amongst this 
population of long-term diamorphine-maintained users. Except for pupil size, observed and 
subjective ratings of drug effect and experience did not vary greatly between doses.  
 
Individually, there were varied changes of respiratory measures between doses. Interestingly, 
there were significantly higher levels of the ventilatory parameters and NRDI in the higher doses 
for Participant A and higher levels of capnography parameters and NRDI for Participant C. 
Participant B, who showed severe overall responses, did not show significant differences between 
doses except in TcCO2 (a higher level in the 110% dose session) and VT (lower level in the 
repeated 100% dose session). SpO2% did not significantly change between doses for any of the 
participants.  
 
8.5.2 Interpretation of Results  
Generally, the results from baseline to successive time points post-drug administration were as 
expected across all the respiratory depression measures. There were significant changes at time 
points that are correlate with the peak effect of the drug (eMC, 2013; Klous, Van den Brink, Van 
Ree, & Beijnen, 2005). For example, there were more pronounced changes in the initial first few 
minutes for NRDI, SpO2%, ETCO2% and respiratory rate. TcCO2 is a delayed measure and thus 
the significant changes occurred after the 15-minute time point.  
 
What is of note is the variation in responses between doses across the three participants. There 
are two specific points in relation to this: firstly, it must be prefaced that the numbers are too small 
to form any definitive conclusions and the discussion on these data must only be considered as 
an opportunity to reflect on preliminary findings. Secondly, whilst some of the observations are 
unexpected, the observations are not unusual. The three cases presented in this chapter are all 
male, long-term injecting heroin users with similar use history and patterns; the differing aspects 
of these cases are related to daily use, prescribed dose and concomitant drug use. Thus, 





All participants showed a dose response effect in % difference from baseline to peak ETCO2% 
which was interestingly the opposite effect seen in the NRDI % difference from baseline to nadir. 
Frequency of apnoeic pauses showed a dose-response effect in two of the participants. Across 
the three participants, NRDI and respiratory rate did not reduce with increasing doses of 
diamorphine. Oxygen saturation and carbon dioxide reduced and increased, respectively, with 
increasing doses of diamorphine proportionally but these were not significant. Participant B 
showed major impairment with an increasing 10% dose of diamorphine. With respect to drug 
effects and experience, very few measures showed notable changes. Pupil size showed a 
significant dose response effect, with decreasing diameter at higher dose levels, which has also 
been shown in the previous acute heroin study. There was a lower level of drug sedation 
experienced in the 120% dose session compared to the 110%, but not between 100% and 110%, 
which does not follow a dose response effect. 
 
From these data, it could be suggested that it is more likely that overdose is more affected by 
individual variability rather than one or two overarching factors. The rest of this section will discuss 





8.5.3 Case 1, Participant A 
This participant administered 30mg as the usual dose, intravenously, for the study. Considerable 
respiratory depression was seen across all sessions but no significant differences occurred 
between usual and increased diamorphine doses. There was no indication that a 10% or 20% 
increase produced any more impact on this participant than their normal dose. In two sessions, 
baseline levels were also disturbed, i.e. in the two 100% dose sessions, there were apnoeic 
pauses, high levels of both ETCO2 and TcCO2 in the time prior to drug administration. It would 
appear that there is cause for concern more generally with this particular case and there could be 
an effect of the morphine sulphate which, in this case, was a long-acting form and was taken 
three to four hours prior to the study session, at each study session. Nevertheless, the scheduling 
of prescribed medications did not differ from his normal routine as noted through in-depth medical 
history and discussion with participant on each study day.  
 
An interesting further analysis for this type of case would be an examination of the situation at 
different points in the addiction treatment. Fortunately, it is possible to compare the results for this 
participant from this study with the previous study on heroin overdose by my supervisors (5 years 
previously) as the same participant took part in both studies. From direct comparison, we observe 
that there were more pronounced effects seen in the previous dose for this participant where 
100mg diamorphine was self-administered (IV) and the same physiological measures were 
recorded, with the exception of TcCO2. For all measures, baseline values were more severe with 
the higher dose. It is somewhat expected that a higher dose would cause more severe respiratory 
depressant responses, but this creates further questions such as why would this occur if he is 
titrated to this particular dose? Also, why would there be less of an effect with a lower dose when 
the tolerance is high and the patient is stable? It could also be asked whether, if a 67% reduction 
in daily dose produces less pronounced effects, should it then be further encouraged that patients 
taper their dosing? On the other hand, it is also the case that this particular participant showed 
pronounced effects across every single dose session, and thus, clearly is affected by the 
respiratory depressant effects of opioids whether on a high or low dose, or a proportionally higher 
or lower dose injection. More detailed discussion of dose optimisation is discussed further on in 





8.5.4 Case 2, Participant B 
This participant’s usual dose was 100mg IV for the study and administered by the study doctor. 
There were considerable changes from baseline to successive time points as well as between 
the doses. Although overall, there was no statistically significant difference between the doses for 
Participant B, physiological measures did appear more severe compared to the other two 
participants. Additionally, a 10% increase affected his responses quite considerably and it was 
decided by the study team that it was not safe to proceed to the next dose increment of 20%. 
Figure 8-3 highlights the different observed responses to 100% and 110% doses.  
 
The response observed in Participant B corresponds with the pharmacological hypothesis that an 
increase in dose leads to an increase in physiological responses and a more severe respiratory 
depressant effect. There are two points of consideration in relation to this. Firstly, the dose-
sensitive effect may be related to the fact that his usual/habitual route of administration is 
intramuscular rather than intravenous, as tested in this study. Thus, an intravenous dose could 
be providing him with a more intense dose effect. However, if this were the case, we would expect 
there to be a severe response in the 100% dose sessions. It would be difficult to extrapolate this 
any further until there was further examination into the impact of route. For example, would he be 
expected to show similar responses whilst using IM? It would seem logical to hypothesise that 
there would be a less severe response with IM for this particular participant. Secondly, the dose-
sensitivity could also be related to the extra 10% increase, this being equivalent to an extra 10mg 
diamorphine. The difference in response is considerably different, and this raises the question 
that if users slightly alter their doses of diamorphine in this way, how frequently do users reach 





8.5.5 Case 3, Participant C 
This was an intramuscular user administering a usual dose of 200mg diamorphine IM. There were 
no prominent differences between doses, but it must be noted that a level of respiratory 
depression was still reached. For example, his level of carbon dioxide was consistently over the 
6.5% threshold. This indicates that alveolar ventilation is insufficient to maintain arterial carbon 
dioxide within the normal range. High levels of carbon dioxide do commonly occur with opioid use 
(Lehmann, Neubauer, Daub, & Kalff, 1983), however, combined with the commonly observed 
overlap with lung disease, this creates further problems for the user  (Jolley et al., 2015b) (see 
Chapter 5 on overlap between heroin addiction and lung disease). The brief assessment of lung 
disease at the screening for this study shows that this particular participant also had underlying 
lung disease. Additionally, there appeared to be changes from baseline to peak or nadir effect for 
each of the measures that were comparable to the other two participants. Overall, this participant 
also reached similar respiratory depression criteria, and in some cases the frequency of these 
were higher than the other two participants, e.g. the frequency of respiratory pauses in the 100% 
dose session (41 pauses). Thus, although there appears to be an overall less severe respiratory 
depressant effect with intramuscular administration compared to the IV users, there was still a 
level of respiratory depression, and although, there was a more delayed responses and less 
intense initial post-dose effect, the duration of effect persisted until the end of the study session.  
 
Interestingly, this participant’s level of drive became less severe with each session. The question 
of whether this is related to environmental factors must be raised. There is further discussion on 
this specific topic of environmental factors contributing to opioid overdose vulnerability further on 





8.5.6 Secondary Outcomes: Subjective & Observer Ratings  
All subjective and observer ratings increased from baseline to successive time points and there 
was variation between participants in how sensitive they were to dose changes.  
 
Pupil size decreased significantly with each dose session and also, from baseline to successive 
time point in each session. As described in the previous chapter pupil size is a common measure 
of opioid effect as well as injury to the central nervous system. Contraction of the circular muscles 
that constrict the pupil response to light causes smaller pupil diameter, and a decreased, or 
pinpoint pupil, is commonly present in combination with decreased level of consciousness and 
respiratory depression. The findings here are also consistent with the previous study on acute 
heroin effects where pupil size was the only measure to show any difference between the two 
injecting routes of administration. It is also interesting and fits the pharmacological hypothesis that 
the pupil diameter significantly reduced with each increase in dose.  
 
However, examining pupil size individually shows a different picture. It appears that only one 
participant showed variation between the doses, therefore, it is difficult to conclude whether this 
measure reliably demonstrated a dose response effect. Furthermore, the pupil size in the final 
(repeated 100% dose) was significantly lower than the first 100% dose session. This indicates a 
potential influence of environmental factors. This will be discussed in further detail later on in this 
chapter.  
 
Overall, a greater level of drug sedation and drug effect was experienced in the 110% dose 
session and even greater in the repeated 100% dose session. Individually, these experiences 
varied even further. A similar pattern was observed in the staff rating of intoxication which 
appeared to show an increase in the 110% dose session compared to baseline but the greatest 
increase was in the repeat 100% dose session. A greater level of drug liking was experienced in 
the repeated 100% dose session which was an unexpected finding. It is thought that the drug 
liking experience increases as the dose increases. This suggests that perhaps again, 






There are two main weaknesses of the findings and conclusions reported in this chapter. Firstly, 
it is difficult to draw conclusions based on small the number of participants presented in this 
chapter. Due to the unexpected obstacles, the data presented in this chapter were limited to a 
case presentation for the purposes of submitting the thesis.  
 
Secondly, pharmacokinetics was not conducted on the participants. In the initial drafting of the 
study protocol, taking blood samples from this population were deemed unsuitable. This was 
driven by the initial consultations with service users, as well as the fact that peripheral venous 
access is known to be difficult amongst long-term injecting drug users. In fact, there were issues 
related to peripheral venous access during assessment of whether IV would be suitable in 
amongst all participants who screened for the study.  
 
8.5.8 Strengths  
This is a greatly in-depth study that has been able to take a dwindling number of patients from a 
community of users who often feel insecure about their treatment to conduct crucial investigations 
into the physiological and subjective responses of increased doses of diamorphine. The ability to 
investigate critical questions of risk factors of heroin overdose in a reliable, well-designed study 
has provided a strong opportunity to elucidate some of the long-held questions in the field. 
Furthermore, the ability to capture as realistic scenario as possible, given the considerable 
number of influential factors, is a great strength of the study. From a physiological perspective, 
the findings in this study were also congruent. There were low levels of minute ventilation and 
increasing levels of end-tidal carbon dioxide, post-dose. These are expected physiological 
findings post-opioid dose.  
 
8.5.9 Significance of Apnoeic Episodes 
There were some observations in this study that were unexpected or that raised further questions 
and encouraged consideration. Throughout each study session, one of the most striking 
phenomena was the length of pauses observed in every study session. Whilst our safety 
guidelines were clear that a 20 seconds apnoea was a criterion that could result in an intervention 
(with a cascade level from least intrusive to most intrusive), it was most surprising that often the 




disturbed in any way. Further, in some sessions these pauses and patterns remained evident for 
the length of the study session of 60 minutes (see 55 minutes post-dose in Figure 8-4). This was 
unexpected as the half-life of diamorphine is around 2-3 minutes. The metabolite morphine does 
remain for longer around 3-4 hours, but the peak effects are usually at around 15 minutes (eMC, 
2016) (slightly sooner for intravenous). 
 
Discussions were held with respiratory physiology and sleep medicine colleagues in relation to 
the data in this chapter. Apnoeic episodes and the pattern of flow breathing were a frequent point 
of discussion. In Sleep Medicine, there is a clear typology of breathing patterns that are centred 
on apnoeic pauses and the size of inspiratory breaths. Generally, it is considered that any pause 
in breathing of over 10 seconds that is also combined with hypoxaemia is considered dangerous 
and abnormal. In Sleep Medicine, this particular characteristic is considered a crucial feature of 
sleep apnoea (U. P. S. T. Force, 2017; Jayaraj, Mohan, & Kanagasabai, 2017). Obstructive Sleep 
Apnoea (OSA) and Central Sleep Apnoea (CSA) are the main forms of sleep apnoea, with CSA 
being more prevalent over OSA among users of opioids (Correa et al., 2015; Fahim & Johnson, 
2012; Farney, Walker, Cloward, & Rhondeau, 2003; Teichtahl & Wang, 2007; D. Wang et al., 
2005). OSA does still occur among people using opioids (between 8%-10% (Van Ryswyk & Antic, 
2016)) but the mechanisms are not fully understood and it is thought to be related to the opioid-
induced reductions in airway muscle activation (Hajiha, DuBord, Liu, & Horner, 2009). Further, it 
is thought that untreated sleep apnoea where patients stop breathing and which frequently occur 
during sleep ultimately leads to atrial fibrillation, cardiac arousal, stroke, brain or other vascular 
diseases or potentially death. It is understood that chronic use of opioids can also affect breathing 
during sleep, including non-apnoeic hypoxaemia, central and obstructive apnoeas and ataxic 
(irregular) breathing (Alattar & Scharf, 2009; Farney et al., 2003; Teichtahl & Wang, 2007; J. M. 
Walker et al., 2007). The onset and severity of respiratory depression and sleep-disordered 
breathing is highly affected by inter-individual variability and the factors underlying this 
susceptibility to overdose in certain individuals are poorly understood. 
 
In the data presented here, some of the observed irregular patterns of breathing resemble ‘sleep-
disordered breathing’ patterns. There are distinct patterns of breathing that fall under this umbrella 
and there are also suggestions that a distinct ‘opioid-induced’ type of sleep-disordered breathing 




condition (Javaheri & Randerath, 2014; Randerath & George, 2012). In this study, breathing 
patterns could also be described as such due to the observed differing abnormal patterns (Figures 
8-3 & 8-4). Similar varied patterns have been noted in studies exploring effects of opioid use: 
ataxic, Biot’s, Cheyne-Stokes, as well as types that fall under OSA and CSA types of breathing 
have all been described in chronic opioid users (Farney et al., 2003; Mogri, Desai, Webster, Grant, 
& Mador, 2009; Van Ryswyk & Antic, 2016; Wang & Teichtahl, 2007; Webster, Choi, Desai, 
Webster, & Grant, 2008). Furthermore, opioid-induced sleep apnoea appears to be prevalent in 
between 30% and 90% of chronic opioid users (Fahim & Johnson, 2012). In a similar study of 
opioid administration in patients who use opioids for chronic pain, the patterns of breathing were 
seen as a mix of Biot’s breathing and ataxic (Walker et al., 2007). Ataxic breathing is essentially 
a complete irregular pattern of breathing with irregular pauses/apnoeas. Biot’s breathing is 
sometimes used interchangeably with ataxic breathing and it is described most effectively in the 
original research paper:  
This irregularity of the respiratory movements is not periodic, sometimes slow, sometimes rapid, 
sometimes superficial, sometimes deep, but without any constant relation of succession between 
the two types, with pauses following irregular intervals, preceded and often followed by a sigh 
more or less prolonged. (Biot, 1876) 
Furthermore, some of the patterns observed in this study also appear to display ‘waxing and 
waning’ patterns characteristic of Cheyne-Stokes breathing. This particular condition can be seen 
most distinctively in Figure 8-4 in the 100% dose session of Participant A. Cheyne-Stokes 
respiration is characterised by gradual decrease in volume of inspiratory and expiratory breaths 
that results in temporary pause in breathing with a subsequent increase or faster rate of breathing. 
The pattern repeats every few seconds to 2 minutes and the oscillation resembles a crescendo-
diminuendo pattern and is also associated with changes in levels of oxygen and carbon dioxide 
(Berssenbrugge, Dempsey, Iber, Skatrud, & Wilson, 1983; N. S. Cherniack & Longobardo, 1973; 
Dowell et al., 1971; Guyton, Crowell, & Moore, 1956). This pattern is not consistently present in 
all of the cases.  
 
There is clearly not a regular pattern of breathing occurring amongst all of the participants, post-
opioid dose administration, but it can be stated that perhaps a distinct ‘opioid-induced’ type of 
CSA is occurring amongst these participants. However, whilst sleep-disordered breathing is 
somewhat beyond the scope of this thesis, the patterns of breathing observed in this study warrant 




8.5.10 The Effect of Repeat Dosing 
As mentioned in Chapter 3, when discussing the role of the environment factors and tolerance in 
opioid overdose vulnerability, it is imperative to consider the significant work of Siegel and others. 
This work arose from the difficulty in understanding the increase in heroin deaths in the 1980s in 
Canada and reflected on Pavlovian conditioning principles and its relation to drug tolerance 
(Siegel, 1982, 1983). Many differing views were presented to explain the causes of these worrying 
trends at that time and many of the proposed causes of deaths centred on the similarly discussed 
causes today. These causes were threefold: some people may be dying from a true 
pharmacological overdose (Huber, 1974), others may be dying from doses that are not expected 
to be fatal and presumably in individuals that are tolerant to the opioid effect (Brecher, 1972; 
Reed, 1980) and finally, some may also be dying from a synergism between the opioid and other 
drugs or adulterants. It was therefore described that some deaths are: ‘an idiosyncratic reaction 
to an intravenous injection of unspecified material(s) and probably not a true pharmacologic 
overdose of narcotics’ (Cherubin, McCusker, Baden, Kavaler, & Amsel, 1972, p. 11). It is of note 
that this would be relevant to today’s trends, both in the UK and globally.  
 
Siegel’s work reflected on animal study investigations into a model of tolerance with underlying 
Pavlovian conditioning principles (Siegel, 1983). The interpretation of tolerance by Siegel and 
others was not based on a physiological one, but rather based on the premise that the individual’s 
experiences with the drug administration environment has as much of an important contribution 
to tolerance dependence as physiological and pharmacological factors. This was thought to be 
another potential cause of overdose death. There was some evidence that in some cases 
overdose may be as a result of a conditional failure of tolerance when the usual pre-drug cues do 
not accompany the usual pharmacological consequences (O’Brien et al., 1992b; Siegel, 1983, 
1984).  
 
In relation to data presented in this chapter, it is reasonable to ask whether there could be a 
different mechanism at play here. Could there also be a potential combination of 
physiological/pharmacological as well as psychological? Or, ultimately, is there just no reliable 





Participants in this study were asked at every visit whether the effects of the drug appeared to be 
affected by the foreign nature of a laboratory setting and were asked to compare their experiences 
to previous visits in the study. None of the participants felt that the overall experience differed 
greatly from their usual experience at home and it must be stated that these particular participants 
are more likely to be used to administering their diamorphine in a clinical, hospital setting than 
their street-using peers.  
 
Furthermore, there are a considerable number of studies that might contribute to understanding 
the unpredictability of opioid overdose. In the case of opioid analgesia medication, it is understood 
that the tolerance of analgesic properties of opioids develops faster than tolerance to respiratory 
depressant effects. With long-term use, this delayed tolerance restricts the therapeutic window 
and potentially places patients at increased risk for respiratory depression (Boyer, 2012; Etches, 
1994; Gal, DiFazio, & Moscicki, 1982; White & Irvine, 1999). Could a similar phenomenon be 
occurring with a tolerance to the maintenance effects?  
 
8.5.11 Speed of Administration 
During the diamorphine administration, it was possible to record the speed of injection. When self-
administering, speed of injection was no more than six seconds and was only slightly increased 
in one case when it was administered by the study doctor (12 seconds). This increased speed of 
injection did not appear to diminish the respiratory depressant effects of the diamorphine, in fact 
the session with the longest administration was the one that saw the most pronounced effect in 
all of the study sessions. During the planning phase of the study, there was discussion of 
incorporating a time range for injection. It was initially thought that injecting over 1 or 2 minutes 
would be most suitable. The discussion was originally centred on nurse administration via cannula 
but as the study protocol developed, self-administration was preferred to resemble the accurate 
injecting situation and this timing of injection became ‘self-administer the diamorphine in under 1 
minute’. In practice, the speed of injection was much quicker.  
 
It is not known whether a slower administration would have resulted in less severe responses, 
but we could logically assume that this might be the case. However, this would not be reflective 




8.5.12 Implications for Clinicians and the Community  
There are three main implications for clinicians. Firstly, a clinical investigation into whether this 
type of monitoring could actually reduce the risk of respiratory depression is required. Could 
intensive monitoring reduce risk of significant respiratory depression? Findings here and the 
previous heroin administration study show that there is need for careful physiological studies of 
the mechanisms and how and where these data can drive technology. These types of intricate, 
detailed physiological measurements are able to identify markers that could be used to identify 
‘at-risk’ patients and potentially allow for an early detection of risk of opioid overdose. It is feasible 
that this type of testing could be conducted in patients before treatment and, in the future, even 
be used as a means of providing opioid users better information on which to choose their 
treatment. However, as mentioned in Chapter 5 these methods require further validation in larger 
scale, prospective studies.  
 
Secondly, there is the issue of dose variability and titration. It should be made clear that there is 
no suggestion from this study that heroin maintenance medication should be reduced for the 
purposes of reducing risk of overdose. A careful balancing act is already involved in the process 
of dose optimisation, and the negative effects of opioids are very well-understood. The UK 
guidelines on clinical manage of drug misuse and dependence (The ‘Orange Book’) (DOH, 2017) 
state that the objective of dose optimisation is a complete cessation of heroin and other illicit 
opioid use. Additionally, better outcomes of cessation of all heroin use are usually observed at 
higher doses of opioid substitution drugs. It is generally recommended that average doses of 
methadone are between 60 and 120mg and buprenorphine between 12 and 16mg daily, with 
some requiring higher or lower than this range. Finally, guidelines state that patients need to be 
informed on what is likely to be most effective for them.  
Taking these points into consideration, the data presented in this chapter and the data that may 
continue to arise from this study could be used to help further inform patients in the process of 
treatment optimisation. Further, there are potentially informative pieces of advice that could arise 
from this type of work. There are a potential four pieces of information that could be considered 
by the clinical and service user communities further. Firstly, should non-IV, i.e. IM and SC, be 
further encouraged for clients to move forward to? Secondly, underlying lung disease could be 
considered an important factor in increasing vulnerability overdose, and subsequently, opioids 




to the previous point, having a respiratory infection, from a cold to a chest infection may also leave 
the user more vulnerable and it may be sensible to be aware of extra precautions. Fourthly, if in 
an informal using situation, how long should friends, relatives or peers wait if someone is not 
breathing? Additionally, should the response to the pause in breathing be a simple physical 
manoeuvre such as a nudge, or should there be a cascade of events, starting from verbal, then 
physical, then painful and then act upon the situation if there is no response to painful stimuli? 
The latter point is part of standard practice and training in relation to overdose prevention, but if 
clinical data are showing a more complex phenomenon, it is pertinent that this training and 
practice is more nuanced. Although it must be noted that these pieces of information are 
inconclusive thus far, this work does allow one to develop a stronger picture of how this could 
proceed.  
 
Thirdly, another implication for clinicians is that respiratory depression occurred at all doses in 
this study. It is of note that the responses between the two 100% dose sessions were not identical, 
suggesting that the responses differ despite the same dose being administered. This could be 
related to environmental factors as highlighted previously, and it is an interesting phenomenon 
that has been observed in supervised injectable treatment clinics, as mentioned in the introduction 






8.5.13 Public Health and Policy-Related Implications   
There have been great efforts to address overdose deaths through public health and policy 
initiatives. By collaborating with other public bodies, the Office of National Statistics (ONS) annual 
report on deaths related drug poisoning in England and Wales (ONS, 2018), as well as the 
National Records of Scotland’s publication (NRS (National Records of Scotland), 2018) on drug 
related deaths in Scotland contribute the predominant mortality trends within the UK. Within these 
reports, there is often crucial discussion of potential causes behind any changes to the numbers 
of deaths. Since the major upward trend of opioid-related deaths in the UK from 2012, the main 
reasons that were provided in these reports were based on the occurrence of a Heroin Drought 
(M. Harris et al., 2015) and subsequent increase in purity as being responsible for this increase. 
Essentially, the issue was connected to small fluctuations in the black market. However, as has 
been discussed in the introductory chapters and through the data presented in this chapter, the 
issue is clearly more complex. Previous literature has shown that it is uncertain whether small 
fluctuations in the market actually result in an increased risk of overdose (Darke, 2011b, 2014; 
Darke et al., 2010a; Darke & Farrell, 2014; Davidson et al., 2003; Degenhardt et al., 2011). 
However, the governmental reports have repeatedly communicated this reason as being the 
centre of increases in deaths, and this has been further promoted by media outlets. Although it 
appears that this argument has been diminishing (ONS, 2018), the issue with this delves deep 
into the political nature of addiction treatment. Does the issue of providing reasons that have little 
or no evidence potentially mask more complex and controversial factors that may be contributing 
to the increase in deaths in the UK? Moreover, it is certain that the year-on-year financial burden 
experienced by the National Health Service and subsequent cuts to addictions services since 





8.5.14 Future Research 
I propose that there are three further routes of exploration from these data that I will highlight: 
1) Further this study and gather more data: in combination with this, explore whether IV and IM 
actually do lead to differences in physiological and subjective effects within subjects. There is 
progression with this point, and an application to the ethics committee will be made in order to re-
invite the same participants that have been examined thus far to undertake the same sessions 
but with administration of a different route of injection. This would lead to a strong within-subject 
design.  
2) Explore genetic influences behind overdose vulnerability: there had been discussion of 
including a genetic component within the study presented here. Advice was sought from experts 
within the social genetics field and colleagues from the Addictions Department of King’s College 
London including from Professor John Marsden. The proposed idea stands that the OPRM1 gene, 
which is related to mu-opioid receptor sensitivity where the respiratory depressive actions lie, may 
have some involvement in individual variability of drug metabolism (Befort et al., 2001; 
Chidambaran et al., 2015; Goldstein, 2001; Manini, Jacobs, Vlahov, & Hurd, 2013). This is thought 
to be related specifically to the polymorphism A118G. There is a great deal of literature on pain 
responses and alcohol consumption in the presence of this polymorphism (Bilbao et al., 2015; 
Ray & Hutchison, 2004; Sloan et al., 2018; Yu, Wen, Shen, & Zhang, 2018), but limited to no 
evidence on physiological responses in opioid overdose. However, there are still questions that 
need to be addressed, e.g. what is the mechanism with which this receptor polymorphism exerts 
the effect? Is this a phenotypic effect? The other limitation with this is related to effect size. The 
sample size for this study (n=12) would be considerably too small to see an effect within a genetic 
study. This would clearly not be feasible amongst diamorphine-maintained patients in the UK. 
There could be some scope to expand this type of study to other opioid prescribed patients, or to 
street heroin users but this would be a separate exploration.   
3) Alongside this work to further understand the physiology, there is significant scope for 
incorporating laboratory-based measures into wearable ‘smart’ technology. There is some 
development with this type of investigation and is discussed in the final chapter. As this thesis is 
being written, a plan to implement an exploration into wearable measures into the current study 





A dose-incremental, single-blind, within-subject study into the effect of incremental doses of 
diamorphine on physiological and psychological measures in tolerant users was conducted. In-
depth analysis on three participants as part of a case series presentation in this chapter aimed to 
demonstrate the interim results of this ongoing clinical experimental study. Primary outcomes 
were based on physiological measures of oxygen saturation, carbon dioxide, respiratory drive 
and results were varied across all doses and participants. In two of the participants, there 
appeared to be some effect of dose increases but in-depth analyses showed that one of these 
individuals had disturbed baseline measures prior to drug administration. The third participant 
administered intramuscularly and results did appear to be less severe, although still showed some 
signs of respiratory depression.  
 
Ultimately, the data presented and observed thus far show an inter-individual variability that is not 
predictable. This is in accordance with available literature on the seemingly erratic nature of fatal 
overdose cases. Overall, it would appear that long-term heroin users are not necessarily tolerant 
to the respiratory depressant effects of opioids but crucially, continuation of the investigation is 
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9.1 Summary of Principal Findings and Contribution to the 
Addictions Field.  
Chapter 1: This opening chapter describes the overview of global and national opioid-related 
deaths and considers the reasons behind the increase in the UK death figures over the last six 
years, particularly focussing on purity. It also examines why it is difficult to interpret global drug-
related deaths (DRDs) data and reflects on the opioid crisis in the USA.  
 
Chapter 2: This chapter examines the history of heroin use and heroin addiction treatment in the 
UK and the reasons why the experimental study of heroin effects is possible in the UK. Prior to 
the 1970s, the mainstay treatment for heroin addiction in the UK was diamorphine prescribing. It 
is unlikely that a similar structure that existed prior to the 1970s in the UK will exist again and 
hence it is vital to learn as much as possible from the retrospective examination of data from this 
earlier era and to consider their relevance to the situation of today.  
 
Chapter 3: This chapter describes the distinct pharmacological and physiological effects of heroin 
and other opioids and focusses on the underpinnings of respiratory depression and respiratory 
function in long-term opioid users. Opioids are a particularly interesting group of drugs that have 
been used for centuries for their pain-relieving, sedative, anti-anxiety and cough suppressant 
effects. However, they also possess a side effect which has been the great focus in 
pharmaceutical development over many decades: respiratory depression - a dangerous reduction 
in breathing. The severity of respiratory depressant effects varies between opioids, but there is 
no opioid agonist that does not have this effect. This chapter also describes physiological 
mechanisms in three distinct cases: in an opioid overdose, in healthy individuals, and amongst 
those with underlying chronic lung disease. Finally, this chapter provides a rationale for each 
physiological measure of respiratory depression used in this thesis. 
 
Chapter 4: this chapter highlights the various physiological and respiratory measures, criteria, 
assessments and techniques that were involved in the studies related to this thesis and were 
used to measure the level of respiratory depression. The chapter also describes the subjective 
measures of drug effect and breathlessness. Without a standard measure of respiratory 




incorporated. It is possible to detect respiratory depression in individuals using reliable and 
accurate physiological measures.  
 
Chapter 5: This chapter is devoted to an observational study examining respiratory function 
among clients of a drug treatment centre. Everyday respiratory depression exists within healthy 
drug users as well as those with lung disease. Compared to controls, a significant respiratory 
system ‘burden’ was seen. Being able to elicit these data by means of a simplified, practical 
method shows that it can be taken further into a clinical setting or inform further technological 
developments to improve early detection of opioid overdose.  Furthermore, the results also show 
that certain personal, behavioural, drug treatment and use factors are related to chronic 
respiratory depression. Finally, the results also show that the neural respiratory drive to breathe 
appears to be significantly lower in opioid users with underlying lung disease compared to controls 
with lung disease.  
 
Chapter 6: This chapter re-examines data from a previous study on acute heroin effects (Jolley 
et al., 2015). Results from the data presented in this chapter suggest a varied physiological and 
subjective response to differing routes of heroin administration. It is not clear from these data 
whether intravenous (IV) does actually have a more pronounced physiological effect compared 
to intramuscular (IM) administration. However, subjective effect and pupil size were significantly 
more pronounced in the IV group compared to the IM group in the initial 3 minutes post-dose. 
Experimental studies of this type are challenging and thus re-investigation of data obtained from 
previous studies serves a valuable purpose in providing preliminary information for future studies.  
 
Chapter 7: This chapter discusses the development of the study protocol for the experimental 
heroin overdose study (described more fully in chapter 8). As part of the development process, 
consultations were conducted with researchers and clinical colleagues, as well as service users. 
This chapter also discusses the clinical trial procedures that were involved in setting up the trial 
itself. Many obstacles were experienced throughout the trial setup and even during the initial data 
collection period. It is thus important to examine the difficulties and realities of conducting these 





Chapter 8: In this final research chapter, an experimental study of heroin overdose using a dose-
incremental, single-blind, within-subject design is described, reporting on investigation of the 
effect of risk factors (increased dose of diamorphine and familiarity of setting) on physiological 
and psychological measures in tolerant users. In-depth analysis on three participants as part of a 
case series presentation in this chapter aims to demonstrate the interim results of this ongoing 
clinical study. In two of the participants, there appeared to be some effect of dose increases but 
in-depth analyses showed that one of these individuals had disturbed baseline measures prior to 
drug administration. The third participant administered his heroin intramuscularly and signs of 
respiratory depression were less pronounced than those of the other participants, however, there 
appeared to be some less severe signs of respiratory depression.  
 
The research presented in this thesis represents hugely important pieces of exploratory work 
captured through realistic using scenarios on which are only being conducted now despite some 
of these questions having needed attention for many decades. Experimental study of opioid 
overdose requires attention for better harm reduction approaches to reduce risk of overdose, but 
this type of experimental study has rarely received much attention. It is worth stating that 
diamorphine has existed as a medication for over 130 years and has been used in the treatment 
of heroin addiction for a century, i.e. since before the Rolleston Committee in 1926. Further, opiate 
addiction treatment services and heroin clinics have existed to a greater or lesser extent, for 
approximately 50 years. The question that is important but rarely considered is why so few similar 
studies have been conducted. The likely answer is that they have not been examined precisely 
because of the very nature of the drug being studied (i.e. heroin). There is something circular and 
counter-productive about this situation. For example, in the USA, public and regulatory concerns 
about heroin make it almost impossible for researchers to study the effects of diamorphine (and 
so other opioid medications such as hydromorphone are used as surrogates for heroin). In fact, 
diamorphine is not recognised by the Food and Drug Administration (FDA) as treatment for opioid 
users. In the UK, despite the recent and necessary strict clinical trial regulations, this type of study 





9.2 Strengths and Weaknesses of the Thesis  
The strength of this thesis is related to the robust examination of certain factors associated with 
heroin overdose and in the development and testing of criteria and techniques which lay the 
foundations for an experimental model of acute opioid overdose. This is the first examination of 
the effects of increased heroin dose on overdose vulnerability in a realistic heroin-using scenario.  
 
There are three main weaknesses in this thesis. Firstly, the inability to complete the originally-
envisaged larger study described in Chapter 8 due to administrative and bureaucratic obstacles 
highlighted in Chapter 7. It is expected that, beyond the work described in this thesis, this study 
will continue to recruit participants to complete the anticipated sample size that I plan to continue 
as a post-doctoral researcher. Additionally, further amendments to the study will also allow testing 
of different routes of opioid administration as well as different measurement tools. It is thus likely 
that this issue can be resolved.  
 
Secondly, all the studies reported in this thesis had small sample sizes (n=3-20), from which it is 
difficult to generalise or to formulate large-scale conclusions. Conducting detailed physiological 
studies is time-consuming as they gather many variables. They are also subject to a high level of 
attrition due to the within-subject designs, substantial burden on, or simply a lack of, available 
participants. These types of physiological studies tend to involve a within-subject design and thus, 
data reported in this thesis constitute exploratory work. However, testing of generalisability to 
other opioid users is yet to be conducted and should be the focus of future studies.  
 
Thirdly, this thesis brings together the two very different disciplines of Addictions Sciences and 
Respiratory Medicine. My supervisors are experts in their respective fields, however, as a result 
of their respective disciplinary orientations differing degrees of importance were given to different 
aspects of the findings. This made for interesting discussions but also produced conflicts as to 
the significance of certain issues. I instigated several discussions with supervisors and the study 
team on aspects of the studies that were particularly interesting and/or of concern. For example, 
the significance of apnoeic episodes and the length of pauses in breath caused surprise as well 
as concern. Some of the wider literature on this issue has been raised in Chapter 8. The degree 




highlights an uncertainty in the interpretation of results that should be considered as part of the 
process of developing an approach to a complex and truly multi-disciplinary investigation. 
9.3 Implications for Clinicians  
9.3.1 Issue of Multi-Morbidity  
As discussed in chapters 3 and 5, it is widely understood that people with mental health conditions 
have increased risk of physical ill-health, delayed diagnoses and higher mortality rates (Davies et 
al., 2014). Respiratory conditions potentially contribute to the high mortality figures and it has 
been noted that better pathways need to be enabled to screen for, and treat, health conditions 
including lung disease (PHE, 2017). Furthermore, the issue of underlying pulmonary morbidity in 
individuals who are at risk of opioid overdose is an issue that requires careful clinical assessment 
and complex service planning (ACMD, 2016). 
 
A great deal of the existing literature relates to asthma and heroin inhalation (Cygan et al., 2000; 
Hughes & Calverley, 1988; Krantz et al., 2003; Levine et al., 2005): however, very little is actually 
known of the link between heroin administration and lung disease, let alone overdose risk. There 
is a need to establish a stronger connection between clinical and experimental investigation of 
the respiratory system with opioid-induced respiratory depression and overdose risk. In addition 
to the brief report (Jolley et al., 2015a) on the prevalence of lung disease in a drug and alcohol 
treatment centre showing that 38% of clients showed signs of COPD (a majority of whom had 
either injected or smoked heroin), there are a further two studies showing a relationship between 
impairment of lung function (using either measures of Forced Expiratory Volume in the first 
second or CT scan of the lungs) and smoking heroin (Buster, Rook, et al., 2002; Walker et al., 
2015). 
 
As mentioned in chapter 5, more robust interventions need to exist to better identify chronic 
respiratory diseases in the opioid-using community. Even if overdose is not a potential 
risk/consequence, there is a clear requirement for this from the perspective of general health and 
well-being of this, often multi-morbid, population. In relation to this, drug users who smoke have 




opioid users appear to show the highest rates of smoking (Bowman et al., 2012; Clemmey et al., 
1997; Guydish et al., 2011; Pajusco et al., 2012; Tacke et al., 2001). More targeted nicotine 
replacement therapy or e-cigarette interventions for smoking cessation among opioid users could 
be one way to resolve this. Some studies have evaluated whether contingency management is 
effective at reducing tobacco smoking among opioid users, and have observed positive results 
(Dunn et al., 2010; Dunn, Sigmon, Thomas, Heil, & Higgins, 2008; Shoptaw et al., 2002; Sigmon 
et al., 2016; Tuten, Fitzsimons, Chisolm, Nuzzo, & Jones, 2012), but further work needs to be 
done in this area.  
 
There was also an issue of unawareness of respiratory disease: in chapter 5, among those that 
showed signs of lung disease, 62% were unaware and had not previously complained of any 
respiratory symptoms. One participant in chapter 8 was also another case. While these findings 
were not part of the original aims of the studies, it is important in the context of issues described 
in this thesis, as well as the fact that chronic lung disease progresses slowly and can result in a 
significant burden to the individual. Raising awareness is evidently crucial to resolve this issue. 
There is work being conducted in this area through lung health screening clinics. One is led by Dr 
Caroline Jolley in South London, and another group is based in the North West of England, who 
have assessed feasibility of such clinics in community drug treatment centres. These clinics are 
an example of strategies that can deliver relevant screening at point of access of drug treatment. 
In these clinics, a lung health screening to record symptoms that might indicate lung health 
problems as well lung function tests and oxygen readings are taken (Burhan et al., 2018; Jolley 
et al., 2015a). This work is also relevant to the issues pertaining to smoking cessation, as it is 
potentially effective approach in targeting relevant individuals.  
 





9.3.2 Chronic and Severe Respiratory Depression Amongst Experienced and Long-Term 
Opioid Users  
It is understood that there is an increased vulnerability amongst older opioid users (Gao et al., 
2016; Pierce et al., 2018) and age is a risk factor for opioid overdose (Bartu, Freeman, Gawthorne, 
Codde, & Holman, 2004; Darke, Kaye, & Duflou, 2006; Warner-Smith, Darke, Lynskey, & Hall, 
2001). However, as mentioned in chapter 5, it is still unclear whether this is a sensitivity to opioids 
or whether there are other underlying age-related conditions influencing this vulnerability. What 
appears to be reasonable to state from the data presented in this thesis and from previous 
research to date is that a significant level of respiratory depression exists amongst various groups: 
in older and experienced users, in those on oral maintenance medication, in those on diamorphine 
maintenance who inject intravenously and intramuscularly and with normal and higher-than-
normal doses. Some of these specific risk factors have been examined in this thesis, however, 
the issue of increased vulnerability in older, experienced users is one that requires attention.  
 
In chapter 5, age was found to be inversely associated with neural respiratory drive index (NRDI), 
indicating that NRDI may be decreasing with age in opioid-dependent users (ODU). However, 
there were no differences in respiratory depressant measures between a median age split of 
younger and older users in this study. The duration of drug use was associated with the two 
measures of carbon dioxide, ETCO2 and TcCO2. It appeared to show that the longer the period 
of drug use, the higher the levels of carbon dioxide. Hypercapnia, generally present with 
hypoventilation, is a common effect of opioid use. Further, the duration of drug use, similar to age, 
also showed an inverse association with NRDI and a positive correlation with the number of 
apnoeic pauses (lasting longer than 10 seconds) and the level of TcCO2. Thus, the longer the 
duration of use, the more episodes of respiratory depression were observed. Duration of drug use 
reported in this study did not take into account any periods of entry into drug treatment; it is a 
general measure of years of opioid use. Nonetheless, a dampened level of drive, an increase in 
apnoeic pauses, and a higher level of carbon dioxide is a highly risky situation.  
 
In chapter 8, the three participants were all longstanding heroin users, with an average use history 
of 43 years, which, for all three, is longer than half of their lifetimes (average age of 61 years old). 




criteria of respiratory depression. The two participants who showed severe responses were not 
aware of this, nor had they any complaints of respiratory-related symptoms or problems. The 
participant with less severe responses had never experienced an overdose in his use career 
spanning four decades. One other had taken part in the previous acute heroin study (Jolley et al., 
2015b) and had an understanding that his oxygen saturation levels could drop to critical levels. 
Nevertheless, it is difficult to state whether age had any impactful effect on physiological 
responses to diamorphine in these individuals.  
 
There are challenges to raising concerns about increased risk of overdose with long-term clients 
who are established in their treatment and often have stable working lives or a routine that is 
difficult to impede or to disrupt. Despite being on high doses of diamorphine, there is usually little 
interference into the treatment for reasons specific to overdose risk as this is an area that is 
usually well-understood by many in the opioid-using community.  
 
The questions that can be raised here are: what can be done clinically? Should there be clinical 
intervention or discussion of results with participants from these types of studies? In what other 
form can these discussions take place? The subsequent section discusses potential clinically 
relevant outcomes of these findings.  
 
9.3.3 Feedback to Participants: ‘From Participant Back to Patient’ 
Whilst it was not officially structured in this way, the results of these studies were used to have 
informal discussions between the clinician and the participant. This was relevant for both studies 
discussed in chapters 5 and 8. The signals obtained from the studies were used as a form of an 
evidence-based resource to prompt discussion and provide a visual source to guide the 
conversation. The discussions were generally well-received but no formal evaluation of these 
conversations was conducted. Given the complex nature of opioid overdose deaths and the 
potential overlap between observed respiratory depression and respiratory disease, it is important 
to provide innovative approaches to engaging users with these issues. Future studies should 
consider whether it is worth exploring an evaluation of behaviour interventions in parallel with 





Highly specific behavioural interpretations might be worth developing. In a separate line of study 
of apparently entrenched injectors, a targeted behavioural/clinical assessment for groin injectors 
was developed (Senbanjo, Tipping, Hunt, & Strang, 2012). Groin-injecting carries significant risks 
of injury to the femoral vein and femoral artery, bacterial and blood borne viral infections and more 
serious complications such as deep vein thrombosis, pulmonary embolism, chronic venous 
disease, among others (Behera, Menakuru, & Jindal, 2003; V. A. Cooke & Fletcher, 2006; Kozelj, 
Kobilica, & Flis, 2006; Senbanjo & Strang, 2011; Syed & Beeching, 2005). Groin injectors are 
usually unaware of these risks and tend not to present for treatment until more serious 
complications arise (Williams & Abbey, 2006). A clinical service used ultrasound scanning for 
groin injectors in order to assess this particularly risky practice. In preliminary findings of this work 
(Senbanjo et al., 2012), it was found that single-session portable ultrasound scanning prompted 
major changes in injecting behaviour including cessation of groin injecting (Senbanjo & Strang, 
2015). Perhaps a similar intervention could be implemented, for the long-term opioid users 
displaying markers of severe respiratory depression. One main question that arises here would 
be related to what the desired behaviour change would be – whether this be a reduction in dose, 
non-intravenous use or a full tapering off from opioids completely. These types of questions need 
answering in order to establish how these physiological techniques could help in a clinical setting.  
 
There are also points raised in the discussion section of chapter 8 that are relevant to the wider 
discussion of feedback to drug users. The significance of, and advice in relation to, four main 
questions were discussed in this chapter: 1) Is it advisable to encourage non-IV routes of 
administration? 2) How important is it to be aware of the potential masking of lung disease 
symptoms due to depressant effect of opioids? 3) Can the common cold/flu and chest infection 
leave users more vulnerable? and, 4) How significant are apnoeic episodes and how can users 
be appropriately advised users on this? These are all points to consider further.  
 
9.3.4 Measuring and Monitoring Overdose Risk  
As mentioned in chapter 5, these types of detailed physiological measurements could potentially 
be used to identify ‘at-risk’ patients. It is feasible that this could be conducted in patients before 
treatment and, in the future, could even be used as a means of providing opioid users with better 




understand whether these measures could actually reduce the risk of respiratory depression. 
Could intensive monitoring reduce risk of significant respiratory depression?  
 
It would be very difficult to conduct a larger scale validation study for the diamorphine-maintained 
individuals, but this would be possible among clients seeking oral opioid maintenance treatment. 
However, heroin (particularly street heroin) is usually where most of the risks lie. It would therefore 
be crucial to examine this in a population of users that are either using street heroin or other street 
opioids. However, there is a critical ethical consideration with this type of research. The solution 
to this would be to investigate these questions among users who are prescribed a pharmaceutical 
equivalent in a controlled setting to develop tools that are practical and can be easily monitored 
within a home setting or, at the very least, a portable drug treatment setting to provide ease for 
patients. Further discussion on portable, wearable and practical technologies is discussed further 







9.4 Scientific Implications  
9.4.1 A Good Model of Acute Overdose in a Laboratory  
The varied responses observed in the heroin overdose study (Chapter 8), as well as the chronic 
respiratory depression that was seen in the observational study (Chapter 5) enable a distinct 
understanding of, and attribution of influences on, the physiological and pharmacological 
underpinnings of heroin overdose.  
 
Chapter 5 shows that investigation into chronic, everyday respiratory depression can be observed 
without disrupting the individual’s treatment pattern or drug using pattern. Chapter 8 describes a 
greatly in-depth study that has been able to work with a dwindling number of patients from a 
community of heroin users who often feel insecure about their treatment – and it has been 
demonstrated that it is possible to work with such participants to conduct crucial investigations 
into the physiological and subjective responses of increased doses of diamorphine. The ability to 
investigate critical questions of risk factors of heroin overdose in a reliable, well-designed study 
has provided a strong opportunity to elucidate some of the long-held questions in the field. 
Furthermore, the ability to capture as realistic a scenario as possible, given the considerable 
number of influential factors, is a great strength of the study. Data presented in these chapters 
illustrate the relative ease with which it was possible to detect respiratory depression. 
 
9.4.2 How Can these Findings Be Accounted for? 
Whilst there are very few studies examining detailed physiological responses to diamorphine, 
there are some studies that have investigated the acute physiological effects of opioids, non-fatal 
overdoses, and dose response effects. 
 
In clinics where supervised heroin (diamorphine) maintenance is provided, there are occurrences 
of rare but evident overdose events (Jolley et al., 2015b; Oviedo-Joekes et al., 2009; Strang, 
Metrebian, et al., 2010). In the UK-based RIOTT clinic, the rate was reported to be around 1 in 
every 6,000 injecting events (Strang, Metrebian, et al., 2010), and in the Canadian NAOMI clinic 
this figure was around 1 in 8,000 injecting events (Oviedo-Joekes et al., 2009). Also, in a very 
different type of setting, Roxburgh et al. examined the frequency and severity of non-fatal 




(Roxburgh et al., 2017). This centre did not provide the medication, but it clinically observed 
injection events. They used the Glasgow Coma Scale (GCS), pulse oximetry and whether 
naloxone was administered to define whether non-fatal overdoses had occurred. There were 
2,500 overdoses out of a total of 500,000 injections. Heroin overdose occurred at three times the 
rate of oxycodone during the period and appeared to be more severe in terms of levels of reduced 
oxygen saturation and consciousness. After adjusting for potential confounders, the authors noted 
that the clients who had a GCS score of less than 8 and oxygen saturation of less than 85% at 
initial observation were more likely to have injected heroin. It is interesting that the levels of 
oxygen saturation were equal to or just under the levels that were observed in data in chapter 8 
(two of three displayed levels below 85% and one displayed levels above 85%), and the GCS 
score demonstrated normal levels of consciousness in every session (i.e. the highest GCS score).  
 
Further studies that have looked at pulse oximetry and specifically heroin maintenance studies 
showed that even normal doses can sometimes lead to hypoxaemic situations. In some studies, 
the level of participants’ regular dose of diamorphine showed significant changes in oxygen 
saturation (blood oxygen level) in half of all testing sessions (Dursteler-Mac Farland et al., 2000; 
Stoermer et al., 2003; Stohler et al., 1999). The previous study on acute effects after 
administration of heroin showed also similar results to the heroin overdose study (Chapter 8) but 
that study did not alter opioid dose (Jolley et al., 2015b). This is in accordance with the findings 
in this thesis and further confirms that respiratory depression can occur despite stabilised doses 
of administered heroin.  
 
It is necessary next to examine dose-sensitive or high-dose effects of opioids. Whilst minimal, 
there are a few experimental studies that are comparable to this aspect of the heroin overdose 
study. Reputable studies have conducted this type of increased opiate dose and have 
successfully shown that this type of study can be implemented without any serious side effects to 
the subjects. These experimental studies similarly showed a mixture of expected and predicted 
findings as well as more unexpected findings.  
 
One study examined the effects of high dose diazepam 0mg versus 40mg in combination with 
high-dose opioids (methadone and buprenorphine) 100% versus 150% of daily dose conducted 




of physiological and subjective measures, including oxygen saturation, pupil size, respiratory rate 
and blood pressure as well as subjective measures of drug effects including sedation, dysphoria, 
euphoria and VAS of drug strength, drug-liking and sedation. The high dose opioid was related 
to lower SpO2 levels and psychological performance in the methadone group but did not affect 
the buprenorphine group. Interestingly, only one participant showed a SpO2 reading below 90%. 
Another study focused on the craving effects of a 33% increase in oral methadone to patients 
who are on a daily dose of methadone (Curran et al., 1999). They showed that this increase was 
a primer for craving of heroin. There was no examination into physiological effects of an increased 
dose (Curran et al., 1999).  
 
A Dutch study conducted a double-blind randomized investigation on the pharmacological 
differences between inhalation (IH) and intravenous (IV) routes of administration of heroin, taking 
patients from the Dutch Heroin on Medical Prescription Research Project (Rook et al., 2006). 
Their regular doses alternated between 67%, 100% and 150% (and similar to the study in Chapter 
8, they only changed the one dose of the day). More positive subjective drug effects were 
experienced in the IH group compared to IV despite the lower Cmax (peak serum concentration of 
a drug) in the IH group. This study also showed that dose increases had a higher response in 
subjective effect than dose reductions. This study did not measure pulse oximetry or other 
physiological measures but noted that blood pressure and heart rate were significantly different 
from baseline in the IV group and only marginally different between doses in the IH group.  
 
Whilst not specifically on overdose, there have also been some studies on chronic opioid users 
and lung disease, which also show the great prevalence of comorbidity. Palmer et al. showed that 
drug users have a significantly higher prevalence of respiratory diseases than matched non-drug 
user controls (Palmer et al., 2012).  
 
9.4.3 Difficult Discussions Regarding Science and Safety  
As discussed in chapter 8, one of the participants in the study (Participant B) showed severe 
responses to diamorphine in the 110% dose session. A difficult situation developed with regard 
to the decision of whether or not to re-invite this participant for the subsequent dose increase. 
This was disputed across two or three meetings and email exchanges among study team 




respiratory physician argued that there was a clear safety issue and it would be detrimental to 
continue increasing the dose of diamorphine for this participant, and that the observed long 
apnoeic pauses and low tidal volume, along with low levels of SpO2% were potentially critical 
responses that did not warrant a further increment. Others, including my other supervisor, an 
addictions professor, and also, a former supervisor (also a clinical academic), expressed 
disappointment that this increased dose was not able to be examined as it was considered to 
have been a potentially good test of whether dose increments truly do have a predictive effect. 
Additionally, it was seen that strict procedures were in place if any serious adverse events were 
to occur. In the end the decision was to err on the side of caution and not proceed with the +20% 
increment. This represents a difficult and interesting dilemma. Chapter 8 also discusses the 
differing levels of significance of apnoeic episodes and the wider literature on this topic. It is 
certainly crucial to have these discussions and an understanding that even among colleagues 
working towards the same aim, there are diverging viewpoints on the relative importance of 






9.5 Implications for Policymakers  
There have been great efforts to address overdose deaths through public health and policy 
initiatives. By collaborating with other public bodies, the Office of National Statistics (ONS) annual 
report on deaths related to drug poisoning in England and Wales, as well as the National Records 
of Scotland’s publication on drug-related deaths (DRDs) in Scotland and the Northern Ireland 
Statistics and Research Agency (NISRA) contribute to the figures of mortality trends within the 
UK (NISRA, 2016; NRS (National Records of Scotland), 2018; ONS, 2018). Within these reports, 
there is often discussion of potential causes behind any changes to the numbers of deaths. 
Further, in recent years, the government agency (under the Department of Health and Social 
Care) Public Health England (PHE), the Local Government Association (LGA) representing all of 
the local authorities in England and Wales as well as the non-departmental Advisory Council on 
the Misuse of Drugs (ACMD) have contributed to the discussion when changes in DRDs are 
reported (ACMD, 2016; LGA, 2017; PHE, 2016b, 2017). This thesis raises several questions and 
issues that should be considered by policymakers. This section will briefly summarise the issues 
with defining and registering deaths in England, Wales, N. Ireland and Scotland as well as the 
causes and drivers of deaths in the UK.  
 
9.5.1 Defining, Registering and Comparing Deaths in the UK 
As mentioned in the introductory chapters, interpreting trends and patterns in opioid-related 
deaths are centred on the definitions and methods of recording deaths. The definition of a DRD 
is:  
Death where underlying cause is drug abuse or drug dependence and deaths where underlying 
cause is drug poisoning and where a substance controlled under the Misuse of Drugs Act 1971 
was mentioned on the death certificate (Christophersen et al., 1998).  
Generally, methods of recording deaths are comparable in England, Wales and Northern Ireland 
(N. Ireland). The system of death registration and certification requires all deaths related to drug 
poisoning to be referred to a coroner for investigation. Information on the specific substances 
involved in deaths are taken from the information provided on the coroner’s death certificate. In 
Scotland, the system of registration differs and requires DRDs to be investigated by a ‘procurator 
fiscal’ (NRS (National Records of Scotland), 2018). Details from the death registration in addition 
to information from a specifically-designed questionnaire are used to identify DRDs. A forensic 




post-mortem examination. There are a few issues with the system in Scotland; the main problem 
is that post-mortem paperwork only asks about the drugs that were ‘implicated in, or which 
potentially contributed to, the cause of death’, thus, any death that involved drugs that were not 
considered to have had been directly influenced by drugs are not included in the opioid deaths 
data (ACMD, 2016). Deaths coded to opioid abuse also do not include those which resulted from 
injection of contaminated heroin, which they do in England, Wales and N. Ireland. This is because 
the NRS can identify deaths which occurred as a result of the use of contaminated heroin. These 
factors mean that comparison between countries is compromised.  
 
The timing of death registration is also an issue. Registrations in England, Wales and N. Ireland 
do not occur until the coroner’s inquest is completed, which can sometimes take many months or 
even years. Thus, a death registered in a given year could have actually occurred in the years 
prior to the registration year. In England & Wales, the most recent ONS report on drug-related 
deaths describes a distinct and increased delay in the registration of deaths up to 2017 (ONS, 
2018). There was a slight increase of 3% of registered deaths occurring in the preceding years to 
the report and a median delay of 10 days (ONS, 2018). It is difficult to state whether this difference 
relates to any difference in the death data for the 2017 registered deaths, but it is interesting to 
note. In Scotland, on the other hand, the death registration includes deaths that are almost always 
ones that occurred in that year. Thus, again, comparing data becomes more compromised.  
 
Despite these differences, measurements of opioid-related deaths right across the UK involve a 
high-quality certification system that use common International Classification of Disease coding. 
There is, however, a particular need to improve comparable information from toxicological tests 
carried out in post-mortem examinations and also to record whether the people who die were 
currently receiving a medical prescription for an opioid (ACMD, 2016). Further, whilst ‘consistent 
and useful’, there are many flaws in the current collection methods that mean trends over time 
are difficult to interpret (ACMD, 2016). It is currently impossible to assess whether the increase 
in deaths involving polydrug use (including opioids) is an increasing trend of use or is alternatively 
a result of better identification and recording. To capture this type of information would further our 
understanding of the potential complex treatment needs of users. It is also related to the data 
presented in chapter 5 on the prevalence of lung disease in a long-term opioid-using population, 




capturing the wider burden of opioid use on infections and chronic diseases, given the issues 
discussed earlier and in previous chapters of ageing, complex needs and multi-morbidity 
(RCPsych, 2011). It is important to be able to assess this in order to be able to provide better and 
more targeted service planning. The ACMD’s apt recommendation - that there should be greater 
standardisation of coroners’ reporting of DRDs and non-fatal overdoses from local to national 
systems and through the various channels of reporting - is a welcome contribution to the policy 
debate (ACMD, 2016).  
 
9.5.2 Causes and Drivers of Opioid-Related Deaths in the UK 
The causes of the recent increases in opioid-related deaths in the UK have been discussed in 
detail in the introductory chapters. Examining the causes through a wider lens allows reflection 
on potentially impactful factors. There are four potential causes and drivers of the changes in 
numbers of opioid-related deaths in UK (ACMD, 2016): 
1. The ageing of the heroin-using population; 
2. Changes in the availability and purity of heroin at street level; 
3. Changes in the provision of drug treatment; 
4. Socio-economic changes. 
Two of the main drivers listed are examined by this thesis: ageing and purity. Previous literature 
has shown that heroin users appear to become more vulnerable to death from overdose as they 
age, and this is exacerbated by risk behaviours such as smoking, chronic alcohol use, polydrug 
use, poor diet and lack of exercise (etc.) (Darke, 2016; Merrall, Bird, & Hutchinson, 2012; Pierce, 
Bird, Hickman, & Millar, 2015). Reflections on data related to age from this thesis are mentioned 
earlier in this chapter.  
 
In relation to the issue of purity and the Heroin Drought in 2011/12 where purity levels dropped 
and then increased at street level, there were reports that during this time, some stopped using 
or felt effects from the adulterants  (Hallam, 2011; M. Harris et al., 2015). The after-effects of the 
Heroin Drought on purity and availability of heroin at street level was suggested to have had a 
direct impact on the number of opioid-related deaths during the subsequent years (Hallam, 2011; 
M. Harris et al., 2015), but very little investigation has been conducted on the UK heroin shortage, 




& Trace, 2004; Degenhardt et al., 2005; Degenhardt, Conroy, Gilmour, & Hall, 2005; Dietze et al., 
2004; Maher et al., 2007). Related literature on the issue of unknown purity as a risk factor for 
overdose was described in more detail in chapter 3, where evidence in support or opposition is 
uncertain. Data from chapter 8 in this thesis show a varied response to differing doses of 
pharmaceutical heroin. Continuation of this type of investigation is crucial to elucidate the 
significance of purity. Beyond this, it may be that availability and price may be more impactful to 
the number of deaths than unpredictable purity fluctuations but this would need further 
investigation (ACMD, 2016; Harris et al., 2015).  In any case, any period of shortage or ‘drought’ 
and adulteration probably requires heightened and careful service provision (Harris et al., 2015).  
 
With regard to treatment-related issues, it has been discussed that periods of both entry and 
cessation into and out of treatment are associated with increased risk of overdose and death 
(Cornish et al., 2010; Pierce et al., 2016). There are data from England that show an increase in 
deaths among people who had recently left treatment (PHE, 2016a). Most recently, a 14% 
increase of people who died whilst in contact with treatment services was reported by Public 
Health England (PHE) (PHE, 2016a). It would be important to specifically examine this increase 
in people who have died whilst in contact with drug treatment, through toxicological or review-
type investigation, to find out whether there are any points of note or for further exploration.  
 
In relation to socio-economic factors in the UK, drug death rates are substantially higher in the 
most deprived areas, which may reflect the prevalence of problematic heroin use in these areas 
(ACMD, 1998; Rhodes, 2009). Life expectancy between the richest and poorest has been growing 
since 1993 (Mayhew & Smith, 2016). Furthermore, financial hardship and suicide risk (Barr, 
Taylor-Robinson, Scott-Samuel, McKee, & Stuckler, 2012) and DRDs (Bogdanowicz et al., 2016) 
are known to be related. Further, areas that experienced the highest rates of DRDs have also 
experienced the greatest reductions in functioning for local authority services and welfare benefits 
for working-age adults (Beatty & Fothergill, 2016; Hastings, Bailey, Bramley, Gannon, & Watkins, 
2015).  
 
Overall, opioid-related deaths are clearly not straightforward and evidently require more complex 
and innovative approaches for research and prevention. Additionally, there are factors beyond 




must be considerate to a wide range of factors and thus, it is important to consider the connecting 
drivers of opioid-related deaths. 




9.6 Improvements for Future Work 
There were three main practical issues in the measurement phase of the study sessions in the 
studies presented in chapter 5 and 8 that potentially led to the participants not feeling as 
comfortable and relaxed as they could have been or data collection not being as efficient as it 
could have been.  
9.6.1 Frequent Intervening and Number of People Present During Monitoring  
For the heroin study described in chapter 8, the issue of intervening/interrupting the participant 
during the study session for the purpose of collecting data was a consistent topic of discussion 
among the study team members, from the initial drafting of the protocol up until the present. In 
order to obtain subjective drug measures and pupil size, researchers were required to engage 
and interact with the study participant to take these measures. The initial first few minutes are the 
most crucial in an intravenous dose administration. The steps involved were: baseline measure 
with a face mask, injection (if self-injecting, sometimes the face mask needed to be taken off 
because of visual interference), initial subjective measures, and then measures again at 3 
minutes. Considering that there were many procedures in this period of time, in some cases it 
was thought to be somewhat disruptive to the continuous monitoring of respiratory measures. 
Improvements were made in order to smooth the process (e.g. the nurses who recorded the 
observer ratings such as the Glasgow Coma Scale - that ask questions about verbal 
communication and motor abilities - minimised their intervention and limited their questioning to 
the essentials). Thus, with each study session, this battery of recordings in the initial first few 
minutes became much smoother.  
 
There were also issues in relation to the number of people in the room during the monitoring 
session. As part of diamorphine prescribing regulations, it is required that two nurses (or medical 
professionals) are witnesses to the preparation of the medication as well as to the administration 
of the medication. Thus, two nurses were always present in the room, in addition to the study 
doctor, researcher (myself) and sometimes the PI, along with other interested members of the 
study. Great effort was made to minimise the number of people in the initial first few minutes of 
monitoring to only include the required people for the study. However, in a handful of cases, there 




results did not appear to show that the participant was more roused than other sessions, but this 
remains a consideration for future work.  
 
That said, the accounts from participants suggest that they did not experience any major degree 
of unease. As discussed in chapter 8, they were asked at every visit whether the effects of the 
drug appeared to be affected by the setting and were asked to compare their experiences to 
previous visits in the study. None of the participants felt that the overall experience differed from 
their usual experience at home. It must be stated that, as patients who had been on injectable 
diamorphine prescriptions for many years, these particular participants are more likely to be used 
to administering their diamorphine in a clinical, hospital setting than their street-using peers.  
 
9.6.2 Electrical Noise and Subjective Nature of EMG Signal Analysis 
There are several sources of variation in the signal of EMGpara that were discussed in the Methods 
chapter (Chapter 4). One of the potential sources is in the anatomical differences which can 
influence the position or orientation of the electrodes relative to the muscle. After recording the 
signals in the study, offline analysis includes detecting and excluding contaminated signals which 
is performed manually by selecting signal samples for analysis after visual inspection of the signal. 
However, computer algorithms do exist to reduce the time required for analysis and the subjective 
nature of EMG signal selection. These algorithms are not commercially available and thus, were 
not utilised in this thesis. However, it would be instructive to incorporate these types of methods, 
which include reducing or eliminating the QRS complex of the ECG and selecting uncontaminated 
EMGpara following objective determination of the degree of signal contamination. This is relevant 
to all studies in this thesis. 
 
9.6.3 Potential Solutions to the Issues 
A potential solution to some or all of the aforementioned issues would be to measure in a closer 
environment to the participant’s usual scenario. Usually this would be within the home. Thus, 
consideration should be given to developing three potential methods: 
1. Mobile versions of the measures where reliable data can be extrapolated. As discussed in 
the next section, this type of research is still in the early stages of development and requires 




independent of researchers, it could measure continuously wherever the participant was and 
would be less burdensome.  
2. To be able to transport the measures to the homes of the participants. Currently, this is an 
impractical technique as the equipment is very heavy and not made for use outside of a 
laboratory, however: 
3. There are tools that are being developed as more practical ways of measuring physiological 
responses to opioid administration. For example, an automated measure of EMGpara using a 
machine for use among patients with severe COPD (Suh et al., 2015). From a physiological 
perspective, the manual data acquisition of EMGpara and SpO2 and ETCO2 allows one to 
explore the data in more detail and with much more reliability. For the purposes of these initial 
studies, it may not be suitable to use automated machines but future studies could potentially 
incorporate them. Further, some of the equipment used in the current study are easy to 






9.7 Future Research 
9.7.1 Using the Experimental Model for Other Important Questions  
The methods and measurements presented in each of the data chapters in the thesis represent 
a robust method on which to base further related questions. This section will highlight some of 
the rationale behind important further research questions that could arise from this model of opioid 
overdose.   
 
9.7.1.1 Other Opioids 
The growing rate of fentanyl overdose deaths is becoming, or in some cases has become, a 
considerable concern. As already described in chapter 1, in the USA, it is estimated that nearly 
40% of heroin-related deaths involved fentanyl, with many unaware that fentanyl was what they 
had consumed (Frank & Pollack, 2017) (see Chapter 1). According the most recent figures, in 
New York City, fentanyl was the most common substance involved across all overdose deaths 
(57% of deaths) in 2017 (NYC Department of Health and Mental Hygiene, 2018). In the UK, 
although the numbers are small, a 29% increase in fentanyl deaths was observed from 2016 to 
2017. The total number of deaths for 2017 was 75. It has been suggested that similar mixing of 
fentanyl into heroin might be occurring in the UK as it is in the USA and Canada (ONS, 2018). 
The questions here would be: are there any potentially safe doses of fentanyl? How does illicitly 
manufactured fentanyl differ from pharmaceutical fentanyl in its clinical effects? Is there an 
interaction between heroin and fentanyl in their respiratory depressant effect? This would be a 
difficult study to perform but fentanyl is a medically used drug with safe dose ranges and is 
considered to have a good therapeutic margin (Kanowitz, Dunn, Kanowitz, Dunn, & VanBuskirk, 
2006).  
 
In relation to hydromorphone, a Canadian study centred in a supervised clinic that provided 
diamorphine and hydromorphone, in a similar method to the RIOTT study in the UK, also 
examined whether the clients could distinguish between hydromorphone and heroin (Oviedo-
Joekes et al., 2009). Interestingly, the clients could not distinguish between the two, which raises 
the possibility of many important clinical benefits, for example, giving more choice to users on 




within this experimental model is whether or not hydromorphone is safer in terms of respiratory 
depression compared to heroin.  
 
Buprenorphine has been discussed in more detail in the introductory chapters as well as in 
chapter 5. Buprenorphine is considered to have a lower risk of respiratory depression and 
overdose rates compared to methadone and other OST medications, showing a ceiling effect 
(Dahan et al., 2006; Strang et al., 2017; Walsh, Preston, et al., 1994) but it is well-known that 
buprenorphine deaths do occur (Hakkinen, Heikman, & Ojanpera, 2013). No differences in 
physiological responses between buprenorphine and methadone were observed in the 
observational study in this thesis (Chapter 5). It is conceivable to examine buprenorphine further 
in similar studies, or to expand the observational study in chapter 5 to allow for examination of a 
larger sample of users.  
 
9.7.1.2 Other Routes 
Testing the differences between IM and IV administration further within the same subjects would 
be an effective way of measuring whether these routes do actually lead to differences in 
physiological and subjective effects within subjects. As highlighted in chapter 6, there is a good 
reason to do this. Further, as highlighted in chapter 8, plans to do this are already underway. The 
facilities, staff, equipment and administrative procedures have progressed in such a way that 
allow adaptive changes to the current protocol and add further questions to the study. An 
application to Ethics will be made in order to re-invite the same participants from the study in 
chapter 8 that have been examined thus far to undertake the same sessions but with 
administration of a different route of injection, i.e. IM instead of IV or vice versa. This would lead 
to a strong within-subject design.  
 
As mentioned in chapter 6, it would also be important to examine the difference between IV use 
of heroin and other routes of administration such as chasing or snorting. This would be difficult to 
do among people who are prescribed injectable diamorphine but potentially likely among illicit 
heroin users. As mentioned previously, this type of study would ethically be more difficult to 






A positive aspect of opioid overdose is that it can actually be reversed and there is a huge body 
of related research on this (Alqurshi et al., 2016; McDonald, Campbell, & Strang, 2017; McDonald 
et al., 2018). There has been development, refinement, testing and advocating for, the pre-
provision of naloxone in the community (take-home naloxone) to reverse opioid overdose and 
thereby prevent deaths. Naloxone is a remarkable rapid-acting mu-opioid antagonist (and is an 
everyday medicine in anaesthetic rooms, emergency departments and ambulances). However, 
there are questions within this area that could be answered through the use of a model of 
overdose. A missing element to current experimental studies of naloxone is the conduct of 
experimental studies involving actual opioid users instead of healthy volunteers. This is clearly a 
challenging area which most people have regarded as impossible but would give a potentially 
very important perspective. There are some preliminary responses on this topic from recent 
qualitative interviews about factors associated with engagement with the research (Neale, 
Tompkins, McDonald, & Strang, 2018). There is no question that this is difficult, but it is possible 
if the studies are designed appropriately. The questions that arise from this are related to 
determining how effective naloxone is at reversing different opioids, and whether there is a dose-
response relationship in the reversal. Furthermore, we need to consider the ways in which 
naloxone reverses opioid action. Should overdose only ever be reversed enough for respiratory 
function to re-start? These are crucial questions for which answers are needed, and the answers 
will directly influence the manner in which emergency naloxone is administered, both by medics 
and paramedics and also by lay responders.  
 
9.7.1.4 Stages of Treatment 
It is an important to question whether an individual who has tapered their opioid substitution 
medication, to be either fully opiate-free or at a lower stable dose, displays similar chronic 
respiratory depression criteria to those discussed in chapter 5. It could be hypothesised that, if 
someone has tapered off their opioid medication and is not on any opioid, they would show less 
of an everyday respiratory depression response to that which we have observed. Similarly, is 
there a difference before someone is started on treatment? Is treatment genuinely protective 




protective than injectables but a large scale, case-control study would be required to determine 
this.  
 
9.7.1.5 Co-drugs, Particularly Other Depressant Drugs 
It is understood that, even with a well-tolerated dose of heroin, the presence of other central 
nervous system depressant drugs, such as benzodiazepines, can prove fatal (Darke, 2011). As 
described in chapter 2, alcohol and benzodiazepines are the most commonly co-administered 
drugs. Polydrug use is possibly an extremely important risk factor in overdose deaths. In terms of 
the physiological effects, benzodiazepines have been shown to decrease oxygen saturation 
significantly in the presence of opioid substitution drugs such as methadone and buprenorphine 
(Lintzeris et al., 2007, 2006). Furthermore, co-administration of a depressant greatly increases 
the likelihood of a fatal situation because it potentiates the respiratory depressant effects of 
heroin. In the presence of depressants, a normal dose of heroin may be fatal (Darke, 2011). 
However, whether this apparent increased risk of respiratory depression occurs via a potentiation 
of opioid effects or a synergistic action of more than one depressant is not well understood. Plans 
to incorporate a benzodiazepine element in the study in chapter 8 have been described in the 
process chapter (Chapter 7). There were discussions with service users about the feasibility of 
conducting this type of study. None stated that it would be too risky or unfeasible. The reason 
why it could not proceed came down to the unexpected cost of placebo drugs and the need to 
focus on diamorphine. Future studies could incorporate costs in the budgeting stage of the study 
development. It would be pertinent to study the combined effects of opioids and benzodiazepines.  
 
9.7.2 Wearable Technologies  
An exciting possibility for clinicians and the wider public health domain is that, in future, these 
data may be able to drive technology and to allow for an early detection of risk of opioid overdose. 
The eventual aim would be for these tools to be implemented in a method that is fast-responding 
and life-saving. The next section will outline the future work that should be taken forward with 





Alongside this work to further understand the physiology, there is definitely scope for developing 
the wearable technology aspect of this work. As described in chapter 5, there are already some 
early developments with this type of investigation. As this thesis is being written, a plan to 
implement an exploration into wearable measures into the current study is being conducted. 
There are discussions with a colleague in the USA about analysing, in real time, the distinctive 
‘motion signatures’ that may underlie the process of preparing for and administering, an injection 
of heroin. It would be particularly important to be able to capture the actual self-injection 
manoeuvres involved. Additionally, although there are many issues with pulse oximetry as a 
delayed measure of respiratory depression, there is a view that with the correct type of sensor, it 
could be possible to detect reduced levels of oxygen saturation via a wearable and wireless 
sensor. The practical issues around such measurement require further exploration but it is a viable 
course of experimentation to undertake.  
 
Furthermore, there are discussions with colleague in Canada who specialise in fibre-optics and 
have developed practical methods of measuring respiratory arrest and even respiratory 
depression through a wearable sensor built into a t-shirt (Guay, Gorgutsa, Larochelle, & 
Messaddeq, 2017). There are current plans to allow these t-shirts to be tested in the overdose 
study here within our group in the near future. If these t-shirts are effective at reliably and 
sensitively recording respiratory depression, the logical next step would be to incorporate an 
algorithm for an alarm that would be triggered by a Bluetooth sensor. This could also involve the 
transmission of geo-positioning for the purpose of informing emergency services.  
 
As discussed in chapter 5, deaths from opioid overdose could be prevented if the onset of the 
overdose were detected in time. Informing future research into practical wearable versions of 
these measures in order to reliably monitor and ultimately prevent fatal overdose events is crucial. 
Future studies need to concentrate on taking this model further, i.e. investigating how can we 
predict vulnerability to a fatal overdose.  
 
9.7.3 Investigating Genetic Variability 
The theory related to genetic variability and overdose risk is rooted in the OPRM1 gene which is 




thought that there is some involvement in individual variability of drug metabolism (Befort et al., 
2001; Chidambaran et al., 2015; Goldstein, VanDenKerkhof, Sherlock, Sherlock, & Harper, 2001; 
Manini et al., 2013). There is a great deal of literature on pain responses and alcohol consumption 
in the presence of this polymorphism, but there is limited, if any evidence on physiological 
responses in opioid overdose (Bilbao et al., 2015; Ray & Hutchison, 2004; Sloan et al., 2018; Yu 
et al., 2018).  
 
There had been discussion of including a genetic component within the study presented here and 
this has been discussed in more detail in chapter 8. Ultimately, a large sample size is required 
see an effect within a genetic study. This would clearly not be feasible amongst diamorphine-
maintained patients in the UK. There could be some scope to expand this type of study to other 






Despite knowledge of respiratory depressant effects of opioids, the actual vulnerabilities to, and 
mechanisms of, overdose are still not well understood. There is no gold standard measure of 
respiratory depression, and methods used in clinical settings such as anaesthesia involve the use 
of invasive techniques, or techniques that are not sensitive to the impact of chronic lung disease. 
Collaboration between Addiction Sciences and Respiratory Medicine, that I have been a central 
part of, has allowed the development of reliable and sensitive techniques to measure respiratory 
depression among long-term opioid users. It has thus been possible to test risk factors that have 
been commonly thought to be involved in overdose risk but never thoroughly investigated. 
Increased purity (equivalent to increased dose), routes of administration, setting, differing opioids 
and underlying chronic lung disease have all been explored in this thesis. The key findings of this 
thesis are threefold: 1) that experimental research into heroin overdose is possible; 2) that 
respiratory depression exists across a broad clinical sample – including amongst older and 
experienced opioid users on various doses and via differing routes; and 3) that there is an 
additional respiratory system ‘burden’ of underlying lung disease in long-term users. It has also 
been possible to lay the foundation for future research to carry forth the baton and develop 
innovative approaches to measuring risk of overdose.  
 
Opioid-related problems and deaths are continuously present in the UK and unfortunately, the 
recent increases in trends are not only the highest on record but also, do not appear likely to 
diminish any time soon. This is also true for the USA which is experiencing one of the most severe 
epidemics of overdose deaths that has ever been seen in record numbers (both total and per 
capita) (Sanger-Katz, 2018). Moreover, restrictions to the NHS infrastructure and the socio-
economic impact of post-2009 Britain leave colossal challenges to drug treatment services, as 
well as to allied primary and emergency care services that are fundamental in maintaining healthy 
lives of drug users.  
 
The message is clear that there is no simple solution to this complex issue of overdose but 
persisting and developing work in this area to etch away at questions and draw alongside other 
health-related phenomena is essential. Beyond this, good research is the very least that drug 
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Appendix A. Literature Review  

















































4679 records identified 
through database searching 
(Medline: 2457 via OVID; 
EMBASE: 1810 via OVID; 
PsychINFO: 412 via OVID) 




Title review of 2875 
records 
222 articles screened based 
on titles and abstracts 
review
53 full-text articles assessed 
for eligibility
15 studies included 
38 full-text articles 
excluded, with reasons
2653 records excluded 
based on titles review
3 additional records 





Appendix A-3: Search Strategy 
1. exp heroin dependence/ or heroin dependen*.mp. 
2. exp drug dependence/ or drug dependen*.mp. 
3. exp opiate addiction/ or opiate addict*.mp. 
4. diamorphine/ or heroin addict*.mp. 
5. maintenance therapy/ or heroin maintenance.mp. 
6. opiate/ or opiate prescription.mp. 
7. Heroin treatment.mp. 
8. Addicted to heroin.mp. 
9. drug abuse/ or drug addict*.mp. 
10. or/1-9 
11. follow-up.mp. or exp follow up/ 
12. observation*.mp. or exp observation/ 
13. exp case study/ or case.mp. 
14. year*.mp. 
15. exp mortality/ or mortality.mp. 
16. exp death/ or death*.mp. 
17. or/11-16 
18. 10 and 17 
19. Limit 18 to year=”1965-1975” 
Inclusion criteria:  
1. Reporting period of study must be between the years 1960 and 1975 
2. Study population includes patients prescribed pharmcaceutical heroin as part of heroin 
addiction treatment  
3. Text of article must be English  
4. Outcome reported must include mortality  
Exclusion Criteria: 
1. Article texts not in English  
2. Reporting period outside of the time period of interest, 1960 to 1975  





Appendix B. Heroin purity and heroin-related deaths  
Studies correlation heroin purity with heroin-related deaths.  
Author (Year) Study Location Study Period Fatal/Non-
Fatal 
Study Details Main Findings 




Fatal Case report (n=3) No clear role of heroin in fatalities. Purity not involved in 
these deaths. 
Darke et al (1999) SW Sydney, 
Australia 
Feb 1993 to 
Jan 1995 
Fatal Time Series 
Analysis/Observational 
(n=322 heroin samples. 
N=61 deaths) 
Moderate but significant correlation (0.57) between 
mean purity of heroin and overdose fatalities.  
Risser et al 
(2000) 
Vienna, Austria 1987-1995 Fatal Post-mortem and seizure 
analysis 
No significant relationship between heroin-related 
deaths and heroin concentration seizures in that time. 
Degenhardt et al 
(2004) 
NSW, Victoria & 
South Australia, 
Australia 
1996-2003 Fatal & Non-
fatal 
Observational Overdoses decreased by 40% (fatal) and 85% (non-
fatal) during heroin shortage period. 








Time series analysis on 
overdoses from hospital 
emergency departments 
Fatal and non-fatal heroin overdoses decreased during 
the heroin drought. Heroin supply reduced related 
deaths and didn't cause an increase in other drug-
related deaths. 
Risser et al 
(2007) 
Vienna, Austria 1999 Fatal Time series - Post-mortem, 
emergency incidents, and 
seizure analysis 
No relationship between heroin related incidents and 
fluctuations in purity of street heroin. 
Toprak & Cetin 
(2009) 
Istanbul, Turkey 1990-2000 Fatal Post-mortem and seized 
opium derivatives 
Weight of heroin and number of seizures, but not purity, 
were associated with heroin-related deaths. 




1994-2012 Fatal Post-mortem Slight positive correlation between overdose deaths 
and mean heroin street purity. 
Unick et al (2014) Various 
locations, USA 
1992-2008 Fatal & Non-
Fatal 
Hospital admissions versus 
purity and price 
Purity not associated with heroin overdose but 




Appendix C. Additional Data and Resources (Chapter 5) 


















1 ODU 50s M 30 Healthy Yes 3 Current 10 
2 ODU 40s F 25.3 Healthy Yes 7 Current 7 
3 ODU-LD 40s M 21.1 Mild COPD Yes 4 Current 12 
4 ODU-LD 30s M 18.7 Mild COPD Yes 3 Current 8 
5 ODU 50s M 37.8 Healthy No 0 Ex 31 
6 ODU-LD 60s M 27.95 Severe COPD No 0 Ex 15 
7 ODU-LD 60s M 19.64 Mild COPD No 0 Current 9 
8 ODU 40s M 31.4 Healthy Yes 3 Current 17 
9 ODU 40s F 32.7 Healthy Yes 1 Ex 19 
10 ODU-LD 50s M 27.7 Moderate COPD No 0 Current 91 
11 ODU-LD 40s M 19.74 Moderate COPD Yes 10 Current 30 
12 ODU-LD 50s M 32 Mild COPD No 0 Current 15 
13 ODU-LD 40s F 29 Asthma Yes 2 Current 10 
14 ODU-LD 30s M 34 Severe COPD Yes 3 Current 5 
15 ODU-LD 40s M 19 Severe COPD No 0 Current 15 
16 ODU 40s M 25 Healthy Yes 1 Current 25 
17 ODU-LD 40s M 23 Mild COPD No 0 Current 37 
18 ODU 30s M 29 Healthy Yes 2 Current 2 
19 ODU-LD 30s F 24 Mild COPD No 0 Current 25 



































1 19 IV No 
Alcohol & 
cannabis 
No Yes Yes No No Yes No No 
2 15 IV No 
None 
other 
No No Yes Yes Yes No No Yes 
3 20 IV No 
None 
other 
No No No No No No No No 
4 16 IV Yes 
Alcohol & 
benzos 
No Yes Yes Yes Yes Yes Yes No 
5 27 IH No Benzos No No Yes Yes No No Yes No 
6 15 IV Yes Benzos No No No Yes No No Yes Yes 
7 20 Both No Cannabis No No No No No No Yes No 
8 18 IV No Alcohol No Yes Yes No No No No No 
9 23 IV No 
None 
other 
No No No No No No No No 
10 36 IH No Alcohol No Yes Yes No No No Yes No 
11 16 IV No 
None 
other 
Yes No No No No No No No 
12 25 IH No 
Alcohol & 
cannabis 
No No No No No No No No 
13 27 IV No Cannabis No No No No No No No No 
14 19 IV No 
None 
other 
No No No No No No No No 
15 23 Both Yes Cannabis No No Yes No No No Yes No 
16 43 IH No Alcohol Yes No No No No No No No 
17 15 Both No Cannabis No No Yes Yes No Yes Yes No 
18 20 IV No 
Alcohol & 
benzos 
No No Yes Yes No No Yes No 
19 34 IH No Benzos No No No Yes No No No No 






















Typical freq. of dose 
1 Buprenorphine 16 2 1 5 4 No Supervised daily  
2 Diamorphine Injectable 400 unknown 168 20 4 Yes Split Dose 
3 Buprenorphine 2.8 0.35 60 20 2 Yes Split Dose 
4 Methadone 60 1 2 19 15 Yes Supervised daily  
5 Methadone 50 0.83 1 30 4 No Once daily 
6 Methadone 75 1.25 42 45 4 Yes Split Dose 
7 Methadone 40 0.67 24 30 6 Yes Once daily 
8 Buprenorphine 12 1.5 1 12 5 No Once daily 
9 Buprenorphine 8 1 24 25 6 No Once daily 
10 Buprenorphine 4 0.5 2 8 6 Yes Once daily 
11 Buprenorphine 8 1 3 25 16 No Supervised daily  
12 Buprenorphine 6 0.75 12 20 7 No Supervised daily  
13 Buprenorphine 20 2.5 1 9 4 No Supervised daily  
14 Oral Diamorphine 450 unknown 3 16 4 No Split Dose 
15 Buprenorphine 16 2 24 2 2 Yes Once daily 
16 Buprenorphine 12 1.5 12 2 5 No Supervised daily  
17 Methadone 80 1.33 96 8 1 No Supervised daily  
18 Methadone 105 1.77 4 15 6 Yes Split Dose 
19 Buprenorphine 16 2 60 5 1 No Once daily 





Appendix C-4: Presence (yes) or absence (no) of respiratory depression criteria between all 
ODU grouped by prescribed OST. 
 









10 secs  
Yes No Yes No Yes No Yes No 
Methadone 2 4 4 2 2 4 4 2 
Buprenorphine 2 10 8 4 4 8 5 7 
Diamorphine 
Injectable 
0 1 1 0 1 0 1 0 
Oral Diamorphine 1 0 1 0 1 0 1 0 
Total 5 15 14 6 8 12 11 9 
 
Appendix C-5: Gas transfer results for all ODU participants, median (IQR; interquartile range). 
TLCO: carbon monoxide transfer factor; KCO: carbon monoxide transfer coefficient.  
 Value % predicted 
TLCOc 6.75 (5.9-8.6) mmol∙min-1∙kPa-1 71 (63.8-78) 
KCOc  1.2 (1-1.3) mmol∙min-1∙kPa∙L-1 77.8 (65.5-83) 
 
Appendix C-6: Additional findings for study. Comparison of differences between age (younger 
and older), OST type, route of heroin administration and smoking pack years (heavier and 
lighter) with respiratory depression criteria. Mann-Whitney or Kruskal-Wallis Tests were used. 

























Age – younger 
or older  
0.35 0.8 0.25 0.52 0.9 0.11 0.4 0.03* 













Appendix C-7: earlobe blood gas results for all groups where applicable, median (IQR). N/M: 
not measured; pO2: partial pressure of oxygen; pCO2: partial pressure of carbon dioxide; 
HCO3-: bicarbonate.  
 
  ODU Controls ODU-LD LD Controls 
Baseline SpO2 
(%) 











































Name:                      DOB:  
 
Gender F/M  
 
Smoker: Y/N   How long: 
 
Breathlessness scale: 0  1  2  3  4  5  6  7  8  9 10  
 








Spirometry: Normal  Mild   Moderate  Severe  
 
FEV1:  %predicted 






Buprenorphine/Methadone/Other                                  Dose:  
 
 
Duration of this treatment: 
 
 
No. times in treatment:  
 
 
First entry into treatment: 
 
 
Other drug use 
 
Other prescribed drugs:  
 
Other drugs:  











Details related to previous heroin use 
Age of first heroin use: 
 
Have you ever had a near-overdose?  How many times? 
 
Current living situation 
Alone/with a partner/children/friends/family/Other 
 
Daily routine 
What time did you take your dose today?  
 
What time do you normally take your dose?  
 
Do you split it? If so, how? 
 
What did you have today? Drugs and diet included.  
 
What is a typical day for you? 
 
 
Urine & Alcohol Screen 
Drugs present:  
AMP   BZO   COC   MDMA   MTD   OPI   THC 









Appendix D. Summary Timeline of Steps in the AOO Study  
Step Date 
Protocol Draft  Dec-14 
Revisions to protocol and decision on type of study - CTIMP by 
the MHRA 
Apr-15 
Full Budget and Costing form Jul-15 
Scientific Review  Nov-15 
Risk Assessment Committee Final Decision Jan-16 
Assignment of Sponsorship Jan-16 
Assignment of Clinical Research Associate (CRA)  Mar-16 
Arrangement of kick-off meeting  May-16 
MHRA application/competent authority application Jul-16 
IRAS completion Jul-16 
Pharmacy contact Oct-16 
Initial Research Ethics Committee (REC) meeting Oct-16 
Response to requested amendments by REC  Nov-16 
Full acceptance from REC Nov-16 
Response to HRA review amendments Jan-17 
HRA approval Jan-17 
Sponsorship approval  Mar-17 
Database management and creation of database Mar-17 
Initial contact with external agencies Apr-17 
Substantial amendment to include external agencies Jun-17 




Meeting and training the RNs Dec-17 
Ordering equipment, materials and IMP Oct-17 
Validating the database Nov-17 
Green light for recruitment given by Clinical Trials Office  Dec-17 
Pharmacy duties and tasks  Jan-18 
Recruitment and invitation of participants for study sessions Feb-18 






Appendix E. Additional Data and Resources (Chapter 8) 
Appendix E-1: AOO Protocol 
EudraCT number: 2016-001877-34 
REC: London South East National Research Ethics Committee 
 
Inclusion Criteria  
Each subject will be selected according to the following inclusion criteria: 
Diamorphine-injecting subjects who have been in treatment for a minimum of one month; 
1. Male or female; 
2. ≥ 18 years; 
3. Capable of providing voluntary written informed consent; 
4. A non-custodial stable residence and telephone number; 
5. Venous access has to be suitable for intravenous drug administration and 
cannula insertion; 
6. Oxygen saturation reading of ≥92%;  
7. Forced expiratory volume in 1 second ratio, predicted % (FEV1%) of >50% 
(spirometry); 
8. Absence of acute respiratory illness for 6 weeks prior to screening or any study 
day.  
Exclusion Criteria  
Subjects who meet any of the following criteria will be excluded from the study: 
1. Dependent use of cocaine or amphetamines requiring specific treatment. This 
will be assessed at Pre-Study Screen.  
2. Active significant medical condition (e.g. hepatic failure or severe hepatic 
disease) as determined by clinical assessment, medical history and as advised 
by their treating clinician. This will be assessed by the clinical investigator at 
Pre-Study Screen, for example: 
a. Severe hepatic insufficiency (liver function tests conducted within the 
last 6 months prior to screening): Patients with clinical features of 
hepatic failure (e.g. encephalopathy, ascites, jaundice, prolonged 




Child-Pugh Classification B or C). Patients with liver disease (e.g. HCV, 
HBV infection) without features of hepatic failure are potentially eligible.  
b. Severe respiratory insufficiency or the inability to reliably perform 
physiological tests of respiratory function (spirometry).  
c. Pre-existing renal or cardiac issues that the study physician or treating 
clinician considers inappropriate for the purposes of this trial.  
3. In cases where subjects are able to perform spirometry, a FEV1% of ≤50% as 
confirmed by spirometry at Pre-Study Screen.  
4. Oxygen saturation reading of <92% as confirmed by finger pulse oximetry at 
Pre-Study Screen.  
5. Acute illnesses that make participation inappropriate, as assessed by the study 
physician. Presence of acute respiratory illness within 6 weeks prior to 
screening or any of the study sessions. This will be assessed during screening 
and on each study day. If acute illness is present, subject will be asked to return 
6 weeks post-acute illness. Acute diarrhoeal conditions caused by antibiotic-
induced pseudomembranous colitis or by poisoning will be assessed by the 
study physician. Assessment at Pre-Study Screen and on each Study Visit. 
6. Subjects suffering from acute alcoholism or delirium tremens. This will be 
assessed at Pre-Study Screen.  
7. Subjects who have suffered from head injury or have been with diagnosed 
phaeochromocytoma. These will be assessed at Pre-Study Screen.  
8. Risk of paralytic ileus or biliary colic assessed by the study physician. This will 
be assessed at Pre-Study Screen.  
9. A benzodiazepine prescription that is above the standard therapeutic dose 
range (e.g. if oral Diazepam above 30mg/daily; BNF, 2016). This will be 
examined by medical notes at the Pre-Study Screen. A drug test on each Study 
Visit will be performed to assess whether there is any presence of 
benzodiazepines that the participant is not prescribed. Concomitant medication 




10. Subjects prescribed other contraindicated drugs: monoamine oxidase inhibitors 
(or within 2 weeks of their discontinuation), 4-quinolone antibacterials, 
phenothiazines, tricyclic antidepressants, anxiolytics (see above), hypnotics, 
cisapride, domperidone and metoclopramide, cimetidine and selegiline. This will 
be assessed at Pre-Study Screen. 
11. Alcohol and other drug use on the specific study days. A drug screen 
(Angelscope) and breathalyser (BACtrack, Xtend®) will be used to confirm 
additional drug/alcohol use on the study days. A positive drug screen (excluding 
prescribed drugs) and an excessive blood alcohol content (BAC) (based on the 
legal driving limit in England & Wales of 0.8g/L) will result in a re-invitation to an 
alternative study date. This will be assessed on each Study Visit.  
12. Current psychiatric diagnosis of major depression with suicidal ideation, 
psychosis, bipolar disorder, or any psychiatric disorder that would compromise 
the subject's ability to complete the study. These will be assessed at Pre-Study 
Screen.  
13. At screening and on each study day, if there is a chance that female subjects 
may be pregnant; subjects will undergo a pregnancy test. A positive pregnancy 
test will result in an exclusion from the study. In addition, mothers who are 
lactating, women of childbearing potential who refuse to use adequate 
contraception and pregnancy tests during the study, or women who are planning 
to become pregnant during the period of the study will also be excluded. This 
will be assessed at Pre-Study Screen and on each Study Visit by the clinical 
investigator.  
14. Any other factor that in the opinion of the study physician would make the 
subject unsafe or unsuitable for the study. This will be addressed at Pre-Study 
Screen and on each Study Visit by clinical investigator.  
 







Selection of Participants  
Participants will be opioid-dependent patients undergoing prescribed injectable diamorphine 
(pharmaceutical heroin) treatment with long-term history of heroin injecting use. The minimum 
time period for current treatment with diamorphine maintenance will be one month.   
All patients on diamorphine maintenance between the inclusive ages will be informed of the 
study by direct clinical care staff. Any potential participant will be further informed of the study 
details by investigators, have an opportunity to ask questions, be informed of their right to 
withdraw, and be provided with a copy of the patient information sheet.  
If participation is chosen, the PI or co-investigators, in accordance with the Clinical Trial 
Regulations, the Declaration of Helsinki 1996 and GCP requirements will take consent. A copy 
of the signed consent will be provided to the participant.  
 
Screening Tests 
Measurements at screening will include spirometry (forced expiratory volume in 1 second 
(FEV1) and slow vital capacity (VC)) to report the predicted FEV1% ratio which will indicate the 
presence or severity of respiratory illness relevant to the study. If the ratio falls at or below 
50%, subject will not be eligible for the study. Furthermore, pulse oximetry will also be 
measured and any reading below 92% will deem the subject ineligible for the study. Vital signs 
(blood pressure and heart rate) will also be measured.  
Additionally, female subjects who are of childbearing potential who may have a chance of 
being pregnant will undergo a pregnancy test (a urine test). Female participants of 
childbearing potential will be asked to take contraceptive precaution during the period of time 
within the study.  
 
Tests Prior to Each Study Visit 
A drug screen (a dipstick urine test, Angelscope) and breathalyser (BACtrack, Xtend®) will be 
used to confirm additional drug/alcohol use on each of the study days. The purpose of the 
drug/alcohol test is to prevent any potential concomitant acute effects of other drugs that are 
not described in the patient medical records. Vital signs (blood pressure and heart rate) as 




All testing will be immediate and any used equipment will be discarded immediately after use. 
No samples will be stored or analysed further.  
An assessment of pregnancy status will be addressed at each study visit by the clinical 
investigator. 
 
Presence of Acute Respiratory Illness  
If acute respiratory illness is reported to have occurred within 6 weeks prior to screening or 
any study session, the subject can be re-invited 6 weeks after the initial acute illness. 
Spirometry testing will be repeated (if subject already had this test at screening) upon their 
return. Acute respiratory illness includes acute respiratory infection, or other acute illness 
impacting normal breathing.   
 
Withdrawal of Subjects  
The study may be prematurely discontinued by the Sponsor or Chief Investigator on the basis 
of new safety information or for other reasons given by the ethics committee concerned. 
 
If the study is prematurely discontinued, active participants will be informed and no further 
participant data will be collected. The Competent Authority and the Research Ethics 
Committee will be informed within 15 days of the early termination of the study. 
 
The Investigator will advise the Sponsor of the withdrawal of any subject. Withdrawn subjects 
will be replaced.  
 
A subject may be withdrawn in any of the following circumstances: 
• Adverse events; 
• Inter-current illness; 
• Protocol violations; 
• Withdrawal of consent; 




Participants have the right to withdraw from the study at any time for any reason.  The 
investigator also has the right to withdraw patients from the study drug in the event of inter-
current illness, AEs, SAEs, SUSARs, protocol violations, cure, administrative reasons or other 
reasons.  It is understood by all concerned that an excessive rate of withdrawals can render 
the study uninterpretable; therefore, unnecessary withdrawal of patients should be avoided.  
Should a patient decide to withdraw from the study, all efforts will be made to report the reason 
for withdrawal as thoroughly as possible and an assessment will be made by the clinical team 
as to whether follow-up is necessary (i.e. in case of any adverse events).   
Expected Duration 
The expected duration of the trial is no more than 9 months. The start will be defined as the 
first patient on their first visit. The end of the study will be defined as the database lock date 





Appendix E-2: Full Study Table  
 
  
Assessment Screening All Study Days (4) 










-3 0 3 8 15 30 60 
Informed 
consent 
x          
Pregnancy 
Status/Test 
x x         
Demographic
s,  Medical 
History & BMI 




x x         
Eligibility 
Assessment   




 x  x x x x x x x 
Breathalyser 
for alcohol 




 x         
Spirometry x          
Vital signs: 
HR, BP 




    x      
Airflow & 
ETCO2% 
   x x x x x x x 
EMGpara   x        
TcCO2   x        
SpO2% x x x        




   x x x x x x x 
Staff rating 
(VAS) 




Appendix E-3 Selection of AOO Approval Documents.  














































































































Appendix F. Outputs During PhD 
 
Presentations during PhD 
2018: 
MRC Addictions Research Summer Meeting | June, London, UK 
Oral Presentation: “Heroin Overdose: Experimental Testing and Measurement in the 
Laboratory: Preliminary Findings.” 
 
‘Heroin On Trial’: Heroin-Assisted Treatment in the UK | May, London, UK  




Society for the Study of Addictions Symposium | November, Newcastle, UK 
Poster Presentation: “An Observational Study of the Severity of Respiratory Depression in 
Chronic Opioid Dependence.” 
 
27th International Congress of the European Respiratory Society | September, Milan, Italy 
Poster Presentation: “An Observational Study of the Severity of Respiratory Depression (RDP) in 
Opioid Dependent Patients (ODP).” 
 
2nd Lisbon Addictions Conference | October, Lisbon, Portugal 




Institute of Psychiatry, Psychology & Neuroscience PhD Symposium | May, London, UK 
Poster Presentation: “Pharmaceutical Heroin Prescribing and Mortality Rates: The ‘British 







Society for the Study of Addictions Symposium | October, York, UK 
Poster Presentation: “Pharmaceutical Heroin Prescribing and Mortality Rates: The ‘British 
System’ of the 1960s and Early 1970s.” 
 
1st Lisbon Addictions Conference | September, Lisbon, Portugal  
Oral presentation: “Pharmaceutical Heroin Prescribing and Mortality Rates: The ‘British System’ 
of the 1960s and Early 1970s.” 
 
Publications during PhD 
1.  Tas, B. & McDonald, R (2016). Commentary on Darke & Duflou (2016): Heroin-related 
deaths – identifying a window for intervention. Addiction 111(9):1614-1615. 
 
2.  Tas, B. & Day, E. (2016). Pharmacology and physiological mechanisms of opioid overdose 
and reversal. In: Strang, J. & McDonald, R. (Eds) (2016). Preventing opioid overdose deaths 
with take-home naloxone. EMCDDA Insights. Lisbon, Portugal.  
 
3.  Strang, J., McDonald, R., Tas, B. & Day, E (2016). Clinical provision of nasal naloxone 
without prior experimental testing and without regulatory approval – imaginative shortcut or 
dangerous bypass of essential safety procedures? Addiction 111(4) doi:10.1111/add.13209. 
 
4.  Winston, I., McDonald, R., Tas, B. & Strang, J. (2015). Heroin Overdose Resuscitation with 
Naloxone: Patient Uses Own Prescribed Supply to Save the Life of a Peer. BMJ Case Reports 
doi:10.1136/bcr-2015-210391 
 
 
